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ABSTRACT 
 
Obsessive-compulsive disorder (OCD), a debilitating psychiatric disorder, affects 2-3% of the 
general population, and represents a global health problem. Evidence from family studies 
suggests that genetic factors play a role in mediating disease development. However, the 
pattern of inheritance is not consistent with monogenic disorders, but is “genetically 
complex”.  
 
Case-control association analysis, which facilitates dissection of the genetic aetiology of 
complex disorders, has yielded many inconsistent results in OCD studies, making 
identification of predisposing alleles difficult. These discrepant findings can largely be 
attributed to inappropriate statistical methodology and the lack of OCD phenotypic resolution. 
Although classified as a single clinical entity according to structured algorithms, OCD 
probably represents a final common outcome of multiple underlying aetiologies. Thus, 
numerous clinical subtypes of the disorder have been proposed; these “intermediate” 
phenotypes may be more closely related to a particular genetic substrate than the higher order 
construct of OCD. 
 
Furthermore, although genes encoding serotonergic (5-HT) and dopaminergic components are 
most commonly investigated, it is likely that the behavioural manifestations of OCD are 
mediated by a broader network of interconnected neurotransmitter and signalling pathways.  
 
Consequently, the aim of the present study was two-fold: to address the factors that may have 
confounded previous genetic case-control association studies and to investigate the genetic 
aetiology of OCD phenotypes while accounting for these factors.  
 
Case and control individuals were drawn from the reportedly genetically homogeneous 
Afrikaner population. However, as no empirical evidence existed to support the absence of 
genetic substructure, which would confound genetic association studies, a Bayesian model-
based clustering algorithm (Structure), that groups individuals on the basis of observed 
genotype data, was employed to assess population stratification in both case and control 
Afrikaner subjects.  
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OCD patients were clinically stratified by gender, symptom severity, age at onset, the 
presence of selected co-morbid disorders and the presence of selected symptom dimensions, 
to facilitate the identification of susceptibility genes more closely related with these subtypes. 
Candidate genes included those coding for components of the 5-HT (5-HT receptors 1Dβ, 2A, 
2C and 6), dopaminergic (dopamine receptors 1, 2, 3 and 4, dopamine transporter and 
catechol-O-methyltransferase [COMT]), glutamatergic (glutamate receptor subunit 2B 
[GRIN2B]) and neurodevelopmental pathways (brain-derived neurotrophic factor [BDNF] 
and homeobox 8 [HoxB8]), as well as previously uninvestigated genes (angiotensin-
converting enzyme I, inositol-trisphosphate, phospholipase-C-gamma 1 and estrogen receptor 
alpha). The relationship between variants in these genes and OCD (or OCD subtypes) was 
investigated in a single locus and a haplotype context, while meta-analyses using published 
population-based case-control association data were also conducted. 
 
Significant associations noted between distinct COMT variants and OCD implicated COMT in 
the development of a genetically discrete, gender-dependant, early-onset, tic-related 
phenotype in males. Furthermore, investigations of variations in BDNF and GRIN2B point 
towards a genetically distinct, neurodevelopmental subtype of the disorder, mediated, in 
males at least, primarily by dysfunctions in BDNF. The striking gender dimorphism noted in 
these associations indicates the possibility of an epigenetic hormonal influence. Moreover, the 
significant association of polymorphisms within GRIN2B, in both a single locus and 
haplotype context, suggests the involvement of this gene in mediating a phenotypic subtype 
characterised by an early-onset, more severe form of the disorder.  
 
The present investigation forms part of ongoing research to elucidate genetic components 
involved in the aetiopathology of OCD and OCD-related subtypes. Such studies may pave the 
way towards more efficacious pharmacotherapeutic strategies, which will ease the suffering 
of individuals who are afflicted with this incapacitating condition. 
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OPSOMMING 
 
Obsessiewe-kompulsiewe steuring (OKS) is ŉ aftakelende psigiatriese siektetoestand wat 2-
3% van die algemene bevolking affekteer en ŉ globale gesondheidsprobleem verteenwoordig. 
Familiestudies dui daarop dat genetiese faktore ŉ rol in die ontwikkeling van hierdie siekte 
speel. Die patroon van oorerwing is egter nie verenigbaar met dié van monogeniese siektes 
nie, maar is geneties “kompleks”. 
 
Geval-kontrole assosiasie-ontleding, wat die disseksie van die genetiese etiologie van 
komplekse siektes fasiliteer, het teenstrydige resultate in OKS gelewer en dit bemoeilik die 
identifikasie van predisponerende allele. Die teenstrydige bevindings kan grootliks aan 
ontoepaslike statistiese metodiek en die gebrek aan fenotipiese differensiasie in OKS 
toegeskryf word. Alhoewel dit volgens gestruktureer algoritmes as ŉ enkele kliniese entiteit 
geklassifiseer word, verteenwoordig OKS waarskynlik die eindresultaat van veelvoudige 
onderliggende oorsake. Baie kliniese subtipes van die toestand is al voorgestel en dié 
“intermediêre’ fenotipes mag nader verwant aan ŉ spesifieke genetiese substraat as die hoër 
orde konsep van OKS wees. 
 
Verder, alhoewel die gene wat die serotonergiese (5-HT) en dopaminergiese komponente 
kodeer meestal ondersoek word, is dit waarskynlik dat die gedragsmanifestasies van OKS 
deur ŉ breër netwerk van intergekonnekteerde neuro-oordragstof- en seinoordragpaaie 
meegebring word  
 
Gevolglik was die doel van die huidige studie tweevoudig: om faktore wat vorige genetiese 
geval-kontrole assossiasie-studies verwar het aan te spreek en om die genetiese etiologie 
van OKS-fenotipes te ondersoek met in ag neming van hierdie faktore. 
 
Geval- en kontrole-individue is gekies uit die Afrikaner-bevolking wat as geneties homogeen 
beskryf kan word. Daar was geen empiriese bewyse vir die afwesigheid van ŉ genetiese 
substruktuur (wat genetiese assossiasie-studies sou verwar),nie. Daarom is ŉ Bayesiese 
model-gebaseerde groeperings-algoritme (Structure), wat individue op grond van 
waargenome genotipiese data groepeer, gebruik om die populasie-stratifikasie is beide geval- 
en kontrole- Afrikaner-individue te bepaal. 
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OKS-pasiënte is klinies gestratifiseer volgens geslag, ernstigheid van simptome, ouderdom by 
aanvang van simptome, die teenwoordigheid van geselekteerde komorbiede siektetoestande 
en die teenwoordigheid van geselekteerde simptoomdimensies of -groepe, om die 
identifikasie van moontlike vatbaarheidsgene wat nader verwant is aan die verskillende 
subtipes te fasiliteer/vergemaklik. Kandidaatgene het ingesluit: dié wat kodeer vir 
komponente van die 5-HT-(5-HT reseptore 1Dß, 2A, 2C and 6), dopaminergiese (dopamien-
reseptore 1, 2, 3 and 4, dopamien-transporter and katesjol-O-metieltransferase [COMT]), 
glutamatergiese (glutamaat-reseptor subeenheid 2B [GRIN2B]) and neuro-ontwikkelingspaaie 
(brein-gederiveerde neurotrofiese faktor [BDNF] en homeobox 8 [HoxB8]), sowel as die gene 
wat nie voorheen ondersoek is nie (angiotensien-omsettingsensiem I, inositol-trisfosfaat, 
fosfolipase-C-gamma 1 en estrogeen-reseptor alpha). Die verhouding tussen variante in 
hierdie gene en OKS (of OKS-subtipes) is ondersoek in ŉ enkel-lokus en haplotipe konteks, 
en meta-analises, wat gepubliseerde bevolkings-gebaseerde geval-kontrole ontledingsdata 
gebruik het, is ook gedoen. 
 
Beduidende assosiasies gevind tussen spesifieke COMT-variante en OKS in mans, het daarop 
gedui dat COMT in die ontwikkeling van geneties-diskrete, vroeë-aanvang, senutrekking 
("tics") -verwante fenotipe in mans betrokke is. Verder het ondersoeke van variasies in BDNF 
en GRIN2B daarop  gedui dat ŉ geneties-afsonderlike, neuro-ontwikkelings-subtipe van.OKS 
wat, ten minste in mans, primêr deur wanfunksie van BDNF meegebring word. Die 
opvallende geslags verskil wat in hierdie assosiasies gesien word, dui op die moontlikheid van 
ŉ epigenetiese hormonale invloed. Bowendien, die beduidende assosiasie van polimorfismes 
in GRIN2B in beide die enkel-lokus en haplotipe konteks, dui op die betrokkenheid van 
hierdie geen in die meebring van ŉ fenotipiese subtipe wat deur ŉ vroeë aanvang, en meer 
ernstige vorm van die siekte gekenmerk word. 
 
Die huidige ondersoek vorm deel van voortgesette navorsing om die genetiese 
komponente  wat  betrokke  is  by die etiopatologie van OKS en OKS-subtipes, bloot te lê. 
Sodanige studies kan die weg baan na meer doeltreffende farmakoterapeutiese strategieë wat 
die lyding van indi vidue wat deur hierdie aftakelende  toestand geraak word, kan verlig. 
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CHAPTER I: INTRODUCTION 
 
I.1. A BRIEF INTRODUCTION TO PSYCHIATRIC GENETICS 
  
“Of all the hereditary diseases, madness is supposed to be the most constant and persevering, 
for even if one generation escape, the taint is presumed to cling to the succeeding 
branches…” 
John Johnstone (1786-1863) 
  
It is clear that, from the quote by John Johnstone, a genetic viewpoint on the complex genetic 
inheritance of psychiatric disorders has been appreciated for centuries. Indeed, one of the 
founders of modern-day psychiatry, Emil Kraepelin, believed that a psychiatric disorder 
constituted a “heredity taint” (Barondes, 1998). 
 
However, during the early 20th century, psychiatry underwent a long period in which it was 
not considered as belonging to any particular category of medical science (Freimer and 
Sabatti, 2004). Nowadays, with the modern expedience of bioinformatics and biotechnology, 
interest in the field of psychiatric genetics has escalated to phenomenal proportions. More 
recently, there has been a sense of urgency to dissect the aetiology of these disorders, given 
their staggering burden on society (Uhl and Grow, 2004; Murray and Lopez, 1997). 
 
Psychiatric disorders are complex, multifactorial disorders comprising a range of 
environmental and genetic contributions, that can be amalgamated to form an observed, 
normally distributed variable termed liability (Falconer, 1981). Psychiatric disorders may 
therefore be regarded as dichotomous entities by simple virtue of the fact that the underlying 
liability exceeds some threshold (Rannala, 2001). Indeed, multiple thresholds may also exist, 
with individuals who possess liability scores between the threshold values representing the 
mild phenotypic or so-called spectrum cases. 
 
Delineating the contribution of genetics to the development of psychiatric disorders has not 
been easy. Although psychiatric disorders aggregate within families, they do not segregate 
within these families, intimating their complex transmission patterns and genetic aetiology. 
Different genetic mechanisms and interactions, including epistasis, locus heterogeneity, allelic 
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heterogeneity, incomplete penetrance and genetic imprinting, may be implicated in bestowing 
increased susceptibility to a disorder on an individual (Nothen et al, 1993; Souery et al., 2001; 
Stoltenberg and Burmeister, 2000). 
 
Besides the genetic complexity of psychiatric disorders, non-genetic factors also confound the 
detection of genes implicated in these conditions. Genetic factors may be necessary, but are 
not sufficient, to precipitate the clinical phenotype of the disorder. Most complex disorders 
require the simultaneous input from non-genetic (environmental) factors. Possible substrates 
acting as environmental aetiological factors include those of a psychosocial, immunological, 
developmental, nutritional and infectious nature. Despite a myriad confounding factors, 
research designs have been employed to analyse the cause of individual differences within the 
normal range of behavioural variation, and the aetiologies of various psychopathologies and 
mental illnesses; subsequently, heritability estimates have been identified for a number of 
psychiatric conditions (Owen and Cardno, 1999). In a recent meta-analysis of the 
epidemiology of anxiety disorders (pertinent to the present dissertation since it included 
obsessive-compulsive disorder [OCD]), it was estimated that the heritabilities across the 
disorders were in the range of 30% to 40%, although the authors acknowledge that this may 
represent an underestimation (Hettema et al., 2001). 
 
Heritability of a disorder refers to the ratio of genetic variance to the overall phenotypic 
variance. It is worthwhile to note that these values are based on a specific situation involving 
a particular phenotype in a population, and may well differ between populations. Heritability 
must thus be viewed as a descriptive statistic of a trait pertaining to a particular population at 
a specific time, and the heritability estimates should be viewed as just that – estimates 
(Sherman et al., 1997). Estimates of heritability are based on a process of biometrical model 
fitting, which allows the determination of whether, and to what extent, genetic and 
environmental factors contribute to the liability to a psychiatric disorder (Owen et al., 2000; 
Sherman et al., 1997). It is important to note, however, that simply estimating the degree of 
heritability does not give one an indication of the mode of inheritance of a disorder. 
 
The present dissertation investigates the genetic contribution that may play a role in the 
heritability of OCD, the main focus being the identification of the genetic substrates 
comprising the disorder. However, in order to understand the underlying genetic basis of the 
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disorder, it is necessary to briefly review the results of studies providing evidence for the role 
of genetics in the pathology of the disorder. 
 
I.2. OBSESSIVE-COMPULSIVE DISORDER (OCD) 
 
I.2.1. Phenotypic Characteristics of OCD 
“Having OCD is like being allergic to life – every waking moment is spent in a state of mental 
hypersensitivity” 
Anonymous 
 
Obsessive-compulsive disorder was described as far back as the 19th century by Esquirol 
(1838), Falret (1850) and Westphal (1878). The German writer, Westphal, formulated the 
modern definition of the syndrome, which was considered to be psychological in origin and 
was classified amongst the group of neuroses. With Freud’s psychoanalysis of the “Rat Man” 
(1909/1955), OCD was hypothesized as being the result of unconscious conflicts and the 
isolation of thoughts and behaviours from their emotional antecedents (Jenike, 2001).  
 
Nowadays, OCD is looked upon as a severe and debilitating condition that is classified as an 
anxiety disorder in the Diagnostic and Statistical Manual (4th Edition) (DSM-IV, 1994). The 
disorder is characterised by pathognomonic features of recurrent obsessions (persistent, 
intrusive thoughts) and/or compulsions (physical or mental rituals or acts), which the 
individual feels compelled to perform so as to reduce distress brought on by the obsessions, or 
to prevent some feared situation. Clinical diagnosis of OCD, according to the DSM-IV, 
requires that the obsessions and compulsions cause significant distress to the patient and 
consume more than one hour a day of their time, ultimately interfering with normal home, 
work and social routine. In addition, the patient should recognise that the obsessions and 
compulsions are excessive and unreasonable. 
 
Around 1938, Westphal described obsessional thoughts as “ideas that in an otherwise intact 
intelligence, and without being caused by an emotional or affect-like state, against the will of 
the person…come into the foreground of the consciousness”. Obsessions include recurrent or 
persistent ego-dystonic ideas, thoughts, images or impulses which the individual attempts to 
suppress or ignore because he finds them morally reprehensible and repugnant. Most patients 
are secretive regarding their obsessions, and consequently experience constant inner turmoil 
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because they are aware that, although their actions are unreasonable, they are powerless to 
resist them. OCD patients commonly endorse obsessions involving contamination, doubt, fear 
of aggression towards others or acting on sexual impulses, disgust with bodily function, and a 
need for symmetry and order (Rasmussen and Eisen, 1988, DSM-IV, 1994) (Table I.1). 
Obsessions are not excessive worries about real-life problems (DSM-IV, 1994). 
 
Compulsions embody the physical corollary to obsessions - they represent the uncontrollable 
urge to repeatedly enact stereotypic behaviours or mental rituals in an attempt to neutralise or 
prevent discomfort brought on by obsessions (DSM-IV, 1994). Compulsions are normally 
amplified beyond utility and usually possess no realistic connection with the obsession they 
are designed to neutralise. Performing compulsions may become a major lifetime activity, 
leading to marital, occupational or social disability. If interrupted whilst performing the 
compulsions, the patient believes that they should be started again in order to be effective. 
Common compulsions include checking, washing, cleaning, counting, querying behaviours 
(asking or confessing), and arranging or hoarding objects (Rasmussen and Eisen, 1988; DSM-
IV, 1994) (Table I.1). 
 
Table I.1. Typical OCD symptoms 
Common obsessions 
Frequency 
(%) 
Common compulsions 
Frequency 
(%) 
Contamination fears 45 Checking rituals 63 
Repetitive doubts 42 Washing/cleaning rituals 50 
Somatic obsessions 36 Need to confess 36 
Need for symmetry 31 Covert counting 36 
Aggressive impulses 28 Ordering/symmetry 31 
Repeated sexual imagery 26 Hoarding 18 
Multiple obsessions  60 Multiple compulsions 48 
Adapted from Rasmussen and Eisen, 1990. 
 
 
Most patients with the disorder suffer from both multiple obsessions and compulsions, 
particularly now that the DSM-IV has redefined compulsions to include mental rituals. A 
remarkable feature of OCD is the “relatively restricted repertoire” of symptom type 
experienced by individuals with the disorder (Samuels and Nestadt, 1997) - the clinical 
manifestations of the condition have been found to remain consistent across populations and 
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cultures, only a limited number of obsessions and compulsions have been described (Robins 
et al, 1984; Nelson and Rice, 1997). 
 
I.2.2. The Epidemiology of OCD 
OCD was originally thought to have a relatively low prevalence of roughly 0.05% in the 
general population, and to be fairly unresponsive to pharmacological forms of treatment 
(Woodruff and Pitts, 1964). This finding was probably due to the clinicians’ relative 
unfamiliarity with the disorder until the last decade. Moreover, patients’ secretiveness about 
their symptoms and the fact that the average wait before seeking psychiatric help was 7.5 
years could have contributed to this finding (Rasmussen and Tsuang, 1986).  
 
It is thus only since the mid-1980s that the disorder has become recognised as one of the most 
common psychiatric disorders, with a significant impact on health and the economy (Du Pont 
et al., 1995). OCD is presently classified as being amongst the most disabling medical 
conditions in the world (Murray and Lopez, 1997). According to well-characterised, 
replicated studies in the US carried out in the Epidemiological Catchment Area (ECA), the 
disorder has a lifetime prevalence of between 1% and 3% (Karno et al., 1988; Robins et al., 
1984; Samuels and Nestadt, 1997; Nestadt et al., 2000[a]; Maina et al., 1999; Weissman et al., 
1994), and affects approximately 50 million individuals worldwide (Fineberg and Roberts, 
2002). 
 
OCD generally pursues a chronic course, marked by episodes of illness with periods of 
incomplete remission (Jenike, 2001). The disorder presents with a bimodal age at onset, 
peaking first in the early teens (early-onset [EO]), and subsequently in the early 20s (late-
onset [LO]). The mean age at onset of OCD is between the ages of 20 and 24 years – more 
than 80% of patients develop symptoms before they reach the age of 35 years (Minichiello et 
al., 1990; Fineberg and Roberts, 2002). Overall, the disorder is slightly more common in 
females than males, with an overall gender ratio of 1.5:1 (Bebbington, 1998; Sasson et al., 
1997; Angst et al., 2004; Fineberg and Roberts, 2002). However, subtle gender differences 
have been found to exist with regard to the age at onset (Antony et al., 1998). EO OCD seems 
to affect more males than females, whereas LO OCD is found to affect more females than 
males. In addition, the mean age of LO OCD in males (21 years) tends to be earlier than that 
for females with LO OCD (24 years).  
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It is possible that the genes thought to contribute to OCD may reflect these gender 
differences, and may perhaps account for a part of the phenotypic variability observed 
between the two sexes. Indeed, Karayiorgou et al. (1997) reported on a sexually dimorphic 
relationship between a candidate gene, catechol-O-methyltransferase (COMT) and OCD. 
These results were subsequently replicated by the same group (Karayiorgou et al., 1999), who 
also observed a sexually dimorphic association between monoamine oxidase A (MAO-A) and 
the disorder.  
 
The heterogeneous nature of OCD in terms of its symptomatology (section I.4.2.2), as well as 
its age at onset, makes the elucidation of its genetic aetiology a rather formidable and 
challenging task. This is because individuals with different symptoms, that may comprise 
different genetic substrates are, by convention, diagnosed with the same general disorder. 
Enormous advances have, however, been made over the course of the last century in an effort 
to disclose the possible psychobiological basis of the disorder and, in doing so, have created a 
solid platform on which many molecular studies can be based. 
 
I.3. AETIOLOGICAL MODELS OF OCD 
 
I.3.1. The Biological Basis of OCD 
OCD is proposed to be a multifactorial disorder, with numerous factors acting together in an 
additive manner to result in the expression of the clinical OCD phenotype. The aetiology of 
the disorder is thought to comprise neurobiological, genetic, behavioural and immunological 
components. Since the focus of the present dissertation is on the genetics of OCD and OCD-
related subtypes, the neurobiological component will briefly be discussed in the context of 
biologic plausibility of the candidate genes that have been selected for investigation in this 
particular study. Of course, as already mentioned, OCD comprises numerous behavioural 
components, and is thought to comprise an immunological component as well (Swedo et al., 
1998); however, a detailed discussion of these components is beyond the scope of this 
dissertation, and, for the sake of brevity, are mentioned briefly in only pertinent sections of 
the thesis. 
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I.3.2. The Genetic Basis of OCD 
 
I.3.2.1. Family studies in OCD 
Familial aggregation of individuals afflicted with a specific psychiatric disorder at a higher 
rate than is prevalent in the general population indicates the possibility that genetic factors are 
involved in the development or course of the disease. Family risk studies are designed to 
determine the extent to which the disorder runs in families because, strictly speaking, all 
genetic disorders should have increased rates of expression amongst relatives. It should be 
noted, however, that familial clustering itself is not foolproof evidence of genetic 
involvement: other factors, such as family environment, culture or infectious agents, may also 
be transmitted within the family unit. 
 
Over the past 60 years, researchers have proposed that OCD is a familial disorder (Kringlen, 
1965; Rasmussen and Tsuang, 1986; Pauls et al., 1995; Nestadt, 2000[a]; Lenane et al., 1990; 
Swedo et al., 1989[a]; Riddle et al., 1990). Direct interview family studies have reported 
higher morbid risks of OCD between first degree relatives of OCD probands compared to 
relatives of psychiatrically normal controls (10% vs. 1.9%, respectively) (Black et al., 1992; 
Pauls et al., 1995). In fact, Pauls et al. (1995) conducted five separate studies, all of which 
confirmed a degree of familiality in OCD. Similar studies on children and adolescents 
reported increased rates (ranging between 20% and 25%) of developing the disorder in family 
members of OCD sufferers (Swedo et al., 1989[a]; Lenane et al., 1990; Rasmussen and Eisen, 
1990; Riddle et al., 1990). Moreover, by employing multivariate analysis, Clifford et al. 
(1984) estimated the heritability of obsessive-compulsive symptoms to be approximately 
40%, and the National Society of Genetic Counselors has estimated the heritability of OCD to 
lie between 40 and 50%. 
 
A recent study conducted by Nestadt et al. (2000[a]) was designed to extend knowledge 
regarding the familial nature of OCD by providing as rigorous a test of the hypothesis as was 
possible. It was reported in this study that a 4 to 15-fold higher lifetime prevalence of OCD 
occurs amongst first-degree relatives of OCD probands. These results replicated those of an 
earlier study (Pauls et al., 1995).  
 
It has also been observed that OCD morbidity rates are significantly higher amongst relatives 
of OCD probands whose age at onset is below 14 years (8.8% vs. 3.4%) (Bellodi et al., 1992). 
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These findings are consistent with those by Nestadt et al. (2000[a]), who found that the age at 
onset of obsessive-compulsive symptoms in probands was strongly related to familiality. In 
this study, no cases were reported in relatives of probands where the age at onset exceeded 17 
years. The differences in rates amongst relatives of EO and LO probands was also reported by 
Pauls et al. (1995). It has also been reported that the risk of subclinical OCD (where 
substantial obsessions and compulsions are experienced, but are not considered severe enough 
to meet full OCD criteria [Lenane et al., 1990]) is greater in relatives of OCD probands with 
EO (<19 years) compared to those with LO (9.4% vs. 2.2%) of the disorder. This suggests 
that an earlier age at onset is likely to be valuable in characterising a familial subtype of the 
disorder, as will be discussed in section I.4.2.2.4 .  
 
Hettema et al. (2001) performed a meta-analysis to estimate summary statistics associated 
with aggregate familial risk and heritability for a number of anxiety disorders, including 
OCD. Information from the five studies included in the meta-analysis (McKeon and Murray, 
1987; Black et al., 1992; Pauls et al., 1995; Nestadt et al., 2000[a]) indicated an odds ratio 
(OR) of 4.0 (95% CI:2.2-7.1) for OCD, and that there was substantial evidence for familial 
aggregation of the disorder. In a more recent two-year follow-up study, it was found that the 
offspring of OCD probands were at a greater risk of developing a lifetime overanxious 
disorder, separation anxiety disorder or OCD (Black et al., 2003). In addition, 23% of the 
offspring of OCD probands developed full-blown OCD, and 30% developed subclinical 
OCD. The investigators concluded that female gender, family dysfunction and high symptom 
levels for OCD were all predictive of broadly-defined OCD (broadly-defined OCD refers to 
clinical and subclinical OCD). 
 
Familial transmission has been found to extend beyond the domain of OCD, and into that of 
disorders occurring co-morbidly with OCD (please refer to section I.4.2.2.1 for a detailed 
discussion on OCD and comorbid disorders), indicating the likelihood of a common 
physiological, genetic and psychological aetiology for these disorders. Indeed, evidence from 
family studies indicates a putative common genetic basis for OCD and Tourette’s syndrome 
(TS) (Pauls et al., 1986; Pitman et al., 1987; Grad et al., 1987) and certain obsessive-
compulsive spectrum disorders (OCSD). It has also been reported that subclinical forms of 
OCD may be transmitted within families, and that they may represent a less severe form of 
OCD, thereby forming a fundamental part of the OCD spectrum (Black et al., 2003). Lenane 
et al. (1990) reported that, of  46 children with OCD participating in their study, the 
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prevalence for subclinical OCD was found to be 13% in the parents of these children, and 4% 
in sibs of the OCD sufferers. In a controlled study, Black et al. (1992) found the morbid risk 
for broadly defined OCD to be 20% amongst primary relatives of first-degree relatives of 
probands. In addition, parents of obsessional probands presented with an increased risk for 
broadly defined OCD compared to parents of the controls (15.6% vs 3.0%, respectively) 
(p=0.034). The same group also investigated OCSDs and found that the risk for developing 
one of these disorders was greater in relatives of probands with OCD. 
 
I.3.2.2. Twin studies in OCD 
Since the 1920s, psychiatric geneticists have cited twin studies as providing evidence of the 
role of genetic factors in the aetiology of mental disorders (Wilson, 1934). The primary 
method of analysis used in this case is the “classical twin method” (Joseph, 2000), which 
compares the concordance (or co-incidence) rates of reared-together identical twins 
(monozygotic or MZ twins) to the concordance rates of reared-together, same-sex non-
identical twins (dizygotic or DZ twins). A pair of twins is said to be concordant for a specific 
condition if both members of the pair express the condition, and discordant if only one 
member of the pair expresses the condition. If only the rearing environment of the twins has 
contributed to the development of the disorder in one twin, then the co-twin, regardless of 
whether MZ or DZ, should also be at risk and the rates for both MZ and DZ twins should be 
elevated compared to the general population rate, and should be equal. However, if genes play 
a role in predisposition to the disorder, the concordance rate for MZ twins will be greater than 
that for DZ twins. It follows that MZ twins will be concordant for any genetically determined 
characteristic, regardless of the mode of inheritance or the number of genes involved. 
 
Twin studies pertaining to OCD are capable of delimiting the genetic and environmental 
influences on the variation in liability to the disorder, although they have been somewhat 
limited by the paucity of the subjects. Nonetheless, the few twin studies that have been 
conducted suggest the involvement of hereditary components, with MZ concordance rates of 
between 53% and 87% and DZ concordance rates between 22% and 47% (Inouye, 1965; 
Rasmussen and Tsuang, 1986; Pauls et al., 1995; Carey and Gottesman, 1981).  
 
In a larger study of twin samples, a higher rate of concordance for OCD and subclinical OCD 
was found in MZ twins when compared to DZ twins (Inouye, 1965; Skre et al., 1993), and the 
specific nature of the symptoms and response to therapeutic agents has been found to be more 
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similar for MZ than DZ twins (Kim et al., 1990; McGuffin and Mawson, 1980). It has also 
been shown that MZ twins show a higher concordance for OCSD than DZ twins (Clifford et 
al., 1984), with heritability recently calculated at between 26% and 33% (Jonnal et al., 2000). 
Although all the results implicate higher concordance rates for MZ, compared to DZ twins, 
the transmission in MZ twins has been shown to be incomplete; hence the hypothesis that 
environmental factors such as birth complications and other physiologic vulnerabilities may 
have significance in the development of OCD (Petronis, 2001). 
 
The cumulative evidence from family and twin studies suggest that some forms of OCD are 
indeed familial, with the possibility of genetic factors playing a role in the phenotypic 
manifestation of these familial forms. Early age at onset seems to indicate a higher degree of 
familial loading, and may therefore be important when characterising familial subtypes 
(Nestadt et al., 2000[b]). However, in the only study of its kind thus far conducted, Albert et 
al. (2002) observed no differences in clinical features between familial and non-familial OCD 
(including age at onset as criterion). Nonetheless, they did observe a lower threshold for 
precipitating events amongst OCD patients with the familial form of OCD, implying that it 
may be this characteristic that sets the familial and non-familial forms apart.  
 
I.3.2.3. Complex segregation analysis of OCD 
Once sufficient evidence for the familial transmission of OCD has been attained, the next step 
is to determine whether genetic factors are responsible for the observed familiality, and, if so, 
what the mode of genetic transmission is. Complex segregation analysis (CSA) is a method 
designed to evaluate the transmission of a trait within a pedigree, to determine whether the 
segregation of a major gene occurs in the presence of familial resemblance of the disorder. 
The analysis also tests the magnitude of the genetic sources of variation in the trait. 
Parameters that are usually estimated in the CSA include transmission probabilities, allele 
frequencies, penetrances for each genotype (for qualitative traits) and genotype means 
(quantitative traits), variance within genotypes and residual correlations not explained by 
Mendelian inheritance (Jarvik, 1998).  
 
The success of a genetic association study depends critically upon the allelic architecture of 
the disease. Allelic architecture refers to the number of alleles involved in a disorder, and their 
respective penetrances (Pritchard and Cox, 2002). It follows that, in order to detect a 
significantly increased frequency in disease alleles in a group of affected individuals, the 
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allelic spectrum should be simple – in other words, a few predominant alleles should account 
for the phenotype (Reich and Lander, 2001). Assumptions regarding the allelic spectrum 
provide insight into the most efficient strategy to employ when searching for genetic 
contributions to complex disorders.  
 
In order to understand the allelic architecture of a disorder, it is important to comprehend how 
the disease causing alleles are (and have been) affected by factors such as population growth, 
mutation rate, genetic drift, and to appreciate the role of selection against disease alleles 
(Reich and Lander, 2001; Pritchard and Cox, 2002). The common disease/common variant 
(CD/CV) hypothesis maintains that the genetic variation underlying complex disorders arose 
within the founding population of contemporary humans; hence the disease alleles are 
common, usually with frequencies in excess of 1% in the general population (Collins et al., 
1997; Lander, 1996; Risch and Merikangas, 1996). The disease allele remains within the 
population at a relatively moderate frequency due to their selective neutrality (Wright and 
Hastie, 2001). If the CD/CV hypothesis is assumed, it is possible for the disease-causing 
alleles to be sought using indirect methods, such as linkage disequilibrium (LD) mapping. 
 
The alternative hypothesis is known as the common disease/rare allele (CD/RA), or genetic 
heterogeneity, model. This model posits that rare alleles at numerous loci, each with a large 
number of alleles, can comprise the genetic contribution to the disorder. In contrast to the 
CD/CV hypothesis, the CD/RA hypothesis suggests that disease susceptibility alleles arose 
independently, in various geographically distinct, dispersed populations (Smith and Lusis, 
2002), with the result that a disease allele in one population may not be evident in another. If 
one adopts this hypothesis, it is important to note that, although the susceptibility alleles 
comprise a large proportion of the genetic risk for the disease, they will not be conducive to 
indirect genetic association methods. 
 
Clearly, it is in the investigator’s best interest to identify the disorder’s underlying allelic 
architecture; indeed, numerous segregation analyses have been conducted in an attempt to 
elucidate the mode of genetic transmission of OCD (Table I.2). In the first published 
segregation analysis, Nicolini et al. (1991) investigated the mode of transmission in OCD 
probands. Their segregation analysis included all affected individuals with a diagnosis of 
OCD, chronic motor tics (CMT) or TS. The investigators found that the autosomal dominant 
model was most compatible with the observed levels of segregation, although, due to the 
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small numbers of probands included in the study, neither the autosomal dominant nor 
autosomal recessive models could be rejected, indicating that OCD cannot be explained by a 
simple mode of transmission. 
 
Cavallini et al. (1999) confirmed the presence of a major locus, with Mendelian properties 
accounting for most of the liability to OCD. They could not, however, exclude the possibility 
of the existence of potential heterogeneity in their model when the phenotypic boundaries 
were widened to include OCD, TS and CMT. They also noted differential penetrance values 
for OCD phenotypes between males and females, with females exhibiting slightly higher 
penetrance values. 
 
In an attempt to limit the phenotypic heterogeneity of OCD, Alsobrook et al. (1999) 
categorised families in the sample according to four factor analytic symptom dimensions of 
OCD (section I.4.2.2.5). Segregation analysis of 96 families allowed only rejection of the no-
transmission model, providing evidence that OCD is indeed genetically transmitted, although 
no specific mode of transmission could be specified. In the most recent, and only controlled, 
segregation analyses conducted, Nestadt et al. (2000[b]) found that neither Mendelian 
dominant nor codominant models could be rejected, indicating the presence of a major locus. 
However, unexplained familial factors were also observed to be important in the expression of 
OCD: for example, significant heterogeneity on the basis of gender of the proband was 
detected. This prompted separate segregation analyses of families with male and female 
probands. The transmission of OCD in female proband families was compatible with the 
Mendelian major locus (either dominant or codominant) model. In the male proband families, 
although a Mendelian mode of transmission was found to be the most compatible, the details 
of this model were found to be less evident than for the female group. 
 
Collective evidence from the segregation analyses indicates that the familial transmission of 
OCD is indeed due, in part at least, to genetic factors, and that this mode of inheritance is not 
simple. The genetic contribution to the disorder is more than likely complex, representing a 
mixed mode of transmission, involving genes of major effect with appreciable impact, 
operating against a milieu of polygenic inheritance. 
 
Once it has been proven that genetic transmission accounts for at least some of the familiality 
of a disorder, the next logical step is to locate the susceptibility gene(s). This can be achieved 
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using a number of molecular genetic methodologies that are broadly categorised into 
parametric (model-based) and non-parametric (non-model-based) strategies. 
 
Table I.2: Complex segregation analyses in OCD 
 
aNo additional information available 
bThe dominant model was found to be more parsimonious than the co-dominant model 
 
I.3.2.4. Genetic linkage studies  
Genetic linkage analysis provides a powerful approach with which to elucidate the underlying 
genetic factors in inherited disorders. Linkage analysis serves to demonstrate the existence of 
a major locus to clarify the observed pattern of inheritance of a particular trait within a family 
(Alsobrook and Pauls, 1998). The objective is to establish the co-segregation of polymorphic 
genetic markers of known chromosomal location with the disease phenotype within a family 
unit or pedigree (i.e., the non-random sharing of marker alleles between affected members of 
each family).  
 
After initial localisation of a putative genetic marker for a disease susceptibility locus by 
means of linkage analysis, it is possible to type additional polymorphic markers in order to 
generate a high resolution map of the relevant genomic region surrounding the disease-
causing gene (Alsobrook and Pauls, 1998). Thereafter, the location of the causative genetic 
variant(s) may be inferred by means of, for example, fine mapping procedures. 
Reference 
No. proband 
families 
No. control Mode of transmission most compatible 
families (i.e models that were not rejected) 
Nicolini et al. (1991) 24a 0 Autosomal dominant or recessive model 
107 (418 1st degree 
relatives; 1121 2
Autosomal dominant model, with 
possibility of polygenic inheritance 
ndCavallini et al. (1999)  
degree relatives) 
0 
All models except mixed model were 
rejected for whole sample; 100 (466 1st degree 
relatives) 
Alsbrook et al. (1999) 0 
Symmetry and ordering symptom subset: 
major locus model 
Mendelian major locus (dominant or 
codominant) model, with familial residual 
effects for whole sample. 
st70 (303 1  
degree 
relatives) 
st80 (340 1  degree 
relatives) 
Nestadt et al. (2000[b]) 
Females: Mendelian dominant or 
codominant model; 
Males: Mendelian model  
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Unfortunately, linkage analysis has had limited success in detecting genes involved in 
psychiatric disorders due to their complex, multifactorial nature. Nowadays, searching for 
linkage between candidate loci and complex psychiatric disorders involves conducting a 
whole genome screen (Risch and Merikangas, 1996; Collins et al., 1997). This strategy 
involves screening the entire genome using evenly spaced genetic markers, to allow 
identification of regions of potential linkage. The regions are recognised by calculating an 
appropriate linkage statistic at each position along the genome, and identifying those regions 
in which the statistic indicates a significant deviation from what would be expected under the 
rule of independent assortment (Visscher and Haley, 2001). A peak is produced where the test 
statistic exceeds a predetermined significance threshold caused by one or more loci that may 
influence the trait. A second stage of mapping may then be applied to fine-map the linked 
chromosomal region.  
 
In genome-wide linkage studies, either sib-pairs or families can be used. This method has met 
with much success in identifying susceptibility loci for psychiatric disorders, including social 
phobia (Gelernter et al., 2004); simple phobia (Gelernter et al., 2003); schizophrenia 
(Stefansson et al., 2002); irritable bowel syndrome (Hugot et al., 2001; Rioux et al., 2001; 
Stoll et al., 2004); bipolar disorder (Middleton et al., 2004), panic disorder (Knowles et al., 
1998) and panic syndrome (Hamilton et al., 2003). 
 
 To date, one OCD genome-wide linkage study has been published (Hanna et al., 2002). This 
study was conducted using seven probands (who ranged in age from six to 17 years),  whose 
age at onset was between three and 14 years. Fifty-six individuals from the seven families 
were initially genotyped with 349 microsatellite markers spaced at any average of 11.3 
centiMorgan (cM). A region on the telomere of chromosome 9p met with the criterion for 
suggestive linkage (using the dominant model, the logarithm of odds score [LOD score] was 
equal to 2.25). The investigators also observed weak evidence for linkage between OCD and 
regions on chromosomes 2q, 6q, 16q, 17q and 19q.  
Hanna et al. (2002) then followed up their initial findings on chromosomes 2q, 9p and 16q 
(i.e., those regions with dominant LOD scores of greater than 1) by genotyping 24 additional 
markers at an average spacing of 1.6 cM in the original 56 subjects, as well as in 10 additional 
family members from one of the families. They found the region that displayed the strongest 
evidence for linkage (with a LOD score of 1.97) was 9p24. Interestingly, there has been a 
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report of 9p monosomy in a patient with TS (Taylor et al., 1991) and a region on chromosome 
6p has also been found to be associated with TS in an Afrikaner subject sample (Simonic et 
al, 1998), providing further support for the proposed genetic link between the two disorders. 
 
Recently, the evidence for linkage on 9p24 has been replicated (Willour et al, 2004) using 50 
pedigrees (consisting of 193 subjects) from the John Hopkins OCD family study (Nestadt et 
al., 2000[a]). Here, genomic DNA samples from all individuals were genotyped for 13 
microsatellite markers spanning a distance of 19 cM across 9p24, with an average inter-
marker spacing of 15 cM. The narrow phenotype model for OCD, combined with dominant 
parameters and penetrance of 0.5, produced the strongest findings in the study (LOD score = 
2.26), with the strongest nonparametric findings also observed under a narrow phenotype 
model (nonparametric linkage signal [NPL] = 2.52; p = 0.006).  
 
It is notable that the original LOD score for chromosome 9p24 (LOD = 2.25) obtained by 
Hanna et al. (2002) resembled the LOD score in the study by Willour et al. (2004) very 
closely. The NPL peak observed by Willour et al. (2004) was situated at D9S1813, which lies 
only 350kb away from that observed by Hanna et al. (2002) at D9S288, suggesting the 
location of a susceptibility locus in that region. The 9p24 chromosomal region spans 
approximately 75 megabases (Mb) and thus contains numerous potential candidate genes that 
could be investigated for the role they may play in the development of OCD. Veenstra-
vanderWeele et al. (2001) conducted a mutation screen of the gene encoding the neuronal and 
epithelial glutamate transporter (situated approximately 350cM centromeric to the NPL peak 
identified by Willour et al. [2004]). They reported eight exonic synonymous single nucleotide 
polymorphisms (SNPs) that did not appear to alter the functioning of the gene. Using a 
family-based association study, the investigators observed no statistically significant 
association between two of the intronic polymorphisms and OCD.  
 
Nonetheless, the results from both the genome scans are noteworthy, and a collaborative 
effort is underway to collect almost 300 sib-pair and multiplex families, in an attempt to 
improve the power of the previous studies, and replicate the results (Willour et al., 2004). 
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Limitations of using pedigree linkage analyses in complex psychiatric disorders 
In OCD, as for all psychiatric disorders, the underlying mechanisms, degree of penetrance and 
mode of inheritance remain unknown (Crowe, 1993). The environmental contribution to the 
aetiology of the disorder, diagnostic misclassification, and the epistatic and additive 
interactions between genes conferring susceptibility to mental illness may also limit the 
success of identifying susceptibility genes utilising linkage strategy (Crowe, 1993; Nothen et 
al., 1993; Souery et al., 2001; Stoltenberg and Burmeister, 2000; Ghosh and Schork, 1996). 
 
Moreover, identifying families with multiple affected individuals poses a problem – there still 
seems to be an amount of stigma attached to being diagnosed with OCD; consequently a large 
proportion of affected individuals prefer to keep their affliction hidden from family members. 
The nature of the susceptibility allele further weakens the power of linkage analysis for 
complex disorders, since the susceptibility allele is neither necessary nor sufficient to produce 
the clinical phenotype (Greenberg, 1993; Hodge, 1993), but may simply increase the chances 
that the allele-carrier will develop the disorder. Therefore, a proportion of the patients will not 
possess the associated allele, in which case the “susceptibility” allele may not necessarily co-
segregate with the disorder (Nothen et al., 1993; Propping et al., 1993). 
 
Overall, it has been found that association designs have a greater power to detect disease 
alleles in disorders with mild risk factors (with a genotypic risk ratio [GRR] < 4) than in 
comparably sized linkage analyses (parametric and non-parametric). This is because for 
diseases with a GRR <2, unrealistic family sample sizes (in excess of 2500) are required to 
achieve the same power as for association studies (Risch and Merikangas, 1996; Risch and 
Botstein, 1996).  
 
I.3.2.5. Genetic association analyses  
Association studies offer an alternative strategy to study genetic factors involved in complex 
psychiatric disorders. Historically, genetic association analyses have been conducted in a 
population-based setting (Silverman and Palmer, 2000), where the aim of the association 
study has been to demonstrate a significantly different distribution of allelic variants in 
affected (case) and unaffected (control) individuals. The basic unit of analysis in association 
studies is the individual, who can be included regardless of the status of their other family 
members.  
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Association studies can be conducted using one of two strategies, both reliant on the CD/CV 
hypothesis (section I.3.2.3). Candidate gene association analyses investigate variants within a 
particular genomic region, based on physiological, biochemical or pharmacological evidence. 
These investigations take advantage of the increased power of association studies to detect 
genes of moderate effect, whilst capturing an account of the current biological understanding 
of the tissues, proteins and genes likely to play a role in the pathogenesis of OCD. An 
alternative to candidate-gene based analyses, known as genome-wide association analyses, 
involves screening the entire genome for causal genetic variants. No prior assumptions are 
made regarding the location of the susceptibility variants, implying that the procedure 
represents an unbiased, systematic approach to identifying the causal variants (Hirschhorn and 
Daly, 2005). Genetic association studies pertaining directly to OCD will be discussed in 
section I.6. 
 
In both of these association methods, the usefulness of the selected marker depends on its 
ability to identify the susceptibility allele. This is achieved by exploiting the preferential 
association between the marker and susceptibility loci, due to a characteristic known as 
linkage disequilibrium.  
 
I.3.2.5.1. Linkage Disequilibrium (LD) 
LD refers to the non-random statistical association of sequence variants along an individual 
chromosome that results in an increased tendency for the alleles of closely linked loci to co-
segregate with an increased frequency across a population. This represents a powerful tool for 
investigating population history, human evolution and the genetic aetiology of complex 
disorders (Jorde et al., 1995; Kidd et al., 1998).  
 
In LD mapping, a group of affected individuals, descended from a single founder, form part 
of a large multigenerational pedigree of which all initial generations, except the current few, 
are missing. Numerous meiotic and recombination events have therefore occurred, narrowing 
the region of DNA that possesses the susceptibility allele. The ability to identify genetic 
components of complex phenotypic variation depends to a large extent on our knowledge of 
how different parts of the genome are correlated. Focussing on LD and haplotype analyses 
(discussed further on) will afford a unique insight into these processes. 
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i. Measures of LD 
The majority of LD measurements represent the pairwise association between markers 
(Pritchard and Przeworski, 2001), with the most widely used being the absolute values of the 
normalised disequilibrium coefficient (|D’|) (Hedrick, 1987; Lewontin, 1964) and the absolute 
value of the correlation coefficient, r2 (Hill and Robertson, 1968). Both of these 
measurements are derived from the LD pairwise coefficient, D, but have slightly different 
interpretations (Wall and Pritchard, 2003).  
 
The value of |D’| = 1 indicates the lack of recombination between the two loci under 
investigation (complete LD), whereas |D’|<1 represents a disruption in LD sometime in the 
past. However, since D’ is not dependent on allele frequencies, |D’| = 1 if three out of the four 
possible haplotypes are present (i.e. the alleles in LD with one another do not have to possess 
the same allele frequencies) (Weiss and Clark, 2002). Although |D’| does not depend on allele 
frequencies per se, it does depend on the size of the sample under study - values of |D’| have 
been found to be inflated in small samples, even when the loci are in linkage equilibrium 
(Gabriel et al., 2002). Moreover, the intermediate values of |D’| are difficult to interpret, and 
have been found to vary in simulations for pairs of sites at a given distance (Wall and 
Pritchard, 2003). 
 
The value of the correlation coefficient, r2 represents the statistical correlation between two 
sites. The value of r2 = 1 if, and only if, no historical recombination has occurred, and the 
markers have the same allele frequencies (i.e. only two out the four possible haplotypes are 
observed in the sample). The value of r2 is useful in that it is indicative of the power of the LD 
study – the inverse of r2 represents the factor by which the sample size should be increased to 
detect statistically significant association between the marker locus and disease, providing a 
rough guide as to the usefulness of a given level of LD (Ardlie et al., 2002; Weiss and Clark, 
2002). Higher values of r2 are indicative of a greater ability of one SNP to predict the 
behaviour of the SNP in LD with it. 
 
Another useful advantage to using the r2 value is that it is related to the average recombination 
fraction in the population which summarises LD over a particular genomic region, not just 
between pairs of markers (Pritchard and Przeworski, 2001). A further advantage of using r2 to 
measure LD is that it is comparable across studies. However, due to its sensitivity to allele 
frequency, it may mean that two markers that are adjacent to one another may yield different 
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r2 values with a third marker (Ardlie et al., 2002). It is therefore at the discretion of the 
investigator to decide on the most appropriate measurement of LD to use in the study 
conducted. In the present study, both D’ and r2 values are represented, in order to allow the 
reader a comprehensive view of pairwise LD between markers investigated. 
 
ii. LD in genetic association studies 
LD patterns are useful in association studies because they impart knowledge regarding the 
genetic distance over which signals of causation may be generated in case-control studies. 
Furthermore, they facilitate the identification of the susceptibility allele by identifying the 
neighbourhood surrounding the variant (Risch and Merikangas, 1996). However, it should be 
noted that there are various factors that disturb the relationship between LD and distance, both 
evolutionary (e.g. population dynamics and natural selection [Nordborg et al., 2002; Reich 
and Lander, 2001; Kruglyak, 1999[a]; Pritchard and Przeworski, 2001]) and genetic 
(recombination, inversion [Pritchard and Przeworski, 2001] and conversion polymorphisms 
[Langley et al., 2000; Ardlie et al., 2002; Frisse et al., 2001], genetic drift and mutation rate 
[Terwilliger et al., 1998; Ardlie et al., 2002]) . Indeed, markers that are closely linked have 
been found to exhibit low levels of LD, or none at all (Clark, 1998; Moffat et al., 2000; Ardlie 
et al., 2002; Kidd et al., 2000; Rieder et al., 1999; Templeton et al., 2000), whilst relatively 
high levels of LD have been observed between markers that are comparatively far apart from 
one another (Collins et al., 1999; Abecasis et al., 2001; Reich et al., 2001; Stephens et al., 
2001; Gordon et al., 2000).  
 
iii. The importance of demographic history in LD association studies 
It is clear that patterns of LD in the human genome are strongly shaped by evolutionary 
history; in turn, each disease has its own genetic architecture, shaped by aspects of population 
dynamics and history. The demographics of any population is complex, with each population 
experiencing differential degrees of isolation, migration, admixture, expansion and 
bottlenecks (Ardlie et al., 2002), aspects of which will inevitably remain unknown. This 
underscores the critical importance of characterising the LD landscape in the region of interest 
in the population under investigation.  
 
Significantly higher levels of LD have been noted in “younger”, more recently founded 
populations (Jorde et al., 2000; Peltonen et al., 2000; Puffenberger et al., 1994; Hall et al., 
2002), implying a large degree of LD over longer stretches of the genome. For example, LD 
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has been found to extend over much longer regions in younger, non-African populations, 
probably reflecting the loss of genetic variation caused by the bottleneck that occurred when 
modern humans migrated out of Africa (Weiss and Clark, 2002; Frisse et al., 2001; Reich et 
al., 2001; Tishkoff et al., 1996; Wall, 2001). Such populations may be useful in the coarse-
mapping of disease susceptibility alleles (i.e. identifying the region in which the allele may be 
situated), but will not be amenable to fine-mapping procedures. Older populations, on the 
other hand, exhibit less LD and larger amounts of recombination over shorter genomic 
regions, thus facilitating fine-mapping procedures (Jorde et al., 2000; Wilson and Goldstein, 
2000).  
 
I.3.2.5.2. Haplotype association analysis 
Single marker investigations may provide little information regarding the association, and, 
although they may be situated in the candidate gene, it is possible that the markers may not be 
in LD with the susceptibility allele. A haplotype refers to a specific combination of alleles that 
co-occur on an individual chromosome, and therefore share a common evolutionary history. 
Single nucleotide polymorphisms (SNPs), genotyped sequentially over the length of a 
chromosome, can be ordered into haplotypes. Such haplotype scanning may provide more 
information regarding variation within specific genomic fragments and interrelationships 
between polymorphisms in the surrounding regions, thereby imparting a greater amount of 
power to the study (Akey et al., 2001). This is because the historical crossover points can be 
analysed with greater accuracy from preserved and non-preserved portions of the mutation-
bearing chromosome, which will, in turn facilitate localisation of the disease allele.  
 
It is also possible that alleles at several SNPs jointly influence susceptibility to a disease by 
influencing regulation and/or functioning of the susceptibility variants, or that the alleles may 
act in combination with one another (much like a “super-allele”) to precipitate the phenotype, 
or certain aspects of the phenotype. Indeed, haplotype association studies have allowed the 
successful localisation of susceptibility genes in Hirschsprung disease (Puffenberger et al., 
2004) and Crohn’s disease (Hugot et al., 2001; Rioux et al., 2001), and in locating candidate 
susceptibility regions in schizophrenia (Shifman et al., 2002) and cerebral malaria (Burgner et 
al., 2003). In addition, the merits of haplotype analyses in association studies have been 
illustrated using known associations between the apolipoprotein E locus and Alzheimer’s 
disease (Fallin et al., 2001), and adenine phosphoribosyltransferase gene and adenine 
phosphoribosyltransferase deficiency (Kuno et al., 2004). 
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i. Haplotype inference 
The investigation and subsequent analysis of haplotype data rests on the assumption that the 
haplotypic phase information pertaining to the individuals in the study is available. 
Ambiguous haplotypes can be resolved using data from relatives or genealogical information, 
allowing one to infer ancestral haplotype compositions. However, these methods are often 
costly (due to extra genotyping efforts) and impractical in population-based case-control 
association studies, where there is usually limited access to any kind of family genetic data. 
An alternative would be to employ laboratory-based molecular haplotyping methodology, 
such as chromosomal localisation, single-molecule dilution or allele-specific polymerase 
techniques (Ruano and Kidd, 1989; Clark et al., 1998; Ruano et al., 1990; Michalatos-Beloin 
et al., 1996), which are also expensive and technologically demanding (Niu et al., 2002). 
 
The solution therefore seems to be to predict the haplotype phase of unrelated, diploid 
individuals probabilistically, based on estimated allele frequencies from the population. 
Several assumption- and likelihood-based methods have been created, these can be roughly 
divided into three major categories, based on the algorithm employed: Clark’s algorithm 
(Clark, 1990); the expectation-maximisation (EM) algorithm (Dempster et al., 1977; Hawley 
and Kidd, 1995; Long et al., 1995; Excoffier and Slatkin, 1995) and the coalescent-based 
algorithm (implemented in the program “Phase” [Stephens et al., 2001]). Recently several 
other methods, mostly based on the three aforementioned ones, have been created and 
successfully used to infer haplotype phase in genetic association studies (Zollner and 
Pritchard, 2005; Niu et al., 2002; Qin et al., 2002; Gusfield, 2001). 
 
Clark’s algorithm assigns haplotypes to phase-unambiguous (i.e. homozygotes or single-site 
heterozygotes) individuals first. For each unresolved, ambiguous haplotype, the aim is to 
determine whether the known haplotype can be formed from some combination of the 
ambiguous sites (hence the “subtraction method” as the alternative name for this method). 
Each time a haplotype is inferred in this way, it is viewed as another potential unambiguous 
haplotype from which the ambiguous haplotypes can be inferred. This chain of inference 
continues until all haplotypes have been recovered, or until one identifies a sequence that 
cannot be derived from any of the known haplotypes (Clark, 1990; Clark et al., 1998). 
 
The EM algorithm obtains maximum likelihood estimates of haplotype frequencies within the 
sample, and uses the initial set of frequencies to calculate conditional distributions for 
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haplotype pairs that an individual carries (the expectation step). In the maximisation step, the 
haplotype frequencies are updated based on haplotypes inferred in the previous step. The EM 
algorithm iterates between the two steps until the frequency estimates converge. This method 
may, however, not be viable when analysing a large number of markers, due to the 
computational burden involved (Fallin and Schork, 2000). 
 
The Phase algorithm uses a combination of the coalescent-based ancestry model and 
Bayesian-based algorithms to assign phases to the linked loci and estimate haplotype 
frequencies accordingly (Stephens et al., 2001). The method regards unknown haplotypes as 
random quantities and aims to evaluate their distribution, given the genotype data. The 
program also confronts certain population genetics features of haplotype inference by 
incorporating prior knowledge that the unresolved haplotypes will be more similar to 
commonly observed, resolved haplotypes. Phase can be applied to both SNP and multiallelic 
data. 
 
In studies comparing the EM and Phase methods, Zhang et al. (2001) observed no major 
differences in accuracy between the two methods. Xu et al. (2002) incorporated levels of LD 
between markers into their study and found that, when LD between the markers was 
maintained, all three methods performed equally well. However, if LD between the markers 
was not maintained, Clark’s algorithm did not perform as well as Phase or the EM algorithms. 
In a more recent study, Adkins (2004) compared the efficacies of leading computational 
methods in haplotype inference (including Phase and EM algorithms) and found that all 
performed with high accuracy, even when identifying rare haplotypes. They also observed 
that haplotype assignment remained accurate among subjects for up to five sites. It is thus 
clear that there is no agreement as to which algorithm may be best in estimating haplotype 
frequencies in population-based association studies; perhaps it would be more conducive to 
the investigators to focus on parameters that decrease the estimation error in computational 
inference of haplotypes. 
 
According to Fallin and Schork (2000), error in haplotype estimation can be reduced by 
following a few pointers. Firstly, they advocate using the appropriate set of markers, taking 
note of LD between them. Some algorithms may not be able to handle the large number of 
haplotypes if the markers in the study are in linkage equilibrium (Zhao et al., 2003). They also 
suggest increasing the sample size and decreasing the haplotype ambiguity (i.e. fewer 
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individuals with haplotypes that cannot be resolved) where possible. Finally, increasing the 
dispersion of haplotype frequency values in a sample can also result in fewer haplotype 
estimation errors: as haplotype values become less uniform, the difference between the most 
and least common haplotypes becomes more extreme. The null-frequency haplotypes can thus 
be accurately predicted as zero, since there will be little evidence from the data for their non-
zero frequencies, resulting in more accurate estimation of the commoner haplotypes. 
 
ii. Haplotype blocks and recombination hotspots 
Recently, studies investigating several genomic regions have indicated the presence of long 
chromosomal tracts in which the markers exhibit strong LD and limited haplotype diversity 
(known as haplotype blocks), separated by areas in which the recombination rate is relatively 
high (recombination hotspots) (Daly et al., 2001; Johnson et al., 2001; Patil et al., 2001; 
Gabriel et al., 2002). Due to the limited haplotype diversity within the haplotype blocks, a 
small number of haplotypes represent the varation in most of the chromosomes within the 
population. Furthermore, high levels of LD within the blocks signify that some of the markers 
contain redundant information, allowing the variation within the haplotype blocks to be 
distinguished by one, or a few, SNPs. Therefore, theoretically, a disease susceptibility gene 
could be mapped to one of the haplotype blocks using a so-called tag SNP, which would 
improve the chances of detecting association when only a fraction of the markers are 
genotyped, saving significantly on time and money (Gabriel et al., 2002; Patil et al., 2001; 
Johnson et al., 2001).  
 
Efforts are presently underway by the United States National Human Genome Research 
Institute, in the form of an international intiative, the HapMap project, which aims to delineate 
the structure and boundaries of common haplotype and LD blocks in the genome, using 
populations from Africa, Asia and Europe (The International HapMap Consortium, 2003). 
However, although the idea of haplotype blocks and recombination hotspots affords an insight 
into the distribution of LD within the human genome, even they seem to have an erratic 
distribution (Stephens et al., 2001; Pritchard and Przeworski, 2001), underscoring the 
importance of investigating the LD landscape for each region of interest, rather than applying 
a general LD value for that particular region. 
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I.4. DETERMINING THE VALIDITY OF AN ASSOCIATION: STATISTICAL 
INFERENCE 
 
“Our belief in a hypothesis can have no stronger basis than our repeated unsuccessful 
attempts to refute it.” 
Karl Popper 
 
Numerous association studies (both family- and population-based) have been conducted in 
order to delineate the genetic contribution to OCD over the past decade. Unfortunately, these 
have been met with very little concrete evidence as to the involvement of any one particular 
gene or genetic variant, since they have yielded mostly inconsistent results, as will be evident 
further on in the dissertation. The discrepancies have resulted in a large amount of scepticism 
regarding the usefulness of candidate-gene based association studies. Doubts have also arisen 
as to the generalisability of these results across certain populations and ethnic groups – it 
seems that there is no guarantee that loci that appear to be associated with OCD in one 
population will have an effect in another. Numerous aspects of the causes and consequences 
of the aforementioned inconsistencies will be dealt with in this section and the next. 
 
A statistically significant association, although initially exciting, cannot (and, indeed, should 
not) be viewed as a necessary causal association. The first step in assessing the validity of the 
result of a case-control association study involves statistical inference. The test of association 
evaluates the evidence for two competing hypotheses: the null hypothesis (H0) states that the 
alleles (or genotypes) under investigation occur at equal frequencies in the case and control 
populations, whilst the alternative hypothesis (H1) states that a significant difference exists in 
the allele and/or genotype frequencies between cases and controls. For categorical variables, it 
is assumed that the test of association follows the known probability distribution of a chi-
square (χ2) variable under the null hypothesis (Lalouel and Rohrwasser, 2001). 
 
Favouring one hypothesis over the other always entails the risk of error. In statistical terms, 
these are known as the Type I and Type II errors (Neyman and Pearson, 1933). The Type I 
error (α) refers to the probability of rejecting the null hypothesis when it is in fact true (i.e. a 
false-positive result), whilst the Type II error (β) refers to the probability of accepting the null 
hypothesis when it should have been rejected (i.e. a false negative result). These probabilities 
are usually predetermined and set at 5% and 20%, respectively (Neyman and Pearson, 1933). 
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The p-value (p) of a statistical hypothesis refers to the possibility of obtaining a value of the 
test statistic (in this case a χ2 value) as extreme as, or more extreme that, that observed by 
chance alone, if H0 is true (Dawson and Trapp, 2004). It is equal to the significance level (α) 
of the test for which one would only just reject the null hypothesis, but, unlike α, is calculated 
after the statistical test has been performed. The p-value is compared with α, and if it is 
smaller, the result obtained is significant. Small p-values indicate that the null hypothesis is 
unlikely to be true - the smaller the p-value, the more convincing the rejection of the null 
hypothesis becomes. 
 
The p-value of significance presents one with a dichotomous, qualitative index of the strength 
of evidence against the null hypothesis, and to most researchers, the resultant values simply 
indicate whether the results are either significant or not; they do not give one any indication of 
the magnitude of the effect, and cannot incorporate additional evidence (Lilford and 
Braunholtz, 1996; Rothman, 1986). Consequently, the strength of evidence in one study 
cannot be related to, or combined with, the strength of evidence from another study. Hence, p-
values are often misleading (and misunderstood) – investigators may become excited about a 
“highly significant” result (i.e. a low p-value) without taking supplemental evidence or factors 
into account. A common misconception is that, if p< 0.05 (i.e. the null hypothesis is rejected), 
the positive predictive value (Vecchio, 1966) of the test is 95%, where in actual fact it may be 
quite low, due to insufficient power (Sterne and Davey-Smith, 2001).  
 
It thus is important to remember that the validity of the p-value is ultimately determined by 
the quality of the input data and subsequent analyses, and should be interpreted in conjunction 
with supplemental evidence (e.g. from OR [the effect size (ES) of the study and confidence 
intervals (CIs)] in order to make the appropriate scientific judgement and to inform research 
decisions. The ES of a variant is the name given to a family of indices that measure the 
magnitude of the experimental effect (in other words, it represents the difference between the 
null and alternate hypotheses.  
 
In candidate gene LD-based analyses, where a marker allele is normally used as a proxy for 
the disease susceptibility allele, the term “apparent ES” refers to the ES of the marker locus 
(Zondervan and Cardon, 2004). Therefore, ES in population-based association analyses 
depends on the agreement between the marker and disease allele frequencies (hereafter 
referred to as MAF and DAF, respectively), and the extent of LD between the marker and 
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disease alleles. When LD is not complete, and the MAF is equal to the DAF, the apparent ES 
will be approximately proportional to the true ES, multiplied by the value of D’. When LD is 
complete, and the MAF is greater than the DAF, the apparent ES will differ from the true ES 
by a scale factor of the allele frequency ratios. However, when MAF is less than DAF, even in 
complete LD, apparent ES will decay rapidly with increasing discrepancy between MAF and 
DAF, since not even complete LD will be able to compensate for the fact that the disease 
allele may occur on haplotypes other than the marker haplotype. 
 
In case-control association studies, investigators normally adopt a method of inductive 
inference to determine whether sufficient support exists for a causal association between the 
candidate gene and the phenotypic trait. This involves investigating the likelihood that other 
factors (namely, confounding, chance and bias) could have resulted in the statistically 
significant observations. Once these factors have been eliminated as agents delivering the 
positive association, one can move onto the process of causal inference for association 
(Campbell and Rudan, 2002). 
 
I.4.1. CONFOUNDING 
In epidemiology, confounding is defined as a “situation in which a measure of the effect of an 
exposure on risk is distorted because of the association of allele exposure with other factors 
that influence the outcome of the study” (Last, 2000). When referring to confounding in 
genetic association studies, the “exposure” would refer to the allele or genotype under 
investigation; hence the definition of confounding for our purposes would be: a situation in 
which the measure of the effect of a genetic variant on OCD is distorted because of the 
association of the genetic variant with other factors that influence the outcome of the study. 
Confounding is thus a problem of comparison, where there is an imbalance in extraneous risk 
factors, measured or unmeasured, between case and control individuals. For a genetic variable 
to be a confounder, it requires two associations: first, the confounder must be associated with 
the disease, and second, it must be associated with the genetic variable in the underlying 
population from which the sample is drawn. A variable will not be considered to be a 
confounding factor if it merely represents an intermediate risk in the causal chain between the 
genetic variant and OCD (Schoenbach and Rosamond, 2000). 
 
Restricting the analysis to a group of participants with only certain characteristics or 
stratifying the disorder within categories of potential confounders whilst holding all other 
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factors constant, will eliminate the influence that potential confounders may have on the 
outcome. One of the most serious potential confounders in population-based case-control 
association analyses is population stratification (Risch, 2000). Population stratification or 
substructure results from non-random mating between subgroups within a population, and 
may confound the results of an association study, depending on the extent of the genetic 
differences between the groups. This confounder will be discussed in more detail in the 
following section. 
 
I.4.1.1. Population stratification 
“Human populations differ from one another almost entirely in the varying 
proportions of the allelic genes of the various sets of hereditary factors, and not 
in the kinds of genes they contain. The extreme positions held by those who on 
the one hand maintain that there are no significant genetic differences between 
human races, and those who on the other hand hold that certain races are 
‘superior’ and others ‘inferior’, require drastic modification in the light of the 
accumulated data on the gene frequency dynamics of human populations.” 
Laurence Snyder, 1951  
 
The definition of race is usually subjective and based on proxies such as skin colour, 
language, physical properties and geographical location (Bamshad et al., 2003; Pritchard et 
al., 2000), with little insight into the genetic differences or similarities between populations 
(Foster and Sharp, 2002; Witzig, 1996; Goodman, 2000). Indeed, genetically similar groups 
may be labelled differently due to cultural differences or geographical location. Likewise, 
genetically dissimilar groups may be classified as a single population.  
 
Comparative studies of within-group versus between-group genetic diversity indicates that 
approximately 90% of genetic variation occurs within human populations. Consequently, only 
10% of genetic variation attributed to between-group differences (Lewontin, 1972; Cavalli-
Sforza and Piazza, 1975; Jorde et al., 2001; Barbujani et al., 1997), which influences average 
differences in physical characteristics, disease susceptibility and treatment outcome amongst 
populations. In all the major population groups, there seems to be some degree of cryptic 
population substructure, which generally follows ethnic lines (Ziv and Burchard, 2003).  
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In population stratification, the observed association between a genetic susceptibility variant 
(G) and disease (D) is biased, due to the fact that G is associated with some true risk factor 
that varies with ethnicity. Therefore, if the population under investigation comprises cryptic 
subpopulations in which allele frequencies for the candidate gene and baseline risks of disease 
differ, it may result in spurious association between a genetic variant and the disease under 
investigation. This is because any allele that has a higher frequency in the subpopulation 
possessing a greater disease risk will appear to be associated with the disease. Likewise, it is 
also possible that population stratification may result in a Type II error – if a disease is more 
prevalent amongst a subgroup possessing a lower frequency of the disease-causing allele, the 
association with the disease will be masked (Deng, 2001).  
 
Population stratification normally arises when the genetic background of the source 
populations differ between cases and controls (Cardon and Palmer, 2003), although it can also 
occur as a result of “cryptic relatedness” within a population considered to represent a sample 
of independent cases and controls. The hypothesis is that, if the disorder (in this case OCD), 
has a genetic aetiology, the affected individuals in the study are likely to be more genetically 
similar than case-control pairs, because they share a common genetic disorder that has, in 
essence, a common genetic basis. Thus, under the initial assumption of an independent sample 
and no genetic association with the disease, the false-positive rate may be increased due to 
cryptic relatedness within the case subjects (Bacanu et al., 2000; Devlin and Roeder, 1999). 
 
In most epidemiological and disease risk studies, self-reported ancestry can serve as a suitable 
proxy for genetic clustering, with the obvious exception of recently admixed populations 
(Thomas and Witte, 2002). However, in case-control genetic association studies that require 
the identification of loci with very small effects, even the slightest difference in genetic 
ancestry between cases and controls may result in false positive results. Therefore, in such 
studies, if one is uncertain about the presence of cryptic subpopulations or the degree of 
admixture in the population from which the sample is drawn, methods that are capable of 
detecting, and correcting for, such stratification should be employed. The goal when 
correcting for population stratification is to determine whether cases and controls differ in 
ancestry to such an extent that an excess number of markers will, by chance, be associated 
with disease status. One can account and correct for stratification by using better measures of 
populations, making use of family members as controls and by means of genomic adjustment 
(Thomas and Witte, 2002). 
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I.4.1.1.1. Better measures of populations 
As has already been mentioned, broad conventional population categories usually result in 
confounding due to population stratification. It has therefore been proposed that more 
specific, detailed information regarding a subject’s ethnic origin be obtained when conducting 
association studies, so that individuals can be allocated to the finest ethnic origins that can be 
determined. For example, in mixed ethnic families, it may be more valuable to obtain 
information regarding the origins of an individual’s parents and grandparents. This allows one 
to construct a covariate for each stratum in the analysis (rather than allocating the individual 
to a single stratum), noting the proportion of ancestors derived from each stratum, 
subsequently adjusting for these covariates using a multiple logistic regression model 
(Thomas and Witte, 2002). 
 
I.4.1.1.2. Using family members as controls 
Two major family-based association tests presently make use of parents and siblings as 
family-based controls: the transmission disequilibrium test (TDT) and the haplotype relative 
risk (HRR). Briefly, the TDT compares the frequency of a marker allele at a given locus in a 
sample of probands with the frequency of the parental non-transmitted alleles (“controls”). If 
transmission of the marker allele from heterozygous parents to affected individuals exceeds 
that expected by chance alone, it is assumed to be associated with the disorder in some way 
(Spielman et al., 1993).  
 
The haplotype relative risk test looks at an affected individual and both his/her parents (Falk 
and Rubenstein, 1987). All three individuals are typed for a genetic marker that is 
hypothesised to be associated with susceptibility to the disorder. The genotypic frequencies in 
affected children are calculated and compared to the genotypic frequencies formed by 
merging the parental alleles that are not transmitted to the affected child. In effect, this creates 
a “pseudo-control” genotype from the alleles that are not transmitted to the affected offspring 
(Terwilliger and Ott, 1992). The marker allele frequencies are then compared between the 
case and pseudo-control group, and the resulting odds ratio is known as the HRR (Falk and 
Rubenstein, 1987; Schaid, 1998; Schulze and McMahon, 2002). 
 
However, utilising family members in genetic studies may not always be the most feasible 
option, since the studies have been found to possess limitations. Not every case has a sibling, 
and Teng and Risch (1999) found that using unaffected siblings as controls resulted in a 
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substantial decrease in power when compared to studies using unrelated controls. When using 
parents as controls, at least one parent has to be readily available, and the possibility exists 
that some of the parent-case trios will be discarded because they are uninformative. Moreover, 
TDT-related methods yield approximately two-thirds of the genotyping efficiency of the case-
control design, because for every case-control pair, genotype information is required from two 
parents and the proband. Finally, it is especially difficult to obtain large collections of family 
members for psychiatric disorders, since there seems to be a certain amount of stigma 
attached to being diagnosed with a psychiatric disorder. 
 
Therefore, population-based case-control association analyses offer numerous advantages 
over the family-based association methods, including easier and cheaper recruitment of 
subjects; greater power to detect associations where the GRR is low; the inclusion of a more 
representative sample of subjects than in family-based designs, and the ability to explore 
environmental co-actions. 
 
I.4.1.1.3. Genomic Adjustment 
If population substructure affects candidate gene allele frequencies, then, theoretically, there 
should also be systematic differences in the allele frequencies at other genes (Devlin and 
Roeder, 1999; Pritchard and Rosenberg, 1999). It is these differences that are exploited when 
using genomic adjustment to detect and control for population stratification. These methods 
can be divided into two broad categories: first, model-based or structured association (SA) 
methods, which assume that the heterogeneous sample population is composed of genetically 
homogeneous subpopulations. Programs implementing this design are Structure (Pritchard et 
al., 2000) and latent class analysis (LCA)  programs (such as L-POP) (Sham and Purcell, 
2002). Second, non model-based, or genomic control methods, which correct for population 
stratification by accounting for overdispersion of statistics generated by population 
substructure can also be implemented. Genomic Control (GC) (Devlin and Roeder, 1999) is 
an example of a program implementing non model-based methodology. Both categories 
utilise a panel of polymorphic markers that may or may not be linked to the candidate locus.  
 
i. Model-based methods 
Model-based methods attempt to detect the underlying population substructure and adjust the 
association accordingly. They are conducive to association studies since they allow the 
identification of situations resulting in false positive and negative findings, and the choice of 
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markers should not bias the subsequent correction in any way. Structure (Pritchard et al., 
2000) is a Bayesian model-based algorithm that assigns individuals probabilistically to one or 
more subpopulations based on allelic frequencies at each locus studied. It involves genotyping 
random markers (in linkage equilibrium with each other) in order to reflect the baseline 
genetic differences between cases and controls. The procedure places individuals into ‘K’ 
number of clusters. ‘K’ is chosen in advance, but can be varied across independent runs of the 
Structure algorithm. It is possible for individuals to have membership in multiple clusters; in 
this case, the program will indicate an estimate of the fraction of the individual’s genome that 
originated from each of the ‘K’ subpopulations, providing a means for capturing the degree of 
admixture. 
 
The major drawback of this method is that, although it allows the detection of population 
structure, the algorithm itself offers no means of adjusting the significance value if the 
stratification is found to influence the validity of the association. However, a program called 
“strat” has been designed (Pritchard, 2000) in order to correct for confounding due to 
stratification. Structure is a presently widely-used program, and has been successfully 
implemented in numerous studies attempting to delineate human population structure 
(Rosenberg et al., 2002; Bamshad et al., 2003), the genetic structure of certain dog breeds 
(Parker et al., 2004) and it has even been used to distinguish between selected breeds of 
chickens (Rosenberg et al., 2001). 
 
A slightly modified approach to the methods implemented in Structure is represented by the 
latent class analysis (LCA) of population substructure (Satten et al., 2001; Purcell and Sham, 
2004). This implementation involves the simultaneous estimation of population membership 
and the effect of the disease-susceptibility variant in case subjects in the respective 
subpopulations, thus bypassing the 2-stage procedure required by Structure.  
 
ii. Non-model-based methods 
Genomic Control (GC) methods utilise unlinked markers that are usually independent of 
disease to calculate a correction factor to control for the inflated χ2 value that is a consequence 
of population stratification (Devlin et al., 2001; Devlin and Roeder, 1999; Bacanu et al., 
2000). In other words, the method involves re-calibrating the χ2 value for association 
according to how many of the control markers (the null loci) are found to be associated with 
the disease. It is therefore important to choose the control markers so that they are randomly 
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distributed and thus provide a true reflection of the overall differences between case and 
controls; any marker that assumes a higher degree of differentiation between cases and 
controls will result in an overly conservative adjustment of the χ2 values.  
 
A drawback of this method is that the number of markers required can be prohibitive – for a 
reliable and valid correction for the presence of population substructure, 50 or more control 
markers may be required (Devlin et al., 2001). Moreover, the method is limited only to SNPs 
(Bacanu et al., 2000; Devlin and Roeder, 1999). It has also been found that GC methods do 
not control against a Type I error if the difference in candidate allele frequencies between 
populations is small (Redden and Allison, 2003). 
 
Accuracy to detect population substructure using genomic adjustment 
The resolution at which population substructure can be detected depends largely on a 
combination of the characteristics of the genetic data utilised in the study, including expected 
heterozygosity  or number of alleles at a locus (Shriver et al., 1997; Bamshad et al., 2003) and 
maximal difference in allele frequencies between the populations under investigation 
(Rosenberg et al., 2001). The more informative a marker, the greater the power with which to 
accept or reject the null hypothesis of no genome-wide differences in allele frequencies 
between the case and control populations will be. For biallelic markers, informativity will be 
maximised if one allele is absent in one of the subgroups or populations under investigation, 
and is only limited to one of the populations (Bamshad et al., 2003).  
 
The accuracy with which subpopulations are characterised will also depend on the level of 
genetic variance within and between the subpopulations. A positive Fst value (a measure that 
determines overall genetic differentiation between subpopulations) indicates that individuals 
from the same subpopulation are more genetically similar than those from different 
subpopulations. One also has to take note of the variance within subpopulations – if variances 
within subpopulations are high, it becomes more difficult to assign individuals to a particular 
population (Bamshad et al., 2003). Interestingly, Bamshad et al. (2003) found that Alu 
insertion/deletion markers possessed higher Fst values than microsatellite markers, and that 
these values were similar to those obtained for diallelic markers, and could be attributed to the 
high mutation rate of these polymorphisms. These polymorphisms have been successfully 
utilised to infer population structure, and have been found to possess comparable power to 
detect structure and assign origin – Bamshad et al. (2003) found that a minimum of 60 Alu 
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markers were required to assign individuals to the correct continent of origin with a mean  
accuracy of 90%. 
 
The number of markers required depends on a combination of the number of alleles, 
heterozygosity and Fst values. Obviously, a population that exhibits a fine substructure 
requires a larger number of markers (and larger sample size) to resolve this substructure, 
although, in such a case, the degree to which the genetic association is confounded would be 
lower (Pritchard and Rosenberg, 1999). 
 
I.4.1.1.4. The value of isolated populations in genetic association studies, and a brief 
overview of the genetic history of the South African Afrikaner 
The statistical power to detect a true association depends, to a large extent, on the amount of 
background noise within the population from which the subjects are sampled. This “noise” 
comprises a number of genetic and environmental aspects, which may vary amongst 
populations. Association studies in heterogeneous populations present with varying degrees of 
background noise; consequently, large samples are required to attain sufficient statistical 
power. In homogeneous populations, however, environmental and genetic variation is limited, 
improving the signal-to-noise-ratio, and the statistical power of the study. 
 
By definition, all isolated populations originate from a few founders. Most of these 
populations experience bottlenecks, after which periods of rapid population growth (due to 
increased reproduction, not immigration) occur. During the bottleneck, the population 
experiences inbreeding and random genetic drift, ultimately limiting the genetic diversity and 
the number of new mutations occurring within the current population. Since recessive and 
neutral alleles are both subject to genetic drift in a population isolate, each population usually 
has its own set of recessive diseases that occur at relatively high frequency. Genetic drift will 
have much the same effect on rare marker alleles and haplotypes as it does on recessive and 
neutral alleles; common marker alleles and haplotypes will, on the other hand, not be affected 
to any large extent by drift, unless the number of initial founders is very small. 
 
It is highly probable that, for complex diseases, the underlying susceptibility alleles are 
relatively common (section I.3.2.3), and experience very little selection pressure (Lander, 
1996; Collins et al., 1997; Risch and Merikangas, 1996). Consequently, these variants predate 
the “Out-of-Africa” expansion, and the genome segments on which they are located have 
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experienced recombination over a large number of years (approximately 100 000 years), 
erasing much of the LD around the susceptibility locus. A high marker density will thus be 
required in order to detect these susceptibility variants using LD mapping strategies 
(Kruglyak, 1999[b]).  
 
Exploiting the genomic structure of populations that exhibit an increased level of LD will thus 
be conducive to the detection of the underlying susceptibility alleles. Decay of LD is related 
to the number of recombination events and the effective population size (Hartl and Clark, 
1997); therefore, one of the major demographic features influencing LD mapping studies is 
the number of generations to the most recent common ancestor (MRCA) (Wright et al., 1999). 
Recombination events serve to equilibrate linked alleles – for disease alleles that are relatively 
ancient, the number of recombination events that would have occurred is high, therefore, the 
surrounding genomic regions that are identical-by-descent (IBD) will be relatively small. The 
rate of decay of LD is reduced by other factors that reduce the effect size of the population, 
such as inbreeding.  
 
It is thus evident that isolated populations, with relatively less average time to the MRCA, and 
a high occurrence of inbreeding, exhibit higher degrees of LD over longer genomic distances 
compared to more stable, outbred populations (Graham and Thompson, 1998; Shifman and 
Darvasi, 2001). One will recall from the section on LD and haplotype mapping, that the value 
of r2 is directly proportional to the required increase in sample size when testing the 
association between a single SNP and complex disorder (Ardlie et al., 2002; Shifman and 
Darvasi, 2001; Laan and Paabo, 1997). Consequently, due to the extended levels of LD, 
isolated populations require a smaller increase in sample size to identify the specific disease 
gene, and are therefore more conducive to the genetic association mapping procedure. 
Ultimately, the genetic heterogeneity will also be reduced, resulting in a significant increase 
in GRR, making the association between variant and disease easier to detect (Shifman and 
Darvasi, 2001). 
 
Genealogical records form the mainstay of any genetic investigation in isolated populations, 
since they allow for the identification of large pedigrees. These pedigrees will probably 
comprise multiple affected individuals, and, by utilising the genealogical records, one will be 
able to delineate the number of meiotic steps separating affected individuals, which will 
facilitate the identification of IBD segments (Kruglyak, 1999[b]; Heutink and Oostra, 2002). 
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Genealogical records also allow the identification of genetic “incomers”, facilitating the more 
accurate estimation of genetic variability (Angius et al., 2001). 
 
The South African Afrikaner population: a brief overview of their history and suitability in 
localising disease-susceptibility genes by means of association studies  
The Afrikaans-speaking Caucasian sub-population in South Africa, often referred to as 
Afrikaners, are of predominantly Dutch, German and French descent (Dunning et al., 2000; 
Jenkins, 1990; Botha and Beighton, 1983). Their history over the past 350 years has 
contributed to their geographic and cultural isolation, and their relative genetic homogeneity. 
 
The Dutch were the first Caucasians to settle in the Cape in 1652, and their numbers were 
subsequently boosted by French Hugenot and German immigrants. By 1687, the founding 
Afrikaner population consisted of only about 90 families (Theal, 1964). From this time on, the 
settler population expanded rapidly with large families of 10 or more children (Botha and 
Beighton, 1983), and marriage between family members was common in early generations. 
Over a period of about 300 years, the Afrikaner population underwent a 2500-fold increase, 
compared to Britain’s population increase at the same period, which was only six-fold 
(Jenkins, 1990). This population growth was almost entirely due to reproduction, as the 
immigration following the founding event in 1652 was minimal (Jenkins, 1990).  
 
The Afrikaner immigrants spread inland from about 1838, forming small, geographically 
isolated communities. Their language and religion (most Afrikaners were members of the 
Dutch Reformed Church) contributed further to their isolation and social cohesion. This 
cultural identity has, for the most part, been maintained, largely due to intermarriage (Botha 
and Pritchard, 1972).  
 
The bottleneck caused by the original founding event resulted in increased genetic drift, with 
a substantial loss in genetic diversity, and a consequent increase in the frequency of 
previously rare alleles. Indeed, genetic drift by a founder event has been suggested for the 
high rate of certain monogenic diseases in Afrikaners, such as familial hypercholesterolemia 
(Defesche et al., 1996), keratolytic winter erythema (Starfield et al., 1997), hypertrophic 
cardiomyopathy (Moolman-Smook et al., 1999), myotonic dystrophy (Goldman et al., 1996), 
Fanconi anemia (Rosendorff et al., 1987; Tipping et al., 2001), variegate porphyria 
(Groenewald et al., 1998), long QT syndrome (de Jager et al., 1996) and progressive familial 
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heart block type I (PFHB I) (Brink et al., 1995). In addition, a large number of conserved 
haplotypes have been found to be situated around these rare disease genes (Pronk et al., 1995; 
Groenewald et al., 1998). 
 
Gordon et al. (2000) performed a background linkage disequilibrium (BLD) study in the 
Afrikaner population and found that significant evidence for BLD (up to distances of about 
5cM) existed. These results were in line with those obtained by Hall et al. (2002), who 
performed a comparative BLD study between Afrikaners and two other inbred populations 
(from Finland and Sardinia) and two outbred populations (from Britain and North America). 
The results indicated consistently higher mean levels of LD in Afrikaners for distances over 
3cM compared to the other populations. In fact, in some regions on chromosome 18, they 
found that LD was detectable at a distance of approximately 6cM in Afrikaners. However, it 
should be noted that in a previous study by Dunning et al (2000), who compared LD between 
markers on chromosomes 13q12-13, 19q13.2 and 22q13.3-ter in two inbred populations 
(Afrikaners and Ahskenazim) and one outbred population (East Anglian British), no 
significant differences in allele frequencies or LD were detected. These disparate results may 
be due to the recent finding that LD is not uniform throughout the genome, and further 
emphasises the importance of measuring LD between markers within the region of interest, 
for the population used in the study. 
 
In summary, the ethnically and relatively genetically homogeneous Afrikaner population 
presents with unique characteristics advocated for the successful elucidation of genetic risk 
factors in OCD. Firstly, the original Afrikaner group was a small number of founders. In 
addition, population expansion in the Afrikaner subpopulation occurred as a result of 
population growth, not immigration. Furthermore, at present, the Afrikaner population 
represents a large population (about 3 million) whose genealogy can be examined using well-
preserved death certificates, birth notices, ship records of immigration and records from the 
original Dutch trading company that settled in the Cape in 1652. Finally, Afrikaners are a very 
religious group, and the Dutch Reformed Church has kept very good records over the last few 
hundred years that further facilitates genealogical investigation. 
 
The Afrikaner subpopulation has already been used successfully in a comparative genome 
scan of patient and control groups to identify a number of markers associated with TS 
(Simonic et al., 1998; Simonic et al., 2001), a disorder thought to share a common genetic 
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aetiology with OCD. Moreover, from a sample of 98 Afrikaner schizophrenia probands, 87 
have been genealogically traced to a single couple who immigrated to South Africa 
approximately 12.5 generations ago (Karayiorgou et al., 2004), suggesting that the affected 
individuals share a small number of disease alleles.  
 
Mention should, however, be made of the drawbacks of using isolated populations in the 
search for complex genes. Firstly, the related genetic findings may not be valid, especially in 
larger, more outbred populations, particularly if the isolated populations possess new 
mutations that are associated with OCD, or if old mutations remain in the isolated population, 
whilst they become extinct in older populations (Heutink and Oostra, 2002). Secondly, 
epistatic interactions may account for the variation in allelic associations between 
populations. Thus, in the genetic context of an isolated population, it may be that associations 
are produced that are not detectable elsewhere in the world. 
 
However, for Afrikaners, it is likely that their Northern European origin will enable any 
findings within this population to be extrapolated to a number of other Western populations. 
In addition, even if only a subset of susceptibility variants segregated with the original 
founders, the knowledge gained from the identification of these will be important in imparting 
insight into the molecular and cellular mechanisms of OCD.  
 
I.4.2. HETEROGENEITY OF OCD 
The second major confounding factor presenting a major obstacle in delineating the genetic 
contribution to OCD is the genotypic and phenotypic heterogeneity of the disorder.  
 
I.4.2.1. Genetic heterogeneity  
Genotypic heterogeneity refers to the production of the same or similar phenotypes by 
different genetic mechanisms. Genetic heterogeneity is divided into two categories – allelic 
heterogeneity, where different alleles at a locus can produce variable expression of a 
condition, and locus heterogeneity, the phenomenon whereby mutations at different loci are 
able to produce the same phenotype. However, if the CD/CV hypothesis holds true for 
common disorders, it is unlikely that the allelic architecture of OCD will be very complex, 
since population theory predicts that the half-life of the ancestral allelic spectrum will be very 
long – in the order of 1.5 million years (Reich and Lander, 2001), and is therefore unlikely to 
contribute to any large extent to between-study heterogeneity. If the disease-causing allele 
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frequencies are found to differ between populations, it is most likely due to their rare 
occurrence, or the fact that they have been subjected to strong selection pressure, resulting in 
a relatively short period of time to the MRCA (Colhoun et al., 2003). 
 
I.4.2.2. Phenotypic heterogeneity 
It is likely that the disease phenotype characterised by OCD represents a final common 
pathway of multiple aetiologies. The disorder is currently defined and diagnosed according to 
structured algorithms (such as is presented in the DSM-IV [APA, 1994]). The phenotype as 
described by these structured algorithms provides a relatively homogeneous view of the 
disorder, which facilitates treatment. However, it is unknown how much bearing this 
diagnosis has on the underlying genetic aetiology of OCD, since this characterisation 
represents a combination of related subtypes, which may present with distinct genetic 
aetiologies. Classifying OCD according to these subtypes should be more informative and 
statistically powerful (Silverman and Palmer, 2000), since the traits are are probably 
controlled by fewer loci and environmental factors. Such proximal phenotypes may further 
strengthen the genetic signal by increasing the effective population size that is informative for 
mapping, since even individuals who do not present with the clinical phenotype of OCD may 
present with the proximal phenotype under consideration.  
 
Subtypes of OCD that have been investigated as proximal phenotypes include those based on 
obsessive and compulsive symptom dimensions (Baer, 1994; Leckman et al., 1997; Mataix-
Cols et al., 1999; Summerfeldt et al., 1999; Calamari et al., 1999); co-morbidity with related 
psychiatric disorders (Mataix-Cols et al., 2000; Sobin et al., 2000; Leckman et al., 2003; 
Keuthen et al., 1996; Stanley et al., 1997), particularly tic disorders (Holzer et al., 1994; 
Leckman et al., 1995; Zohar et al., 1997); demographic and clinical features, namely, age at 
onset, severity (Rasmussen and Tsuang, 1986; Minichiello et al., 1990; Noshirvani et al., 
1991) and gender (Lensi et al., 1996). It is important to keep in mind that, as one increases the 
number of subgroup analyses using the same sample, the chance of spurious association 
increases. Therefore, although subgroup analyses represent a valid means of generating 
hypotheses (Cardon and Bell, 2001), these should ideally be conducted using different patient 
samples. The following section deals with those subtypes, in particular, that are investigated 
in the present study. 
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I.4.2.2.1. Identification of subtypes based on comorbidity with related disorders 
A wide range of DSM Axis I and II disorders are found to occur co-morbidly with OCD, and 
vice versa (Perugi et al., 1997; Fireman et al., 2001; Tukel et al., 2002) (Table I.3). In fact, it 
has recently been reported that less than one-third of OCD patients will be diagnosed without 
a lifetime history of a co-morbid pathology, probably indicating the poor discriminant validity 
of the present OCD diagnosis (Denys et al., 2004[a]). 
 
 
Table I.3. Co-morbid disorders and associated current and lifetime frequencies in OCD 
patients 
 
 
 
 
 
 
 
 
Current and lifetime frequencies are given as percentages 
Adapted from Rasmussen and Eisen, 1998. 
. 
These disorders are associated with OCD due to common phenomenology and treatment 
responses (Stein, 2000). Many of the comorbid disorders have also been found to occur more 
frequently in relatives of OCD probands (Nestadt et al., 2003). However, the presence of co-
morbid disorders in OCD cannot be easily explained – it is not known whether the 
relationship between the disorders represents a common genetic diathesis or some sort of 
psychodynamic or developmental commonality (Stoltenberg and Burmeister, 2000).  
 
Presently, there appears to be a large degree of variability in the reported rates of OCD co-
morbidity, probably due to the differing diagnostic methodologies employed by various 
researchers (Denys et al., 2004[b]). However, the majority of studies report that the most 
frequently associated co-morbid disorder occurring secondarily to OCD is major depressive 
disorder (MDD) (Goodwin et al., 1969; Weissman et al., 1994; Rasmussen and Eisen, 1994; 
Rasmussen and Eisen, 1992, Jenike, 2001, Denys et al., 2004[b]), indicating that the two 
disorders may share some neuropathological aspects (Insel et al., 1982; Mancini et al., 2002).  
 
Diagnosis Current Lifetime 
Major depression  (MDD) 31 67 
Specific phobia 7 22 
Social Phobia 11 18 
Eating Disorder 8 17 
Alcohol abuse 8 14 
Panic Disorder (PD) 6 12 
Tourette’s syndrome (TS) 5 17 
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In order to determine whether there are underlying clinical constructs that distinguish OCD-
related subgroups, Nestadt et al. (2003) performed latent class analyses on 450 OCD patients 
and observed the existence of two major OCD subgroups – one exhibiting co-morbid panic 
disorder (PD), tic disorders and agoraphobia, and the second characterised by the presence of 
co-morbid generalized anxiety disorder (GAD), recurrent major depressive disorder (MDD) 
and OCSD. Familial loading was evident in both groups. The authors suggested that these two 
groups represent aetiologically distinct subgroups, each comprising a certain degree of 
familial liability. In the group characterised by GAD, MDD and OCSD, however, the 
familiality was graded, with a better likelihood for the relatives to develop OCD with an 
increase in OCD-related co-morbid diagnosis in the proband. Furthermore, age at onset was 
observed to be later for the PD/tic disorder/agoraphobia group, whereas for the other group, 
earlier age at onset was associated with increase in OCD-related co-morbidity (Nestadt et al., 
2003). Overall, it was concluded that the second group possessed a multifactorial aetiology, 
with genetic and environmental interaction necessary for the expression of the phenotype.  
 
The reduced familial loading and later age at onset for the group comprising tic disorders 
contradicts what has been found in literature with regard to OCD presenting with comorbid tic 
disorders (Grados et al., 2001; Rosario-Campos et al., 2001; Pauls et al., 1995). This may be 
due to the exclusion of co-morbid TS in OCD patients in the study. Perhaps if TS had been 
included, tic disorders would have fallen into the group comprising OCSDs and would have 
been associated with early age at onset and higher familial loading, as has been found in other 
studies (Chacon et al., 2004). 
 
I.4.2.2.2. Obsessive-compulsive spectrum disorders (OCSDs) 
OCSDs refer to those psychiatric syndromes which may be related to OCD with respect to 
phenomenology, and other associated features such as clinical course (age at onset, chronicity 
of course), co-morbidity, familial transmission and response to behavioural and 
pharmacologic treatment (Hollander and Wong, 1995; Hollander and Benzaquen, 1997; 
Ravindran, 1999; Jenike, 1989); consequently, they may serve as marker traits with potential 
predictive value. OCSDs are so named because OCD is considered to represent the prototype 
for the group of disorders enveloped by this conceptual scheme. Many of these so-called 
spectrum disorders appear highly comorbid with OCD, and it is therefore important to address 
their relationship to OCD, with emphasis on the possible shared genetic aetiology between 
them. 
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Conceptualisations of OCSDs differ between researchers, resulting in a fair amount of 
discrepancy as to which disorders can be included in the scheme. One outlook proposes that 
OCSDs may be viewed along a continuum in which compulsive, ego-dystonic disorders, 
characterised by good insight, excessive harm avoidance and risk aversion, are situated at one 
pole, whilst impulsive, ego-syntonic disorders, characterised by a lack of insight, and risk-
seeking behaviour, are situated at the other end (Figure I.1) (Stein and Hollander, 1993; 
McElroy et al., 1994; Hollander and Cohen, 1996; Hollander, 1998). Both groups of disorders 
are proposed to share several common features, including symptom profile (repetitive 
thoughts and behaviours), associated features (such as age at onset), aetiology (biologic and 
neurologic factors) and response to pharmacotherapeutic interventions (Hollander, 1998; 
Stein, 2000).  
 
Risk-aversive Risk-seeking 
 High harm avoidance Low harm avoidance 
High anticipatory anxiety Low anticipatory anxiety  
 
 
 COMPULSIVE IMPULSIVE 
 
 
 
 
 
Figure I.1. The hypothetical axis of the spectrum of obsessive-compulsive disorders. The 
compulsivity/impulsivity dimension, with predominantly compulsive components on one end, 
and predominantly impulsive components on the other. 
Trichotillomania OCD Tourette 
Syndrome 
Sexual compulsions 
Pathological  Impulse control disorders BDD 
gambling Hypochondriasis 
Anorexia nervosa 
Abbreviations: OCD: obsessive-compulsive disorder; BDD: body dysmorphic disorder. 
 
OCSDs are now recognised as distinct diagnostic entities related to OCD and are found to 
affect up to 10% of the American population (Hollander et al., 1996). The range of disorders 
include grooming disorders (e.g. trichotillomania [TTM] - hair pulling) (Swedo et al., 
1989[b]; Swedo and Leonard., 1992; Christenson et al., 1991; O’Sullivan et al., 1997), 
impulse control disorders, such as repetitive self-mutilation (Favazza, 1992) and compulsive 
buying (McElroy et al., 1991; 1994), somatoform disorders (such as body dysmorphic 
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disorder (BDD) and hypochondriasis) (Hollander et al., 1989; Ravindran, 1999), eating 
disorders (anorexia and bulimia nervosa) (Rubenstein et al., 1992; Ravindran, 1999; Bellodi 
et al., 2001), and tic disorders (e.g. TS) (Stein and Hollander, 1995, Miguel et al., 1997). 
 
I.4.2.2.3. Subtyping according to the presence or absence of tics 
Tic-related versus non-tic-related OCD is presently thought to be one of the clearest 
distinctions that can be made amongst OCD subtypes (Leckman et al., 2000). Evidence for the 
distinction stems from differential phenomenology and symptomatology (Leckman et al., 
2000; McKay et al., 2004), demography (males and EO OCD present with co-morbid tics 
more often [Grados et al., 2001]), and neurology (Hanna et al., 1991), between OCD patients 
presenting with co-morbid tic disorders (OCD+tics) and OCD without tics (OCD-tics). 
 
Of particular interest is the proposed neurobiological, genetical and clinical relationship 
between TS and OCD (Leckman, 1993; Pauls et al., 1991; Robertson et al., 1988; Comings 
and Comings, 1987; Frankel et al., 1986; Lees et al., 1984; Nee et al., 1980). TS is a 
developmental neuropsychiatric disorder characterised by motor and vocal tics (DSM-IV, 
1994; Leonard et al., 1992). TS and OCD have been found to share certain clinical features, 
such as waxing and waning of symptoms, early age at onset and egodystonic behaviour 
(Eapen et al., 1997[a]).  
 
Tic disorders are hypothesised to represent part of a familial OCD phenotype (Grados et al., 
2001; Eapen et al., 1997[a]). Indeed, evidence from family studies indicates the putative 
common genetic basis for OCD and TS (Pauls et al., 1986; Pitman et al., 1987; Grad et al., 
1989). Rates of OCD amongst first-degree relatives of TS probands have been reported to 
range from 6%-26% (Pauls et al., 1986; Pitman et al., 1987; Eapen et al., 1993), greater than 
for the control samples in the respective studies. Moreover, Grados et al. (2001) found that tic 
disorders were twice as common amongst relatives of OCD probands compared to relatives of 
controls. These results were consistent with those attained by Pauls et al. (1995), who 
observed tics in 4.6% of OCD case relatives, compared to 1% in control relatives. In addition, 
Riddle et al. (1990) observed that, of 21 children and adolescents with OCD, more than half 
had parents with motor tics. 
 
An earlier age at onset amongst first-degree relatives with OCD+tics, compared to OCD 
without tics has also been observed (Grados et al., 2001), suggesting the likelihood of an 
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association between the age at onset of OCD and the expression of tics.  Moreover, it has been 
found that, when comparing obsessive-compulsive symptoms in individuals with OCD and 
TS, the OCD probands who shared a common symptom profile with TS patients all had a 
family history of OCD (Eapen et al., 1997[a]). 
 
Although family studies have thus far provided the most convincing evidence for an overlap 
between tic disorders and OCD, a wide range of brain imaging studies have implicated the 
basal ganglia and related cortical thalamic structures in the aetiopathology of tic disorders, 
compatible with a serotonergic (5-HT)-dopaminergic dysfunction in OCD-related TS (Eapen 
et al., 1997[a]). However, recent biochemical data suggest that 5-HT dysregulations in OCD + 
tics and OCD-tics patients may be distinct, indicating subtle differences in their underlying 
neuropathologies (Cath et al., 2001). Pharmacotherapeutic evidence has also provided 
evidence for the partial involvement of the 5-HT system in the pathophysiology of OCD-
related tic disorders. George et al. (1993) observed a synergistic effect of a combination of 
neuroleptic and selective serotonin reuptake inhibitor (SSRI) therapy in the treatment of TS 
patients who presented with obsessive-compulsive symptoms, although the SSRI itself caused 
worsening of the TS symptomatology. Moreover, McDougle et al. (1994) observed the 
efficacy of a combined neuroleptic and SSRI therapy in OCD patients presenting with 
comorbid tic disorders, and that OCD patients who presented with a family history of tic 
disorders were less responsive to SSRI monotherapy, suggesting the involvement of other 
neurotransmitter systems in the pathology of OCD + tics. 
 
A dysfunction in dopaminergic neurotransmission has been implicated in the pathology of TS 
(Segawa et al., 2003), based mainly on parallels between tics, vocalisations and obsessive-
compulsive behaviours seen in some patients with encephalitis lethargica (Devinsky, 1983), 
which is thought to be dopaminergically mediated. OCD has also been found to be prevalent 
amongst individuals suffering from tic disorders (Steingard and Dillon-Stout, 1992): lifetime 
prevalences of OCD in TS have been found to range from 50% to 62% (Pitman et al., 1987; 
Pauls et al., 1986). Moreover, in children diagnosed with TS, it was found that significantly 
more met diagnostic criteria for OCD, in comparison to control children (Apter et al., 1993; 
Grad et al., 1987). Interestingly, it has also been suggested that some forms of EO OCD may 
represent genetic variants of TS (Eichstedt and Arnold, 2001). 
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Cytogenetic abnormalities associated with the OCD/TS/tic disorder phenotype have been 
reported. An individual with an abnormality in chromosome 7q31, resulting in the disruption 
of the inner mitochondrial membrane peptidase 2 like (IMMPL2) gene (a human homologue 
of the yeast mitochondrial inner membrane subunit 2) was observed by Petek et al. (2001). 
Moreover, a gene encoding an axonal membrane protein, contactin-associated protein 2 
(CNTNAP2), has been found to be interrupted in a family presenting with OCD/TS phenotype 
(Verkerk et al., 2003). Finally, rearrangements in chromosome 18q22 have been associated 
with the OCD/TS/tic disorder phenotype in 3 separate instances (Boghosian-Sell et al., 1996; 
State et al., 2003; Cuker et al., 2004). 
 
Given the observations from family and cytogenetic studies, it has been hypothesised that the 
association between some forms of OCD and TS may be a result of the common underlying 
genetic factors predisposing the individual to develop tic disorders.  
 
I.4.2.2.4. Subtyping according to age at onset  
Once believed to be rare in children, OCD is now recognized to be as prevalent in children as 
in adults (Flament et al., 1988; Valleni-Basile et al., 1994). Distinct peaks for the age at onset 
of OCD exist; for EO OCD, a mean age of onset of 10 years has been observed (Geller et al., 
1996; Hanna, 1995; Riddle et al., 1990; Swedo et al., 1989[a]; Thomsen, 1993), whilst forLO 
OCD, the mean age at onset has been observed as 21 years (Karno et al., 1988; Minichiello et 
al., 1990; Pauls et al., 1995; Rasmussen and Eisen, 1992; Thyer et al., 1985). 
 
It has been suggested that EO OCD represents a developmental subtype of OCD (Geller et al., 
2001; Rosenberg and Keshavan, 1998). Indeed, EO OCD has been found to exhibit distinct 
patterns of neuropathology (Busatto et al., 2001) and phenotypic expression (reviewed by 
Geller et al., 1998) compared to LO OCD. With regard to the latter, EO OCD has been 
associated with male preponderance (Geller et al., 1998; Millet et al., 2004; Fontenelle et al., 
2003), although this has not been consistently observed (Riddle et al., 1990; Rosario-Campos 
et al., 2001; Flament et al., 1988). Moreover, EO OCD presents with a higher rate of TS and 
comorbid tic and disruptive disorders when compared to LO OCD (Geller et al., 1996; 
Rosario-Campos et al., 2001; Millet et al., 2004).  The correlation between tics and EO OCD 
is indeed striking: it was reported in one study that 20-59% of children with OCD present 
with tics (Leonard et al., 1992), whilst in another, 48% of EO OCD patients presented with 
tics (Rosario-Campos et al., 2001). 
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In addition, a higher number of obsessions and compulsions have been demonstrated in EO 
OCD patients (Millet et al., 2004; Sobin et al., 2000; Fontenelle et al., 2003) compared to LO 
OCD patients. EO OCD patients seem to experience more somatic fears, symmetry and 
superstitious obsessions and more cleaning, repeating, counting and tapping/rubbing 
compulsions (Sobin et al., 1999; 2000; Fontenelle et al., 2003; March et al., 1996). The 
obsessions and compulsions have also been found to be more severe in EO OCD, as 
evidenced by increased Y-BOCS scores (Rosario-Campos et al., 2001; Fontenelle et al., 
2003). Moreover, Sobin et al. (2000) found that LO OCD patients reported a relatively large 
delay between the appearance of clinically important symptoms and full syndromal OCD 
compared to EO OCD patients, suggesting a less aggressive form of the disease in LO. 
 
It has also been hypothesized that 5-HT may play less of a role in the development of this 
subtype (Eichstedt and Arnold, 2001), based on evidence from pharmacological studies, 
where it has been found that EO OCD is associated with a poor response to SSRI 
monotherapy (Rosario-Campos et al., 2001; Ackerman et al., 1994; Ravizza et al., 1995). 
Given the clear association between tic disorders and EO OCD, it may be hypothesised that 
dopamine is involved in the pathophysiology of EO OCD. However, the possibility that other 
neurotransmitter systems may be involved in the pathology of EO OCD cannot be ruled out. 
For example, a large amount of support for the glutamatergic hypothesis of EO OCD has 
recently been obtained (section I. 6.1.3 ).  
  
Support for the genetic contribution to EO OCD stems from the results of two genome-wide 
linkage studies, based on EO OCD probands, where evidence for suggestive linkage was 
found on chromosome 9p24 (Hanna et al., 2002; Willour et al., 2004) (please refer to section 
I.3.2.4 for a more detailed discussion). Moreover, it has recently been found that diagnosis of 
OCD (according to the obsessive-compulsive scale found in the Child Behavioural Checklist 
[CBCL]) was influenced by genetic (55%) and environmental (45%) factors in a younger 
OCD sample (<12 years). In the older sample (>12 years), only common environmental 
factors were found to contribute to the development of the disorder (Hudziak et al., 2004).  
 
Further support for the genetic contribution to EO OCD stems from a recent observation that 
EO OCD patients experienced a more gradual appearance of symptoms, whilst LO OCD 
patients exhibited a sudden symptom onset usually succeeding some kind of environmental 
trigger or depressive episode. The latter is, in turn, indicative of the environmental nature of 
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LO OCD compared to EO OCD (Millet et al., 2004). However, it is important to note that 
some forms of childhood-onset OCD are environmentally triggered. Indeed, more than 60% 
of children with Sydenham’s chorea (a neurological manifestation of rheumatic fever) have 
been found to exhibit the onset of obsessive-compulsive symptoms (Swedo et al., 1989[c]). 
Furthermore, for a subset of children with OCD, symptom exacerbation has been found to 
occur after group A β-hemolytic-streptococcal infections (Leonard and Swedo, 2001; Trifiletti 
and Packard, 1999). 
 
An inverse relationship between age at onset and familial loading has also been observed. 
Morbidity risks for obsessive-compulsive symptoms have been found to be twice as high in 
family members of EO OCD probands compared to relatives of LO OCD probands (Pauls et 
al., 1995). In line with these findings, Nestadt et al. (2000[b]) reported no cases of OCD in 
relatives of LO OCD patients. Likewise, observed increased rates of tics, OCD and TS have 
been observed amongst the relatives of EO OCD probands (Leckman et al.,2003; Pauls et al., 
1995; Grados et al., 2001). 
 
Taken together, these results suggest that EO OCD exhibits a stronger familial component 
than LO OCD, with increased rates of OCD and tic disorders found amongst relatives of EO 
OCD probands. It is, however, not yet clear whether the differences between EO OCD and 
LO OCD represent a specific neurobehavioural subtype of OCD, or a developmentally 
variable manifestation of the same disorder.  
 
I.4.2.2.5. Identification of subtypes based on obsessive and compulsive symptom dimensions 
According to diagnostic nosology, the definition of OCD is based upon the presence of 
obsessive and compulsive subgroups of symptoms that have been found to be relatively stable 
over time (Mataix-Cols et al., 2002; Rufer et al., 2005). Factor analyses have yielded 
remarkably consistent results in demonstrating the presence of three to five symptom 
dimensions, or subtypes (Leckman et al., 1997; 2001; Baer, 1994; Mataix-Cols et al., 1999; 
2002; Summerfeldt et al., 1999; Cavallini et al., 2002; Calamari et al., 2004), which may be 
present in varying combinations and degrees within each patient (Mataix-Cols et al., 2002). 
These symptom dimensions are indicated in Table I.4. Please note that symptom dimensions 
and symptom subtypes are used interchangeably through the rest of this dissertation. 
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Table I.4. Symptom dimensions in OCD 
 
 
 
 
 
 
 
 
Some of thes ns of 
genetic inheritance (Leckman et al., 2003; Alsobrook et al., 1999), co-morbidity (Samuels et 
al., 2002), pharmacotherapeutic response (Black et al., 1998; Winsberg et al., 1999; Mataix-
Cols et al., 1999; 2002) and neurological substrates (Saxena et al., 2004; Phillips et al., 2000; 
Mataix-Cols et al., 2004), indicating the possibility of distinct biological underpinnings for 
specific obsessive and/or compulsive contents. Indeed, a neuro-imaging study has indicated 
that some of the symptom dimensions may comprise different neural substrates. Here, the 
severity of aggressive/sexual/religious symptoms were found to correlate with regional 
cerebral blood flow in the striatum, whereas contamination/washing symptom severity 
correlated with blood flow in mainly cortical regions (Rauch et al., 1998). In a more recent 
study, Mataix-Cols et al. (2004) observed that OCD patients experiencing checking 
compulsions exhibited activation of brain areas involved in motor and attentional functions, 
but when the same OCD patients experienced washing compulsions, brain regions involved in 
the processing of emotions (particularly disgust) were found to be activated. Moreover, 
neurochemical dysfunctions involving the dopaminergic system have recently been implicated 
in the pathology of checking compulsions, given the recent findings from an animal model 
(discussed in more detail in section I.6.1.2) (Schetzman et al., 1998; 2001). 
 
e mensions have been shown to rise differential patter
vidence for a genetic contribution to the symptom dimensions stems from two recent 
symptom di  comp
E
complex segregation analyses (Alsobrook et al., 1999; Leckman et al., 2003). Alsobrook et al. 
(1999) stratified their OCD patient sample according to four symptom factors, and found that 
the relative risk of OCD was higher in relatives who obtained high factor scores on the  
aggression/sexual and symmetry/ordering symptom dimensions, indicating that these 
subtypes may possess a familial component. Segregation analysis of their entire dataset 
(consisting of 96 probands [experiencing hoarding, contamination, symmetry/ordering and 
Symptom Dimension Obsession Compulsion 
Hoard Hoarding Hoarding ing 
S dering Sy Repe ting, ordering 
Contamination Contamination Was
Sex Sexu Chec nting, repeating 
A Ag Chec
ymmetry/or mmetry ating, coun
hing 
king,  couual/religious al/religious  
ggressive gressive king 
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aggression/sexual symptoms] and 453 first degree relatives) allowed rejection of only the no-
transmission model, consistent with the hypothesis of a genetically heterogeneous aetiology 
for OCD.  
 
When their analyses were limited to only families with probands who had high 
hese results have been corroborated in a recent study by Hanna et al. (2005), who found that 
.4.2.2.5.1. Hoarding as a genetically distinct symptom dimension 
D. Hoarding is probably 
symmetry/ordering scores, only the no-transmission and polygenic inheritance models were 
rejected, indicating the possibility of the involvement of a major locus. On the other hand, 
limiting the analyses to only those families with OCD probands with high aggression/sexual 
symptom scores did not produce any significant results, with the polygenic model of 
inheritance reaching only a borderline rejection (p=0.06). This indicates the possibility that, 
whilst some OCD subtypes may be more genetically mediated than others, OCD as a whole 
appears to be genetically modulated in a heterogeneous model. 
 
T
ordering compulsions were significantly more common in familial OCD probands. Leckman 
et al. (2003), on the other hand, investigated the transmission of the aforementioned symptom 
dimensions in families with TS. They found evidence for genetic transmission in all four 
factors, with dominant inheritance the most likely mode of transmission for aggressive, sexual 
and religious type symptoms, and the symmetry/ordering obsessive-compulsive symptoms, 
and recessive inheritance the most parsimonious solution for the transmission of 
contamination and hoarding symptoms. However, whether these results can be extrapolated to 
OCD patients without TS remains to be seen. 
 
I
Hoarding, in particular, has been studied as a distinct subtype of OC
an evolutionarily conserved trait, associated with survival in times of adversity; however, 
extreme forms of hoarding may contribute to the symptomatology of OCD and/or related 
disorders. Frost and Gross (1993) describe compulsive hoarding as the acquisition of and 
failure to discard possessions of little use or value. Although hoarding obsessions and 
compulsions are exhibited most often by OCD patients (Frost et al., 1996), they have also 
been observed in other neuropsychiatric disorders including anorexia (Frankenburg, 1984), 
organic mental disorders (Greenberg, 1990), psychotic disorders (Luchins et al., 1992), TS 
(Zhang et al., 2002) and Attention Deficit/Hyperactivity disorder (Moll et al., 2000). Hoarding 
has also been found to be associated with the presence of personality disorders including 
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obsessive-compulsive and avoidant personality disorders (Mataix-Cols et al., 1999; Samuels 
et al., 2002). 
 
Compared to the other symptom dimensions, a wider range of studies have been conducted in 
nimal studies have also implicated dopamine and 5-HT dysfunctions in the aetiology of 
onetheless, pharmacological and imaging studies conducted using OCD patients have 
oarding behaviours have also been found to exhibit distinct genetic underpinnings. A recent 
order to determine the underlying pathology relating to hoarding, probably due to its 
involvement in multiple neuropsychiatric disorders. Animal studies have indicated that the 
phenotype is mediated by the ventromedial striatum, globus pallidus and dorsal thalamus 
(Mogenson et al., 1988); which have all previously been implicated in OCD. Food hoarding 
in rodents is thought to be mediated via the anterior cingulate gyrus (de Brabander et al., 
1991), the hypothalamus (Blundell et al., 1973), and the hippocampus and the septum (Kolb, 
1974).  
 
A
hoarding (Blundell et al., 1973; Kalsbeek et al., 1988; Kelley and Stinus, 1985; Fantino et al., 
1988), and it has also been proposed that gonadal steroids, benzodiazepines and opiates may 
modulate hoarding behaviour (Coling and Herberg, 1982; Kavaliers and Hirst, 1985). 
However, it remains debatable whether animal hoarding behaviours can be equated to those in 
humans (Saxena et al., 2004). 
 
N
highlighted neurobiological distinctions between OCD hoarders and non-hoarders. Indeed, the 
presence of hoarding obsessions appears to presage a poorer response to SSRI monotherapy, 
in comparison to OCD nonhoarders (Mataix-Cols et al., 1999; 2002; Black et al., 1998; 
Abramowitz et al., 2003; Baer, 1994; Saxena et al., 2002; Winsberg et al., 1999). In addition, 
lower glucose metabolism in the anterior and posterior parts of the cingulate cortex, which 
modulates activity in some of the brain regions implicated in OCD, has been observed in 
hoarders (Saxena et al., 2004).  
 
H
genome scan of the hoarding phenotype in TS patients revealed significant allele-sharing for 
both the quantitative and qualitative forms of the trait on 4q35-35 (p=0.007), 5q35.2-35.3 
(p=2x10-5) and 17q25 (p=2x10-4) (Zhang et al., 2002). Interestingly, 17q25 has recently been 
postulated to be involved in the aetiology of TS (Paschou et al., 2004), indicative of a putative 
common genetic aetiological link between TS and the hoarding phenotype. The results may, 
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however, simply corroborate previously conducted studies investigating the genetic aetiology 
of TS. To this end, the finding on chromosome 5q is interesting, since chromosome five has 
never been implicated in the pathophysiology of TS, and may as such represent a distinct 
hoarding locus. 
 
Further evidence indicating that hoarding represents a distinct clinical subgroup stems from a 
.4.3. EFFECT MODIFICATIONS 
in epidemiological studies, refers to the variation in the 
ffect modifiers are usually regarded as part of the background, and are assumed to be 
.4.3.1. Epistasis 
 non-additive interactions that occur between loci or genes, and can thus 
study by Samuels et al. (2002), where OCD probands with hoarding were compared to OCD 
probands who did not exhibit the hoarding phenotype. The investigators found that OCD 
patients presenting with hoarding symptoms possessed an earlier age at onset of the disorder, 
increased severity of OCD symptoms, and a higher prevalence of social phobia and 
pathological grooming behaviours, including nail-biting, skin picking and TTM.  
 
I
Effect modification, a term often used 
relationship between exposure (i.e. the genotype in the present study) and the disorder (OCD) 
due to some modifying factor, which is known as the effect modifier (Schoenbach and 
Rosamond, 2000). Effect modification is thus not concerned with whether an association 
between a genetic variant and disease exists, but more with the specifics of the association. 
 
E
uniformly distributed; consequently, they are normally disregarded in association studies. 
However, it is important to identify those modifying factors that do not exhibit uniform 
distribution across cases and controls, or populations, since they have the potential to result in 
inconsistencies across association studies. More importantly, such modifications may be 
involved in disease aetiology.  
 
I
Epistasis refers to the
impact the expression of a trait or phenotype quite substantially (Frankel and Schork, 1996). 
In genetic association studies involving complex traits, investigating loci in isolation 
undermines the complex, multigenic nature of such traits, and affords one a representation of 
only the marginal effect that the locus may have on disease expression. The power of the 
study will also be reduced if the effect of one gene is masked or altered by that at another 
locus (Cordell, 2002). Indeed, evidence of for such genetic interactions has been reported in 
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complex diseases such as Alzheimer’s disease (Kamboh et al., 1995), sporadic breast cancer 
(Ritchie et al., 2001), and type  2 diabetes (Cho et al., 2004; Hu et al., 2004). 
 
The core issue in analysing epistatic interactions is the choice of regions to investigate. The 
 is also imperative to remember that a statistical interaction need not imply a biological 
onetheless, considering the different modes of interaction between putative susceptibility 
ideal would obviously be to perform genome scans on the disorder, from which the choice of 
regions to include in such analyses would, theoretically, become clearer. However, for OCD, 
the findings from such scans have not been clear-cut (section I.3.2.4.). This, together with the 
relatively small amount of data from presently available literature indicating which regions 
may be suitable for inclusion in epistatic analyses, results, at best, in estimates of regions that 
interact with one another (Sullivan et al., 2004). Moreover, the issue of multiple testing 
becomes relevant, because if one investigates K loci, the number of possible pairwise 
comparisons is K(K-1)/2. Therefore, investigating the significance of each of these marker 
pairs will require stringent means to control the possibility of false positive results (Hoh et al., 
2001).  
 
It
interaction (Cordell, 2002). In statistical terms, epistasis refers to a departure from 
independence whereby the joint effect of two genes is greater than their individual effects 
(Cordell, 2002). Statistical tests for epistasis are thus restricted to testing specific hypotheses 
pertaining to defined quantities within mathematical models, which do not always correspond 
to biological models of epistasis (Cordell et al., 2001; Cordell, 2002). It is only if a prior 
biological model has been postulated in a fair amount of detail that statistical modeling will 
provide insight into underlying biological mechanism of OCD. Unfortunately, in OCD, the 
present knowledge regarding the underlying biological models is incomplete; hence one is not 
able to specify prior biological models upon which to base such analyses. 
 
N
loci has been found to improve power with which to detect modest genetic effects (Cordell et 
al., 1995; 2000; Cox et al., 1999). Furthermore, even identifying the most parsimonious 
statistical model for the joint effects of alleles at particular loci will improve our 
understanding of OCD, and facilitate the identification of further genetic loci which may a 
role in development of the disorder (Cordell et al., 2001). 
 
 
 56
I.4.3.2. Epigenetics 
fer to changes in the genetic material that alters gene expression in a 
n epigenetic framework has been proposed to explain the role of environmental mechanisms 
pigenetic marks have been found to differ across individuals, producing what is known as 
pigenetics has been hypothesised to play a role in the development of mood disorders and 
Epigenetic effects re
manner that is heritable, but that are non-mutational and are thus fully reversible (Tycko and 
Ashkenas, 2000) epigenetic effects (or epigenetic “marks”) usually occur as a result of DNA 
methylation and/or histone modification, (Bird et al., 2002; Hmadcha et al., 1999; Jenuwein 
and Allis, 2001), and can result in, amongst others, genomic imprinting and X- chromosome 
inactivation (Bestor et al., 1994). 
 
A
in complex disorders (Bjornsson et al., 2004); epigenetic mechanisms, by providing a 
transitional fine-tuning of the genome, allow for the preservation of information on 
environmental exposures. Indeed, epigenetics is also important in neural development – the 
mature adult nervous system requires genetic and environmental factors and interactions to 
allow organization and maturation; sensory deprivation results in aberrant responses and 
ultimately disease (Abdolmaleky et al., 2004).  
 
E
the epigenetic “polymorphism”, comprising 2 “epialleles”. Epigenetics may thus, at least 
partially, explain the inconsistent results often found in genetic association studies. If 
epigenetic phenomena are responsible for the association between a disorder and a genetic 
variable, the higher the epigenetic difference between cases and controls, the stronger the 
association will be, and vice versa. Epigenetics may also (once again, at least partially) 
explain how seemingly non-functional polymorphisms may be associated with a particular 
disorder (although one can not discount the possibility that the non-functional variant may be 
in LD with a functional variant, which may precipitate the clinical manifestation of the 
disorder).  
 
E
schizophrenia, since the chromosomal locations of the putative susceptibility loci for these 
disorders are compatible with those of genes that contribute to DNA methylation 
(Abdolmalesky et al., 2004; Asherson et al., 1994; Ohara et al., 1997). TS has also been 
proposed to possess possible parent-of-origin (epigenetic) effects: a greater motor-tic 
complexity and earlier age at onset has been found to occur when the disorder is maternally 
inherited, and a greater vocal-tic complexity has been observed when the disorder is 
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paternally inherited (Eapen et al., 1997[b]). This indicates the possibility for some forms of 
OCD (especially those with co-morbid tic disorders) to possess epigenetic parent-of-origin 
effects.  
 
I.4.4. CHANCE 
a theoretically alternative explanation for any association (Rothman, 1986). 
.4.4.1. Multiple comparisons 
ically complex, necessitating the investigation of numerous 
he most common form of multiple testing occurs where numerous markers, located in 
here is presently no consensus as to the most appropriate means to correct for multiple 
Chance is always 
Although it may be that chance is sometimes too readily accepted as a means of validating or 
explaining complex results, one should never attempt to dismiss it as an explanation before 
examining the phenomena which may have resulted in it being responsible for the final 
observation namely, lack of adjustment for multiple comparisons, insufficient power and 
measurement error. 
 
I
Psychiatric disorders are genet
candidate genes for the role they may play in the development of the disorder of interest. 
When one performs multiple, independent tests on the same dataset, with each test possessing 
a Type I error risk equivalent to the predefined level of statistical significance, the overall 
probability of making a Type I error increases. 
 
T
independent genomic regions, are investigated for association to a disorder. Other forms of 
multiple testing include subgroup analyses (such as stratifying the dataset according to age, 
gender or phenotypic variables), and pooling alleles from multi-allelic polymorphisms 
(Nyholt et al., 2001). Pooling alleles seems to be common practice in genetic association 
studies, and it is imperative to remember to correct for multiple testing if the statistical 
grounds for grouping alleles together was created after examining the original dataset.  
 
T
testing. The family-wise error rate (FWER) seems to be the most often controlled quantity, 
and represents the probability of obtaining one or more false positive results out of all the 
hypotheses tested. The most often cited correction for the FWER is the Bonferroni correction, 
which posits that, if there are m statistical tests, each test is controlled so that the probability 
of obtaining a false positive result is less than, or equal to, α/m. 
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However, when performing the Bonferroni correction, one assumes that the prior probabilities 
 should be mentioned at this point that that it is not possible to control for a Type I error 
deed, alternative means of correcting for multiple testing have also been created, in an effort 
 summary, it is evident that if one is testing multiple independent hypotheses, using the 
for each candidate gene or variant tested are all equal; therefore, the test does not control for 
dependence that may exist between variants in LD with one another. Investigating markers 
that are in LD with each other does not represent independent tests as such, since each new 
test does not provide a completely independent opportunity for a Type I error to occur (Ott, 
1999). Consequently, it is not necessary to apply conservative adjustments for multiple testing 
(such as the Bonferroni correction).  
 
It
without increasing the probability of a Type II error (Rothman, 1990). As the risk of the Type 
II error increases, the sensitivity of the test decreases, increasing the chances of overlooking a 
potentially important association. Methods that control for multiple testing therefore do so at 
the cost of decreasing the sensitivity of the investigation – the more conservative the test, the 
greater the probability of making a Type II error. It is therefore becoming increasingly more 
popular for investigators to employ less stringent means of correcting for multiple testing. 
 
In
to eliminate the increase in Type II errors caused by the multiple correction tests. For 
example, Murray (1991) proposed a method for adjusting for multiple comparisons that 
preserves the sensitivity of the investigation: he proposed that an a priori hierarchy of 
comparisons, in which there is a single comparison of primary interest, be described at the 
outset of the investigation. The results from these associations should be accepted at face 
value, and not corrected for. Thereafter, he suggests that a limited number of secondary 
investigations be performed, the results of which carry a lighter weight, although any 
significance should not be too lightly dismissed (a kind of hypothesis-based test). Any 
comparison made after the primary and secondary comparisons should be purely exploratory 
to generate hypotheses for future studies. Significance in this case should be awarded very 
little weight until the results have been replicated in independent studies, and these studies 
should be clearly labeled as exploratory (Bender and Lange, 1999).  
 
In
same dataset, some measure of adjustment for, or in the very least acknowledgment of, 
multiple testing is required. This becomes particularly important in confirmatory studies, 
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where the significance tests are used as tools for statistical evaluation and not simply to 
generate hypotheses. 
 
I.4.4.2. Inadequate power 
The power of a study is defined as the probability of rejecting the null hypothesis when it is 
appropriate to do so. Mathematically, power = 1- the probability of a Type II error (β). 
In other words, it represents the probability of reaching the right conclusion; consequently, it 
is imperative that the power of an association study be as high as possible, so that one can put 
the results of a study into perspective. A low statistical power results in the experiment 
possessing poor predictive value (Vecchio, 1966; Pfeiffer and Gail, 2003). 
 
The power of case-control association studies is determined by numerous factors, which are 
not necessarily mutually exclusive. These include: sample size; the frequency of the allele 
and/or genotype under investigation (which determines the maximal LD between them); the 
desired p-value; and the ES of the gene (or variant) (i.e. the penetrance of the allele) (Pfeiffer 
and Gail, 2003; Schork, 2002; Hwang et al., 1994; Berry et al., 1998; Long and Langley, 
1999; Cox and Bell, 1989). Most of these variables will be unknown in an association study 
of a complex disorder (such as OCD), although tenable estimates of power can be obtained by 
making reasonable assumptions regarding most of the susceptibility loci. 
 
Determining adequate and efficient sample size is often critical in designing worthy case-
control association experiments. The larger the sample size, the greater the power of the study 
(Long and Langley, 1999). In determining the sample size required to attain a particular 
statistical power for case-control association analyses, it is necessary to know the extent of 
LD between the marker and susceptibility loci. This is because the required sample size 
increases with decreasing LD by a factor of 1/r2, where r2 represents the correlation 
coefficient, a measure of LD between two markers (section I.3.2.5.1) (Kruglyak, 1999[a]). 
The significance level and ES will also influence the number of subjects that need to be 
recruited for the study – the sample size is inversely proportional to both. 
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I.4.5. BIAS 
“Garbage in, garbage out” 
 
Bias, or systematic error, refers to a type of differential error in which the measurements in a 
sample are skewed in one direction, due to imperfect sampling or classification procedures, 
and results in the dataset misrepresenting the true sample (Vineis and McMichael, 1998). It is 
thus important to avoid, or at least minimise, the inclusion of factors not related to the 
aetiology of OCD in the study, so as not to mask any modest differences (and therefore 
association) thought to exist between OCD patients and healthy controls. Sources of bias 
include selection bias, interviewer bias, information bias, interpretation bias and publication 
bias (Vineis and McMichael, 1998; Schoenbach and Rosamond, 2000; Kaptchuk, 2003).  
 
Publication bias arises when statistically significant results are more likely to be published 
than research presenting null, or non-significant, results (Easterbrook et al., 1991). It has been 
found that non-significant associations are rarely submitted for publication and if they are, 
there is relatively little chance of them being published. This skews any review of published 
results in favour of positive association results, and consequently compromises meta-
analytical studies (discussed in the forthcoming section). However, a graphical method of 
detecting this bias has been developed, in which the effect sizes of the individual studies are 
plotted on the vertical axis, and some measure of precision (sample size or standard error) is 
plotted on the horizontal axis. In the absence of publication bias, this plot should take on the 
shape of an inverted funnel, the assymmetry of which can be detected visually, or statistically 
(using Begg’s [Begg and Mazumdar, 1994] or Egger’s [Egger et al., 1997] tests).   
 
One explanation for publication bias is the misconception that non-significant association 
studies are of poorer quality than those yielding significant results. In fact, Easterbrook et al. 
(1991) tested this hypothesis, and found no association between the quality of design and the 
likelihood of publication. There was also no evidence suggesting that studies reporting 
positive associations were of any higher quality that those with non-significant results. 
Interestingly, one of the factors they did find increased the likelihood of publication was an 
investigator’s enthusiasm for his/her study, gauged by the rating on the importance of study 
findings. To this end, a positive finding is usually regarded as more important than a negative 
finding, largely due to the erroneous belief amongst researchers that a negative result (i.e. 
p>0.05) equates to the non-existence of an association. In reality, before any association 
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between a genetic variant and disorder can be excluded, the statistical power of the study 
needs to be calculated, to ensure that no associations were “missed” due to insufficient power. 
Fortunately, the confirmation of negative results is becoming increasingly popular amongst 
research scientists, since well-designed association studies producing non-significant results 
may highlight the presence of previously reported (and published) false associations. 
 
One way of overcoming publication bias would be to encourage scientists to publish brief 
reports of their negative association studies in some kind of web-based format on the internet 
(Little et al., 2002). A step towards achieving this goal has been realised by the “Genetic 
Association Database” (http://www.geneticassociationdb.nih.gov/), an archive of published 
human genetic association studies in complex diseases and disorders, presented in a web-
based format.  
 
I.4.5.1. Meta-analysis 
As discussed in the previous section, the investigator needs to assess the overall contribution 
of the particular hypothesis being tested as multiple studies and tests accumulate. Numerous 
statistical methods exist to perform such evaluations, with meta-analysis gaining increasing 
popularity (Egger et al., 2002). Meta-analysis employs statistical methodologies that combine 
the results from a number of studies to detect a common main effect, whilst controlling for 
variations brought about by study-dependent factors (Glass, 1976; Fisher, 1925). 
 
Meta-analyses have the potential to increase the precision and statistical power of association 
studies, thereby highlighting areas in research where there is a lack of evidence, and identify 
where further studies are required (Egger et al., 2002; Munafo and Flint, 2004). It is, however, 
important to realise that meta-analyses do not represent a panaceae for the case-control 
genetic association study. Indeed, it has been found that performing meta-analyses can 
introduce further bias and risk for confounding into an investigation, largely due to between-
study heterogeneity and publication bias (as discussed in the aforegoing section) (Gambaro et 
al., 2000).  
 
Critics of the method have voiced concern over how much heterogeneity (genotypic, 
phenotypic and methodological) can be included in the meta-analysis for the results to still be 
acceptable. If between-study heterogeneity is expected, it may be conducive to employ a form 
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of weighted pair (Woolf, 1955), or random variable analysis (Naylor, 1996) in order to control 
for confounding caused by such heterogeneity. 
 
Meta-analyses thus represent a potentially powerful tool for genetic association studies. 
However, one must be cautioned that it cannot be considered a substitute for adequately 
powered genetic studies, but rather an adjunct to well-conducted studies, facilitating the 
identification of further avenues of research potential. 
 
I.5. DETERMINING THE VALIDITY OF AN ASSOCIATION: CAUSAL 
INFERENCE 
 
“The world is richer in association than in meanings, and it is the part of wisdom to 
differentiate the two” 
John Barth, novelist 
 
Once confounding, chance and bias have all been eliminated as possible contributory factors 
to an observed association, the validity thereof can be assessed by employing a set of 
inductive epidemiological criteria, originally proposed by Hill in 1965 (Hill, 1965). These 
criteria, some of which are applicable to genetic association studies, include consistency (or 
replication) and biologic plausibility. 
 
I.5.1. REPLICATION, REPLICATION, REPLICATION 
In the absence of a more extensive understanding of the effects at the molecular level that 
may contribute to the aetiology of OCD, replication (preferably in multiple independent 
studies) may be the most powerful evidence in favour of causality (Campbell and Rudan, 
2002). In fact, it has been suggested that statistically significant associations should be 
replicated before any declaration for a susceptibility gene is accepted (Colhoun et al., 2003; 
Little et al., 2002). In population-based genetic association studies conducted on OCD, a large 
degree of inconsistencies in results has been observed; however, the problem of non-
replication is not limited to OCD investigations, but seems to be plague most association 
studies investigating the genetic aetiology of complex disorders. 
 
At least three studies investigating how wide-spread the problem of non-replication of 
population-based genetic association studies in complex disorders is, have been conducted. 
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Hirschhorn et al. (2002) observed that only the results of six studies (out of 166 “positive” 
genetic association studies) were consistently reproduced. Similarly, Ioannidis et al. (2003) 
performed 55 meta-analyses (comprising 579 study comparisons), and found that only 16% of 
the genetic associations identified were replicated without the influence of heterogeneity or 
bias. On the other hand, in a recent study Lohmueller et al. (2003) concluded that 
approximately a quarter of previously published associations are true, with false negative 
associations (usually due to underpowered studies) accounting for a large proportion of the 
inconsistent results. The authors subsequently advocate testing previously reported 
associations, replicated at least once, in large samples to identify the true genetic risk factors.  
 
It could, of course, be argued that the inconsistencies and inability to replicate statistically 
significant findings may represent true variations of underlying associations between 
populations (Colhoun et al., 2003), as co-factors associated with the disease may be 
represented variably in different populations. Factors such as different degrees of LD between 
marker and susceptibility alleles, allele and haplotype frequency differences, environmental 
modifiers and patient ascertainment strategies may all contribute towards discrepant genetic 
association results between populations (Vieland, 2001; Stephens et al., 2001; Glatt et al., 
2001).  
 
As already mentioned, the degree of LD between the marker and disease-susceptibility alleles 
may vary between populations. For this reason, LD should always be examined within the 
context of the study population, rather than simply assuming LD between two variants based 
on the results from another study involving a different population. Moreover, association 
studies may be difficult to replicate if the variant under investigation possesses a low ES, 
variable penetrance and/or allele frequencies across populations. In particular, significant 
associations with rare alleles (with a frequency of below 5%) are more likely to be 
population-specific, and thus less likely to be replicated (Campbell and Rudan, 2002; 
Pritchard, 2001; Wright and Hastie, 2001). 
 
To circumvent the potential lack of replication, it may be conducive to examine alternative, 
more common (where possible, functional) variants in the same gene for association with the 
disorder. It has also been suggested that an “internal check” for association be conducted in 
the same population as the original positive study (Campbell and Rudan, 2002). Ideally, 
replication should be conducted in both family- and population-based association studies, 
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demonstrating both linkage and association of the variant with the disorder, further 
reinforcing evidence for the association (Owen et al., 1997). 
 
In order to interpret an association that has not been consistently replicated, it is necessary to 
distinguish which of the factors are most relevant to discrepancies between the studies that 
results in non-replication, and to control for them. It is also important to note that a lack of 
replication does not negate the causal relationship between the variant and the disorder; 
instead, it may indicate the need for further studies in certain populations, or a more detailed 
analysis of the gene containing the variant under consideration (Tabor et al., 2002).  
 
I.5.2. BIOLOGICAL PLAUSIBILITY OF THE CANDIDATE GENES AND 
POLYMORPHISMS IN GENETIC ASSOCIATION STUDIES 
A candidate gene is one that, on the basis of prior physiological, genetic or biochemical 
characterisation, is suspected to contribute to the aetiology of the disorder under investigation. 
Candidate genes can be categorised into either positional candidates, chosen on the basis of a 
genomic location that has previously been found to be associated with the disorder, or 
hypothesis-driven candidates, chosen because of their (hypothesised) role in the aetiology of 
the disorder.  
 
Obviously, any investigation into the causality of an observed association needs to account for 
the biological validity of the candidate gene, which depends on the prior probability that the 
candidate gene (and the variant under investigation) are involved in (in this case) OCD 
pathology. Therefore, it follows that a low prior probability of candidature will result in an 
increased risk of attaining false positive results.  
 
In theory, the idea of prior probability would enable one to quantify biologic plausibility on a 
probability scale, and to incorporate it into subsequent statistical analyses; in reality, however, 
the prior probability that a candidate gene is involved in the development of OCD is difficult 
to determine exactly, due to the presently incomplete knowledge regarding the biological 
mechanisms of pathology. Prior probability can therefore, at best, be estimated, and is thus 
largely subjective and hypothesis-driven (Freimer and Sabatti, 2004).  
 
On the basis of such estimation, the prior probability that a candidate gene is biologically 
plausible is increased if the gene has been found to be associated with existing familial forms 
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of the disorder and/or the same disease in a population of different ethnicity; if the gene 
variant is found to be involved in molecular mechanisms of the disorder; if the gene possesses 
a high mRNA copy in tissues thought to be affected by the pathological process of the 
disorder; and if sufficiently valid experimental evidence (for example, animal studies, gene 
knock-out models) exists to support the role of the candidate gene (or variant) in the disorder 
(or related disorders). 
 
The prior probability that the variant under investigation is involved in the disorder (or is in 
LD with a susceptibility allele) cannot be dismissed when assessing the biologic plausibity of 
candidate genes. Given the wide array of variants that one can choose from in an association 
study, available data needs to be sifted through to prioritise and select which polymorphisms 
will be most conducive to detecting association. The most likely polymorphisms to be 
associated with disease are those that affect the function of the candidate gene and its 
associated protein (Tabor et al., 2002). Therefore, at first glance, it would seem that an 
expedient approach would be to identify variants within the coding regions of candidate genes 
for use as markers. However, even non-coding variants have been found to influence gene 
function, especially those contained in regulatory regions (Horikawa et al., 2000). 
Consequently, searches restricted to only coding variants may bypass important information 
contained within the non-coding regions. Unfortunately, present knowledge pertaining to the 
characterisation of regulatory regions and their effect on level of gene or phenotype 
expression is still in its infancy. In spite of this, it is known that the functional effects of 
polymorphisms within candidate genes are normally complex, and that, at a molecular level, 
the combinatorial nature of alleles should be taken into account. Therefore, it would be more 
conducive to the study that the genetic variants under investigation be considered in their 
haplotypic context, rather than in isolation. 
 
I.6. THE PRESENT STUDY 
The aims of the present study were two-fold: firstly, to investigate selected candidate genes 
for the role that they may play in the development of OCD, taking into account the biological 
and statistical intricacies that encompass such studies (many of which have been mentioned in 
the previous sections), and secondly, to determine whether any type of cryptic population 
substructure, which would possibly confound the results of the association studies, exists 
within the Afrikaner population. The following sections expand on these two facets of the 
present analyses. 
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The genetic diathesis provided by family and twin studies in OCD (sections I.3.2.1 and 
I.3.2.2) provides a solid foundation for conducting population-based case-control association 
studies, which forms the basis of the present dissertation. An extensive literature search was 
conducted in order to select candidate genes and variants within candidate genes for 
investigation in the present genetic association studies. The candidate genes were prioritised 
according to biological validity as follows: first, genes encoding products that have been 
shown to play a role in the aetiology of OCD or OCD subtypes (based on animal, 
pharmacological and previous genetic studies) were selected. Second, genes coding for 
protein products that have been shown to be involved the pathophysiology of disorders 
closely related in aetiology to OCD, or disorders occurring co-morbidly with OCD (for 
example MDD), were chosen for investigation.  
 
The choice of polymorphisms within selected candidate genes is also important in association 
studies (section I.5.2); in the present study variants were prioritised according to the 
following criteria: those known to affect the function of the relevant gene were given the 
highest priority. Polymorphisms in plausible candidate genes with minor allele frequencies of 
greater than 5% (according to published or validated data) were also prioritised, given the 
present CD/CV hypothesis regarding the genetic aetiology of many complex disorders 
(section I.3.2.3). It should be mentioned that various concerns have been raised regarding the 
reliability and validity of SNP data deposited in public databases, with only 50 to 60% of 
SNPs in the database representing bona fide sequence variations (Marth et al., 2001). 
However, SNPs that are reported to occur in multiple human subpopulations have been found 
to be particularly well-validated (Marth et al., 2001). Therefore, where possible, SNPs that 
have been validated in more than one population were preferred over those that had been 
validated in only one population (particularly if it had been validated using a small number of 
individuals, or in a population geographically unrelated to the Afrikaners).  
 
I.6.1. Factors influencing the selection of OCD candidate genes  
As mentioned in the previous section, the probability that a candidate gene is involved in the 
aetiology of OCD is increased if it is found to be transcribed at fairly high levels in the tissue 
affected by the pathological process. It is thus imperative to take the neurobiological and 
neurochemical aetiology of OCD into account when choosing candidates for investigation in 
genetic association studies. 
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Presently,  a fairly large body of evidence exists to support the neurobiological basis of OCD, 
including the observation that 90% of OCD patients exhibit neurological “soft signs” 
consistent with some neurological disorder; for example, the emergence of obsessive-
compulsive symptoms as part of postencephalitic Parkinson’s syndrome (Graybiel and Rauch, 
2000) and the onset of OCD following head trauma (McKeon et al., 1984). 
 
Initial proposals focused on a role for basal ganglia abnormalities associated with OCD since 
several other disorders involving basal ganglia pathology have been found to either occur co-
morbidly with OCD, or to exhibit obsessive and/or compulsive symptoms (Cummings and 
Frankel, 1985; LaPlane et al., 1989). Such disorders include von Economo’s encephalitis 
(Schilder, 1938), Sydenham’s chorea (Swedo et al., 1989[c]) and TS (Cummings and Frankel, 
1985; Luxenberg et al., 1988). Indeed, results from cumulative functional and structural 
neuroimaging studies have converged to form a relatively cohesive picture implicating a 
dysfunction in the cortico-striato-thalamo-cortical (CSTC) network (a neuronal loop linking 
the basal ganglia and frontal association areas [Alexander et al., 1986]) in the pathology of 
OCD (Rauch, 2003; Luxenberg et al., 1988; Robinson et al., 1995; Saxena et al., 1998; 
Rosenberg et al., 1997; 2000; Rauch et al., 1994; 1997; Lacerda et al., 2003; Pujol et al., 
2004; Swedo et al., 1989 (a); Szeszko et al., 2004; Baxter et al., 1987; 1988). Furthermore, 
evidence collected from a constellation of functional and structural neuroimaging studies has 
also implicated the prefrontal cortex (PFC) in the aetiology of the disorder (Baxter et al., 
1987; 1988; Saxena et al., 1998; Otto, 1990; Rauch and Baxter et al., 1998).  
 
Thus, taken together, neuroimaging studies implicate the orbitofrontal-subcortical circuits in 
the pathophysiology of OCD. A working hypothesis explaining the involvement of the CSTC 
pathway in the development of OCD is that the disorder is associated with a failure to inhibit 
subsets of CSTC “mini-circuits”, resulting in hyperactivity of the CSTC circuit (Modell et al., 
1989; Rapoport, 1991; Rapoport and Wise, 1988; Baxter et al., 1992; 1994; Insel, 1992). 
Obsessive-compulsive symptoms arise when processing of cortical input to the basal ganglia 
is defective, resulting in an excitatory drive and excessive cortical activity, which further 
exacerbates the abnormal basal ganglia function (Greenberg et al., 2000). .  
 
Obviously the main interest, from a genetics point of view, would be to identify the 
neurotransmitter systems that play a role in the proposed CSTC dysfunction in OCD. The 
CSTC circuitry is innervated by a variety of neurotransmitter pathways – 5-HT and dopamine 
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serve to modulate the activity of efferents from the basal ganglia, whilst glutamate has been 
found to moderate excitatory inputs to the network (Baxter et al., 1996). These 
neurotransmitter systems thus play a pivotal role in maintaining both physiological and 
psychological processes in the brain.  
 
This section therefore provides a review of current literature pertaining to neurochemical 
hypotheses of OCD, followed by a brief summary, in the form of a table, of the genetic 
components within each of the pathways that have been investigated in genetic association 
studies (either family- or population-based). Thereafter, the presently investigated candidate 
genes, and variants therein, within each of the pathways are discussed. 
 
I.6.1.1.  The serotonergic hypothesis of OCD 
5-HT is a monoamine neurotransmitter which is synthesized from the essential amino acid 
tryptophan in a two-step process. Tryptophan hydroxylase (TpH) catalyzes the rate-limiting 
step in the synthesis of 5-HT by converting tryptophan (Trp) to 5-L-hydroxytryptophan. L-
amino acid decarboxylase subsequently converts 5-L-hydroxytryptophan to 5-HT. The 
vesicular monoamine transporter type-2 (VMAT2) transports 5-HT into presynaptic vesicles. 
These vesicles then release 5-HT extraneuronally, where 5-HT interacts with postsynaptic 
receptors including 5-HT2A and 5-HT2C. 5-HT also binds to somatodendritic (5-HT1A) and 
terminal (5-HT1B) autoreceptors. The serotonin transporter (5-HTT) transports 5-HT from the 
extraneuronal space back into the presynaptic neuron. MAO-A breaks down 5-HT within the 
presynaptic neuron. 
 
Serotonergic releasing neurons have their cell bodies located in brainstem raphe nuclei and 
provide highly collateralised axonal innervation to almost all areas of the central nervous 
system (CNS) by virtue of bifurcation of the neurons. Prominent forebrain serotonergic 
terminal regions include the hypothalamus, cortex, hippocampus, amygdala and striatum, with 
particularly dense innervation in the cerebral cortex, basal ganglia and limbic structures 
(Figure I.2). It is important to note that serotonergic innervation does not function 
homogeneously because the neuronal projections have a high degree of anatomical, 
morphological and pharmacological specialisation. 
 
The synaptic effects of serotonin neurotransmission are mediated by a number of pre- and 
postsynaptic serotonergic receptors. Of all the CNS neurotransmitters, 5-HT represents the 
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most perplexing array of receptor interactions. 5-HT receptors are presently divided into 
seven classes (5-HT1 to 5-HT7) and these classes comprise a total of 14 structurally and 
pharmacologically distinct mammalian receptor subtypes (Hoyer et al., 1994; Hoyer and 
Martin, 1996). All 5-HT receptors (with the exception of 5-HT3) belong to the superfamily of 
G-protein coupled receptors, all containing the predicted 7-transmembrane domain structure. 
 
Amongst others, 5-HT play as important role in controlling self-esteem, stabilising mood, 
facilitating co-operative and competent social behaviour and allowing for the suppression of 
aggression; behavioural paradigms which are all characteristically disturbed in psychiatric 
disorders (Jacobs, 1991; Golden et al, 1991; Chopin and Briley, 1987). The study of 
peripheral markers of 5-HT function is based on the assumption that, in OCD, peripheral 
abnormalities may reflect abnormal 5-HT function in the CNS. Peripheral markers in these 
studies include 5-HT content of whole blood and platelets, platelet imipramine-binding 
capacity and the concentration of the major end metabolite of 5-HT, 5-hydroxyindoleacetic 
acid (5-HIAA) in the cerebrospinal fluid (CSF). Reports indicate that CSF 5-HIAA 
concentrations tend to decrease in certain subgroups of OCD patients, particularly those 
responding to pharmacotherapy (Insel et al., 1985; Thoren et al., 1980; Flament et al., 1987), 
although these findings have proven inconsistent and difficult to replicate (Hanna et al., 1991; 
Leckman et al., 1995; Lopez-Ibor, 1988). 
 
More recently, studies have been undertaken to determine the availability of 5-HTT in OCD 
patients. This is a protein that is critical to the regulation of 5-HT, and represents the initial 
site of SSRI action. As such, 5-HTT may be useful as a marker of 5-HT function in OCD. 
Indeed, the availability of the 5-HTT has been found to be significantly reduced in the 
midbrain and upper brainstem of OCD patients (Stengler-Wenzke et al., 2004). These results 
were not, however, consistent with those from two previous studies, in which no difference 
(Simpson et al., 2003), and an increase (Pogarell et al., 2003) in 5-HTT availability were 
noted when OCD patients were compared to controls. The most likely explanation for the 
aforementioned discrepant results is difference in study designs (Stengler-Wenzke et al., 
2004); nonetheless, the particular area of study seems promising and requires further 
attention. 
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Figure I.2. Schematic representation of serotonin pathways in the central nervous system. 
Five pathways are indicated, including projections from midbrain raphe to prefrontal cortex 
(1); basal ganglia (2); hippocampus (3), hypothalamus (4), and spinal cord (5) (After Stahl, 
1996). 
 
The acute administration of a pharmacological agent that affects the 5-HT system allows the 
functional integrity of the system to be assessed. Meta-chloropiperazine (m-CPP) is a potent, 
relatively non-selective, 5-HT receptor agonist, which is utilised in studies to assess central 5-
HT receptor sensitivity in OCD. This 5-HT agonist has complex effects on brain systems in 
that it binds potently to 5-HT receptors 2C (5-HT2C) and 2A (5-HT2A), and with weaker 
affinity to 5-HT receptor 1A (5-HT1A) (Kahn and Wetzler, 1991), and has been shown to 
exacerbate OC symptoms in patients (Zohar et al, 1987; Hollander et al., 1991; 1992[a]; 
Broocks et al., 1998). Many hypotheses abound regarding the exacerbation of OCD 
symptoms after m-CPP administration, one being that it exacerbates an underlying 5-HT 
hyperfunction, and in doing so, increases OCD symptomatology (Hollander and Stein, 1997). 
However, it is important to note that these results were not consistent in other investigations 
of m-CPP challenge (Charney et al., 1988; Goodman et al., 1995; Khanna et al., 2001). 
Administration of other 5-HT probes have also been used in pharmacologic challenge 
research, for example, the selective 5-HT receptor 1D (5-HT1D) agonist, sumatriptan, has been 
used to explore the role of, in particular, the 5-HT1Dβ/1Dα receptors in OCD (refer to section 
I.6.1.1.1[i] for a more detailed discussion on the role of sumatriptan challenges in OCD). 
Here, as with m-CPP investigations, inconsistent results have been found, possibly indicating 
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the heterogeneous neurobiological aetiology of the disorder (Zohar and Insel, 1987; Charney 
et al., 1988; Zohar et al., 1987; Barr et al., 1993). 
 
The neurobiological actions of medication commonly used in the treatment of OCD and 
related disorders has also shed some light on the neurochemical pathology of such disorders. 
Clomipramine (CMI), a tricyclic antidepressant, was first introduced in 1966, but it was not 
until the mid-1980s that the full potential of this potent 5-HT reuptake inhibitor (SRI) in the 
treatment of OCD was realised (Greist and Jefferson,1998). CMI has been found to be 
superior in treating OCD when compared to other non-5-HT antidepressants (Thoren et al., 
1980; Ananth et al., 1981). It was thus proposed that it was the ability of CMI to inhibit 5-HT 
reuptake that was responsible for its anti-OCD properties. Subsequently, alternatives to CMI 
treatment, namely, SSRIs, have been formulated, each with effective anti-OCD properties. At 
present, SSRIs represent first-line pharmacotherapy in the treatment of OCD (Greist and 
Jefferson, 1998; Rapoport and Inoff-Germain, 2000; Zohar and Insel, 1987; Leonard et al., 
1989; Greist et al., 1995; Piccinelli et al., 1995). These agents also tend to be effective in a 
variety of disorders that share phenomenological characteristics with OCD, such as TTM and 
BDD (Stein, 2000; McElroy et al., 1994). 
 
Understanding the mechanism of action of SSRIs in the treatment of OCD has enabled the 
identification of many of the 5-HT components that may be involved in mediating the 
disorder. 5-HT released from the raphe neurons into the synapse can act on a variety of 
postsynaptic 5-HT receptors, as well as at the 5-HT1A and 5-HT1B/D presynaptic auto-
receptors, which normally act to decrease 5-HT neuronal firing rates, thereby maintaining 
effective levels of 5-HT in the synaptic sites (Gothert, 1990). After administration, SSRIs 
block the reuptake of 5-HT into the presynaptic nerve terminal almost immediately, 
increasing the concentration of 5-HT present in the synapse. This results in an increased 
activation of the presynaptic inhibitory receptors, which causes a reduction in the firing rate of 
the 5-HT neurons.  
 
However, after a lag period of approximately 2 to 3 weeks, downregulation and subsequent 
desensitisation of the autoreceptors causes a disinhibition of 5-HT release at the axon 
terminals. This results in an increased 5-HT firing rate, which ultimately increases the 5-HT 
concentrations in the cortex to therapeutic levels. It is proposed that it is the desensitisation of 
the presynaptic receptors and subsequent increase in synaptic 5-HT that brings about the 
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desired effect of the SSRIs, and acts as a likely explanation as to why the delay exists in 
achieving full therapeutic effects when employing an SSRI treatment regimen in OCD (Nutt 
et al., 1999; Blier and Montigny, 1998; El Mansari et al., 1995; Blier and Bouchard, 1994).  
 
It should, however, be noted that a significant proportion of OCD patients do not respond to 
SSRI monotherapy – the mean response rate to SSRIs has been reported to be approximately 
50% (Greist et al., 1995; Stein et al., 1995). In addition, pharmacological challenge studies in 
drug-free OCD patients have, as of yet, identified no consistent abnormality in 5-HT function 
(Barr et al., 1992; Goodman et al., 1995). This could be explained in terms of the involvement 
of other neurotransmitter systems in the pathology of the disorder. In fact, it has been 
proposed that if there is any possibility of an isolated dysfunction of the 5-HT system, it is 
probably only present in a small group of OCD patients who respond well to SSRI 
monotherapy (Khanna et al., 2001). Paradigms have therefore been developed to evaluate the 
role that other neurotransmitter or neuropeptide systems may play in the neuropathology of 
the disorder.  
 
Based on the aforementioned information, a number of genetic association studies (both case-
control and family-based) have been conducted, in various populations, in order to investigate 
the contribution that genes encoding components within the 5-HT system may have in the 
aetiology of OCD and related subtypes (Table I.5). 
 
I.6.1.1.1. Serotonergic candidate genes investigated in the present study 
 
i. The 5-HT Receptor 1Dβ gene (5HT1Dβ) 
In the brain, 5-HT1Dβ  pre- and postsynaptic receptors are concentrated in the basal ganglia, 
striatum and frontal cortex, with the highest receptor densities found in the basal ganglia 
(Moret and Briley, 2000; Graeff, 1997), and may be situated either pre- or post-synaptically 
relative to 5-HT neurons. 5-HT1Dβ auto-receptors are found primarily at the sites of 5-HT 
release (i.e. synaptic terminals or axonal varicosities) (Gothert, 1990), and their primary 
function is to inhibit the release of 5-HT by modulating the firing rates of the neurotransmitter 
from the neurons (Gothert and Schlicker, 1987).  
 
The 5-HT1Dβ receptor is not only found on 5-HT neurons, but may also be situated on non-5-
HT neurons (Uphouse, 1997), where it acts as a heteroreceptor, controlling the release of 
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neurotransmitters other than 5-HT. Such neurotransmitters include acetylcholine, glutamate, 
noradrenaline and γ-aminobutyric acid (Iyer and Bradberry, 1996; Gothert, 1990). 
 
The receptor has been clearly implicated in basic behavioural activities in animals:  
5-HT1Dβ auto-receptor knockout mice exhibit an increase in aggression and impulsivity, as 
well as increased alcohol consumption (Huang et al., 1999; Montgomery and Fineberg, 1989). 
Pre-clinical evidence of the role that the 5-HT1Dβ autoreceptor may play in OCD has been 
obtained from animal studies, where it was found that, in the orbito-frontal cortex, the 
enhanced release of 5-HT brought about by SSRIs was attributable to the desensitisation of 
the 5-HT1Dβ auto-receptor (el Mansari et al., 1995).  
 
The putative role that the 5-HT1Dβ auto-receptor may play in the mediation of OCD in humans 
has been investigated by means of pharmacological challenge with 5-HT probes, namely m-
CPP and sumatriptan. Zohar and Kindler (1992) observed that orally administered m-CPP 
aggravated OCD symptoms, whereas the administration of MK-212 (another 5-HT agonist) 
did not. Taking into account the sites of action of the two receptor agonists (m-CPP stimulates 
5-HT1Dβ, but MK-212 does not), it was proposed that the 5-HT1Dβ receptor may be implicated 
in OCD (Koran et al., 2001). Similarly, the administration of a more selective 5-HT1Dβ auto-
receptor agonist, sumatriptan, to untreated OCD patients, was also found to produce a 
transient worsening of obsessive-compulsive symptoms (Stern et al., 1998; Gross-Isseroff et 
al., 2004; Koran et al., 2001) (although again, this effect was not observed in all studies [Ho 
Pian et al., 1998]). 
 
Moreover, in a functional brain imaging study combined with symptom provocation with 
sumatriptan in OCD patients, Stein et al. (1999) reported a heterogeneous behavioural 
response, with some patients showing acute symptom exacerbation, while others 
demonstrated a decrease in symptoms. It was also reported that those patients exhibiting an 
increase in OCD symptomatology after acute sumatriptan challenge had a poorer response to 
SSRI therapy. Interestingly, anecdotal reports have suggested that the chronic administration 
of sumatriptan has therapeutic effects on depressive, and perhaps on obsessive-compulsive,  
symptoms in OCD patients who are highly resistant to conventional pharmacotherapy (Stern 
et al., 1998; Pathak et al., 2003). 
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Table I.5: Published population and family-based genetic association studies in OCD: serotonergic candidate genes 
 
Sample number 
affected 
Gene Variant(s) Population Study design 
Phenotype 
investigated 
case families 
control 
Result (p-values, and implicated risk allele) Ref. 
5-HTT                  
 Not specified CC OCD 72  72 NS 1 
 European-American FB OCD  35  p<0.03 (La-allele) 2 
 Caucasian American CC OCD 75  397 p=0.023 (LL-genotype) 3 
 Afrikaner CC OCD 54  82 NS 4 
 Jewish (Ashkenazi [A]and non-A) CC OCD 75 (39A)  
172 
(112A) NS 5 
 META-ANALYSISb CC OCD 129  479 NS 4 
 Mexican CC/ FB OCD 115 43 136 NS 6 
 Italian CC OCD 180  112 NS 7 
 German FB OCD  63  NS 8 
 Brazilian CC OCD 79  202 NS 9 
 
5-HTTLPR 
French/German CC/ FB OCD 106 86 171 NS 10 
 17bp VNTR in intron 2 Japanese CC OCD 15  106 
p=0.033 for 12-repeat allele 
aL refers to the “long” allele; cStudies included in meta-analysis are: references 3and 4;c EO OCD ≤ 15 years;; dCaucasians were of US, Italian and Finnish origin 
OR=10.2 (95% CI: 1.34-77.4) 11 
5-HT2A               
 Mexican CC OCD 67  54 NS 12 
 Jewish (Ashkenazi [A]and non-A) CC OCD 75 (39A)  
172 
(112A) NS 5 
 Afrikaners CC OCD 71  129 NS 13 
 
T102C 
SA Caucasians, stratified 
into Afrikaner (Afr) CC 
EOcOCD vs. LO 
OCD 
n(EO)=95[45 Afr]; 
n(LO) = 85 [35 Afr]   NS 14 
 German CC OCD 55  223 p=0.046 (genotype) A-allele 15 
 N. American Caucasian CC OCD 101  138 p=0.015 and p=0.023 (allele and genotype); A-allele in females 16 
 
1438G/A 
N. American Caucasian CC  62  144 A-allele increased in OCD patients p<0.05 17 
 T102C and -1438 A/G Turkish CC OCD 58  83 NS 18 
 C516T Brazilian CC OCD 79  202 p=2x10-4 (genotype); p=7x10-5 ; C-allele) 9 
5-HT2C           
 CC OCD 109  107 NS 
 
Italian 
 OCD+tics vs. OCD-tics n(OCD+tics)=23   NS 
19 
 
ser23cys 
Jewish (Ashkenazi [A]and 
non-A) CC OCD 75 (39A)  
172 
(112A) NS 5 
5-HT1Dβ           
 Italian  FB OCD  32  p<0.006 / OR=5.26 (1.92-13.10) G-allele 20 
 Italian  FB OCD  48  NS 21 
 Italian  FB OCD  121  p=0.02 (G-allele) 22 
 Afrikaners CC OCD 71  129 NS 13 
 Mexican FB OCD  72  Higher Y-BOCS obsession scores for males carrying the G-allele (p=0.034) 23 
 German FB OCD  64  NS 8 
 
G861C 
SA Caucasians, stratified 
into Afrikaner (Afr) CC 
EOcOCD vs. LO 
OCD 
n(EO)=95[45 Afr]; 
n(LO) = 85 [35 Afr]   NS 14 
TPH            
 Jewish (Ashkenazi [A]and non-Ashkenazi) CC OCD 75 (39A)  
172 
(112A) NS 5 
 
rs1800532 
(intron 7) 
German FB OCD  59  NS 8 
 T1095C (exon10) 
American Indians & 
Caucasiansd  OCD 88  142 NS 24 
Abbreviations: OCD: Obsessive-compulsive disorder; CC: population-based case-control association; FB: family-based association OR: Odds ratio; CI: confidence interval; NS: non-significant finding (p>0.05); VNTR: 
variable number of tandem repeats; SA: South African; EO: early-onset OCD; LO: late-onset OCD;; Afr: Afrikaner; 5-HTT: serotonin transporter; 5-HTTLPR: variable number of tandem repeat polymorphism in the promoter 
region of 5-HTT, producing either long (L) or short (S) alleles; 5-HT2A: serotonin receptor 2A; 5-HT2C: serotonin receptor 2C; TPH: Tryptophan hdroxylase;  
References:1: Billet et al. (1997); 2: McDougle et al. (1998); 3: Bengel et al. (1999); 4: Kinnear et al. (2000); 5: Frisch et al. (2000);6: Camarena et al. (2001); 7: Cavallini et al. (2002); 8: Walitza et al. (2004); 9: Meira-Lima 
et al. (2004); 10: Chabane et al. (2004); 11: Ohara et al. (1998); 12: Nicolini et al. (1996); 13: Hemmings et al. (2003); 14: Hemmings et al. (2004); 15: Walitza et al. (2002); 16: Enoch et al. (2001);17: Enoch et al. (1998); 18: 
Tot et al. (2003); 19: Cavallini et al. (1998); 20: Mundo et al. (2000); 21: Di Bella et al. (2002); 22: Mundo et al. (2002); 23: Camarena et al. (2004); 24: Han et al. (1999). 
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Finally, it has been proposed that the 5-HT1Dβ auto-receptor may be involved in the efficacy 
of SSRIs (el Mansari et al., 1995; Dolberg et al., 1996). As stated before,the initial effect of 
the SSRI is to increase 5-HT concentration, the pharmacotherapeutic effect of these agents 
seems to be associated with the subsequent adaptive down-regulation of 5-HT1Dβ auto-
receptors. Hence the importance of investigating the probable role that the gene encoding the 
5-HT1Dβ auto-receptor may play in mediating susceptibility to OCD.  
 
5-HT1Dβ maps to chromosomal location 6q13 (Hamblin et al., 1992; Demchyshyn et al., 1992) 
and is intronless, with a size of 1179 bp (Lappalainen et al., 1995[a]). The polymorphic 
variant analysed in the present study is characterised by a SNP that can be detected by means 
of HincII restriction enzyme. The SNP is created by a silent G-C substitution at nucleotide 
position 861 of the coding region (G861C) (Sidenberg et al., 1993; Lappalainen et al., 
1995[a]). The functional significance of this polymorphism has not yet been established, 
although, individuals homozygous for the G861 allele have been found to possess higher Bmax 
values for 5-HT1Dβ binding in the PFC (Huang et al., 1999). 
 
Preliminary evidence from two genetic studies utilising TDT analysis have implicated the 
possible involvement of the 5-HT1Dβ auto-receptor in the aetiology of OCD (Mundo et al., 
2000; 2002) (Table I.5). In these studies, a significant association was observed between the 
distribution of the polymorphic G861C allelic variants of the 5-HT1Dβ and OCD, with 
preferential transmission of the G-allele to the affected subjects. These results have, however, 
not been replicated in subsequent family (Di Bella et al., 2002; Camarena et al., 2004; Walitza 
et al., 2004) and population-based (Hemmings et al., 2003; 2004) association studies (Table 
I.5).  
 
The variant has also been investigated for its role in early-onset OCD in both family-based 
(Walitza et al., 2004) and population-based (Hemmings et al., 2004) studies, with neither 
study yielding significant results. It should, however, be mentioned that, although Camarena 
et al. (2004) observed no significant association between G861C and the DSM-IV diagnosis 
of OCD, they did observe that subjects with a preferential transmission of G861 exhibited 
higher Y-BOCS Obsession scores than those with the C861 alelle, implicating the gene in the 
severity of obsessions.  
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The present study builds upon data presented in two previously published articles (Hemmings 
et al., 2003; Hemmings et al., 2004), investigating the role that the G861C polymorphism may 
play in OCD and related subtypes. 
 
ii. The Serotonin Receptor 2 genes (5-HT2A and 5-HT2C) 
5-HT2 receptors are widely studied in psychiatric disorders and have been implicated in a 
broad range of behavioural and physiological processes and cellular development. They also 
represent the sites of action of hallucinogens and certain psychotherapeutic drugs (Morilak et 
al., 1994; Kapur and Remington, 1996). These receptors are widely distributed, both 
peripherally and in CNS tissue, occuring in high densities in the cerebral cortex and regions of 
the amygdala and hypothalamus (Uphouse, 1997). To date, genes encoding three human 5-
HT2 receptor subtypes have been cloned, namely the gene encoding the 5-HT2A receptor (5-
HT2A) (Chen et al., 1992), the 5-HT2B receptor (5-HT2B) (Choi et al., 1994) and the 5-HT2C 
receptor (5-HT2C) (Xie et al., 1996). 
 
a. The Serotonin Receptor subtype 2A gene (5-HT2A) 
There is presently a wide range of pharmacological and genetic evidence implicating the 5-
HT2A receptor in the pathophysiology of OCD. Recent case reports indicate that the chronic 
use of hallucinogenic drugs, which are potent stimulators of the 5-HT2A receptor, may have 
beneficial effects in individuals with OCD and related OCSDs (Moreno and Delgado, 1997; 
Leonard and Rapoport, 1987; Hanes, 1996) suggesting a beneficial role of 5-HT2A receptor 
activation. Supporting this notion is the increasing number of reports that describe the 
tendency of clozapine, a 5-HT2A receptor antagonist, to unmask obsessive-compulsive 
symptoms in schizophrenic subjects (Patil, 1992; Baker et al., 1992; Poyurovsky et al., 1996). 
In addition, it has been shown that risperidone, a highly selective, potent 5-HT2A/DRD2 
receptor antagonist, results in the exacerbation of obsessive-compulsive symptoms in 
psychosis (Dodt et al., 1997; Andrade, 1998). 
 
However, confusing the issue somewhat are reports that risperidone has been found to 
enhance therapeutic responses when administered to SSRI-refractory OCD patients 
(McDougle et al., 1995; 1997; 2000; Jacobsen, 1995; Stein et al., 1997; Marek et al., 2003). 
The therapeutic efficacy of augmentation of risperidone to SSRI monotherapy in OCD has 
been hypothesised to be due to a possible synergistic action between the blockade of the 5-
 77
HT2A receptor (due to risperidone) and the activation of non-5-HT2A receptors (due to 5-HTT 
blockade caused by SSRI) (Marek et al., 2003). 
 
The gene encoding 5-HT2A receptor, located on chromosome 13q14-21 (Sparkes et al., 1991), 
has been one of the most widely investigated for its potential role in the aetiology of OCD.  
The gene comprises two alternative promoters, with a silencer element located downstream of 
the second promoter (Zhu et al., 1995). Two variants in particular, one occurring near the 
promoter region (-1438 A/G; dbSNP rs6311), and a silent variation reported to be in LD with 
it, in exon 1 (T102C: dbSNP rs6313), have been found to be associated with numerous 
psychiatric disorders, including anorexia nervosa (Collier et al., 1997; Sorbi et al., 1998; 
Enoch et al., 1998), bipolar disorder (Bonnier et al., 2002; Chee et al., 2001), seasonal 
affective disorder (Enoch et al., 1999) and schizophrenia (Williams et al., 1997; Arranz et al., 
1998). 
 
The function of the T102C polymorphism is presently under debate. Polesskaya and Sokolov 
(2002) investigated the relationship of the C102 and T102 alleles and expression of 5-HT2A in 
post-mortem brain tissue of normal and schizophrenic heterozygous individuals, and found 
that the expression level of C102 was significantly decreased in relation to that of the T102 
allele. Similarly, Khait et al. (2005) assayed platelet 5-HT2A binding kinetics, and observed 
that the T102T genotype was associated with increased 5-HT2A receptor density (and thus 
increased expression). However, Bray et al. (2004), using a quantitative allele-specific primer 
extension assay, observed no differences in expression between the C102 and T102 alleles in 
several adult cortical regions in a post-mortem assay, and concluded that neither allele 
affected mRNA expression.  
 
On the other hand, it is possible that the -1438 A/G promoter polymorphism may affect 
expression by altering promoter function. Spurlock et al. (1998) investigated this possibility 
using a reporter gene assay in heterologous cells and found no significant differences in levels 
of expression between the two alleles. However, in a more recent study, Parsons et al. (2004) 
made use of two different reporter gene assays and found that the presence of the -1438 A 
allele increased promoter activity. However, this was only observed in those cell lines 
expressing endogeneous 5-HT2A, indicating that transcriptional factors may be required to 
elicit this increase.  
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Interestingly, OCD has been found to be associated with the A allele of the -1438 G/A 
promoter polymorphism (Enoch et al., 1998; 2001) (Table I.5) although the association was 
only observed in female subjects, indicative, perhaps, of the differential 5-HT effects 
operating in men and women with OCD. These results were replicated in a study by Walitza 
et al. (2002), who found that the A-allele was associated with OCD in German children and 
adolescents.  
 
A number of studies have also investigated the T102C polymorphism for association with 
OCD, although none have yielded significant findings in Afrikaner (Hemmings et al., 2003), 
Turkish (Tot et al., 2003), Brazilian (Meira-Lima et al., 2004) or Jewish (Frisch et al., 2000) 
populations (Table I.5). However, a more recent study using a Turkish population, Tot et al. 
(2003) found that, although neither the T102C or the -1438A/G polymorphisms were 
associated with OCD per se, the T102T genotype from the T102C variant and the AA 
genotype from the -1438A/G variant were found to be associated with increased severity of 
OCD,as measured by Y-BOCS score. 
 
 
 
 
 
 
 
                                                                                                 I                 II                       III 
 
Figure I.3. Schematic representation of the 5-HT2A locus and flanking region.  The 
location of SNPs investigated in the present study are indicated by arrows. Exons are 
represented by yellow blocks, and introns are represented as horizontal lines between the 
exons (not drawn to scale). The distance between the two SNPs is 1.5kb. 
 
One would assume that, if the two loci are in complete LD with one another, that association 
at one would infer association at the other. It may, however, be that, in some populations, LD 
between the two polymorphisms is not complete, in which case an association between OCD 
and one variant may be detected, while it may not be detectable with the other. Neither of the 
aforementioned studies investigating the role that either of the polymorphisms plays in the 
-1438A/G T102C 
(rs6311) (rs6313) 
5’ 3’    
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development of OCD conducted haplotype analysis. Given the strong potential for the 
involvement of 5-HT2A in the aetiology of OCD, the present study investigates the possible 
involvement of two 5-HT2A polymorphisms in the aetiology of OCD and OCD- related 
subtypes: the promoter region -1438 A/G SNP, and the exon 1 T102C SNP (Figure I.3), using 
both single locus and haplotype analyses. 
 
b. The Serotonin Receptor subtype 2C gene (5-HT2C) 
Numerous animal and pharmacological studies have suggested the possible involvement of  
5-HT2C in the aetiology of OCD and/or OCD related disorders. Mice lacking the gene 
encoding 5-HT2C (5-HT2C) exhibit seizure syndromes, manifested by spontaneous tonic-clonic 
seizures and an increase in grooming behaviour (Heisler and Tecott, 2000). In addition, Chou-
Green et al. (2003) observed that 5-HT2C knockout mice exhibited compulsive-like 
syndromes, demonstrated by several defined, highly organized behaviours such as increased 
chewing of non-nutritive clay and the chewing of a plastic mesh screen in a neat pattern.  
 
Pharmacological studies have indicated an acute worsening of obsessive-compulsive 
symptoms after the administration of the selective 5-HT2C/5-HT1A/5-HT1D agonist, m-CPP, 
and a recent study using an animal model of OCD suggests that the 5-HT2C receptors are most 
likely involved in the exacerbation of OC symptoms after m-CPP administration (Graf et al., 
2003; Tsaltas et al., 2005). In addition, it has been suggested that chronic SSRI treatment 
could result in the reduction of mesocorticolimbic dopaminergically-mediated transmission 
via 5-HT2C activation, representing an important step in therapeutic efficacy of SSRIs (Prisco 
and Esposito, 1995; Di Matteo et al., 2001). 
 
The gene encoding 5-HT2C has been mapped to Xq24, consists of 6 exons, and stretches over 
approximately 230kb (Milatovich et al., 1992). A structural variant in the extracellular N-
terminal region of the receptor, resulting in a cysteine to serine amino acid substitution at 
position 23 (cys23ser), has been described (Lappalainen et al., 1995[b]). The function of this 
polymorphism is presently not clear: first, Lappalainen et al. (1999) reported a higher 
cerebrospinal fluid concentrations of the norepinephrine metabolite 3-methoxy-4-
hydroxyphenylethyleneglycol (MHPG) in males possessing the ser23 allele, compared to 5-
HT2C  cys23cys homozygotes, although no changes were noted in CSF concentrations of 
either dopaminergic or 5-HT metabolites. These results were, however, not replicated in a 
more recent study by Jönsson et al. (2004), although it is possible that the selection of subjects 
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may be responsible for the variation in results: Lappalainen et al. (1999) included 73% 
alcohol-violent offenders, with only 27% healthy controls, whilst Jönsson et al. (2004) 
included only healthy controls in their study. On the other hand, results from recent functional 
analyses, comparing the expression of the two alleles, indicated that the 5-HT2C receptor 
expressing the ser23-allele showed reduced high affinity binding to m-CPP and 5-HT, 
compared to that expressing the cys23-allele (Okada et al., 2004). 
 
In a case-control genetic association study to assess the relationship between 5-HT2C and 
OCD, Cavallini et al. (1998) found no significant association between the 5-HT2C cys23ser 
(dbSNP rs6318) variant and OCD in an Italian population, or between the variant and a 
subgroup of OCD subjects stratified according to the presence or absence of tics (Table I.5). 
Likewise, Frisch et al. (2000) observed no statistically significant differences in genotypic or 
allelic distribution between OCD patients and controls drawn from both an Ashkenazi Jewish 
population and a non-Ashkenazi Jewish population. However, the sample sizes in the latter 
study are relatively small (Table I.5), implicating that their results may be inconclusive.  
Therefore, given results from recent animal models, it would be valuable to investigate the 
role that this gene may play in mediating the development of OCD symptoms. The cys23ser 
variant was thus investigated in the present study. 
 
iii. The Serotonin Receptor subtype 6 gene (5-HT6) 
The gene encoding 5-HT6 has, as of yet, not been investigated for the role that it may play in 
the aetiology of OCD and OCD-related disorders. However, it represents an interesting and 
plausible OCD-susceptibility candidate gene for a number of reasons. First, the mRNA of 5-
HT6 has been found to be particularly abundant in the nucleus accumbens, caudate-putamen, 
olfactory tubercle and the striatum (Ruat et al., 1993; Ward et al., 1995; Gerard et al., 1996; 
1997; Branchek and Blackburn, 2000), brain areas that have been implicated in OCD. 
Secondly, dopaminergic neurons are found to occur in large numbers in these regions, and it 
has been proposed that dopaminergic neurotransmission may be modulated by 5-HT via 5-
HT6 in these brain regions (Matsumoto et al., 1999), although no direct evidence exists for the 
involvement of 5-HT6 as yet (Roberts et al., 2002).  
 
Perhaps more relevant to the study of OCD and OCD-related disorders is the observation that, 
in the rat brain, ontogenic studies have revealed that 5-HT6 expression correlates with the 
appearance of the first 5-HT cell bodies (Grimaldi et al., 1998). This suggests that 5-HT6 may 
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play a role in mediating certain aspects of 5-HT growth factor properties; consequently, a 
dysfunction in 5-HT6 may mediate the development of OCD, or related disorders, in 
accordance with the combined 5-HT/neurodevelopmental hypothesis of OCD. Animal studies 
have also indicated that 5-HT6 receptors may play a role in the aetiology of anxiety responses 
(Otano et al., 1999; Pouzet et al., 2002).  
 
A distinctive feature of the receptor is that it exhibits high affinity for antispsychotic 
compounds, such as risperidone and clozapine, which have been found to be efficacious in 
treating OCD patients presenting with comorbid tic disorders (Hollander et al., 2003[a]) and 
for various tricyclic antidepressants, namely CMI, amitryptyline and amoxipine (Monsma et 
al., 1993; Roth et al., 1994; Boess et al., 1997). 
 
The human gene encoding 5-HT6 has been mapped to chromosome 1p35-36, and comprises 
three exons (Kohen et al., 1996). To date, the most widely studied polymorphism in the gene 
occurs in the first exon, and is characterised by a synonymous T to C transversion at 
nucleotide 267 (T267C; dbSNP rs1805054). This variant has been investigated for the role 
that it plays in various neuropsychiatric disorders, including bipolar disorder, schizophrenia 
and Parkinson’s disease (Vogt et al., 2000; Tsai et al., 1999; Messina et al., 2002). The variant 
has also been implicated in patients’ response to antipsychotic agents: the T267T genotype 
has been associated with superior response for both clozapine and risperidone treatment in 
treating the anxiety and depressive characteristics experienced by schizophrenic patients 
(Lane et al., 2004; Yu et al., 1999).  
 
To the author’s knowledge, the present study is the first to investigate 5-HT6 as a candidate in 
a population-based OCD genetic association study. 
 
I.6.1.2.  The dopaminergic hypothesis of OCD 
Dopamine is a catecholaminergic neurotransmitter that is synthesised from the amino acid 
tyrosine by means of the enzyme tyrosine hydroxylase. This reaction constitutes the rate-
limiting step in which 3,2-dihydroxyphenylalanine (L-DOPA) is formed. L-DOPA is 
subsequently decarboxylated by dopa decarboxylase (DDC) to form dopamine. 
 
Once released into the synaptic space, dopamine acts on various types of postsynaptic 
dopaminergic receptors, which allows the transduction of the dopaminergic signals across the 
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post-synaptic neuronal membrane. Excess released dopamine is recaptured via an active re-
uptake mechanism and is inactivated in the pre-synaptic neuron by MAO-A and COMT. 
Dopaminergic neurotransmitters are clustered in the midbrain and branch into four major 
pathways - the nigro-striatal, the mesolimbic, the mesocortical, and the tuberoinfindibular 
pathways (Figure I.4). The neurotransmitter modulates a variety of functions, including 
neuro-endocrine, spatial and memory functioning, cognitive and emotional functioning, and 
reward and motivational behaviour (Jaber et al., 1997; Giros et al., 1992; Pani et al., 2000). 
 
Dopaminergic postsynaptic effects are mediated by at least five physiologically and 
pharmacologically distinct receptors (named DRD1 to DRD5). These five dopaminergic 
receptors can, in turn, be divided into two subfamilies whose properties resemble either those 
of the DRD1 or DRD2 receptors, which were originally defined (Jarvie and Caron, 1993). The 
two subfamilies are termed DRD1-like (which includes the DRD1 and DRD5 receptors) and 
DRD2-like (consisting of the DRD2, DRD3 and DRD4 receptors). Dopaminergic 
neurotransmitter action is terminated by the dopamine transporter (DAT), which is thus 
important in maintaining transmitter homeostasis. DAT can function in either direction, 
transporting dopamine into or out of the neuron, depending on the existing gradient.  
 
Significant homologies have been found to exist amongst the dopaminergic receptor subtypes. 
The receptors belong to the super-family of G-protein coupled receptors, all containing the 
predicted 7-transmembrane domain structure with membrane spanning helices linked by 
intracellular and extracellular loop. The DRD1-like receptors often exert their physiological 
influences by means of stimulating adenylate cyclase via a stimulatory G-protein (Gs), whilst 
DRD2-like receptors exert their influence by inhibiting adenylate cyclase via an inhibitory G-
protein (Gi). 
 
Dopaminergic dysregulation is thought to contribute to the pathophysiology of OCD based on 
neurobiological and pharmacological data obtained from humans and animals. In animal 
models, agents that increase synaptic dopamine levels, such as amphetamine, methylphenidate 
and L-DOPA, produce stereotypies and repetitive behaviour that resemble some of the 
symptomatology manifested by individuals with OCD (Goodman et al., 1990; Fog, 1972; 
Wallach, 1974; Creese and Iversen, 1974). Acute administration of dopaminergic agonists has 
been found to induce perseverative behaviours in rodents, whilst chronic administration 
causes an increased rigidity in perseverative behaviour (Eilam et al., 1989).  
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Rats treated chronically with the DRD2/DRD3 dopaminergic agonist, quinpirole, meet the 
ethological criteria of compulsive checking in OCD (Einat and Sczechtman, 1995; Schetzman 
et al., 1998; 2001), which was found to be partially attenuated by CMI. A more recent study 
has indicated that juvenile male rats are more sensitive to the perseverative actions of 
quinpirole than adult male rats, and that CMI prevents the drug-induced reaction in adult, but 
is less effective in juvenile, male rats (Ulloa et al., 2004). These findings may indicate a lower 
sensitivity in 5-HTT (Ulloa et al., 2004) in juvenile rats, analogous with findings that EO 
OCD is a predictor of poor response to treatment (Rosario-Campos et al., 2001; Ackerman et 
al., 1994; Ravizza et al., 1995) (please refer to section I.4.2.2.4 for a more detailed discussion 
on the clinical features of EO OCD). 
 
In addition, a novel transgenic mouse model of cortical and limbic neural stimulation has 
recently been characterised. These mice express a neuropotentiating transgene in a subset of 
DRD1-expressing neurons in regions of the amygdala and cortical areas that project to the 
orbitofrontal cortex and striatum. Chronic potentiation of these neurons (known to induce 
efferent glutamatergic neurotransmission to the striatum) resulted in the transgenic mice 
exhibiting TS/OCD-like behaviours, including repeated leaping, OCD-like persistent 
grooming, non-aggressive OCD-like repeated biting of cagemates, episodes of repetition or 
perseverance of normal behaviours and repeated climbing or leaping and tics (Nordstrom and 
Burton, 2002, Campbell et al., 1999[a]; 1999[b]; McGrath et al., 2000). These results not only 
indicate the possibility that DRD1 may be involved in such OCD-like behaviour, but also that 
this behaviour may be mediated through glutamatergic activity (section I. 6.1.3). 
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Figure I.4. Four dopamine pathways in the brain: (a) the nigrostriatal dopamine pathway 
projects from the substantia nigra to the basal ganglia, and is thought to control movements. 
(b) The mesolimbic dopamine pathway projects from the midbrain ventral tegmental area to 
the nucleus accumbens. (c) The mesocortical pathway projects from the midbrain ventral 
tegmental area to the limbic cortex. (d) The tuberoinfundibular pathway extends from the 
hypothalamus to the anterior pituitary gland (after Stahl, 2000). 
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Joel and Doljansky (2003) created a rat model of OCD that simulates a deficiency in response 
feedback mechanism that has been hypothesised to underlie obsessions and compulsions. 
They found that post-signal attenuation leads to a response involving excessive lever pressing, 
akin to the excessive, unreasonable behaviour noted in OCD. Administration of a DRD1 
antagonist reduced the number of compulsive lever presses and, based on further 
electrophysiological data, it was proposed that the reduction in lever pressing depended on a 
phasic increase in the stimulation of DRD1. In addition, results from a recent DAT-
knockdown mouse model indicate that hyperdopaminergic mice exhibit excessively strong 
and rigid manifestations of a complex fixed action pattern (thought to characterise a number 
of human disorders involving the basal ganglia, including OCD and TS), in comparison to 
wild-type mice (Berridge et al., 2005). It is, however, not presently known whether the 
sequential stereotypic behaviours of the DAT knockdown mice depend on DRD1 circuit 
activation (as observed by, for example, Campbell et al. [1999(a)]) or not. Nonetheless, 
results from the aforementioned investigations suggest a role for dopaminergic receptors, 
DRD1, DRD2, DRD3 and DAT in the aetiology of OCD. 
 
Functional neuroimaging studies have also implicated the role of the dopamine system in 
OCD: DRD2 binding in the left caudate has been found to be significantly lower in OCD 
patients compared to controls (Denys et al., 2004[c]), and van der Wee et al. (2001) reported 
an increased dopamine transporter (DAT) binding ratio in the left basal ganglia of OCD 
patients. Likewise, Kim et al. (2003) reported an increased DAT binding ratio in the right 
basal ganglia, and a tendency towards increased DAT binding in the left basal ganglia, in 
OCD patients. Conversely, Pogarell et al. (2003) did not report any difference in DAT 
binding ratios between OCD and control subjects. On the whole, these studies suggest the 
probable involvement of the dopamine system (and in particular, DRD2 down-regulation and 
an increased concentration of DAT) in the pathophysiology of OCD. 
 
Baseline concentrations of dopamine and its metabolite, homovanillic acid (HVA) have also 
indicated a role for dopamine in the pathology of OCD (Hollander et al., 1992[b]; Zahn et al., 
1996), although, once again, not all studies have yielded consistent results (Thoren et al., 
1980; Benkelfat et al., 1991). Moreover, Marazziti et al. (1992) reported an increase in 
dopamine neurotransmission in patients with the disorder, based on increased platelet levels 
of sulfotransferase (an enzyme involved in dopamine catabolism).  
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In pharmacological challenge studies, Brambilla et al. (1997; 2000) examined the function of 
the dopaminergic system in a group of individuals with OCD by measuring growth hormone 
(GH) (Brambilla et al., 1997) and cortisol (Brambilla et al., 2000) responses to stimulation 
with apomorphine (APO), a short acting dopamine agonist. Results of these experiments are 
thought to be good indicators of postsynaptic dopaminergic function in the hypothalamus and 
hypothalamo-pituatary-adrenal (HPA) axis, respectively. However, inconsistent results were 
found in the two studies: in the first investigation, GH responses to APO were found to be 
blunted in OCD patients, indicative of a dysregulation in the dopaminergic system in these 
individuals, but in the second, cortisol responses to APO were found to be equivalent in OCD 
patients and controls. These findings suggest heterogeneity in the dopaminergic system 
functions in OCD, with dopamine neurotransmission being impaired in brain regions related 
to OC pathology, and normal in other brain regions (Brambilla et al., 2000). 
 
Finally, a significant improvement has been noted in SSRI non-responders with OCD when 
neuroleptics, which are primarily dopamine antagonists, are added to the ongoing SSRI 
monotherapy (McDougle et al., 1994, 2000; Stein et al., 1997; Shapira et al., 2004). In 
particular, it has been suggested that particularly OCD patients who exhibit tics benefit from 
the combined SSRI/ dopamine antagonist treatment, suggesting that both the 5-HT and 
dopamine systems may be involved in the clinical manifestation of specific subtypes of OCD. 
 
I.6.1.2.1. Dopaminergic candidate genes investigated in the present study 
 
i. The Dopamine Receptor 4 gene (DRD4) 
DRD4 belongs to the group of DRD2-like dopamine receptors, and represent G-protein 
coupled receptors in that the α-helices are organised into seven relatively hydrophobic 
transmembrane spanning segments joined by three less hydrophobic intracellular peptide 
segments. The third intracellular loop, situated between transmembrane segments 5 and 6, 
provides the link to G-proteins, facilitating interaction with other downstream molecular 
elements, which represents the initiation of dopaminergically-mediated neurotransmission 
(Oak et al., 2000; Van Tol et al., 1991). It is interesting to note that both norepinephrine and 
epinephrine bind to DRD4 with high affinity, although not as efficiently as dopamine, 
suggesting the involvement of DRD4 in a wider range of signal transduction pathways than 
originally thought (Lanau et al., 1997). 
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Table I.6: Published population and family-based genetic association studies in OCD: dopaminergic candidate genes 
 Sample number 
 
affected Ref. 
Gene Variant(s) Population Study design 
Phenotype 
investigated 
case families 
control 
Results (p-value and allele implicated) 
 
DRD4          
 13bp deletion  CC OCD 157  162 NS 1 
 Mexican CC OCD+tics  vs. OCD-tics 61[n (OCD+tics) =12]   p=0.018 2 
 N. American Caucasian CC OCD 118  118 
p=0.021; NS for genotype (overall allele 
frequency) 3 
 Jewish (Ashkenazi [A]and non-A) CC OCD 75 (39A)  172 (112A) non-Ashkenazi: A7
a less frequent in OCD (p=0.04) 4 
 CC/FB OCD 49 34 63 
CC: p<1x10-4 (genotype); p=1x10-4 (allele); 
FB: p=0.03 for genotype and allele analyses 
Both implicated A2b as protective allele 
 
French 
 OCD+tics  vs. OCD-tics n(OCD+tics) =16   NS 
5 
 Afrikaner CC OCD 71  129 NS 6 
 
48bp VNTR 
SA Caucasians, 
stratified into 
Afrikaner (Afr) 
CC EO** OCD vs. LO OCD n(EO)=95[45 Afr]; n(LO) = 85 [35Afr]   
SA Caucasians: p=0.0128 (overall allele 
frequency); 
NS for Afrikaners 
7 
DRD2          
 Screened exons 4, 5, 6  CC OCD 45  26 NS 8 
 Mexican CC OCD 67  54 NS 
 
Taq1A 
  OCD+tics (n=12) vs. control    p=0.014 (CC-genotype implicated as risk factor) 
9 
 ser311cys N.American Caucasian CC OCD 110  110 NS 3 
DRD3          
 Italian CC OCD 97  97 NS 10 
 Mexican CC OCD 67  54 NS 9 
 
ser9gly 
N.American 
Caucasian CC OCD 103  103 NS 3 
DATk          
 N.American Caucasian CC OCD 103  103 NS 3 
 Jewish (Ashkenazi [A]and non-A) CC OCD 75 (39A)  172(112A) NS 4 
 Afrikaners CC OCD 71  129 NS 6 
 
3’ UTR 40bp 
VNTR 
SA Caucasians, 
stratified into 
Afrikaner 
CC EOcOCD vs. LO OCD n(EO)=95[45 Afr]; n(LO) = 85 [35Afr]   NS 7 
 rs100532 German FB OCD  64  NS 11 
MAO-A          
 N. American FB OCD  110  Males: p=0.0186 (TDT ) , p=0.0129 (HHRR) for  G-allele as risk factor; OR=2.9 (1.23-6.81) 
 
Exon 8 T-G  
  OCD+MDD  (males only)  25  p=0.0004 (G-allele as risk factor) 
12 
 Mexican CC / FB OCD 122 51 (19 females) 124 
CC: p=0.0053 (C-allele in males); FB: p=0.022 (T-
allele as risk factor in OCD females compared to 
OCD males) 
13 
 
Exon 14 
T1046C 
Afrikaner CC OCD 71  129 NS 6 
COMT          
 N.American Caucasian CC OCD 73  148 
p=2x10-4 (LLdgenotype and  Ld-allele as risk factor 
in males);OR=8.40 (2.44-28.91) 14 
 Japanese  OCD 17  35 NS 15 
 N.American Caucasian FB OCD  
110  
(54 male)  
Males ( for Ld-allele as risk factor): p=0.0079 (one-
tailed TDT); p=0.0146 (one-tailed HHRR); 
OR=2.58 (0.92-5.87) 
12 
 Not specified FB OCD  67  Homozygosity for H
e or Ld allele as risk factors 
p=0.006f 16 
 Afrikaner CC OCD 54  54 p=0.0017 (HLe genotype as risk factor) 
aA7 refers to the DRD4 48bp VNTR 7-repeat allele; bA2 refers to the DRD4 48bp VNTR 2-repeat allele c EO OCD ≤ 15 years; dL refers to the COMT val158met low-activity allele (met158, or A); eH refers to the COMT val158met high 
activity allele (val158, or G); f non-informative matings excluded; gMeta-analysis included investigations by references 15; 14; 16, 12, 18; Abbreviations: OCD: obsessive-compulsive disorder; CC: case-control; FB: family-based OR: 
odds ratio; CI: confidence interval;; EO: early-onset OCD; LO: late-onset OCD; NS: non-significant (p>0.05); VNTR: variable number of tandem repeats polymorphism; SA: South African; Afr: Afrikaner; TDT: Transmission 
disequilibrium test; HHRR: haplotype-based haplotype relative risk analysis; DRD4: dopamine receptor 4; ); DRD2: dopamine receptor 2; DRD3: dopamine receptor 3; DAT: dopamine transporter; MAO-A: monoamine oxidase A; 
COMT: catechol-O-methyltransferase; SA: South African.; ERE: estrogen response element. 
References: 1: Di Bella et al. (1996); 2: Cruz et al. (1997); 3: Billet et al. (1998); 4: Frisch et al. (2000); 5: Millet et al. (2002); 6: Hemmings et al. (2003); 7: Hemmings et al. (2004); 8: Novelli et al. (1994); 9: Nicolini et al. (1996); 10: 
Catalano et al. (1994); 11: Walitza et al. (2004); 12: Karayiourgou et al. (1999);  13: Camarena et al. (2002); 14: Karayiourgou et al. (1997); 15: Ohara et al. (1998); 16: Schindler et al. (2000); 17: Niehaus et al. (2001); 18: Alsobrook et 
al. (2002); 19: Erdal et al. (2003); 20: Azzam and Matthews (2003); 21: Meira-Lima et al. (2004); 22: Kinnear et al. (2001). 
17 
 
Probands collected 
from Israel, France 
and USA 
FB   56  p=0.048 (L-allele as risk factor in females) NS in males 18 
 Turkish CC OCD 59  114 NS 19 
 META-ANALYSISg  OCD 144  337 NS 
 
val158met 
Brazilian CC OCD 79  202 NS 
20 
21 
 C/T in ERE Afrikaner CC OCD 48  48 NS 22 
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The DRD4 protein is expressed in a number of brain regions, with the highest expression 
noted in the PFC (Ariano et al., 1997). Although expression has also been established in the 
amygdala, hippocampus and hypothalamus (Cohen et al., 1992; O’Malley et al., 1992; 
Meador-Woodruff et al., 1994; 1996; Lidow et al., 1998), recent investigations suggest that 
the participation of DRD4 in the PFC is more critical than in other areas (Falzone et al., 
2002). Selective lesions and pharmacological challenge studies have indicated that modified 
dopaminergic neurotransmission in the PFC impairs alertness, behavioural reactions to stress 
and waking memory performance (Espejo, 1997; Simon et al., 1980). The receptors are 
thought to act as inhibitors of neuronal firing, particularly in the PFC, given that DRD4 
knockout mice exhibit supersensitivity to cocaine, methamphetamine and ethanol, and also 
exhibit a reduction in exploration of novel stimuli (Oak et al., 2000; Rubinstein et al., 1997; 
2001). 
 
It has been found that, in rats, and thus possibly humans, DRD4 is located on the terminals of 
corticostriatal glutamatergic projections, thus implicating the receptor in the control of 
glutamate release into the basal ganglia (Tarazi and Baldessarini, 1999; Tarazi et al., 1997; 
1998). If this can indeed be extrapolated to humans, it may have important consequences for 
the support of the involvement of dopamine and glutamate in the development of OCD, as the 
basal ganglia is one of the main areas of pathology for this disorder (section I.6.1). It could be 
hypothesised that the DRD4 and certain glutamatergic genes are interacting with each other 
epistatically and in doing so, contribute to the pathology of OCD. 
 
Both atypical and typical antipsychotics exhibit relatively high affinities for DRD4, indicating 
that the receptor may contribute to their antipsychotic effects, and subsequently the 
pathologies of disorders treated by such drugs (Tarazi et al., 1997[a]; 1998; Florijn et al., 
1997; Tarazi et al., 1997[b]; Murray et al., 1995; Tarazi and Baldessarini, 1999). Indeed, the 
behavioural effects of a number of DRD4-selective dopaminergic agonists and antagonists 
were found to be indicative of antipsychotic activity – these effects included inhibition of 
conditioned avoidance responses and the reversal of deficits in prepulse inhibition (PPI) of 
acoustic startle responses (see Tarazi and Baldessarini, 1999 for review). These results are 
interesting, as deficiencies in PPI in OCD patients have been reported (Schall et al., 1996; 
Swerdlow et al., 1997). 
 
 89
The gene encoding DRD4 (DRD4) consists of four exons, which code for 419 amino acids 
(Van Tol et al., 1991), with the transcription site situated approximately 400bp to 500bp 
upstream from the translational initiation codon (Oak et al., 2000). The gene has been mapped 
to chromosome 11p15.5 (Gelernter et al., 1992) and lies adjacent to the Harvey-Ras oncogene 
and tyrosine hydroxylase gene (Gelernter et al., 1992; Kennedy et al., 1991; Petronis et al., 
1993).  
 
A variable number of tandem repeats (VNTR) polymorphism, occurring within the third 
cytoplasmic loop (situated in the third exon), has been of great interest in psychiatric genetic 
investigations (van Tol et al., 1991; Lichter et al., 1993; Li et al., 1997; Kotler et al., 1997; La 
Hoste et al., 1996; Swanson et al., 1998; Eisenberg et al., 2000; Rowe et al., 1998; Smalley et 
al., 1998; Faraone et al., 1999; Ebstein et al., 1997; Benjamin et al., 1996). This 
polymorphism consists of a variable number of imperfect 48bp motifs that may be repeated 
between 2 and 10 times (van Tol et al., 1991; Lichter et al., 1993; Asghari et al., 1994). To 
date, twenty different receptor protein variants have been found for this polymorphism (van 
Tol et al., 1991; Lichter et al., 1993; Asghari et al., 1994).  
 
The 4-repeat allele (A4) has been reported to be the most common allele, occurring with a 
global frequency of approximately 64%, whilst the 2- and 7-repeat alleles (A2 and A7, 
respectively) are the next most common alleles (Ding et al., 2002; Lichter et al., 1993; Chang 
et al., 1996). A7 exhibits a high degree of variability worldwide with frequencies ranging from 
17% to 39% (Adamson et al., 1995; Chang et al., 1996; Ding et al., 2002). These three alleles 
(A2, A4 and A7) account for more than 90% of the observed allelic diversity in most 
populations. 
 
Presently, no major functional consequences of the polymorphism have been elucidated, 
although small effects on signaling efficiency have been reported. Studies have indicated that 
A7 possesses the ability to blunt the receptor’s response for the reduction of cyclic adenosine 
monophosphate (cAMP), requiring at least three-fold more dopamine to induce responses 
similar in magnitude to receptors containing A4 alleles (Asghari et al., 1995; Wang et al., 
2004). Moreover, A2 alleles have been found to produce DRD4 receptors that have a cAMP 
response that is somewhat blunted, and lies midway between responses for A4 and A7 alleles 
(Wang et al., 2004). 
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The results of functional studies thus indicate the lack of a linear relationship between the 
length of the polymorphism (i.e. number of repeats) and the functional receptor 
pharmacology. Therefore, genetic studies employing strategies that pool short and long alleles 
may result in Type I or II errors in these association studies (Wang et al., 2004; Oak et al., 
2000). Subsequently, it has been suggested that characterising individuals according to the 
presence of A4 allele, versus absence thereof, may be more conducive for testing associations 
between the gene and certain disorders (Grady et al., 2003; Wang et al., 2004).  
 
DRD4 is of interest in molecular studies of psychiatric disorders, due to its involvement in 
higher brain functions and the modulatory role it plays in dopamine synthesis and turnover in 
the brain (Rubinstein et al., 1997). Indeed, it has been widely investigated to determine the 
role it may play in the development of OCD (Table I.6). One of the earliest published studies 
reported on the significantly higher frequency of A7 amongst Mexican OCD individuals who 
presented with co-morbid tics, compared to OCD patients who did not possess co-morbid tics 
(Cruz et al., 1997). Moreover, Billet et al. (1998) observed statistically significant differences 
in overall allele distribution between Canadian OCD and control subjects, although this 
association did not remain significant after correcting for multiple testing.  
 
On the other hand, Frisch et al. (2000) observed a reduced number of A7 alleles amongst 
OCD patients compared with healthy controls, although the authors do concede that this 
significant finding may be as a result of a Type I error due to multiple testing. This result was 
not replicated in a larger French study, which utilised both family- and population-based 
designs (Millet et al., 2003). This same investigation did, however, report a significantly 
lower frequency of A2 amongst OCD patients compared to a control cohort, replicating this 
result in a subsequent family study. Their results remain significant even after correction for 
multiple testing. However, these results were not replicated in a study published by the author 
(Hemmings et al., 2003), where no statistically significant differences in either allele or 
genotype distribution were observed between Afrikaner OCD and control individuals. 
Interestingly, however, in a more recent study, when a South African Caucasian OCD patient 
group was stratified categorically according to age at onset of the disorder, a statistically 
significant difference was noted in the allelic distribution between early and late-onset OCD, 
although no significant differences were noted in the genotypic distribution (Hemmings et al., 
2004).  
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The conflicting results in the aforementioned studies may be due to inconsistency in grouping 
individuals according to genotype. None of the studies characterised subjects according to the 
presence or absence of A4, as suggested by Wang et al. (2004). This could result in false 
positive or false negative results. Discrepancies between the results may also be due to 
variations within the sequence of repeats, and the order in which they appear in different 
populations (Lichter et al., 1993). A certain haplotype may be responsible for an association, 
but this haplotype may in turn be associated with a different repeat length allele in different 
populations. Finally, the variant which has been found to be associated with OCD may in fact 
not be causal, but may simply be in LD with the causal variant situated in DRD4 or an 
adjacent gene. Thus, in an effort to determine the molecular basis of reported positive 
associations in the present investigation, three DRD4 variants were examined for the role they 
may play in increasing susceptibility to OCD or related subtypes.  
 
In the present study, the DRD4 48bp VNTR investigation, reported on by the author in 2003 
and 2004 (Hemmings et al., 2003, 2004), was extended to include more OCD and control 
subjects. Moreover, a C to T  transition, occurring in the region 5’ to the transcription start site 
at position -521 (-521C/T dbSNP rs1800955) (Okuyama et al., 1999) was also investigated 
(Figure I.5). This polymorphism is thought to affect transcriptional activity of DRD4, since 
the activity of the T-allele was reported to be 40% lower than that of the C-allele (Okuyama et 
al., 1999). To the author’s knowledge, the latter polymorphism has not yet been investigated 
for the role that it may play in increasing susceptibility to OCD. 
 
 
 
 
                                                         I                                            II                  III                  IV 
 
Figure I.5. Schematic representation of the DRD4 locus. The location of the polymorphisms 
investigated in the present study indicated by arrows. Exons are represented by yellow blocks, 
and introns are represented as horizontal lines between the exons (not drawn to scale). The 
distance between the two variants is approximately 3kb. 
    
rs1800955 48bp VNTR 
5’ 3’ 
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ii. The Dopamine Receptor 1 gene (DRD1) 
Dopamine receptor 1 (DRD1) represents the most abundant dopaminergic receptor in the 
CNS. It serves to modulate DRD2 activity, regulate neuron growth and differentiation, and 
mediate certain behavioural responses (Clark and White, 1987; Grandy et al., 1990). 
Furthermore, the receptor is expressed at high levels in the dorsolateral PFC, and therefore 
plays an important role in modulating mesocorticolimbic circuitry, and consequently, 
cognitive functioning (Basile et al., 2002). DRD1 in the PFC and associated regions has been 
found to be down-regulated during chronic treatment with neuroleptics, namely, clozapine, 
haloperidol and remoxipride (Lidow and Goldman Rakic, 1994) which have been found to be 
useful as adjuncts to first line SSRI pharmacotherapy in some treatment refractory OCD 
patients (McDougle et al., 1994; 1997). 
 
The DRD1 gene (DRD1) has been mapped to chromosome 5q35.1 (Grandy et al., 1990), and 
codes for approximately 44 amino acids (Sunahara et al., 1990). An A to G transition 
polymorphism, which is situated in the 5’untranslated region (UTR) (Cichon et al., 1994; Liu 
et al., 1995) and that is of unknown functional significance, was investigated in the present 
study. DRD1 has been widely investigated for the role it may play in dopamine-related 
disorders, such as schizophrenia (Liu et al., 1995; Cichon et al., 1996; Kojima et al., 1999); 
TS and addictive behaviours (Comings et al., 1997); alcoholism (Heinz et al., 1996); essential 
hypertension (Sato et al., 2000) and aggression and psychosis in Alzheimer’s disease (Holmes 
et al., 2001; Sweet et al., 1998). Brain metabolic and clinical response to clozapine have also 
been thought to be related to variations in the DRD1 gene (Potkin et al., 2003). 
 
Recent animal studies have supported a role for DRD1 in OCD and associated behaviours 
(section I.6.1.2) (Joel and Avisar, 2001; Joel and Doljansky, 2003). Interestingly, CNS DRD1 
activation has been found to induce modulated grooming behaviour in rodents (Molloy and 
Waddington, 1987; Wachtel et al., 1992). This grooming behaviour is enhanced upon 
administration of DRD1 agonist, SKF38393, and by the removal of 5-HT2A receptors (Lucki 
and Kucharik, 1988). Similarly, the behaviour is attenuated following chronic infusion with  
5-HT2A antisense oligonucleotide (that upregulates 5-HT2A), implicating 5-HT2A in the 
modulation of DRD1-mediated grooming behaviour (Scalzitti et al., 1999). Given these 
findings, it is possible that firstly, if DRD1 mediates certain aspects of grooming behaviors, 
then the gene encoding DRD1 that functions “below par” could result in abnormalities in 
grooming behaviours (e.g. TTM). Secondly, it is plausible that the interaction between the 
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two receptors on a neuronal level implies an interaction on the genetic level; warranting an 
investigation of epistatic effects between the DRD1 and 5-HT2A alleles and the role that this 
may play in the development of OCD and/or TTM. 
 
Despite evidence from animal and pharmacological models implicating DRD1 in at least 
some aspects of OCD, relatively little genetic evidence exists to support these findings. In 
fact, to date, only one case-control association study investigating the role that DRD1 may 
play in OCD has been published. In this study, Thompson et al. (1998) screened the coding 
region of the gene to determine whether any association existed between DRD1 variants and 
TS patients, and TS patients presenting with co-morbid OCD. No association was detected, 
although it should be noted that the study was very small – only 30 cases and 50 controls were 
included. It is thus possible that the results obtained by Thompson et al. (1998) represent false 
negative results due to lack of power. Furthermore, they did not investigate OCD as a single 
phenotype, but rather in conjunction with the occurrence of TS, which may have “diluted” the 
effect that DRD1 has in OCD. Further investigation into the role that DRD1 may play in OCD 
and subtypes of OCD is thus warranted; this was addressed in the present study. 
 
iii. The Dopamine Receptor 2 gene (DRD2) 
Dopamine receptor 2 (DRD2) is expressed throughout the brain, but is found at high levels in 
the basal ganglia, especially in the neostriatum and pars compacta of the substantia nigra 
(Missale et al., 1998). Interestingly, DRD2-like binding potentials in brain regions outside the 
striatum have indicated gender differences, which may reflect either a difference in DRD2 
density and/or affinity (Kaasinen et al., 2002). Indeed, a generally lower DRD2 binding 
affinity was noted in females (Pohjalainen et al., 1998), but these differences have been 
observed only in older age groups, reflecting the possible influence that sex steroid changes 
can have on the dopamine-binding characteristics in the brain (Farde et al., 1995; Pohjalainen 
et al., 1998). 
 
DRD2 represents an interesting gene to study with regard to the role that it may play in 
mediating the development of OCD, given recent evidence obtained from structural, 
functional, clinical and genetic studies. The CSTC circuit is modulated by DRD1 and DRD2 
that are innervated by the substantia nigra (Harvey et al., 2001; Insel et al., 1992), thus any 
imbalance in efficacy of these receptors could result in an imbalance of the circuit, causing 
deficits that may well lead to the development of OCD. 
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As already discussed in section I.6.1.2, pharmacological studies have indicated that the 
DRD2/DRD3 antagonist, quinpirole, may constitute an animal model of OCD checking 
(Szechtman et al., 1998; 2001). Furthermore, chronic administration of inositol to rats has 
been found to result in a significant decrease in DRD2 density (Harvey et al., 2001), which is 
interesting in light of observations that inositol has been found to be effective in the treatment 
of OCD (Fux et al., 1996) (section 1.6.1.5.2). These findings suggesting that a state of 
hyperresponsiveness of DRD2 may contribute to the pathology of the disorder (Harvey et al., 
2001; Brambilla et al., 1997). Additional support for the role that DRD2 may play in OCD 
has been obtained from a recent functional study in which lower left caudate DRD2 binding 
ratios were observed in OCD patients compared to controls. The binding ratios in the left 
caudate were also found to be lower than those in the right caudate in the same OCD patients 
(Denys et al., 2004[c]). 
 
The gene encoding DRD2 (DRD2) has been mapped to chromosome 11q22-23 (Grandy et al., 
1989; Eubanks et al., 1992). The gene consists of 8 exons, with an intron of over 250 kb 
separating the putative first exon from those encoding the receptor protein (Grandy et al., 
1989). The DRD2 Taq1A polymorphism is situated in the 3’ UTR, approximately 9.5kb 
downstream from the gene (Grandy et al., 1989) and results in a T to C transition representing 
the A1 (T) and A2 (C) alleles, respectively. Although this polymorphism does not represent a 
fuctional variant per se, it is thought to be in LD with a variant or gene that affects DRD2 
density within the brain, given that DRD2 density has been found to be 30%-40% lower in the 
caudate nucleus and striatum in A1-carriers (Thompson et al., 1997; Pohjalainen et al., 1998). 
It has also been proposed that the A1-allele may be in LD with a gene or variant that modifies 
the expression of DAT, since alcoholic carriers of the A1-DRD2 allele exhibited a higher 
density of DAT compared with those homozygous for A2 (Laine et al., 2001). Finally, OCD 
patients with compulsive hoarding syndrome exhibited lower glucose metabolism compared 
to nonhoarding patients (Saxena et al., 2004), suggesting that the gene, and particularly the A1 
allele, may play a role in the aetiology of this OCD symptom dimension. 
 
Interestingly, the Taq1A polymorphism has recently been mapped to the last ankyrin repeat of 
the newly discovered ankyrin repeat and kinase domain containing 1 (ANKK1) gene, where it 
represents a potentially functional nonsynonymous SNP (Neville et al., 2004). However, the 
interaction between the ANKK1 and DRD2 genes has yet to be elucidated, and further work is 
required to determine whether ANKK1 is expressed in the brain (Neville et al., 2004).  
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The perceived functionality of the Taq1A polymorphism may be due to a functional, 
synonymous polymorphism, C957T, that has been found to be in LD with both of the 
aforementioned variants (Duan et al., 2003). The 957T variant has been shown to be 
associated with a decrease in DRD2 mRNA translation, stability and diminished dopamine-
induced upregulation of DRD2, which may explain the association of the synonymous, non-
functional variants with various neuropsychiatric disorders (Duan et al., 2003; Hirvonen et al., 
2004).  
 
Genetic association studies investigating the involvement of the DRD2 in OCD have yielded 
inconsistent results (Table I.6). In one of the first investigations, Novelli et al. (1994) screened 
the 8 exons of the gene for mutations in a group of OCD patients with and without tics. No 
structural changes were observed, prompting the suggestion that the gene was not involved in 
the aetiology of the disorder. On the other hand, a later case-control study conducted in a 
Mexican sample demonstrated an association between the homozygous A2 genotype of the 
TaqIA polymorphism and OCD patients with comorbid tic disorder (Nicolini et al., 1998): 
58% of those patients presenting with co-morbid tic disorder possessed the A2/A2 genotype, 
whilst only 27% of the OCD patients without tic disorder carried the genotype (Table I.6). 
However, it should be noted that the investigators did not observe any significant association 
of the polymorphism when the genotype and allele distribution of the polymorphism was 
compared between the unstratified sample of OCD patients and control subjects. In a 
population-based case-control study by Billet et al. (1998), observed no statistical significance 
was observed between either the DRD2 TaqIA polymorphism, or a serine to cysteine 
missense mutation ocuring in the seventh exon, and OCD. The conflicting results may be due 
to the fact that Nicolini et al. (1998) were investigating the genetic aetiology of a subtype of 
OCD (tics), whereas Billet et al. (1998) did not stratify their OCD patients according to the 
presence or absence of tics.  
 
It may thus be possible that DRD2 plays an important role in the development of this OCD 
subtype (i.e. OCD + tics), but that this effect may be masked when the disorder is examined 
as a single entity. Secondly, the conflicting results may be due to the small sample sizes used 
in both the studies, but particularly by Nicolini et al. (1998), where the number of OCD 
patients with tics amounted to only 12, versus 54 without tics. As mentioned in section 
I.4.4.2, small sample sizes may lead to lack of power of the study and subsequent false 
positive results.  
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In order to clarify the role that the receptor may play in mediating the development of OCD, 
the relationship between OCD and haplotypes within DRD2 needs to be investigated in an 
independent population stratifying patients for OCD symptoms and co-morbidity, particularly 
tics. The present study thus investigates the role that the DRD2 TaqIA (rs1800497) 
polymorphism may play in mediating the development of OCD (or clinically-defined subsets 
thereof).    
 
iv. The Dopamine receptor 3 gene (DRD3) 
Dopamine receptor 3 (DRD3) is a D2-like receptor that is expressed almost exclusively in the 
limbic structure of the brain (Sokoloff et al., 1990; Suzuki et al., 1998), with the highest 
concentrations noted in the ventral striatum, islands of Cajella and nucleus accumbens 
(Landwehrmeyer et al., 1993; Sokoloff et al., 1990). The receptor is thus thought to play a 
role controlling motor behaviour, and regulating certain facets of motivation and emotion 
(Landwehrmeyer et al., 1993; Sokoloff et al., 1990). Indeed, DRD3 knockout mice display 
increased motor activity and exploratory behaviour, which may indicate a reduction in anxiety 
(Accili et al., 1996). Furthermore, the administration of DRD3 antagonist, nafatopride, also 
results in increased spontaneous locomotor activity in rats (Sautel et al., 1995), whilst DRD3 
agonists have been found to decrease locomotor activity in rats (Svensson et al., 1994). 
 
The regulatory mechanism controlling DRD3 differs from that of other dopaminergic 
receptors, in that brain-derived neurotrophic factor (BDNF), not dopamine, controls and 
maintains DRD3 expression during development and adulthood (Guillin et al., 2003). Indeed, 
the expression of both BDNF and DRD3 have been found to be down-regulated during 
periods of stress and depression, and these effects are reversed after the administration of 
SSRIs that targets the mesolimbic dopaminergic system (Lammers et al., 2000; Nibuya et al., 
1995). It is thought that the effect of the antidepressant on DRD3 is mediated by its primary 
action on BDNF, implicating a putative interaction between BDNF and DRD3 in mesolimbic 
dopaminergic pathways.  
 
Pharmacological evidence supports the role of DRD3 in anxiety: dopaminergic antagonists 
acting at the receptor have been found to exhibit anxiolytic properties, and the receptor has 
been found to possess similar affinities for typical neuroleptics as DRD2 (Sokoloff et al., 
1990; 1992), although it has also been found to exhibit a high affinity for atypical neuroleptics 
(Guo et al., 1995). Moreover, it has been suggested that DRD3 expression and function are 
 97
down-regulated during stress and depression, and that chronic treatment with noradrenergic 
and SRIs result in the increase of the DRD3 mRNA, thereby reversing the initial effect of 
stress (Lammers et al., 2000). 
 
The DRD3 gene consists of seven exons and has been mapped to chromosome 13p13.3 (Le 
Coniat et al., 1991; Sokoloff et al., 1992). The most widely studied SNP is characterised by an 
A to G transition occurring in the N-terminal extracellular domain in the first exon. The 
transition is non-synonymous, representing a gly to ser amino acid substitution at codon 
position 9 (ser9gly) (Lannfelt et al., 1992). Although the polymorphism results in a modified 
protein sequence, the functional consequences have yet to be elucidated. However, the variant 
is thought to affect the pharmacological properties of DRD3, since the presence of the gly9 
allele in homozygous form displayed a higher affinity for dopamine than either the ser9-
homozygotes or heterozygotes did. Moreover, the gly9gly-homozygotes and ser9gly-
heterozygotes exhibited a significantly higher affinity for the selective DRD3 ligand, 
GR99841 (Lundstrom and Turpin, 1996).  
 
It is of interest to note that it has been demonstrated that DRD2 and DRD3 form functional 
heterodimers, capable of inhibiting the downstream DRD2 effector, adenylyl cyclase, more 
efficiently than DRD2 alone (Scarselli et al., 2001). In light of the unresponsiveness of ser9-
positive schizophrenic patients to antipsychotic medication, and a more pronounced prefrontal 
executive dysfunction in ser9-positive individuals (Rybakowski et al., 2001), it has been 
hypothesised that the ser9-variant may exhibit a reduced capacity to form DRD2-DRD3 
heterodimers, resulting in less efficient signal transduction, although this necessitates further 
investigation. 
 
The earliest study conducted in order to determine whether any association exists between the 
ser9gly variant and OCD, OCD with or without tics, or a family history of OCD and tics was 
by Catalano et al. (1994) (Table I.6). No statistically significant differences were observed in 
genotype or allele frequencies between the OCD and control subjects, or between the various 
OCD sample subsets. It should be noted (as the authors do) that this investigation should be 
viewed as preliminary, since the power of the study to detect a small effect was comparatively 
low (0.30), probably due to the small sample size. However, neither Billet et al. (1998) nor 
Nicolini et al. (1996) observed any association between the ser9gly variant and OCD 
However, a more recent study implicated the gly9gly genotype in the development of 
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obsessive-compulsive personality traits and disorders (Joyce et al., 2003). It could thus be 
hypothesised that, although the receptor may not play a role in the higher order construct of 
OCD, it may well be involved in certain aspects of the symptomatology of the disorder, 
warranting the investigation in the present study. 
 
v. The Dopamine Transporter gene (DAT) 
DAT (or SLC6A3) is a transmembranous protein that is a member of a highly conserved 
group of Na+/Cl- dependent transporters (Kilty et al., 1991; Shimada et al., 1991). DAT plays 
a pivotal role in the removal of dopamine from the synapse in the midbrain; the reuptake and 
diffusion of dopamine by DAT alters the magnitude, duration and spatial domain of 
transmitter induced receptor activation, thereby modifying dopaminergic neurotransmission 
(Giros et al., 1996; Frazer et al., 1999).  
 
DAT is found in high concentrations in the nucleus accumbens, striatum and olfactory 
tubercle (Frazer et al., 1999; Ciliax et al., 1995) and acts exclusively on the plasma membrane 
of the presynaptic dopaminergic neurons (Inada et al., 1996; Kouzmenko et al., 1997; Sano et 
al., 1993; Kelsoe et al., 1996; Souery et al., 1996). Cocaine has been found to bind to DAT in 
the CNS, inhibiting dopaminergic reuptake accordingly (Gawin and Ellinwood, 1988). 
Cocaine exacerbates obsessive-compulsive behaviour in OCD patients, and has been found to 
induce OCD-like behaviour in individuals with a family history of the disorder (Satel and 
McDougle, 1991). Thus, DAT may constitute an important component in the aetiology of 
OCD. Indeed, as already discussed (section I.6.1.2), DAT-knockdown mice have been shown 
to exhibit excessive sequential stereotypy of behavioural patterns, characteristic of disorders 
of the basal ganglia, like OCD and TS (Berridge et al., 2005).  
 
The DAT gene (DAT) is expressed only in the CNS, and within a small subset of neurons 
(Ciliax et al., 1995). The expression of DAT is therefore more restricted than the expression of 
genes encoding other dopaminergic biosynthetic enzymes, and the control of dopamine 
signaling by DAT has been found to be largely region-specific, depending on its density, 
activity and regulation (Madras et al., 2005). DAT represents a single gene product that has 
been mapped to chromosome 5p15.3 (Giros et al., 1992; Vandenbergh et al., 1992). The 
protein encoded by DAT contains 620 amino acids with 12 putative transmembrane domains 
(Kilty et al., 1991). A polymorphic VNTR has been found in the genomic sequence encoding 
the 3’ untranslated region (3’UTR) (Sano et al., 1993; Vandenbergh et al., 1992, 2000). 
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The number of repeats in the 3’UTR VNTR may vary from 3 to 11, although it has been 
found that more than 90% of Caucasian and African-Americans display either the 9 repeat 
(A9) or the 10 repeat (A10) alleles (i.e., 440bp and 480bp alleles respectively) (Vandenbergh 
et al., 1992; Persico et al., 1995; Doucette-Stamm et al., 1995). In fact, in most population 
surveys on DAT allele frequencies at the 3'UTR VNTR, it has been found that A10 occurs 
more frequently, with some regional variation (Doucette-Stamm et al., 1995; Nakatome et al., 
1995, 1996; Kang et al., 1999).  
 
The function of the polymorphism is presently unclear: investigations have yielded 
contradictory results. Heinz et al. (2000) found that the A10/A10-genotype resulted in a higher 
density of DAT, whilst Jacobsen et al. (2000) found that the A10/A10 genotype yielded a 
lower DAT density than the A9/A10 repeat. On the other hand, a study by Martinez et al. 
(2001) suggested that the polymorphism did not play a role in affecting the density of DAT.  
 
The association between the DAT 40bp VNTR and increased susceptibility to OCD has 
previously been investigated, in three separate studies, all of which yielded negative results 
(Billet et al., 1998; Frisch et al., 2000; Hemmings et al., 2003). Although the polymorphism 
has previously been investigated in the Afrikaner population for the role it may play in 
mediating the development of EO OCD (Hemmings et al., 2004), with no significant 
association, the age at onset grouping was categorical, resulting in small sample sizes for 
each. The present investigation involves the investigating the possible association of DAT 
with selected OCD subtypes, including age at onset, which is investigated as a quantitative 
variable, which may impart more power to the study. To the author’s knowledge this is the 
first time that the DAT 40bp VNTR has been investigated for the role that it plays in the 
development of OCD symptom subtypes examined in the present dissertation. 
 
vi. The Catechol-O-methyltransferase gene (COMT) 
COMT (EC 2.1.1.6) is an Mg2+-dependent enzyme that is involved in the inactivation of 
catecholamines (norepinephrine, epinephrine and dopamine) (Axelrod and Tomchick, 1958). 
The gene encoding COMT (COMT), situated on chromosome 22q11.1-11.2 (Grossman et al., 
1992; Winqvist et al., 1992), encodes two distinct forms of the enzyme – soluble COMT (s-
COMT) that predominates in most tissues, and membrane-bound COMT (MB-COMT), most 
abundant in the CNS (Rivett et al., 1983), where it is responsible for approximately 60% of 
the dopaminergic degradation (Lundstrom et al., 1995; Bertocci et al., 1991). S-COMT is 50 
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amino acids shorter than MB-COMT, and its transcription begins near exon 3 (Tenhunen et 
al., 1994). The transcription of each form of the enzyme is driven by different promoters that 
are both located in exon 3: the P1 promoter drives s-COMT transcription, whilst the P2-
promoter drives MB-COMT transcription. Interestingly, both P1 and P2 promoters have been 
found to contain estrogen response elements (ERE) (Xie et al., 1999), and evidence exists to 
suggest that human COMT transcription is downregulated by estrogen, mediated via estrogen 
receptor α (ESRα) and EREs (Jiang et al., 2003).  
 
A widely studied polymorphism in COMT is a biallelic SNP, involving a valine to methionine 
substitution at codon 158 (val158met [rs4680]). This polymorphism has been found to be co-
dominantly associated with either the thermolabile (low activity; represented by the met158 
[A] allele) or thermostable (high activity; represented by the val158 [G] allele) (Grossman et 
al., 1992; Karayiorgou et al., 1998; Lachman et al., 1996; Lotta et al., 1995) form of the 
enzyme. It has recently been shown that the low activity of the enzyme is due to the lower 
expression of COMT (resulting in lower protein levels) in met158 individuals (Doyle et al., 
2004), and that the high activity form of the enzyme is associated with abnormal prefrontal 
cortical function (Egan et al., 2001; Bilder et al., 2002; Goldberg et al., 2003; Malhotra et al., 
2002; Mattay et al., 2003; Gallinat et al., 2003). This may be as a result of the enzyme 
performing a critical role in maintaining dopaminergic flux in this region (Chen et al., 2004). 
 
COMT represents an attractive candidate for OCD genetic studies (Table I.6). Individuals 
with 22q11 microdeletions encompassing COMT have been found to manifest a number of 
psychiatric symptoms, including OCD and increased anxiety (Karayiorgou et al., 1995; Pulver 
et al., 1994; Papolos et al., 1996). Numerous association studies, both family- and population–
based, have investigated the role that the val158met polymorphism may play in the 
development of OCD. Initial reports were exciting, in that Karayiorgou et al. (1997) observed 
a significant association between the met158 (low activity) allele and met158/met158 
genotype and OCD in a North American male sample, although no association was observed 
for the female sample in the same study. Karayiorgou et al. (1999) replicated these findings in 
a family-based sample, providing further impetus for the role of COMT in the disorder. 
Interestingly, in an attempt to replicate the findings by Karayiourgou et al. (1997; 1999), 
Alsobrook et al (2002) observed an association between the met158/met158 genotype and the 
OCD in females, but not in males. Furthermore, although Schindler et al (2000) observed an 
association between homozygosity (either met158/met158 or val158/val158 genotypes) at the 
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val158met locus and OCD, their findings were not gender-specific. In contrast, our group, 
Niehaus et al. (2001), investigated the relationship between the val158met polymorphism and 
OCD in an Afrikaner population, and detected a non-gender-based positive association 
between the heterozygous (val158/met158) genotype and susceptibility to OCD.  
 
On the other hand, no association between the polymorphism and OCD was detected in 
studies by Ohara et al. (1998), Erdal et al. (2003) or Meira-Lima et al. (2004), or in a meta-
analysis which included three case-control (Niehaus et al., 2001; Ohara et al., 1998; 
Karayiorgou et al., 1997) and three family-based (Schindler et al., 2000; Karayiorgou et al., 
1999; Alsobrook et al., 2002) studies, and one unpublished study (Veenstra-Vanderweele, see 
Azzam et al., 2003).  
 
The results from aforementioned studies are, as is the case for many association studies, 
contradictory. However, COMT remains an intriguing gene to investigate in the genetics of 
OCD, given the large role that it plays in the inactivation of dopamine, which has been 
proposed to be involved in the aetiopathology of at least some forms of OCD. The present 
study therefore aims to re-evaluate the role of COMT in OCD, by extending the Afrikaner 
sample genotyped by Niehaus et al. (2001), and by stratifying the OCD sample so there are 
less phenotypic variables to consider when analysing the potential role of the genetic 
variables.  
 
Furthermore, the original study has been extended to include haplotype analysis. The 
val158met has, thus far, been the most widely studied for its role in OCD. However, most of 
the earlier studies testing the activity and stability of COMT were conducted using S-COMT, 
not MB-COMT, which is most relevant to dopaminergic functioning in the CNS, and 
therefore to OCD (DeMille et al., 2002). Consequently, less common variants that contribute 
to the aetiology of the disorder may have been bypassed. Keeping this in mind, two additional 
polymorphisms were genotyped to determine the role they possess in the development of the 
disorder: a SNP occurring at position -1217 (rs2097603), situated within the estrogen 
sensitive region of P2, and a single base insertion/deletion polymorphism, situated 3’ to the 
stop codon of exon 6 (rs362204) (Chen et al., 1996; Karayiorgou et al., 1998) (Figure I.6).  
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These variants, together with the val158met variant, create a gene-encompassing haplotype 
spanning 28kb, and will impart more power to detect genetic associations between COMT and 
OCD than single-SNP studies. 
 
2
rs2097603 
val158met 
rs4680 
P2 promoter P1 promoter 
1.5kb  
MB-COMT
1.3kb  
S-COMT
rs362204 
          I                                                                     II        III                 IV       V           VI 
                                                                                         I                II        III           IV 
5’ 3’ 
 
 
Figure I.6. Schematic representation of the COMT locus.  The location of polymorphisms 
investigated in the present study are indicated by arrows. Exons are represented by yellow 
blocks, and introns are represented by horizontal lines between exons. The diagram also 
indicates the positions of the two promoters, P1 and P2 (blue boxes), and the corresponding 
transcripts (MB-COMT and S-COMT, respectively) (not drawn to scale). The distance 
between rs2097603 and rs4680 is approximately 23.1kb, whilst that between rs4680 and 
rs362204 is approximately 4.9kb. 
 
I.6.1.3. The Glutamate system and OCD 
Glutamatergic pathways, namely the major corticospinal neurons that project from the PFC to 
the anterior striatum, nucleus accumbens and substantia nigra (Taber and Fibiger, 1993; 
Kalivas et al., 1989), represent those that may be relevant to the pathophysiology of OCD 
(section I.6.1). Recent animal and pharmacological data have also suggested that glutamate 
may play a role in mediating certain aspects of the development of OCD. As previously 
 103
mentioned in section I.6.1.2, Campbell et al. (1999) created an animal model of cortical and 
limbic neuropotentiation - these transgenic mice express a neuropotentiating gene in the D1 
neurons in cortical (known to glutamatergically activate orbitofrontal and corticostriatal 
glutamate output) and amygdala (known to indirectly induce amygdalar glutamate output) 
regions (Campbell et al., 1999; McGrath et al., 2000). Chronic potentiation of these neurons 
resulted in transgenic mice exhibiting OCD and TS-like behaviours – namely, episodes of 
perseverance and repetition, non-aggressive biting of cagemates, and skin picking during 
grooming.  
 
The investigators also observed repeated climbing and leaping behaviours, and tics, 
reminiscent of TS symptomatology. Based on these findings, it has been suggested that tics 
and primary compulsions or obsessions are induced by the glutamatergic output from the 
cortical limbic neurons to striatal efferent targets, resulting in the “cortical-limbic-
glutamatergic-neuron” (CGN) neuronal circuit model which has recently been proposed by 
Nordstrom and Burton (2002). 
 
Brain imaging data also provides support for the role of glutamate in OCD. Using proton 
magnetic resonance spectroscopy (1H-MRS) and a direct, non-invasive in vivo measurement 
of N-acetyl-aspartate (NAA), (a reliable marker of neuronal viability and glutamate 
compounds [Birken and Oldendorf, 1989; Tsai and Coyle, 1995]), a glutamatergically-
mediated thalamocortical-striatal dysfunction was observed in OCD patients (Rosenberg et 
al., 2000; Bolton et al., 2001). These NAA abnormalities may be as a result of increased 
metabolic activity in these circuits (Rosenberg et al., 2000). Fitzgerald et al. (2000) also noted 
a decrease in NAA levels in the thalamus that may be associated with the clinical presentation 
of EO OCD. The decrease in NAA levels indicate either reduced neuronal responsivity to 
tonic striatal inhibition, or an excess of glutamatergic activity from the ventral prefrontal 
striatal circuit neurons that project to the thalamus.  
 
It has also been hypothesised that abnormalities in the glutamate-5-HT interactions may 
underlie the aetiology of OCD (Rosenberg and Keshavan, 1998; Moore et al., 1998; 
Rosenberg et al., 2000). Indeed, a reversible, glutamatergically-mediated thalamocortical-
striatal dysfunction has been proposed to represent a biological marker for EO OCD 
(Rosenberg and Hanna, 2000; Bolton et al., 2001; Rosenberg et al., 2004). Furthermore, 
pharmacological investigations suggest that the effects of the SSRI treatment may be the 
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result of a 5-HT-mediated reduction in glutamate concentration in the caudate, cortex and 
ventral striatum (Saxena et al., 1998; Rosenberg et al., 2000). 
 
I.6.1.3.1. Glutamate receptor subunit 2B (GRIN2B)  
The action of glutamate is mediated by two general types of receptors – ionotropic (ligand-
gated) and metabotropic (G-protein coupled) receptors. The present study investigated the 
role that glutamate ionotropic receptor subunit 2B (GRIN2B) may play in OCD, therefore this 
section will focus only on ionotropic receptors, with emphasis on GRIN2B. Ionotropic 
receptors can be further classified into three groups, according to their affinities for glutamate 
analogues: N-methyl-D-aspartate (NMDA), kainic acid (KA) or alpha-amino-5-hydroxy-5-
methyl-4-isoxalzolepropionic acid (AMPA) (Nakanishi et al., 1998). Ionotropic receptors 
have a large extracellular N-terminal domain and four hydrophobic membrane segments, and 
an intracellular C-terminal domain (Petralia and Wenthold, 1992; Tingley et al., 1993). 
NMDA receptors (NMDAR) usually co-exist with AMPA and KA receptors, and are 
generally distributed throughout the brain, the highest concentrations being in the limbic and 
cortical regions, with subsequent roles in cognition, mood and perception (Krystal et al., 
1999). NMDAR also mediate numerous other functions, including excitatory 
neurotransmission, synaptic plasticity and efficacy, memory formation and pain perception 
(Mayer and Westbrook, 1987; Bliss and Collingridge, 1993). 
 
Functional NMDAR are assembled from two ubiquitous NMDAR subunit type 1 (GRIN1) 
components, and two of a family of 4 type 2 subunits (GRIN2A-D) that are differentially 
expressed in the brain (Monyer et al., 1992; Ishii et al., 1993). GRIN1 subunits are capable of 
forming homomeric channels that are responsive either to L-glutamate or glycine, whereas the 
GRIN2 subunits can only function in the heterotrimeric state. These subunits determine the 
pharmacological properties of the receptor, and in doing so, modulate the function of the 
receptor (Monyer et al., 1992; 1994; Ishii et al., 1993).  
 
A defining characteristic of GRIN2 subunits is their long intracellular C-terminal tails, 
required for channel functioning (Sprengel et al., 1998). It is suggested that GRIN2B plays an 
important role in mediating certain aspects of cellular signal transduction, given that, firstly, it 
is found to be the major tyrosine phosphorylating protein in the postsynaptic density fraction 
(Moon et al., 1994). Secondly, alpha-actinin-2, an actin-binding protein that assists in 
regulating receptor localisation and function in the brain, binds to the cytoplasmic tail of 
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GRIN2B (Wyszynski et al., 1997). Finally, a phosphorylation site has been located in the 
carboxyl end domain of this receptor subunit (Omkumar et al., 1996). 
 
Regional specification of specific NMDAR is common in the basal ganglia, with GRIN2B 
abundantly expressed in the striatum (Loftis and Janowsky, 2003; Schito et al., 1997; 
Standaert et al., 1994), and highly expressed in the frontal cortex (Rudolf et al., 1996), areas 
which are believed to be involved in OCD pathology (section I.6.1). Interestingly, in rats, 
GRIN2B was found to be ubiquitously expressed at birth, but during the first three postnatal 
weeks, the subunit became confined to the anterior forebrain structures (Wenthold et al., 
2003). Therefore, a dysregulation of a similar expression pattern in the human brain may be 
consistent with the neurodevelopmental theory of OCD (Rosenberg and Keshavan, 1998). 
 
The gene encoding GRIN2B (GRIN2B) is situated on chromosome 12p12 (Mandich et al., 
1994) and contains 13 exons, with the coding sequences represented by exons 2 to 13 
(Ohtsuki et al., 2001). Studies to identify functional variants within GRIN2B have thus far 
yielded no obvious results (Ohtsuki et al., 2001), suggesting selective pressure to maintain a 
conserved sequence, stressing the crucial role of the subunit in numerous physiological 
processes.  
 
Genetic evidence for the role of glutamate in OCD stems mainly from a recent genome scan, 
based on EO OCD probands, although the investigation of a haplotype containing two SNPs 
within the the gene encoding the glutamate transporter (SLC1A1) revealed no statistically 
significant linkage with the disorder (Veenstra-VanderWeele et al., 2001). In spite of this, the 
possibility that the gene plays a role in the development of OCD cannot be ruled out, since 
regulatory regions of SLC1A1 remain to be sequenced, and there are many more genes 
involved in glutamate neurotransmission. Indeed, in a recent report on the involvement of a 
kainite glutamate receptors in OCD, a positive association between the gene coding for 
kainite receptor type 2 (GRIK2) and OCD was observed, thereby supporting the role that 
glutamate may play in the disorder (Delorme et al., 2004). 
 
Support for GRIN2B, in particular, as a candidate gene in OCD stems from a family-based 
association study in which Arnold et al. (2004) observed significant genotypic and haplotypic 
associations between GRIN2B variations and increased susceptibility to develop OCD. The 
genotypic association, based on a non-additive model of inheritance, observed an association 
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between the 5072T/G (rs890) variant in the 3’UTR of GRIN2B and OCD. The haplotypic 
association, based on a recessive model of inheritance, indicated that the presence of two 
copies of 5072T-5988T variants (also in the 3’UTR) increased susceptibility to OCD. 
However, the authors could not exclude the possibility that the 5072G-5988C haplotype may 
confer a protective role against developing OCD.  
 
The functionality of neither 5072TC nor 5988TC has been elucidated, making it difficult to 
determine the role that these variants may play in OCD. However it is possible that the 
polymorphisms affect transcriptional regulation in some way, or that they are in LD with 
functional variants within GRIN2B that have yet to be identified. Moreover, other variants 
may form haplotypes with those mentioned above, and may thus even strengthen the role that 
the haplotype plays.  
 
In the present study, two polymorphisms within GRIN2B were investigated: the 
aforementioned SNP found by Arnold et al. (2004) to be associated with OCD (5072TC, or 
rs890) (Figure I.7) and an A to G transversion at nucleotide 3743 in exon 13 (rs1806191). 
rs1806191 rs890 
3’5’ 
 
        I          II         III            IV          V   VI  VII      VIII      IX                 X   XI       XII               XIII 
 
Figure I.7. Schematic representation of the GRIN2B locus. The location of SNPs 
investigated in the present study indicated by arrows. Exons are represented by yellow  
blocks, and introns are represented by horizontal lines between the exons (not drawn to 
scale). The distance between the two SNPs is approximately 1.3kb. 
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I.6.1.4. The neurodevelopmental theory of OCD 
The notion that OCD may comprise a developmental subtype has been alluded to in a 
previous section (section I.4.2.2.4). To recap, this developmental subtype is thought to be 
characterised by male preponderance, an earlier age at onset and a more pronounced basal 
ganglia dysfunction (Rosenberg and Keshavan, 1998). Moreover, the observation that 
neurological soft sign abnormalities reported in paediatric patients with OCD do not 
deteriorate with illness progression lends further support to the neurodevelopmental 
hypothesis of the disorder (Rosenberg and Keshavan, 1998). 
 
In addition, it has been found that the PFC undergoes a substantial amount of re-organisation 
during childhood and adolescence (Rosenberg and Keshavan, 1998; Huttenlocher et al., 1979; 
Jernigan and Tallal, 1990). Indeed, in a magnetic resonance imaging (MRI) study by 
Rosenberg and Keshavan (1998), in which treatment-naïve paediatric OCD patients were 
used, abnormalities in the ventral-PFC striatal anatomy were reported. It was proposed that 
these abnormalities represented an early pathological marker related to abberant 
neurodevelopment. Of course, these changes may be related to alterations in any of the 
abovementioned neurotransmitter systems, but may also be as a result of mutations in genes 
more directly involved in neurodevelopment. 
 
I.6.1.4.1.  Developmental candidate genes 
 
i. Brain-derived neurotrophic factor (BDNF) 
The exact role of BDNF in OCD has yet to be elucidated, but a closer look at the function of 
the protein may aid in determining its possible contribution to the aetiology of the OCD. 
BDNF is the most abundant neurotrophin in the brain – it is expressed throughout the CNS, 
with the highest level of expression in the hippocampus and cerebral cortex (Murer et al., 
2001). The protein is an activity-dependent endogenous neurotrophin involved in 
neurodevelopment, neuronal survival, morphology and differentiation (Hoglinger et al., 1998; 
Lindholm et al., 1996). It also plays a pivotal role in modulating synaptic plasticity (Ying et 
al., 2002; Huang et al. 1999) and efficiency (Huang et al., 1999; Lohof et al., 1993). 
Moreover, it is involved in regulating protein activity at presynaptic terminals, allowing 
BDNF to modulate short and long term synaptic transmission (Popoli et al., 2002).  
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It has also been suggested that BDNF may possess a role as an extracellular transmitter, given 
that it is anterogradely transported (Altar et al., 1997; von Bartheld et al., 1996) and is 
released upon neuronal depolarization, triggering rapid intracellular signals via the 
transmembrane receptor, tyrosine kinase B (TrkB) (Altar and DiStefano, 1998). Indeed, it has 
been found that mice lacking the BDNF/TrkB genes have decreased synaptic inervation and 
lower levels of synaptic vesicle protein (Pozzo-Miller et al., 1999), indicating the involvement 
of BDNF in normal neuronal signaling.  
 
It is particularly significant to research into the aetiology of OCD that BDNF has been 
reported to promote and augment the function and growth of 5-HT neurons in the brain 
(Mamounas et al., 1995) and induce the sprouting of 5-HT nerve terminals (Siuciak et al., 
1994; 1996). In addition, knockout mice heterozygous for the BDNF gene show behavioural 
abnormalities that are in line with 5-HT dysfunction, such as an increase in impulsivity, 
aggressiveness and appetite. Interestingly, these effects were reversed using antidepressant 
(including SSRI) therapy (Lyons et al., 1999). BDNF has also been found to modulate 5-HTT 
function (Mossner et al., 2000), which plays a pivotal role in bringing about the therapeutic 
action of SSRIs. Consistent with these findings is the possibility that BDNF may represent a 
downstream target in antidepressant treatment (Nibuya et al., 1995; Hashimoto et al., 2004).  
 
BDNF may also affect the expression of dopamine: the two have been found to reciprocally 
potentiate each other, particularly in the striatum (Kuppers and Beyer, 2001). Certainly, 
evidence exists suggesting that the expression of DRD3 is positively controlled by BDNF 
(Takahashi et al., 2000), and that BDNF modulates the synaptic plasticity of the DRD3-
secreting neurons in the striatum of the brain (Guillin et al., 2003). Chronic stress causes a 
decrease in the expression of BDNF and DRD3, and chronic antidepressant (SSRI) treatment 
increases the expression of both of these genes. This points to, and reinforces the notion of, 
the possibility that antidepressants may act primarily on BDNF, subsequently altering 
dopaminergic neurotransmission, probably by means of DRD3.  
 
Furthermore, recent reports have indicated that an increase in BDNF expression in the 
striatum is associated with the prevention of stereotyped behaviour (Turner and Lewis, 2003). 
To this end, dopaminergic antagonists have been found to attenuate stereotyped behaviours in 
mice (Turner et al., 2001), providing further evidence for a possible link between striatal 
concentrations of, and interactions between, dopamine and BDNF, and stereotyped behaviour 
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(Turner and Lewis, 2003). Therefore, modulation of dopaminergic responsiveness by BDNF 
may contribute to the aetiology of OCD or OCD-related disorders. 
 
The gene encoding BDNF is primarily a developmental gene that is a member of a family of a 
group of proteins known as neurotrophic growth factors that includes neurotrophic factors 3, 4 
and 5 (Hallbook et al., 1991; Rosenthal et al., 1990; Ernfors et al., 1990). These proteins all 
possess similar coding sequences and only slight differences in functionality, and may 
therefore represent part of a larger gene family of growth factors (Okazama et al., 1992). 
Neurotrophins are all synthesised in a precursor form (the pro-protein), and are cleaved 
intracellularly to produce the mature protein. However, the pro-protein forms are also thought 
to possess functional biological activity, since it has been found that they may be secreted and 
cleaved extracellularly (Lee et al., 2001). In particular, cross-species conservation of the 
precursor portion of pro-BDNF has been reported, indicative of possible functional 
importance (Green and Craddock, 2003). 
 
BDNF has been mapped to chromosomal position 11p14.1 (Leibrock et al., 1989), and has 
recently been found to comprise at least six 5’ exons, each with its own putative promoter 
region. These exons are differentially spliced to a single 3’ terminal exon, that contains the 
only functional splice acceptor site for the splicing of different pre-mRNAs. This terminal 
exon also contains the entire coding sequence of mature BDNF (Jiang et al., 2005; Liu et al., 
2005; Marini et al., 2004). 
 
Recently, a common SNP occurring at nucleotide 196 (196G/A; rs6265) in the terminal exon 
of the proBDNF sequence, resulting in an amino acid substitution (val66met), was found to be 
associated with OCD in a family-based case-control association study (Hall et al., 2003) in 
single and multiple loci analyses. Here, a haplotype containing the rare met66 allele was 
identified as possibly imparting a protective effect in OCD.  
 
The val66met variant is located in the 5’pro-BDNF sequence, and although it is unlikely to 
affect biological activity of the mature protein, the results of in vitro transfection studies 
suggest that the met66 allele may affect the intracellular trafficking and activity-dependant 
secretion of BDNF (Egan et al., 2003). These results, however, remain to be replicated in 
vivo. Moreover, the met66-allele has recently been found to be more abundant in individuals 
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with both anxiety and depression, and was found to be associated with increased levels of 
Harm Avoidance, a personality dimension often associated with OCD (Jiang et al., 2005).  
 
On the other hand, it has been hypothesised that the met66 allele allows for more efficient 
processing of the BDNF protein (Mowla et al., 2001; Sen et al., 2003), although this 
hypothesis seems to stem mainly from the observation that the met66-allele may confer 
protection against developing bipolar depression in Caucasians (Sklar et al., 2002;Green and 
Craddock, 2003; Sen et al., 2003). The met66-allele has also been found to confer protection 
against development of EO OCD (Hall et al., 2003). However, the met66-allele has also had 
its share of associations where it has been implicated as the risk allele: it has been found to 
play a role in memory disturbance and poor hippocampal functioning (Egan et al., 2003; 
Dempster et al., 2005), and has been found to be associated with the restrictive subtype of 
anorexia nervosa (Ribases et al., 2003), which has features in common with OCD. One reason 
for the discrepant findings may, of course, be that the val66met variant is not functional, but is 
in LD with a functional variant in the gene, or one nearby. 
 
Thus, despite the controversy regarding the allele implicated in the abovementioned disorders, 
BDNF presents an attractive candidate to investigate for its involvement in OCD and related 
disorders and subtypes in the context of population-based case-control association studies. 
Three polymorphisms were chosen for investigation in the present study, the most terminal 
being the aforementioned val66met polymorphism (dbSNP rs6265), and two intronic SNPs, 
rs2049046 and rs988748 (Figure I.8) These two intronic polymorphisms are located 
immediately upstream of exon 3, the mRNA transcript of which was found to be the major 
Ca2+/activity-inducible transcript in cortical neurons (Tao et al., 2002). These two 
polymorphisms were also found to be associated with OCD in the recent study by Hall et al. 
(2003). 
 
 
 
 
 
 
 
 
 111
 
 
 
 
 
 
 
 
I     II                          III  IV   V                      VI 
 
Figure I.8. Schematic representation of the BDNF locus. The location of SNPs investigated 
in the present study indicated by arrows. Exons are represented by yellow blocks and introns 
are represented by horizontal lines between the exons. (not drawn to scale). The distance 
between rs2049046 and rs988748 is approximately 970bp, whilst that between rs988748 and 
rs6265 is approximately 43.9kb. 
 
ii. The HoxB8 gene (HoxB8) 
HoxB8 is a member of the highly conserved mammalian Hox (homeobox-containing) 
complex that controls early development by supplying positional information along the 
antero-posterior axis (Capecchi, 1997). Numerous Hox genes (including HoxB8) have been 
found to be expressed in the CNS: in a recent study Greer and Capecchi (2002) detected 
HoxB8 expression within the adult mouse olfactory lobe, basal ganglia, hippocampus, cortex, 
cerebellum, brainstem, orbitofrontal cortex, anterior cingulate cortex and caudate-putam, 
some of which comprise the OCD circuit, reinforcing a role for the gene in the development 
of these brain regions. 
 
In the same study, Greer and Capecchi (2002) demonstrated that mice homozygous for a loss-
of-function HoxB8 mutation exhibited pathological grooming behaviours, including excessive 
hair removal, self-inflicted wounds at the overgroomed sites, an excessive amount of time 
spent grooming and excessive grooming of control littermates. By means of histological and 
behavioural analyses, skin and peripheral abnormalities were excluded as reasons for the 
excessive grroming behaviours, leaving them with the conclusion that the pathological 
behaviour was a result of the CNS HoxB8 abnormalities. 
 
rs2049046 rs988748 
val66met  
rs6265 
3’ 5’ 
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The grooming behaviours observed in the HoxB8 knockout mice were reminiscent of those 
exhibited by patients suffering from TTM, suggesting that a dysfunction in a genetically 
controlled neural network may contribute to the aetiology of the disorder. Since TTM is 
considered by some to be part of the spectrum of obsessive-compulsive disorders, 
investigating the gene as a candidate in association studies may provide clues as to the 
proposed neurodevelopmental basis of both disorders. 
 
The human HoxB8 is located on chromosome 17q21-q22 and comprises two small exons. 
Very few genetic association studies using the gene have been conducted, and very few of the 
proposed SNPs therein have been formally validated. To the author’s knowledge, there exists 
no previously published data that investigates the proposed relationship between genetic 
variants within HoxB8 and increased susceptibitly to OCD and/or TTM. Therefore, the 
present study entails genotyping a polymorphism within HoxB8, to elucidate the potential role 
the gene may play in the development of OCD. 
 
I.6.1.5. “Novel” candidate genes 
Based on extensive literature searches, the final candidate genes have been chosen by the 
author due to their potential involvement in pathways related to those presumed to be 
dysfunctional in the pathophysiology of OCD and/or related disorders and subtypes. These 
genes are placed under the heading “novel candidate genes” largely due to the fact that there 
is not quite as much evidence for their involvement in OCD as there exists for the 
aforementioned candidates. However, the evidence which is available is worthy of, at least, 
some exploratory investigation.  
 
I.6.1.5.1. The Estrogen Receptor type alpha gene (ESRα) 
ESRα encodes a transcription factor that regulates numerous neurotransmitter pathways, 
including 5-HT, in the brain (McEwen et al., 1997). The gene has been mapped to 6q25.1, and 
comprises 8 exons. The gene has recently become a popular candidate amongst researchers 
investigating the genetic aetiology of anxiety disorders. A 5’ microsatellite polymorphism 
was observed to be associated with increased susceptibility to anxiety (Comings et al., 1999), 
and more recently it was found that two intronic variants within the gene account for between 
1.6% and 2.8% of the total variance for anxiety experienced by a large cohort of adolescents 
(Prichard et al., 2002).  
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ESRα thus represents an interesting candidate gene to investigate for the role it may play in 
increasing susceptibility to OCD. A point of contention would, however, be that the male: 
female ratio in OCD in the general population is roughly equal; consequently, the role of any 
estrogenic component in the aetiology of the disorder would be questionable. However, 
gender differences have been observed in certain aspects of OCD, the most notable being the 
differences in obsessions and compulsions, comorbidity and age at onset experienced by 
either sex (Tukel et al., 2004; Noshirvani et al., 1991; Lensi et al., 1996; Bogetto et al., 1999; 
Matsunaga et al., 2000; Castle et al., 1995; Fahy et al., 1993; Lochner et al., 2004). In a recent 
study, our group observed that female patients experienced changes in obsessive-compulsive 
symptomatology during the pre- or postmenstrual period, as well as during or after pregnancy 
and menopause (Lochner et al., 2004). These results are consistent with those from an earlier 
study indicating that the postpartum period represents a greater risk factor for OCD in 
susceptible individuals (Maina et al., 1999). The exacerbation of obsessive-compulsive 
symptomatology during these periods may be due to the role that hormones (including 
estrogen and progesterone) play in altering the 5-HT neurotransmission, thereby triggering 
OCD in vulnerable subjects.  
 
Further evidence for a putative role of ESRα in the aetiology of OCD stems from the finding 
that the promoter regions of COMT (P1 and P2) contain EREs (section I.6.1.2.1 [vi]). The 
expression of the gene is therefore modulated by estrogen and estrogenic transcription factors; 
consequently, any dysfunction within the estrogenic modulatory system may result in the sub-
optimal functioning of COMT. This, in combination with numerous other genetic and 
environmental factors, may ultimately precipitate the OCD phenotype. 
 
The present study investigated the role that two SNPs (rs2234693 and rs9340799), situated in 
intron 1(Figure I.9) may play in the development of OCD. 
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Figure I.9. Schematic representation of the ESRα locus. The location of SNPs investigated 
in the present study indicated by arrows. Exons are represented by yellow blocks and introns 
are represented by horizontal lines between the exons (not drawn to scale). The distiance 
between the two SNPs is approximately 46bp. 
 
I.6.1.5.2. The Inositol Polyphosphatase-1 gene (INPP-1) 
Inositol, a glucose isomer, is a key metabolic precursor in the phosphatidylinositol (PI) 
second messenger system (Kofman and Belmaker, 1993; Michell, 1997). PI has been found to 
be the second messenger for numerous hormones and neuotransmitters, including 5-HT 
(Barabian et al., 1989). Exogeneous administration of  myo-inositol itself has been found to 
demonstrate clinical efficacy in a number of neuropsychiatric disorders, including OCD 
(Levine 1997; Fux et al., 1996), panic disorder (Benjamin et al.,1995), depression (Levine et 
al., 1993; 1995; Kaplan et al., 1996) and compulsive skin-picking (Seedat et al., 2001). 
Interestingly, the administration of exogenous inositol has been found to exacerbate ADHD 
symptoms (Levine et al., 1995), and to be ineffective in treating schizophrenia, Alzheimer’s 
disease and autism (Levine, 1997).  
 
Inositol and phosphoinositides are important for numerous cellular processes, including 
neuronal survival, differentiation, neuroprotection, and signal transduction from growth 
factors, hormones and neurotransmitters including 5-HT, dopamine and glutamate (Fisher et 
al., 1992; Harvey et al., 2002; Delmas et al., 2002; Berridge, 1993). However, in order to 
understand the mechanism of action of inositol in attenuating OCD symptomatology, it is 
necessary to briefly consider the major components of the PI signalling pathway (Figure I.10).  
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The PI pathway involves the hydrolysis of membrane phosphatidyl-4,5-biphosphate (PIP2), by 
means of the phosphorylation of phoshpholipase C (PLC), to inositoltrisphosphate (IP3) and 
diacylglycerol (DAG) (Berridge and Irvine, 1984; 1989; Berridge, 1993). IP3 and DAG 
therefore represent the second messengers: DAG activates DAG-regulated protein kinase C 
(PKC) that is responsible for protein phosphorylation, and has also been found to be involved 
in 5-HT release (Harvey et al., 1997; Berridge, 1993; Berridge and Irvine, 1989). IP3 
promotes the mobilisation of calcium from internal stores, thereby activating Ca2+-dependent 
enzymes, including Ca2+-regulated isoforms of PKC and Ca2+-calmodulin-regulated protein 
kinases. IP3 can be dephosphorylated by means of inositol-polyphosphatase-1 (IPPase) and 
inositol monophosphatase (IMPase) to yield inositol. Phosphoinositol can be formed by the 
combination of DAG and inositol, in a reaction catalysed by PI-synthase (Majerus et al., 
1988). PI is subsequently phosphorylated, in two separate steps, to yield PIP2, thereby 
replenishing the supply of membrane PIP2, and completing the cycle (Figure I.10). 
 
The precise mechanism of clinical action of inositol in OCD, or any of the other 
aforementioned disorders, has not yet been elucidated. However, it is interesting to note that 
the spectrum of activity of inositol appears to be very similar to that of SSRIs in humans and 
animals: both inositol and SSRIs require chronic administration of relatively high doses over 
a number of weeks to be effective (presumably due to selective changes in gene expression 
that appear only after a lag period of a few weeks), and the co-administration of SSRIs and 
inositol does not result in the augmentation of their therapeutic efficacy (Fux et al., 1999; 
Levine et al., 1999; Levine, 1997; Einat et al., 1999). 
 
It may therefore be that inositol and SSRIs share a common mechanism of action in the 
treatment of OCD. In fact, it has recently been found that the administration of SSRIs to 
previously untreated OCD patients results in a decreased number of 5-HT2A binding sites, and 
a decrease in platelet IP3 concentrations (Delorme et al., 2004). This proposed involvement of 
the phosphoinositide signalling system in SRI treatment supports the finding by Marazziti et 
al. (2000) who observed an increase in PKC activity (that was most likely due to an increase 
in activity within the PI pathway) in drug-free OCD patients. 
 
These findings suggest that the fundamental defect of the disorders responsive to SSRI and 
inositol therapy (including OCD) may lie not with neurotransmitter synthesis or metabolism, 
but rather, with the regulation of the underlying signalling cascade. It would thus be pertinent 
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to investigate selected components of these signalling cascade(s) as candidate genes for the 
development of OCD, as has been done in the present study. 
 
If one refers to the figure representing the PI signal transduction system (Figure I.10), it is 
clear that IPPase plays an important role in replenishing the levels of membrane PIP2, by 
catalysing the removal of a phosphate group from the inositol ring on IP2, which can then be 
converted by inositol monophoshatase to myo-inositol. It may therefore be that a 
dysfunctionality in the genes encoding IMPase and/or IPPase may play a role in the 
development of OCD, or at least certain neuropathological aspects of the disorder. This 
hypothesis is indeed in line with the previously reported finding by Marazziti et al. (2000), in 
which the increased activity of downstream components of the PI-PLC pathway was noted in 
OCD patients. 
 
IPPase has been suggested as a target for the mood-stabilising effects of lithium (Inhorn et al., 
1988; York et al., 1993), commonly used in the treatment of bipolar disorder, which is found 
to co-occur with numerous anxiety disorders, including OCD (reviewed in Freeman et al., 
2002). Lithium has been found to uncompetitively inhibit IPPase and IMPase (Berridge and 
Irvine, 1989), and it is this characteristic that forms the grounding for the “inositol-depletion” 
hypothesis: by the inhibition of IMPase or IPPase, the level of inositol would be reduced, 
subsequently reducing the synthesis of PI and DAG. Although the effect of lithium has not 
been widely studied in anxiety disorders, Golden et al. (1988) and Stern and Jenike (1983) 
have reported on the possible efficacy of lithium treatment in OCD patients presenting with 
bipolar or epileptiform features. Indeed, a SNP, in the gene encoding IPPase (INPP-1), 
characterised by an A to C transversion at nucleotide position 973, has been shown to be 
associated with lithium response: the 973C variant has been found to be more frequent 
amongst lithium responders, compared to non-responders (Steen et al., 1998; Lovlie et al., 
1999). 
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Figure I.10. Pathways of phosphoinositide degradation and re-synthesis. Receptor-mediated 
hydrolysis of PIP2(PI-4,5P2) via Phosphoinositide-specific PLC (PI-PLC) results in the 
formation of IP3 (I-1,4,5P ) and DAG. IP3  3 binds to intracellular receptors to release 
sequestered Ca2+ & is sequentiall depohosphorylated to form IP  (I-4,5P ), IP2 2 1 (I-4P)  and 
finally inositol, which can be reutilised by PI synthase to form PI. DAG contributes to the 
activation of DAG-regulated PKC proteins, and also joins up with inositol to form PI 
(adapted from Harvey et al., 2002). 
 
Abbreviations: 5-HT : serotonin receptor 2; PLC: phospholipase C; PIP  (PI-4,5P2): phosphatidylinositolbisphosphate; IP2 2 3 (I-1,4,5P3): 
inositol trisphosphate; IP  (I-4,5P2): inositol bisphosphate; IP2 1 (I-4P): inositol monophoshate; IMPase: inositol-1-monophosphatase; 
IPPase: inositol-1-polyphosphatase (INPP-1); 1,2DAG: 1,2 diacylglycerol;PA: phosphatidic acid; PI-4P: phosphatidyl-inositol 4-phosphate 
(PIP).
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INPP-1 maps to chromosomal location 2q32, and is comprised of six exons. Polymorphisms 
within the gene have been linked not only to lithium response in patients with bipolar disorder 
(Steen et al., 1998; Lovlie et al., 1999), but also to autistic disorder, which is thought to share 
some aspects of genetic lability with OCD, given that motor tics, OCD and affective disorders 
were found to be more prevalent amongst first degree relatives of autistic probands (Bolton et 
al., 1998). Indeed, one characteristic of the autism diagnosis is marked resistance to change, 
shown by rigid and repetitive behaviours and restricted interests, representing OC-like 
symptom dimensions which may represent the link between the two disorders. Moreover, 
Hollander et al. (2003[b]) reported, in a recent preliminary investigation, that autistic children 
presenting with more repetitive behaviours were significantly more likely to have parents with 
OC traits or OCD.  
 
Given the proposed involvement of inositol in OCD, the C937A SNP in INPP-1 was 
investigated as a novel candidate gene for the role that it may play in mediating the 
development of OCD. 
 
I.6.1.5.3. The Phospholipase-C gamma-1 gene (PLCγ-1) 
At least eleven PLC isoforms, grouped into four subfamilies, namely β, γ, ε and δ, are found 
in the brain, each representing the product of a separate gene (Rhee et al., 1989; 2001). 
Although all four groups of isozymes serve to activate the inositol phopholipid signalling 
pathway, their mechanisms of activation differ. The mechanisms of activation for the PLC-β 
and PLC-γ subgroups appear to be the most well-founded: PLC-β is activated by G-protein 
coupled receptors (including thromboxan-A2, histamine, vasopressin and endothelin receptors 
[Rhee, 2001]), whilst the PLC-γ class is activated by the tyrosine kinase class of receptors. 
Ca2+ and a recently discovered type of GTP-binding protein appears to play a role in the 
activation of PLC- δ, although this remains to be further investigated (Feng et al., 1996; Rhee, 
2001), and the PLC-ε isozyme is though to be an exchange factor for, and effector of, Ras-
GTP (Lopez et al., 2001; Song et al., 2001 [cited in Rhee, 2001]). 
 
Of particular interest in the present study was the PLC-γ1 isozyme, given its fundamental role 
in the intracellular signalling cascade brought about by numerous growth factors, including 
neural growth factor (NGF) and BDNF (Yuen and Mobley, 1999). As previously mentioned, 
neurotrophic factors play an important role in regulating the survival and differentiation of 
specific neuronal populations during development, and maintain specific neuronal functions 
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during adulthood (Lewin and Barde, 1996). All neurotrophins bind to one or more receptors 
belonging to the tropomyosin receptor kinase (Trk) family. These Trk receptors (Trk A, B and 
C) represent a subgroup of a larger family of proteins with tyrosine kinase enzymatic activity 
(reviewed in Patapoutian and Reichardt, 2001). The binding of the neurotrophin causes 
dimerisation of the relevant Trk receptor, resulting in the phosphorylation of specific tyrosine 
residues on the receptor. These phosphorylated residues provide an ideal docking site for the 
PLC-γ1 isozyme, catalysing the subsequent phosphorylation of the bound enzyme. This 
interaction activates PLC-γ1, and facilitates its interaction with the substrate molecule, PIP2 
(Figure I.10), and subsequent activation of the PI signalling pathway. It has been found that 
signaling pathways activated in neuronal cells by Trk-mediated activation of PLC-γ1 extend 
to the nucleus, implicating its involvement in the regulation of certain transcritional events 
(Toledo-Aral et al., 1995). Moreover, it has recently been found that the activation of PLC-γ 
is required for the regulation of neurotrophin secretion (Canossa et al., 2001). 
 
In an attempt to delineate the physiological fuctioning of the Trk-mediated PLC-γ1 signalling 
pathways, Minichiello et al. (2002) mutated the TrkB PLC-γ1 recruitment site (Y816) in 
mice. Mice homozygous for the mutation (trkBPLC-/PLC-) were found to be more hyperactive 
than control littermates, and possessed significant deficiencies in the induction of early and 
late phases of hippocampal long-term potentiation (LTP) via cAMP response element binding 
protein (CREB) activation (Minichiello et al., 2002). Since BDNF couples to the TrkB 
receptor, and has previously been found to be involved in EO OCD (Hall et al., 2003), it is 
possible that an abnormality in the activation of nuclear transcription factors, via PLC-γ1 
activation, may underlie certain aspects of OCD pathology. Indeed, the need for chronic 
administration of both SSRIs and inositol to achieve clinical efficacy in OCD patients is 
indicative of the effect of these agents on secondary gene expression, which would allow for 
such a change in response over a period of chronic exposure. 
 
Given the aforementioned role that PLC-γ1 plays in the PI signalling pathway, and its 
activation by neurotrophins, which have been implicated in the pathophysiology of OCD 
(section I.6.1.4.1[i]), the gene encoding PLC-γ1 represents a plausible candidate gene to 
investigate for the role it may play in increasing susceptibilty to OCD and related subtypes. 
The gene encoding PLC-γ1 is situated on chromosome 20q12-13 (Bristol et al., 1988), and 
comprises 32 exons. A SNP situated in exon 9, resulting in a ser to gly amino acid 
substitution at position 279 (dbSNP rs8192707), was recently described by Ftouhi-Paquin et 
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al. (2001). Since this SNP occurs in the coding region of the gene, it may possess functional 
consequences (although these have not yet been fully elucidated), and was therefore 
investigated in the present study.  
 
I.6.1.5.4. The Angiotensin Converting Enzyme gene (ACE) 
Angiotensin converting enzyme (ACE) plays an important role in the renin-angiotensin 
system, converting inactive angiotensin I to the active peptide angiotensin II (Ang II) 
(Johnston, 1990). ACE is also expressed in the CNS, with high concentrations in the striatum, 
choroid plexus and periventricular nucleus of the hypothalamus (Bardelay et al., 1989), where 
it functions additionally to catalyse the degradation of substance P (SP) (Skidgel and Erdos, 
1987), a neuropeptide that has recently been of considerable interest in the field of anxiety 
(Griebel et al., 1999; Hasenörhl et al., 2000). It has also been proposed that ACE might 
hydrolyse numerous other neuropeptides, such as Met and Leu-enkephalin, dynorphin and 
neurotensin (Skidgel et al., 1984). 
 
Ang II interacts with its specific angiotensin receptors, AT1 and AT2, and has been found to 
co-localise with dopaminergic neurons in the striatum and substantia nigra (Jenkins et al., 
1995; Hasenörhl et al., 2000). As such, Ang II may regulate the dopaminergic content of 
certain regions of the brain. In rats treated with the ACE inhibitor, perindopril (which has 
been found to cross the blood-brain barrier), striatal dopamine synthesis and release was noted 
(Reardon et al., 2000). Moreover, chronic treatment with the dopamine antagonist, 
haloperidol, has been found to result in elevated DRD2-receptor densities, accompanied by an 
increase in Ang II receptor, AT1, in the nucleus accumbens (Jenkins et al., 1995). Therefore, 
by controlling the level of Ang II in the brain, ACE in turn, could play an important role in 
regulating dopaminergic content. 
 
The function that ACE plays in the degradation of SP is also relevant to the present 
hypothesis that it may be involved in the pathophysiology of at least some forms of OCD. 
Substance P is a member of the tachykinin family, representing the preferential agonist of the 
neurokinin-1 (NK1) receptor. The neuropeptide is widely distributed in the CNS, including 
those areas involved in the regulation of affective behaviour and neurochemical responses to 
stress, including the striatum, nucleus accumbens, hippocampus and the lateral nucleus of the 
hypothalamus (Quartara and Maggi, 1998; Shults et al., 1984; Hasenörhl et al., 2000). 
Another characteristic of SP is that it co-localises in the same neuron with other 
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neurotransmitters, including 5-HT, dopamine, and glutamate (Hasenörhl et al., 2000), thereby 
regulating their release and/or enhancing their effects. 
 
Numerous animal studies have indicated the role that a disruption in SP levels play in anxiety: 
administration of NK1 receptor antagonists was found to yield anxiolytic activity (File et al., 
1997; Santarelli et al., 2001). Conversely, NK1 receptor agonists have resulted in anxiogenic 
behaviour (Aguiar and Brandao, 1994; Duarte et al., 2004). In addition, and importantly, it 
has been found that NK1 receptor antagonists function as efficiently as SSRIs in the treatment 
of major depression  (Kramer et al., 1998). The exact mechanism of therapeutic efficacy of 
NK1 receptor antagonists (and thereby the way in which SP may influence the development 
of such disorders) is presently unknown. However, recent studies indicate that the genetic 
deletion of NK1 receptors results in the desensitization of 5-HT1A receptors (Froger et al., 
2001; Santarelli et al., 2001; 2002), representing a similar mechanism of action to many of the 
classical antidepressants, including SSRIs (Blier and Montigny, 1994; Chaput et al., 1991).  
 
The gene encoding ACE is located on chromosome 17q23 and consists of 16 exons spaced 
over approximately 24kb (Rieder et al., 1999). A well-characterised intron 16 Alu 
insertion/deletion (ins/del) polymorphism has been investigated in numerous somatic and 
psychiatric disorders. This variant has been found to account for 27% to 49% of the total 
variance of serum levels of ACE (Rigat et al., 1990), with the D-allele (i.e. the deletion of the 
287bp Alu sequence) associated with higher levels of circulating ACE (Rigat et al., 1990; 
McKenzie et al., 1995; Villard et al., 1996; Keavney et al., 1998; Tiret et al., 1992; Cambien 
et al., 1988). The polymorphism may also influence interindividual variability in SP levels in 
some parts of the brain, especially those in which SP levels are highly expressed (such as the 
caudate, the putamen, the substantia nigra and certain regions of the hypothalamus) (Arinami 
et al., 1996). In fact, the D/D genotype has been associated with increased susceptibility to 
affective disorders (Arinami et al., 1996), and depression in females (Baghai et al., 2004). 
Moreover, patients with major depression who carried at least one D-allele were found to 
respond better to pharmacotherapy with different antidepressants than those patients who 
were homozygous for the I-allele (Baghai et al., 2001; Bondy et al., 2005).  
 
It is thus possible, that by altering the levels of ACE, the insertion/deletion polymorphism 
may influence the levels of Ang II and/or SP in the brain, and as such, may play an important 
role in the development of OCD and/or related disorders. Indeed, in light of the presented 
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evidence, it would be interesting to compare OCD patients with co-morbid MDD and those 
without, with regard to the presence or absence of such a polymorphism.  
 
I.6.2. ANALYSIS OF AFRIKANER POPULATION STRUCTURE 
As already discussed (section I.4.1.1.4.), the South African Afrikaner population represents a 
potentially important population in which to investigate with regard to the inheritance of 
multifactorial disorders, given its high levels of genetic homogeneity. It is, however 
interesting to note that, to date, no formal analysis has been conducted into whether the 
Afrikaner population represents a unified, genetically homogeneous population, or whether 
certain “sub-populations” exist. This is particularly relevant when conducting case-control 
analyses, since the cases may be more related than the controls due to a recent ancestor who 
possessed a disease-predisposing allele. In such an event, the cases’ contribution to the 
analysis will be correlated, whilst the statistics used assume that they are independent of one 
another. This may result in inflated effective sample sizes, and overoptimistic p-values 
(Devlin and Roeder, 1999). 
 
To determine whether any cryptic sub-populations exist within the Afrikaner sample used in 
the present study, a Bayesian model-based algorithm, Structure (Pritchard et al., 2000), was 
implemented (section I.4.1.1.3[i]). Structure assigns individuals probabilistically to one or 
more sub-populations based on allelic frequencies at each locus. It involves genotyping 
random markers (preferably in linkage equilibrium with each other) in order to reflect the 
baseline genetic differences between cases and controls. The procedure places individuals into 
‘K’ number of clusters. ‘K’ is chosen in advance, but can be varied across independent runs of 
the Structure algorithm. It is possible for individuals to have membership in multiple clusters; 
in this case, the program will indicate an estimate of the fraction of the individual’s genome 
that originated from each of the ‘K’ subpopulations, providing a means for capturing the 
degree of admixture. 
 
The major drawback of this method is that, although it allows the detection of population 
structure, the algorithm itself offers no means of adjusting the significance value if the 
stratification is found to influence the validity of the association. However, a program called 
“strat” has been designed (Pritchard, 2000) in order to correct for confounding due to 
stratification. Structure is a presently widely-used program, and has been successfully 
implemented in numerous studies attempting to delineate human population structure 
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(Rosenberg et al., 2002; Bamshad et al., 2003), the genetic structure of certain dog breeds 
(Parker et al., 2004) and it has even been used to distinguish between selected breeds of 
chickens (Rosenberg et al., 2001). 
 
The polymorphisms included in the population Structure analysis comprised those that were 
genotyped for concurrent psychiatric genetics studies in our laboratory, including some of 
those in the present study. In addition, five Alu insertion polymorphisms were used. These 
autosomal polymorphisms are short interspersed repetitive elements (SINEs), with each Alu 
element represented by a dimeric ~300bp retroposon that is homologous to, and ancestrally 
derived from, the 7SL RNA component of the signal recognition particle (Ullu and Tschudi et 
al., 1984). These polymorphisms are commonly found in introns, intergenic genomic regions, 
and 3’UTRs of genes (Maklolowski et al., 1994). 
 
The Alu insertion polymorphisms were chosen on the basis that they are widely used in 
human evolutionary studies, since these insertion events are widely distributed, infrequent and 
irreversible (Batzer et al., 1994; 1996; Stoneking et al., 1997; Novick et al., 1998). Indeed, the 
Y, Ya and Yb subfamilies of Alu insertion polymorphisms are still active, and produce new 
Alu insertions that are polymorphic in most human populations (Roy et al., 2000; Batzer et al., 
1990; Deininger and Batzer, 1999; Arcot et al., 1995). In addition, the ancestral allele is 
represented by the absence of an insertion; therefore individuals with an Alu insertion at a 
given locus share a chromosomal region that is identical by descent, facilitating investigation 
of population genetic structure and history. 
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CHAPTER II: METHODS AND MATERIALS 
 
II.1. STUDY SUBJECTS 
The protocol was approved by the Ethics Committee of the University of Stellenbosch, and all 
subjects (case and control) provided written informed consent, after being presented with a 
complete description of the study (Appendix III).  
 
All case and control subjects participating in the present study were of Afrikaner descent - 
ancestry was determined based on information provided by each subject regarding his or her 
parents and grandparents. For the purpose of this investigation, subjects were classified as 
Afrikaners if at least three of their four grandparents were of Afrikaner descent.  
 
II.1.1. Control Subjects 
Control subjects were recruited throughout South Africa by trained clinical psychologists and 
via media advertisements. All controls were required to complete a questionnaire pertaining to 
his/her personal demographic data and present state of physical health.  
 
II.1.2. Case Subjects 
 
II.1.2.1. Clinical diagnosis 
One hundred and thirty-two unrelated OCD patients, between 9 and 65 years of age, were 
recruited through physician referral, media advertisements, the Mental Health Information 
Centre (MHIC) and the OCD Association of South Africa (OCDSA) over a period of 
approximately 8 years. To be eligible for inclusion in the study, patients had to meet the 
DSM-IV criteria (APA, 1994) for a primary diagnosis of OCD on the Structured Clinical 
Interview for Axis I disorders – Patient Version (SCID-I/P) (First et al., 1998). All diagnoses 
were made by trained clinical psychologists at the MRC Unit on Anxiety and Stress 
Disorders. 
 
The SCID I/P, and selected sections of the Structured Clinical Interview for Axis II 
Disorders-Patient Version (SCID-II/P) (including obsessive-compulsive, avoidant, 
schizotypal and borderline personality disorders) (First et al., 1998) were used to assess co-
morbidity. Both of these structured diagnostic instruments are used frequently in psychiatric 
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research. In addition, the relatively newly developed structured clinical interview for the 
diagnosis of putative obsessive-compulsive spectrum disorders (SCID-OCSD) (du Toit et al., 
2001) was administered to assess OCD-related conditions not covered by the SCID-I. 
 
The Yale-Brown Obsessive-Compulsive Symptom Checklist (YBOCS-CL) and severity scale 
(YBOCS-SS) (Goodman et al., 1989) were used for the assessment of the typology and 
severity of obsessive-compulsive symptoms, respectively (Goodman et al., 1989). Y-BOCS is 
a 10-item balanced scale that is designed to rate the severity and type of symptoms 
experienced by patients with OCD. The scale measures symptoms, on a scale of 0-4, without 
being influenced by the type of obsessions or compulsions, with the total Y-BOCS score 
indicating the range of severity for patients who exhibit both obsessions. The dimensional Y-
BOCS (DY-BOCS) interview was conducted in the present study to allow for assessment of 
the typology and severity of OCD symptoms.  
 
The YBOCS-CL was developed in 1986 and has been frequently used in research and clinical 
settings since, and is generally assumed to have good validity and reliability (although data on 
the YBOCS-SS is relatively limited). Patients’ level of insight into the senselessness or 
excessiveness of their OC symptoms was assessed using the relevant YBOCS-SS item 
(Goodman et al., 1989). The presence/absence of tics (current and past) and the nature thereof 
(e.g. motor and/or vocal) was assessed with the SCID-OCSD and the Yale Global Tic 
Severity Scale (YGTSS), respectively (Leckman et al., 1989). In the genetic analyses, both 
the categorical phenotype of OCD diagnosis and the quantitative phenotype of total Y-BOCS 
score were considered. 
 
A miscellaneous medical questionnaire, which included questions pertaining to head injury, 
current medication, medical screening, developmental history, the presence of tics (current or 
past) and family history was also answered by the patients. OCD patients with a significant 
history of neurological disease, schizophrenia, schizo-affective disorder, other psychotic 
conditions or a history of substance dependence, as determined from the interviews or 
previous medical records, were excluded from the study. 
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II.2. CANDIDATE GENE ASSOCIATION ANALYSES 
 
II.2.1. Blood Collection 
Blood samples were drawn from OCD subjects and controls by means of venous puncture and 
collected into 5ml ethylene-diamine-tetra-acetic acid (EDTA) tubes. If blood was drawn from 
patients or controls at the MRC Unit on Anxiety and Stress Disorders, it was collected 
immediately and brought to the research laboratory at the MRC Centre for Molecular and 
Cellular Biology. Blood that was drawn from participants around South Africa was couriered 
to the research laboratory within 24 hours of sampling. 
 
II.2.2. DNA Extraction 
 
II.2.2.1.  Extracting nuclei from whole blood 
Blood from three 5ml EDTA tubes per patient was transferred into a 50ml Falcon tube. The 
tube was then filled to 20ml with ice-cold lysis buffer (Appendix I). After gently inverting 
the tubes a few times, the sample was incubated on ice for 5-10 minutes. The sample was then 
centrifuged at 2500-3000 rpm at room temperature in a Beckman model TJ-6 centrifuge 
(Scotland, UK). The supernatant was discarded and the pellet was re-suspended in 20ml ice-
cold lysis buffer, followed by another round of incubation and centrifugation. The supernatant 
was then discarded and the pellet re-suspended in 900μl sodium-EDTA (Appendix I) and 
100μl 10% sodium dodecyl sulphate (SDS) (Appendix I). The nuclei were then either 
immediately used for DNA extraction or stored at -70˚C until the DNA was required. 
 
II.2.2.2.  Extracting DNA from nuclei. 
To the freshly prepared or thawed nuclei, 100μl of proteinase K (10μg/ml) was added and the 
mixture was incubated overnight at 37˚C. After this step, 2ml distilled water, 500μl 3M 
sodium-acetate (Appendix I) and 25μl phenol/chloroform (Appendix I) were added to the 
sample. The tubes were subsequently inverted and mixed gently for 10 minutes on a Voss 
rotator (Voss of Maldon, England) at 4˚C. The mixture was then transferred to a glass Corex 
tube so that the aqueous phase could subsequently be clearly distinguished from the organic 
phase, followed by centrifugation in a Sorvall RC-5B refrigerated super-speed centrifuge 
(rotor SS 34, Dupont Instruments) at 8000 rpm for 10 minutes at 4˚C.  
 
 129
The upper aqueous phase containing the DNA was transferred to a clean Corex tube using a 
sterile plastic Pasteur pipette, taking care not to disturb the interface or the organic phase. 
Approximately 25ml chloroform/octanol (Appendix I) was added to the aqueous phase, after 
which the tube was closed with a polypropylene stopper and gently inverted for 10 minutes. 
This mixture was then centrifuged at 4˚C, followed by the removal of the upper aqueous 
phase as described earlier. The DNA was then ethanol-precipitated by adding two volumes of 
ice-cold 96% ethanol and inverting gently until strands appeared as a white precipitate. 
 
These DNA strands were removed using a yellow-tipped Gilson-pipette and placed in a clean, 
1.5ml Eppendorf microfuge tube. One millilitre 70% ethanol was then added to the DNA and 
the mixture centrifuged in a Beckman microfuge for 3 minutes at 13 000 rpm. The ethanol 
was carefully decanted and the 70% ethanol wash repeated one more time in order to remove 
any excess salts. After careful removal of most of the ethanol, the DNA pellet was air-dried 
for 30 to 60 minutes at room temperature by inverting the Eppendorf microfuge tube on 
Carlton paper. Two hundred microlitres Tris-EDTA (TE) (Appendix I) buffer was added and 
the DNA was resuspended initially by stationary incubation at 37˚C overnight and 
subsequently by gentle mixing in a Voss rotator (Voss of Maldon, England) at 4˚C for a 
further 3 days. This was followed by stationary incubation at 4˚C for one to three weeks until 
the DNA had been completely re-suspended. 
 
Thereafter, the optical density (OD) of the DNA was determined in a Milton Roy series 120i 
spectrophotometer (USA) at 260nm (OD260). The DNA concentration was determined by 
diluting 10μl of DNA in 500μl of TE and multiplying the measured OD260 by a factor of 2.5. 
This gave the DNA concentration in μg/μl. The purity of the DNA was determined by 
calculating the ratio of the OD260 and the OD280, which should be approximately 1.8 for pure 
DNA.  
 
II.3. POLYMORPHISM SELECTION 
Candidate genes were chosen based on an extensive literature search, using the PubMed 
literature database (www.ncbi.nih.gov/PubMed). Variants within the candidate genes were 
selected from those deposited in the National Centre for Biotechnology Information (NCBI) 
database of genetic variation (dbSNP). Variants with minor allele frequencies of greater than 
5% were selected using SNPper, a web-based application developed by The Children’s 
Hospital Informatics Program (CHIP) (http://snpper.chip.org). 
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II.4. POLYMERASE CHAIN REACTION (PCR) 
 
II.4.1. Primer Design  
 
II.4.1.1. External amplification primers 
Where possible, both forward and reverse external amplification primer sequences were 
obtained from published data. If no published data were available, primers were designed 
using nucleotide sequences deposited in the Genbank database 
(http://www.ncbi.nlm.nih.gov/Entrez), and the Primer3 program (Whitehead Institute for 
Biomedical Research, Cambridge MA, USA; http://frodo.wi.mit.edu/cgi-
bin/primer3/primer3_www.cgi). Primer selection parameters (melting temperature (Tm) and 
percentage GC content) were left on the Primer3 default settings.  
 
Each set of amplification primers was screened for melting temperature compatibility, self-
complementarity and primer-primer complementarity using DNAman 4 (Lynnon Biosoft, 
Quebec, Canada) and the Autodimer program (Vallone and Butler, 2004). 
(http://www.cstl.nist.gov/biotech/strbase/AutoDimerHomepage/AutodimerProgramHomepag
e.htm).  
 
II.4.1.2. Internal interrogation primers for SNaPshot genotype analysis 
Internal interrogation primers used in the single nucleotide di-deoxy nucleotide triphosphate 
(ddNTP) primer extension method (SNaPshot analysis [Perkin Elmer Applied Biosystems, 
Warrington, UK]) for genotyping (section II.5.3) were also synthesised using Primer3 
software. These primers were designed to terminate immediately 5’ to the nucleotide base of 
the SNP under investigation (Figure II.1).  
 
To allow for multiplex reactions, interrogation probes with lengths differing by at least 4 to 6 
bases were required, to avoid overlap of peaks after capillary electrophoresis (section II.5.3). 
Using the Autodimer and DNAman software described in the previous section, the internal 
probes were investigated for, and rejected if, they were predicted to undergo self- or cross-
dimerisation, or form 3’ hairpin structures. 
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II.4.2. Primer Synthesis 
All oligonucleotide primers were synthesised on a 50nm scale according to standard 
phosphoramidite methodology at the Department of Biochemistry, University of Cape Town 
(UCT), UCT Medical School, Cape Town, South Africa. DRD4 48bp VNTR primers that 
were labelled with a fluorophore, 6-carboxyfluorescein (6-FAM) were synthesised on a 
100μM scale by Inqaba Biotech, South Africa. External amplification primers used in the 
present study are listed in Tables II.1 (a) and (b). 
 
II.4.3. PCR conditions 
Each locus was amplified individually. DNA amplification was performed in a 50μl reaction 
containing 100ng template DNA, 200μM of each deoxyadenosine triphosphate (dATP), 
deoxythymidine triphosphate (dTTP), deoxycytidine triphosphate (dCTP) and 
deoxyguanosine triphosphate (dGTP) (Promega Corp, Madison Wisconsin USA), 5μl of 10X 
Taq DNA polymerase buffer (Bioline UK Ltd, London UK), 1.5mM MgCl2 (Bioline UK Ltd, 
London, UK), 0.5 units (U) Taq DNA polymerase and 0.5μM of each primer, with bi-distilled 
water (ddH20) making the mixture up to a final volume of 50μl.  
 
Thermal cycling was performed in a GeneAmp® PCR system 9700 (Perkin Elmer 
Biosystems, Foster City, CA, USA) for 30 cycles. In brief, an initial denaturation step (the 
pre-denaturation step) was performed at 94˚C for approximately 3 minutes. Thereafter, a 
denaturation step was performed at 94˚C for 30 seconds (s), followed by the primer annealing 
step, at temperatures of between 55.5˚C and 70˚C (depending on the composition and length 
of the primer sets) for 30s, and an elongation step, performed at 72˚C for 45s. A final 
elongation step, at 72˚C for  7 minutes, was performed. The annealing temperatures and 
length of the PCR amplified product for each set of oligonucleotide primers are presented in 
Tables II.2(a) and (b).  
 
Where the GC content of the product was very high, as for the amplification of the 48bp 
VNTR in DRD4, half of the dGTP in the reaction mixture was substituted with 7-deaza-dGTP 
(Roche Applied Science, Basel, Switzerland) (i.e. 100 μM dGTP, 100 μM 7-deaza-dGTP) in 
order to decrease the melting temperature of the PCR product. Furthermore, the addition of 
either 5 % dimethyl sulfoxide (DMSO) or 5 % formamide was required in order to increase 
the specificity and /or yield of some of the PCR reactions (Tables II.2[a] and [b]).  
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Figure II.1. Overview of the SNaPshot procedure, indicating the positions of the external and 
internal interrogation primers. A: the initial PCR reaction, as described in section 4.3. B: 
The PCR-amplified products, indicating the SNP of interest (in this case, an A to C 
transition). C: the PCR-amplified products are denatured, the interrogation primers, which 
bind immediately adjacent to the SNP site, are added and complementary fluorescently-
labelled ddNTPs are incorporated. The fluorescently-labelled extension primers can then be 
visualised by capillary electrophoresis (section I.5.3) (adapted from Turner et al., 2002).  
Abbreviations: ddNTP: di-deoxy nucleotide triphosphate 
T
A
G
C
C
A
ddNTP (A, C, G, T)
A 
B 
C 
External primer 
External primer 
allele 1
allele 2
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Following amplification, 5μl of each amplified sample was electrophoresed on 2% agarose 
gels (section I.6.1) to verify that a fragment of the expected size had been amplified. In the 
interest of quality control, a negative control (water blank) was included in each batch of 
amplifications performed. 
 
II.5. GENOTYPING 
Depending on the type of polymorphism, four methods of genotyping were employed in the 
present study: agarose gel electrophoresis, allele-specific restriction endonuclease analysis 
(ASREA), single nucleotide dideoxy nucleotidetriphosphate (ddNTP) primer extension 
method (SNaPshot analysis [Applied Biosystems, California, USA]) and separation by 
capillary electrophoresis. Assessment of genotypes was conducted blind to diagnosis, and by 
two independent investigators. Genotypes were only used if the genotyping results obtained 
by the two independent investigators concurred. 
 
II.5.1. Genotyping the VNTR and Alu insertion polymorphisms by agarose gel 
electrophoresis  
Detection of the DRD4 (48bp VNTR), DAT (40bp VNTR) and the Alu insertion 
polymorphisms involved size fractionation of the relevant PCR amplified products on an 
agarose gel of appropriate concentration) (section II.6.1). Table II.3 lists the percentage (w/v) 
of agarose gels used for genotyping these polymorphisms, and the sizes of the alleles that 
could be detected.  
 
II.5.2. Allele-specific Restriction Enzyme Analysis (ASREA) 
The majority of polymorphisms investigated in this study involve the substitution of single 
base pairs, which creates or abolishes a restriction endonuclease recognition site. Genotyping 
variants by exploiting this knowledge is referred to as allele-specific restriction enzyme 
analysis (ASREA). 
 
Briefly, 5μl of the pertinent PCR amplified product was added to a cocktail containing 1-3U 
of the relevant restriction enzyme (Tables II.4[a] and [b]) in the appropriate buffer supplied by 
the manufacturer, with the final volume being 10μl. These reactions were then incubated for 2 
to 3 hours at the optimal temperature for the restriction enzyme.  
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Table II.1 (a). Description of the candidate polymorphisms used in the genetic association analyses, indicating the chromosomal  location 
of the variants and sequences of the external amplification primers. 
 
aG-allele corresponds to the cys23-allele; bG-allele corresponds to the val158 allele; c C+ refers to the insertion of the C-allele, C- refers to the deletion of the C-allele; dA-allele corresponds to the ser9-allele. 
#Variants used in structure analysis as well. Abbreviations: 5-HT2A: serotonin receptor 2A; 5-HT1Dβ: serotonin receptor 1Dβ; 5-HT6: serotonin receptor 6; 5-HT2C: serotonin receptor 2C; DRD4: dopamine 
receptor 4; DRD2: dopamine receptor 2; COMT: catechol-O-methyltransferase;, DAT: dopamine transporter; DRD3: dopamine receptor 3; DRD1: dopamine receptor 1; VNTR: variable number of tandem 
repeats polymorphism.References:1: Arranz et al., 1998; 2: Warren et al; 1993; 3: Present Study; 4: Kohen et al., 1996; 5: Masellis et al., 2001; 6: Ebstein et al., 1997; 7: Rietschel et al., 1997; 8: Okuyama et 
al., 1999; 9: Lichter et al., 1993; 10: Arinami et al., 1997; 11: De Mille et al., 2002; 12: Karayiorgou et al., 1997; 13: Vandenbergh et al., 2000; 14: Crocq et al., 1992; 15: Cichon et al., 1996. 
Gene Chromosomal Location 
Variant 
identification 
DNA 
variant Domain Forward Primer (5’-3’) Reverse Primer (5’-3’) Ref. 
rs6311 
 (-1438A/G)# SNP[A→G] Promoter GGTAGCCTACTGTGGCCTTG TGGGCTTTCCATGCAACTAT 1 
5-HT2A 13q14-21 rs6313 
(T102C) SNP [T→C] Exon 1 
CGCCCGCCGCGCCCCGCGCCCGTCCCCGCC
GTCTGCTACAAGTTCTGGCTT CTGCAGCTTTTTCTCTAGGG 2 
5-HT1Dβ 6q13 
rs6296 
(G861C)# SNP [C→G] 
After Stop 
Codon TCGTCGGACATCACTTGTTG GTGGAACCAGCAGGCATCTT 3 
5-HT6 1p35-36 rs1805054# SNP[ C→T] Exon 1 CTGCAGCGTCTCCGAGGCCTGACTG TGCTGATGCCGCTCATCTGCACTCA 4, 5 
5-HT2C Xq24 
rs6318 
(cys23ser) 
SNP 
[G→C]a Exon 4 GGCCTATTGGTTTGGCCAT CTGCCATGATCACAAGGATG 6, 7 
rs1800955# SNP [C-T] Promoter TCAACTGTGCAACGGGTG GAGAAACCGACAAGGATGGA 8 
DRD4 11p15.5 
N/A 48bp VNTR Exon 3 GCGACTACGTGGTCTACTCG AGGACCCTCATGGCCTTG 9 
DRD2 11q23.2 rs1800497 (Taq1A)# SNP[C→T] 3’UTR CCGTCGACCCTTCCTGAGTGTCATCA CCGTCGACGGCTGGCCAAGTTGTCTA 10 
rs2097603 SNP [A→G] Promoter CTCTGGCGGAAAGGAAT TCGGCATCAAAAGGAGGAAAAAG 11 
rs4680 
(val158met)# 
SNP 
[G→A]b Exon 4 TCACCATCGAGATCAACCCC ACAACGGGTCAGGCATGCA 12 COMT 22q11.2 
rs362204 C+-C-c 3’UTR TGCGGAAGGGGACAGTGCTAC CCGGAGCCGCAGAAGGTCA 11 
DAT 5p15.3 N/A 40bp VNTR# 3’ UTR TGTGGTGTAGGGAACGGCCTGAG CTTCCTGGAGGTCACGGCTCAAGG 13 
DRD3 3q13.3 rs6280 (ser9gly)# 
SNP 
[A→G]d Exon 1 GCTCTATCTCCAACTCTCACA AAGTCTACTCACCTCCAGGTA 14 
DRD1 5q35.1 A-48G# SNP [A→G] Promoter GGCTTTCTGGTGCCCAAGACAGTG AGCACAGACCAGCGTGTTCCCCA 15 
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Table II.1 (a) (continued). Description of the candidate polymorphisms used in the genetic association analyses, indicating the 
chromosomal location of the variants and sequences of the external amplification primers. 
 
Gene Chromosomal Location 
Variant 
identification 
DNA 
variant Domain Forward Primer (5’-3’) Reverse Primer (5’-3’) Ref. 
rs1806191 SNP [A→G] Exon 13 GCAGTGTGCTAAATGGTCTCA AGGAGCGGAGTGATGACTTTA 1 GRIN2B 12p12.3 
rs890 SNP [A→C] 3’ UTR GCAGTGTGCTAAATGGTCTCA AGGAGCGGAGTGATGACTTTA  
rs6265 
(val66met) 
SNP 
[G→A 
]a 
Exon 6c AAAGAAGCAAACATCCGAGGACAA ATTCCTCCAGCAGAAAGAGAAGAGG 2 
rs2049046 SNP [A→T] Intron 5
c CTCTGTCAACCGTCTACCTGTG CTGCATTCGAATTGCTTGTG 1 BDNF 11p14.1 
rs988748 SNP [C→G] Intron 5
c TTGGAGTAGGGTTCCTCCAGT AGAGGGCATGAAGCTGGATA 1 
HOXB8 17q21.32 rs2303486 SNP [A→T] Promoter AAAACAGCCCTCAGACTGTCA GGTGGGAGGTGGGGAGTA 1 
rs9340799# SNP [A→G] Intron 1 
CTGCCACCCTATCTGTATCTTTTCCTATTCTC
C 
TCTTTCTCTGCCACCCTGGCGT
CGATTATCTGA ESRα 6q25.1 
rs2234693 SNP [C→T] Intron 1 
CTGCCACCCTATCTGTATCTTTTCCTATTCTC
C 
TCTTTCTCTGCCACCCTGGCGT
CGATTATCTGA 
3 
PLC-γ1 20q12 rs8192707
 
(ser279gly) 
SNP 
[G→A]
b 
Exon 9 GAGCTTTGCCGAGTGTCC ATCGGGCTCACCTCATCCAGG 4 
ACE 17q23 N/A Alu ins/del Intron 16 CTGGAGACCACTCCCATCCTTTCT 
GATGTGGCCATCACATTCGTCG
TCAGA 5 
INPP-1  2q32 rs1882891# SNP [C→A] Exon 6 TAACCAGCAACAGGACAAAG CTAGAAGAAACGGCAGTGAAAC 6 
aG-allele corresponds to the val66-allele; bA-allele corresponds to the ser279-allele; cthe polymorphism occurs in pro-BDNF;  #Variants used in structure analysis as well. 
Abbreviations: GRIN2B: glutamate receptor subunit 2B; BDNF: brain-derived neurotrophic factor; HoxB8: homeobox gene B8; ESRα: estrogen receptor α; INPP-1: inositol polyphosphate-phosphatase 
1; PLC-γ1: phospholipase-gamma; ACE: Angiotensin-converting enzyme; 3’UTR: 3’ untranslated region. References: 1: Present study; 2: Sen et al., 2003; 3: Yaich et al., 1992; 4: Ftouhi-Paquin et al., 
2001; 5: Rigat et al., 1992; 6: Steen et al., 1998. 
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Table II.1 (b). Description of the variants used in “Structure” analysis, indicating the chromosomal location and the sequences of external 
amplification primers. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abbreviations: FXIIIB: Factor 13B; YaNBC182:Ya subfamily Alu insetion sequence NBC182; DLX6: Distal-less like homeobox 6;  TPA25: Tissue plasminogen activator Alu insertion;  
ADRA1C: Adrenergic receptor α1C; DBH: Dopamine-β hydroxylase; YaNBC241: Ya subfamily of Alu insertion repeats; PV92: predicted variant Alu insertion repeat; 5-HTT: serotonin 
transporter; SNAP25: Synaptosomal-associated protein 25kDa; GNAS: guanine nucleotide-binding α subunit of G; SNAP29: Synaptosomal-associated protein 29kDa; VNTR: variable number 
of tandem repeats. 
References: 1: Batzer et al., 1996; 2: Carroll et al., 2001; 3: Nabi et al., 2003; 4: Tishkoff et al., 1996; 5: Barr et al., 2001; 6: Nabi et al., 2003; 7: Watkins et al., 2001; 8: Comas et al., 2001; 9: 
Gelernter et al., 1997; 10: Barr et al., 2000; 11: Jia et al., 1999; 12: Saito et al., 2001.  
 
 
 
Gene Chromosomal Location 
Variant 
identification Type of variant Forward Primer (5’-3’) Reverse Primer (5’-3’) Reference 
FXIIIB 1q31-32 N/A Alu insertion TCAACTCCATGAGATTTTCAGAAGT CTGGAAAAAATGTATTCAGGTGAGT 1 
YaNBC182 7 N/A Alu insertion GAAGGACTATGTAGTTGCAGAAGC AACCCAGTGGAAACAGAAGATG 2 
DLX 7q21.3 DLX int1C/T SNP [ C→T ] TGGTGCAGCTTCCTTTACCT TGGTGCAGCTTCCTTTACCT 3 
TPA25 8p12 rs4646972 Alu insertion GTGAAAAGCAAGGTCTACCAG GACACCGAGTTCATCTTGAC 4 
ADRA1C 8p21 cys492arg SNP [ C→T ] ATGCTCCAGCCAAGAGTTCA TCCAAGAAGAGCTGGCCTTC 5 
YaNBC241 15 N/A Alu insertion GGTTCCAATAGAGAGCAACAGAA ACCTTAAGCTTTCCCCCAGA 7 
PV92 16q24 N/A Alu insertion AACTGGGAAAATTTGAAGAGAAAGT TGAGTTCTCAACTCCTGTGTGTTAG 8 
5-HTT 17q11 N/A VNTR ATGCCAGCACCTAACCCCTAATGT CGACCGCAAGGTGGGCGGGA 9 
SNAP25 20p12 SNAP25 MnlI SNP [ G→T ] TTCTCCTCCAAATGCTGTCG CCACCGAGGAGAGAAAAT 10 
GNAS 20q13.2 rs7121 SNP [A→G] CTCCTAACTGACATGGTGCAA TAAGGCCACACAAGTCGGGGT 11 
SNAP29 22q11.21 C56T SNP [ C→T ] GGAAGGAGTTCGCGCGACGA GCGAGTCCACACCAGCCCTG 12 
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Table II.2 (a). PCR conditions for the genetic variants investigated, indicating optimal 
primer annealing temperatures, additives and size (in bp) of the resultant product. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
# Variants used in “Structure” analyses as well; asize of the insertion allele indicated; bsize of the 4-repeat allele indicated; csize of the 10-
repeat allele indicated.  
Abbreviations: 5-HT2A: serotonin receptor 2A; 5-HT1Dβ: serotonin receptor 1Dβ; 5-HT6: serotonin receptor 6; 5-HT2C: serotonin receptor 
2C; DRD4: dopamine receptor 4; DRD2: dopamine receptor 2; COMT: catechol-O-methyltransferase;, DAT: dopamine transporter; DRD3: 
dopamine receptor 3; DRD1: dopamine receptor 1; VNTR: variable number of tandem repeats polymorphism. GRIN2B: glutamate receptor 
subunit 2B; BDNF: brain-derived neurotrophic factor; HoxB8: homeobox gene B8; ESRα: estrogen receptor α; INPP-1: inositol 
polyphosphate-phosphatase 1; PLCγ1: phospholipase-gamma; ACE: Angiotensin-converting enzyme; DMSO: dimethylsulphoxide. 
[MgCl2] of 1.5mM was used in all reactions. 
 
 
Gene Variant identification TA (ºC) Additive 
Amplimer 
(bp) 
rs6311 (-1438A/G)# 63 None 468 
5-HT2A 
rs6313 (T102C) 60 None 372 
5-HT1Dβ rs6296 (G861C)# 60 None 662 
5-HT6 rs1805054# 63.5 DMSO 578 
5-HT2C rs6318 (cys23ser) 60 None 184 
rs1800955# 59 Formamide 380 
DRD4 
48bp VNTR 60 7-deaza-GTP 475
b 
DRD2 rs1800497(Taq1A)# 60 None 310 
rs2097603 55.5 DMSO 306 
rs4680(val158met) 60 None 95 COMT 
rs362204 66 None 277 
DAT 40bp VNTR# 70 None 480c 
DRD3 rs6280 (ser9gly)# 55 DMSO 462 
DRD1 rs4532# 68 DMSO 405 
rs1806191 60 None 1456 
GRIN2B 
rs890 60 None 1456 
rs6265 (val66met) 63 None 274 
rs2049046 60 DMSO 270 BDNF 
rs988748 60 None 178 
HOXB8 rs2303486 60 None 420 
rs9340799# 61 DMSO 1300 
ESRα 
rs2234693 61 DMSO 1300 
INPP-1 rs1882891 59 DMSO 584 
PLCγ1 rs8192707 64 DMSO 282 
ACE ACE Alu ins/del# 63.5 None 534a 
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Table II.2 (b). PCR conditions used in the amplification of the polymorphic sites in the genes 
utilised in “Structure” analyses, indicating optimal primer annealing temperatures, additives 
and size (in bp) of the resultant product. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
asize of the allele containing the insertion indicated.  
Abbreviations: FXIIIB: : Factor 13B Alu insertion polymorphism; YaNBC182: Ya subfamily Alu insertion sequence NBC182; DLX6: 
Distal-less like homeobox 6; TPA25: Tissue plasminogen activator Alu insertion; ADRA1C: adrenergic receptor α 1C; DBH: dopamine beta 
–hydroxylase; YaNBC241: Ya subfamily Alu insetion sequence NBC241; PV92: predicted variant Alu insertion repeat; 5-HTT: serotonin 
transporter;  SNAP-25: synaptosomal-associated protein of 25 kDa; GNAS: guanine nucleotide-binding α subunit of G; SNAP-29: 
synaptosomal-associated protein of 29 kDa; DMSO: dimethylsulfoxide.  
[MgCl2] of 1.5mM was used in all reactions. 
 
 
For the subsequent genotyping of the polymorphisms, the digested products were 
electrophoresed through either agarose (section II.6.1), or 12% non-denaturing 
polyacrylamide (section II.6.2) gels, depending on the size of the resultant fragments. As a 
control for incomplete digestion, an aliquot of undigested PCR amplified sample was co- 
electrophoresed alongside samples to be genotyped. Moreover, the 5-HT2C, COMT 
(val158met), DRD3, DRD1, BDNF (val66met), INPP-1, SNAP-25 and SNAP-29 amplified 
products contained internal controls for restriction digestion in the form of additional, 
invariant, restriction enzyme recognition site that resulted in constitutive fragments produced 
during restriction digestion (Tables II.4[a] and [b]). 
 
 
 
 
 
 
Gene Variant identification TA (ºC) Additive 
Amplimer 
(bp) 
FXIIIB N/A 51 None 795a 
YaNBC182 N/A 60 Formamide 563a 
DLX DLX int1C/T 60 None 203 
TPA25 N/A 53 Glycerol 570a 
ADRA1C cys492arg 58 None 501 
YaNBC241 N/A 55.5 None 392a 
PV92 N/A 55.5 Glycerol 450a 
5-HTT 44bp VNTR 66 None 419a 
SNAP25 SNAP25 MnlI 60 None 261 
GNAS rs7121 59 None 345 
SNAP29 C56T 68 None 377 
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Table II.3. Expected size fragments produced by the DRD4 48bp VNTR, DAT 40bp VNTR, 
Alu insertion polymorphisms and 5-HTT 44bp VNTR, with the % (w/v) agarose gel used to 
resolve the fragments for genotyping. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
aL: “long” allele; bS: “short” allele cI: allele formed by the  insertion of an Alu element; dD: allele formed by the deletion of an Alu element;. 
Abbreviations: DRD4:Dopamine receptor 4; DAT: Dopamine Transporter; FXIIIB: : Factor 13B; YaNBC182: Ya subfamily Alu insertion 
sequence NBC182; TPA25: Tissue plasminogen activator Alu insertion; YaNBC241: Ya subfamily Alu insertion sequence NBC241; PV92: 
predicted variant Alu insertion repeat; ACE: Angiotensin-converting enzyme; VNTR: variable number of tandem repeats. 
Gene Polymorphism Allele Fragment size % (w/v) agarose gel 
A2 379 
A3 427 
A4 475 
A5 523 
A6 571 
A7 619 
DRD4 48bp VNTR 
A8 667 
3 
A2 160 
A6 320 
A7 360 
A8 400 
A9 440 
A10 480 
DAT 40 bp VNTR 
A11 520 
2 
Ic 795 
FXIIIB Alu ins/del 
Dd 501 
2 
Ic 563 
YaNBC182 Alu ins/del 
Dd 287 
2 
Ic 570 
TPA25 Alu ins/del 
Dd 260 
2 
Ic 392 
YaNBC241 Alu ins/del 
Dd 66 
3 
Ic 450 
PV92 Alu ins/del 
Dd 130 
2.5 
La 419 
5-HTT 44bp VNTR 
Sb 375 
2 
Ic 534 
ACE Alu ins/del 
Dd 243 
2 
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Table II.4(a). Genotyping details  for SNPs in candidate genes that were genotyped using 
ASREA. 
 *invariant restriction enzyme recognition sites. Only the underlined ones were visible on the gels used in the present study, and 
could thus serve as a control for complete digestion. 
1 Promega Corp., Madison, WI. USA; 2 New England Biolabs, Beverly, MA., USA; 3 Roche Applied Science, Basel, Switzerland. 
Abbreviations: 5-HT2A: serotonin receptor 2A; 5-HT1Dβ: serotonin receptor 1Dβ; 5-HT6: serotonin receptor 6; 5-HT2C: serotonin 
receptor 2C; DRD4: dopamine receptor 4; DRD2: dopamine receptor 2; COMT: catechol-O-methyltransferase;, DRD3: dopamine 
receptor 3; DRD1: dopamine receptor 1; GRIN2B: glutamate receptor subunit 2B; BDNF: brain-derived neurotrophic factor; 
HoxB8: homeobox gene B8; ESRα: estrogen receptor α; INPP-1: inositol polyphosphate-phosphatase 1; PLCγ1: phospholipase-
gamma; 12% PAGE: 12% non-denaturing polyacrylamide gel electrophoresis 
 
Gene Polymorphism Restriction enzyme Allele Fragment size (bp) 
Allele 
detection 
A 468 
rs6311 MspI 
G 244 + 224 
2.5% 
agarose 
T 372 
5HT2A 
rs6313 HpaII1 
C 156+216 
2.5% 
agarose 
G 662 
5-HT1DB rs6296 HincII1 C 482+180 
2% agarose 
T 578 
5-HT6 rs1805054 RsaI1 C 449+129 
2.5% 
agarose 
C(ser23) 150+30+4* 
5-HT2C rs6318 NlaIII2 G(cys23) 130+30+20+4* 
3% agarose 
C 380 
DRD4 rs1800955 FspI2 
T 228 +152 
2.5% 
agarose 
T  310 
DRD2 rs1800497 TaqI1 
C  130+180 
2.5% 
agarose 
A 306 
rs2097603 HindIII1 
G 271 + 75 
2.5% 
agarose 
G(val158) 82 + 13* 
rs4680 NlaIII2 
A(met158) 68 + 14 + 13* 
12% PAGE 
C deletion 278 
COMT 
rs362204 BglI1 
C insertion 196 + 82 
2.5% 
agarose 
A (ser9) 304+111+47* 
DRD3 rs6280 MscI3 
G  (gly9) 206+98+111+47* 
3% agarose 
G 259+146* 
DRD1 A-48G DdeI3 
A 146*+42+217 
2.5% 
agarose 
G(val66) 217+57* 
BDNF rs6265 NlaIII2 
A(met66) 140+77+57* 
3% agarose 
G 1300 
rs9340799 XbaI1 
A 910+390 
1.5% 
agarose 
C 1300 
ESRα 
rs2234693 PvuII1 
T 850+450 
1.5% 
agarose 
C 256+143+142+43* 
INPP-1 rs1882891 DdeI3 
A 215+41+143+142+43* 
2.5% 
agarose 
G(gly279) 282 
PLC-γ1 rs8192707 BlpI2 
A(ser279) 203+79 
2.5% 
agarose 
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Table II.4(b). Genotyping details  for SNPs genotyped using ASREA that were included in 
“Structure” analyses. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*invariant restriction enzyme recognition sites. Only the underlined ones were visible on the gels used in the present 
study, and could thus serve as a control for complete digestion. 
1 Promega Corp., Madison, WI. USA; 2 New England Biolabs, Beverly, MA., USA; 3 Roche Applied Science, 
Basel, Switzerland.  
Abbreviations: DLX6: Distal-less like homeobox 6; ADRA1C: adrenergic receptor α 1C; SNAP-25: 
synaptosomal-associated protein of 25 kDa; GNAS: guanine nucleotide-binding α subunit of G; SNAP-29: 
synaptosomal-associated protein of 29 kDa; 12% PAGE: 12% non-denaturing polyacrylamide gel electrophoresis. 
 
 
 
 
 
 
 
 
Gene Polymorphism Restriction enzyme Allele 
Fragment 
size 
Allele 
detection 
C 203 
DLX int1C/T ApoI2 
T 176+27 
3% Agarose 
C(cys492) 502 
ADRA1C cys492arg PstI1 
T(arg492) 477+25 
3% Agarose 
T 256+6* 
SNAP25 SNAP25 MnlI MnlI2 
G 211+44+6* 
2% Agarose 
T 345 
GNAS rs7121 FokI2 
C 263+82 
2.5% 
Agarose 
A 425 
ABCG1 G2457A HhaI 1 
G 321+104 
2% Agarose 
C 269+108* 
SNAP29 C56T DdeI3 
T 177+108*+92 
12% PAGE 
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II.5.3. Genotyping by Single Nucleotide ddNTP Primer Extension (SNaPshot) Analysis  
The SNaPshot genotyping method (Applied Biosystems, Foster City, California, USA) 
involves the extension of an oligonucleotide probe (that terminates immediately 5’ to the SNP 
of interest) by one of four fluorescently-labelled dideoxynucleotides complementary to the 
base sequence at the SNP site of interest (Figure II.1). Please refer to section II.4.1 and Table 
II.5 for the details on design and sequences of the interrogation primers, respectively. 
 
Table II.5. Sequences of the internal interrogation primers (5’-3’) used in the SNaPshot 
genotyping procedure. 
Gene dbSNPa Internal interrogation primer sequence (5’-3’) 
rs2049046 CTGCATTCGAATTGCTTGTG 
BDNF 
rs988748 AACCAACGCAGAGGGTCT 
rs1806191 GTTTGTCGCCCGTCCCGTGCTTGAT 
GRIN2B 
rs890 GCTTCCTCACCTAAATGAAAAGATC 
HoxB8 rs2303486 AGACTCCTGAGTGAGG 
 
Abbreviations:a: identification on the NCBI SNP Database, http://www.ncbi.nlm.nih.gov/SNP/index.html;  
BDNF: brain-derived neurotrophic factor; GRIN2B: glutamate receptor subtype 2B; HoxB8: homeobox gene 
type B8. 
 
II.5.3.1. PCR reaction clean-up 
The first step in the SNaPshot reaction entails a PCR-product purification step, to remove 
excess dNTPs and to dephosphorylate unincorporated outer primers that may interfere with 
the SNaPshot reaction. Here, 5μl of the relevant PCR products were incubated with 0.33U 
ExoI (Amersham, Little Chalfont, Buckinghamshire, UK) and 0.66U shrimp alkaline 
phosphatase (SAP) (Roche Applied Science, Basel, Switzerland) at 37˚C for one hour, 
followed by an enzyme deactivation step at 75˚C for 30 minutes. The purified PCR template 
was subsequently stored at 4˚C until required. 
 
II.5.3.2. Primer extension reaction conditions 
For multiplexing, equal quantities of PCR templates were mixed in a tube. Likewise, all 
internal interrogation primers to be used in a single multiplex reaction were premixed to yield 
a final concentration of 0.2μM for each primer. The extension reaction, comprising 3μl of 
previously cleaned, pooled PCR products, 3μl SNaPshot Multiplex Ready Reaction mix 
(Applied Biosystems, Foster City, California, USA), 1μl pooled internal primers and 1μl de-
ionised water, was performed by repeating the following cycle 27 times: 96˚C for 10s, 50˚C 
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for 5s, and 60˚C for 30s. Thereafter, a post-extension purification step was employed to avoid 
further primer extension. This was performed by adding 1U of SAP to the sample, which was 
subsequently incubated at 37˚C for one hour, and then at 72˚C for 30 minutes to deactivate the 
enzyme. 
 
II.5.3.3. Analysis on ABI Prism 3130 Genetic Analyser 
The fluorescently extended probes were separated and detected on an ABI Prism 3130 
Genetic Analyser capillary electrophoresis system (Applied Biosystems, Foster City, 
California, USA). After an appropriate spectral matrix using materials from the matrix 
standard DS-02 (Applied Biosystems, Foster City, California, USA) was created, the ABI 
Prism 3130 Genetic Analyser was used with filter set E5 to process the data from the 5 dyes, 
namely dR110, dR6G, dTAMRA, dROX and LIZ.  
 
Fluorescently labelled extension reactions were prepared for capillary electrophoresis analysis 
by mixing 9 μl of Hi-Di formamide (Applied Biosystems, Foster City, California, USA), 1μl 
of the SNaPshot product and 0.4μl  of GeneScan-120 LIZ internal sizing standard (Applied 
Biosystems, Foster City, California, USA). The samples were then denatured by placing them 
at 95˚C for 2 minutes. The prepared samples were then stored on ice until loaded into the 
capillary electrophoresis system. 
 
 A 36cm capillary array filled with denaturing POP4 performance optimised polymer 
(Applied Biosystems, Foster City, California, USA) was used for DNA fragment separation. 
Genetic Analyser electrode running buffer with EDTA was used in 1x concentration. Typical 
run module parameters were: run temperature 60˚C, capillary fill volume 38000 steps, pre-run 
voltage 15kV, data delay 3600s and run time 14000s. 
 
Two negative controls were electrophoresed with each multiplex: a PCR template without 
primers, and the internal pooled primers without template. Allele assignment was 
subsequently performed using ABI Prism Genotyper software (GeneMapper ID, Ver 3.7 
[Applied Biosystems, Foster City, California, USA]). 
 
II.5.4. Allele Separation by Capillary Electrophoresis 
In order to implement quality control for the DRD4 48bp VNTR genotyping process, 
additional high precision allele analysis was conducted by capillary electrophoresis on the 
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ABI Prism 3130 Genetic Analyzer (Applied Biosystems, Foster City, CA, USA). Here, the 
PCR was performed using a forward primer labelled with 6-FAM. The fluorophore-labelled 
PCR-amplified products were subsequently electrophoresed on a 2% agarose gel to ensure 
that the correct fragment was amplified. 
 
Depending on the concentration of DNA as estimated from  gel electrophoresis, the products 
were diluted 10-fold using ddH2O. 1μl of the diluted 6-FAM-labelled product was mixed with 
0.5μl ROX1000 fragment size standard (Applied Biosystems, Foster City, CA, USA) and 9μl 
Hi-Di formamide (Applied Biosystems, Foster City, CA, USA).  
 
For each run, the capillary column was filled with POP-7 sieving medium. The prepared 
products were then denatured at 95˚C for 2 minutes and snap-cooled and stored on ice until 
loaded onto the capillary electrophoresis system. The electrophoretic separation was 
performed for 20 minutes at a field strength of 415V/cm, and a capillary temperature of 60˚C 
for each loading. 
 
Analysis of the resulting electropherogram was performed using ABI Prism software 
(GeneMapper ID, Ver 3.7 [Applied Biosystems, Foster City, California, USA]). The allele 
sizes (provided in Table II.3) were automatically determined by the software by use of the 
local Southern size calling method to establish a best-fit curve generated from the internal size 
standard, ROX1000 (Applied Biosystems, Foster City, California, USA). 
 
II.5.5. Quality Control for Genotyping 
In order to ensure genotyping accuracy, replicate samples were included in the PCR-
amplification reactions and subsequent genotyping procedures, and only assays that provided 
100% concordance between replicates were utilised in the analyses. 
 
II.6. GEL ELECTROPHORESIS 
 
II.6.1. Agarose Gel Electrophoresis 
Agarose gels were used in the present study to verify success of the PCR (section I.4.2), and 
to resolve fragments of different sizes in order to genotype selected polymorphisms (sections 
I.5.1 and I.5.2). Horizontal agarose gels, of either 15x9x1cm or 7x9x1cm dimensions, were 
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all impregnated with 0.5μg/ml ethidium bromide (EtBr). 1X TBE running buffer (Appendix 
I) was used to facilitate all agarose gel electrophoreses.  
 
To verify the success of PCR-amplification, 8μl of the amplified product was mixed with 2 μl 
bromophenol blue loading dye (Appendix I), and electrophoresed in a 2% (w/v) agarose gel. 
For the genotyping of the VNTRs and Alu insertion polymorphisms (Table II.3), 10μl of the 
amplified product was mixed with 2μl bromophenol blue loading dye, and electrophoresed in 
a 2 - 3% (w/v) agarose gel.  
 
For the genotyping of selected polymorphisms detected by ASREA, 10μl of the digested 
product was mixed with 2μl bromophenol blue loading dye. This mixture was subsequently 
electrophoresed in a 2-3% (w/v) agarose gel, depending on the size of the product after 
digestion with the appropriate restriction enzyme (please refer to Table II.4 for a list of those 
SNPs genotyped by ASREA that required agarose gel electrophoresis). 
 
The molecular size marker, co-electrophoresed with all PCR-amplified products was one of 
the following:  bacteriophage λ DNA, digested with the PstI restriction enzyme (Promega, 
Madison, WI, USA) (λPst [Appendix I]), Marker X (Roche Applied Science, Basel, 
Switzerland), Marker XIV (100bp marker [Roche Applied Science, Basel, Switzerland]), 
Marker VI (Roche Applied Science, Basel, Switzerland) or Low Molecular Weight Marker 
(New England Biolabs, Beverly, MA, USA). Electrophoresis typically occurred at 10V/cm 
for between 30 minutes and 1 hour in 1X TBE running buffer. 
 
All gels were visualised on a longwave ultraviolet transilluminator (3UVTM Transilluminator 
model LMS-26E), and photographed using a video printer (Sony). 
 
II.6.2. 12% non-denaturing Polyacrylamide Electrophoresis 
Non-denaturing polyacrylamide gels were used for the resolution of fragments formed during 
ASREA of selected SNPs (Tables II.4[a] and [b]).  Briefly, 2μl  bromophenol blue dye 
(Appendix I)  was added to 10μl of each of the samples to be electrophoresed. This mixture 
was then loaded into a polyacrylamide gel, of 100x80x1mm dimensions, containing 12% 
acrylamide and 1x TBE buffer (Appendix I).  In all cases, either λPst marker (Appendix I), 
Marker X (Promega, Madison, WI, USA) or Marker XIV (100bp marker [Promega, Madison, 
WI, USA]) and an undigested sample were co-electrophoresed as controls. 
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Electrophoresis was performed in 1x TBE running buffer (Appendix I) at 100-120 V for 1.5 
to 2 hours. After completion of electrophoresis, the polyacrylamide gel was placed immersed 
in a solution of 0.1% AgNO3 (Appendix I) and gently shaken for 10 minutes on a Labcon 
orbital shaker (Labcon Pty Ltd, Maraisburg, RSA). The AgNO3 solution was then discarded 
and the gel subsequently rinsed with water. Thereafter, developing solution (Appendix I) 
then poured so as to cover the gel, which was gently shaken until stained bands became 
visible. The gels were then thoroughly rinsed using dH2O, and viewed using a white light 
illuminator (Lauda Thermostat, Germany) and photographed using a video printer (Sony). 
 
II.7. STATISTICAL ANALYSES 
R: A language and environment for statistical computing (R Foundation for Statistical 
Computing, Vienna, Austria. ISBN 3-900051-07-0, URL http://www.R-project.org.R) was 
used for all statistical analyses unless otherwise specified.  Functions from base R and 
specific R packages were used. Specific programs were written for applications when 
functions could not be found. In order to test the association between the relevant phenotype 
and multiallelic markers (DAT 40bp and DRD4 48bp VNTRs) CLUMP (Curtis and Sham, 
1995) was used.  
 
II.7.1. Statistical Analyses of Demographic Data 
Initial demographic analyses were conducted to determine whether between-group differences 
existed in gender (Fisher test for equality of proportions) and age (Wilcoxon test for equality 
between medians).  
 
II.7.2. Statistical Analyses of Clinical Data 
Clinical variables, such as total Y-BOCS score , age at onset of OCD,  the presence or 
absence of specific symptom subtypes (classified under the clusters of hoarding, 
symmetry/ordering, sexual/religious, aggression and contamination/washing symptom 
dimensions) and selected co-morbid disorders (MDD, BDD, anorexia, TTM, TS, 
hypochondriasis, social and specific phobias, dysthymic disorder, SIB, IED, tics, GAD and 
panic disorder), were tabulated for OCD individuals. These main clinical variables were also 
compared between genders within the OCD patient subset.  
 
Continuous variables are summarised as medians with corresponding 95% CIs, and p-values 
are for nonparametric tests of equality of medians (Wilcoxon when comparing two medians; 
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Kruskal-Wallis when comparing more than two). Categorical variables were represented as 
counts, with their associated frequencies and p-values for Fisher’s exact test for equality of 
proportions. 
 
II.7.3. Statistical Analyses of Genetic Data 
The aim of the present study was to determine whether, in each of the polymorphisms within 
selected candidate genes, any significant differences in allelic or genotypic distribution 
existed between Afrikaner OCD and control subjects, or within OCD patients in specific OCD 
subgroups. Increased allele or genotypic frequencies in OCD subjects, compared to controls, 
or in OCD subjects in a particular OCD subgroup compared to those in another subgroup, 
could indicate that either the allele or genotype confers increased susceptibility to OCD (or 
the phenotype represented by the OCD subgroup under investigation), or is in LD with such a 
risk variant.  
 
However, comparing the allele frequencies between cases and controls is not statistically valid 
without the prior assumption that the alleles within each subject are segregating independently 
of one another. For this to be true, the population under investigation should obey the Hardy-
Weinberg law, which states that, in a large, randomly mating population, the allelic and 
genotypic frequencies remain constant from one generation to the next. Thus, for a locus 
comprising segregating alleles A and a, with population frequencies of p and q respectively, 
the genotypic frequencies within a population in Hardy-Weinberg equilibrium (HWE) will be 
equivalent to p2 (AA), 2pq (Aa) and q2 (aa).  
 
In the present study, exact p-values for a test of HWE were calculated using the R package 
“genetics”. Because 5-HT2C represents a SNP on chromosome X, resulting in hemizygous 
genotypes in the male population, HWE was calculated using the female population. 
 
In order to provide a measure of informativeness of each genetic marker, heterozygosity (H) 
was also calculated. 
 
 
 
 
 
 148
II.7.3.1. Genetic investigations 
In all genetic analyses involving 5-HT2C cys23ser, males and females were analysed 
separately.  
 
II.7.3.1.1. Single locus analyses 
i. Categorical Data 
Categorical analyses involved comparing  
1. allele and genotype distributions between OCD and control subjects,  
2. OCD subjects experiencing certain symptom subtypes (hoarding, symmetry/ordering, 
sexual/religious, contamination and aggression obsessions and compulsions) and those 
not experiencing the relevant symptom subtype,  
3. OCD subjects presenting with co-morbid MDD and those without, and 
4. OCD subjects presenting with co-morbid tics and those without. 
  
Analyses involving dichotomous categorical data were performed using the Fisher test, from 
which the exact p-values were calculated. The genotypic ORs, their 95% CIs and 
corresponding p-values were calculated for each marker under the assumption of the HWE.  
 
For multi-allelic loci, “CLUMP” software was implemented [Sham and Curtis, 1995]. This 
program generates a novel chi-squared value by “clumping” columns together in a 2-by-2 
table, ultimately designed so that the χ2  value is maximal. This is akin to testing a post-hoc 
hypothesis that a certain row has higher χ2 values than the other columns, without the need for 
correction for multiple testing. 
 
Post-test powers were estimated for each single locus analysis individually. These values 
approximate the probability for a new study of rejecting the null hypothesis, given the sample 
size in our study, and assuming that the given that the specific effect size that is observed is 
the true effect size. Power estimates were calculated assuming the absence of any genotyping 
errors. 
 
ii. Numerical data 
The genotype and allele distributions in terms of two quantitative variables were also 
investigated, namely severity of OCD as measured by the total Y-BOCS score  and age at 
onset of OCD.   
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Analyses involving the total Y-BOCS score were performed using the Wilcoxon test for 
allelic association and the Kruskal-Wallis test for genotypic association. The estimated 
medians and their 95% CIs constitute their effect measures.  
 
To assess whether the genotypes of the candidate genes under investigation influenced the age 
at onset of OCD, Kaplan-Meier disease-free survival functions were calculated. The survival 
functions for each genotype were compared using the logrank test (R package “survival” 
[version 2.17]). The estimated medians of the survival functions and their 95% CIs represent 
the effect measures. For bi-allelic variants, where the number of individuals carrying a 
particular homozygous genotype was less than 5, those subjects were included in the same 
group as heterozygous individuals. For multi-allelic variants, rare genotypes were grouped 
together in the analyses. 
 
Power analyses were not conducted for numerical data, since power calculations based on the 
medians of numerical values are complex and require numerous assumptions regarding the 
underlying distributions. These power calculations are also inaccurate for groups of below 30. 
 
II.7.3.1.2. Multi-locus analyses 
 
i. Linkage disequilibrium (LD) 
Pairwise LD was assessed using the LD function from the R statistical genetics package. 
Values of D’> 0.33 (Moffat et al., 2000; Kruglyak, 1999), and r2> 0.1 (Ardlie et al., 2002; 
Tiret et al., 2002) were applied as a criterion for useful LD. 
 
ii. Haplotype analyses 
Where more than one polymorphism had been genotyped per gene, haplotype analyses were 
conducted  using “haplo.stats” (version 1.2.0). This program assigns the probability for the 
occurrence of each haplotype in each individual and then directly models an individual’s 
phenotype as a function of the inferred haplotype, weighted by their estimated probability to 
account for haplotype ambiguity. It then generates both global and haplotype-specific score 
statistics with associated p-values (Schaid et al., 2002) (a global haplotype score statistic is 
that which is obtained by applying a global test for association on H-1 df [where H is the 
number of haplotypes for which data is available], and a haplotype-specific score refers to a 
 150
test for association for that particular haplotype). The number of simulations for the empirical 
global and specific p-values was set at 1000. 
 
To avoid possible errors in the haplotype estimation process, haplotype analyses were limited 
to those haplotypes with an expected count of more than 5. 
 
II.7.4. Multiple comparison considerations 
P-values attained in the present study were not corrected for multiple testing, given the 
present uncertainty about which test is most appropriate. The statistically significant 
associations can only be validated when their biological meanings have been identified; 
moreover, p-values depend largely on the sample size; hence the emphasis is placed on the 
OR values (calculated for all categorical analyses) and their corresponding 95% CIs, which 
will provide one with a measure of the strength of association. 
 
II.7.5. Meta-analyses  
Meta-analyses were performed on published data pertaining to the relation between OCD and 
the 5-HT2A T102C (rs6313); 5-HT2A -1438A/G (rs6311); DRD3 ser9gly (rs6280); DRD2 
Taq1A (rs1800497); 5-HT2C ser23cys, COMT val158met (rs4680) and DAT 40bp VNTR 
polymorphisms. 
 
II.7.5.1. Literature search 
To identify studies eligible for inclusion in the meta-analyses, a literature search using the 
National Library of Medicine’s PubMed search engine, was conducted 
(www.ncbi.nih.gov/PubMed). The keywords “obsessive-compulsive disorder”, “obsessive-
compulsive*”, “OCD”, “genetics”, “5-HT2A”, “5HT2A’, “HTR2A”, “5-HT2C”, “5HT2C”,  
“HTR2C”, “DRD2”, “DRD3”, “DAT”, “DAT1”, “dopamine transporter”, “COMT”, 
“serotonin”, “dopamine” “receptors”, “case-control” and “association”, used in numerous 
different combinations, were used to search for the relevant articles. Retrieved articles were 
surveyed, and the reference sections were reviewed to identify studies that may not have been 
indexed by PubMed.  
 
II.7.5.2. Inclusion Criteria 
Only population-based case-control studies were included in the meta-analyses. Studies were 
only included if they investigated subjects with OCD as their primary diagnosis. Moreover, 
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only studies involving the relevant polymorphisms in each gene under investigation were 
utilised (T102C and -1438A/G in 5-HT2A, ser23cys in 5-HT2C, ser9gly in DRD3, Taq1A in 
DRD2, val158met in COMT, the 48bp VNTR in DRD4 and the 40bp VNTR in DAT). The 
control data in each included study had to obey HWE. Studies also had to be published in a 
peer-reviewed journal and to represent original data.  
 
Application of these criteria yielded four 5-HT2A T102C and 5-HT2A -1438A/G studies, three 
5-HT2C ser23cys studies, four DRD3 ser9gly studies, three DRD2 Taq1A studies, two DRD4 
48bp VNTR studies and two DAT 40bp VNTR studies for inclusion in the meta-analysis.  
 
II.7.5.3. Characteristics of the included studies 
It was also important to account for possible moderating influences that may have influenced 
the effect size obtained in a particular study, or which may have resulted in heterogeneity 
between the study samples. Each study was thus coded according to the following possible 
moderating influences: ethnicity of the sample, the mean age of the control and OCD groups, 
the mean age at onset of OCD, the gender index and the diagnostic system used. These 
descriptive characteristics are represented separately for each meta-analysis, in Tables II.6 (a) 
to (h). 
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Table II.6 (a). Descriptive characteristics of the studies (excluding the present study) included in the 5-HT2A -1438A/G (rs6311) meta-
analysis. 
 
 
 
 
 
 
aGender index= (female cases/male cases)/(female controls/male controls). Abbreviations: DSM: Diagnostic and Statistical Manual; SADS-L: Structured Clinical Interview for Affective Disorders and 
Schizophrenia-Lifetime Version (NIAAA); SCID-I: Structured Clinical Interview for DSM-IV Axis I Disorders (NIMH); Y-BOCS: Yale-Brown Obsessive-Compulsive Scale; DIPS: Diagnostisches 
Interview bei psychischen Storungen im Kindes-und Jugendalter. 
Dashes indicate missing or insufficient data. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Reference Ethnicity Diagnostic System Used 
Method of 
Assessment 
n 
(OCD) 
Mean age OCD 
subjects (y) 
Mean age 
at onset 
(y) 
n 
(control) 
Mean age 
control 
subjects (y) 
Gender 
Indexa 
Enoch et al. 
(2001) 
N. American 
Caucasian DSM-III-R SADS-L, SCID-I 101 
Males:  
39.7±9.2 
Females: 
41.7±11.9 
14.8±9 138 
Males: 
40.25±12.4 
Females: 
39±12.9 
0.56 
Tot et al. 
(2003) Turkish DSM-IV 
SCID-I, 
Y-BOCS 58 30±9 21±7 83 27±5 1.95 
Walitza et al. 
(2004) German DSM-IV Y-BOCS, DIPS 55 12.11±2.11 - 77 25.2 0.83 
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Table II.6 (b). Descriptive characteristics of the studies (excluding the present study) included in the 5-HT2A T102C (rs6313) meta-
analysis. 
 
Reference Ethnicity Diagnostic System Used 
Method of 
Assessment 
n 
(OCD) 
Mean age 
OCD 
subjects (y) 
Mean age 
at onset 
(y) 
n 
(control) 
Mean age 
control 
subjects (y) 
Gender 
Indexa 
Nicolini et al. 
(1996) Mexican DSM-III-R 
DIS (Spanish 
version), Y-BOCS 67 32.3±10.8 - 54 36.4±11.4 2.23 
Frisch et al. 
(2000) 
Ashkenazi 
Jew DSM-IV SADS-L, SCID-P 39 - - 112 - 0.92 
Frisch et al. 
(2000) 
non-
Ashkenazi 
Jew 
DSM-IV SADS-L, SCID-P 36 - - 60 - 0.69 
Tot et al. 
(2003) Turkish DSM-IV SCID-I, Y-BOCS 58 30±9 21±7 83 27±5 1.95 
Meira-Lima et 
al. (2004) Brazilian DSM-IV SCID, Y-BOCS 79 33.6±10 - 202 33.9±9 0.81 
aGender index= (female cases/male cases)/(female controls/male controls). Abbreviations: DSM: Diagnostic and Statistical Manual; SADS-L: Structured Clinical Interview for Affective 
Disorders and Schizophrenia-Lifetime Version (NIAAA); SCID-I: Structured Clinical Interview for DSM-IV Axis I Disorders (NIMH); SCID-P: Structured Clinical Interview for DSM-IV 
Patient Version; Y-BOCS: Yale-Brown Obsessive-Compulsive Scale.  
Dashes indicate missing or insufficient data. 
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Table II.6 (c). Descriptive characteristics of the studies (excluding the present study) included in the 5-HTc ser23cys 
(rs6318) meta-analysis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
aGender index= (female cases/male cases)/(female controls/male controls). Abbreviations: DSM: Diagnostic and Statistical Manual; SADS-L: Structured Clinical Interview for 
Affective Disorders and Schizophrenia-Lifetime Version ; SCID-P: Structured Clinical Interview for DSM-IV Patient Version. 
Dashes indicate missing or insufficient data. 
 
 
 
Table II.6 (d). Descriptive characteristics of the studies (excluding the present study) included in the DRD2 Taq1A 
(rs1800497) meta-analysis. 
 
 
 
 
 
 
 
 
 
 
aGender index= (female cases/male cases)/(female controls/male controls). 
 Abbreviations: DSM: Diagnostic and Statistical Manual; Y-BOCS: Yale-Brown Obsessive-Compulsive Scale; DIS: Diagnostic Interview Scale. 
Dashes indicate missing or insufficient data. 
Data from Billet et al.(1998) was excluded due to inconsistencies in their data. 
 
Reference Ethnicity 
Diagnostic 
System 
Used 
Method of 
Assessment 
n 
(OCD) 
Mean age 
OCD subjects 
(y) 
Mean age 
at onset 
(y) 
n 
(control) 
Mean age 
control 
subjects (y) 
Gender 
Indexa 
Cavallini et al. 
(1998) Italian DSM-III-R Y-BOCS 109 31.41±11 19.86 107 33.13±11 0.99 
Frisch et al. 
(2000) 
Ashkenazi 
Jew DSM-IV 
SADS-L, 
SCID-P 39 - - 112 - 0.92 
Frisch et al. 
(2000) 
non-
Ashkenazi 
Jew 
DSM-IV SADS-L, SCID-P 36 - - 60 - 0.70 
Reference Ethnicity 
Diagnostic 
System 
Used 
Method of 
Assessment 
n 
(OCD) 
Mean age 
OCD 
subjects 
(y) 
Mean age 
at onset 
(y) 
n 
(control) 
Mean age 
control 
subjects (y) 
Gender 
Indexa 
Nicolini et al. 
(1996) Mexican DSM-III-R 
DIS (Spanish 
version),  
Y-BOCS 
67 32.3±10.8 - 54 36.4±11.4 2.23 
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Table II.6 (e). Descriptive characteristics of the studies (excluding the present study) included in the DRD3 ser9gly (rs6280) 
meta-analysis. 
 
 
 
 
 
 
 
 
aGender index= (female cases/male cases)/(female controls/male controls).  
Abbreviations: DSM: Diagnostic and Statistical Manual; Y-BOCS: Yale-Brown Obsessive-Compulsive Scale; DIS: Diagnostic Interview Scale. 
Dashes indicate missing or insufficient data. 
 Data from Billet et al.(1998) was excluded due to inconsistencies in their data. 
 
 
 
 
 
Table II.6 (f). Descriptive characteristics of the studies (excluding the present study) included in the DAT 40bp VNTR 
meta-analysis. 
 
aGender index= (female cases/male cases)/(female controls/male controls). Abbreviations: DSM: Diagnostic and Statistical Manual; SADS-L: Structured Clinical Interview for 
Affective Disorders and Schizophrenia-Lifetime Version ; SCID-P: Structured Clinical Interview for DSM-IV Patient Version. 
Dashes indicate missing or insufficient data. 
Data from Billet et al.(1998) was excluded due to inconsistencies in their data. 
 
Reference Ethnicity 
Diagnostic 
System 
Used 
Method of 
Assessment 
n 
(OCD) 
Mean age 
OCD 
subjects (y) 
Mean age 
at onset 
n 
(control) 
Mean age 
control 
subjects (y) 
Gender 
Indexa 
Catalano et al. 
(1994) 
N. 
American DSM-III-R Y-BOCS 97 33.5±12.1 20.6±10.9 97 30.7±8.6 0.63 
Nicolini et al. 
(1996) Mexican DSM-III-R 
DIS (Spanish 
version), Y-BOCS 67 32.3±10.8 - 54 36.4±11.4 2.23 
First Author Ethnicity 
Diagnostic 
System 
Used 
Method of 
Assessment 
n 
(OCD) 
Mean age 
OCD 
subjects (y) 
Mean age 
at onset 
(y) 
n 
(control) 
Mean age 
control (y) 
Gender 
Indexa 
Frisch et al. 
(2000) 
Ashkenazi 
Jew DSM-IV 
SADS-L, 
SCID-P 39 -  112 - 0.92 
Frisch et al. 
(2000) 
non-
Ashkenazi 
Jew 
DSM-IV SADS-L, SCID-P 36 -  60 - 0.69 
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Table II.6 (g). Descriptive characteristics of the studies (excluding the present study) included in the COMT val158met 
(rs4680) meta-analysis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
aGender index= (female cases/male cases)/(female controls/male controls). Abbreviations: DSM: Diagnostic and Statistical Manual; SCID-I: Structured Clinical Interview for DSM-
IV Axis I Disorders (NIMH); Y-BOCS: Yale-Brown Obsessive-Compulsive Scale 
Dashes indicate missing or insufficient data. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Reference Ethnicity Diagnostic System Used 
Method of 
Assessment 
n 
(OCD) 
Mean age 
OCD 
subjects 
Mean 
age at 
onset 
n 
(control) 
Mean age 
control 
subjects (y) 
Gender 
Indexa 
Karayiorgou 
et al. (1997) 
N. 
American 
Caucasian 
DSM-III-R - 73 - - 148 - 0.76 
Ohara et al. 
(1998) Japanese DSM-IV - 17 - - 135 - - 
Meira-Lima 
et al. (2003) Brazilian DSM-IV 
SCID, Y-
BOCS 79 33.6±10 - 202 33.9±9 0.81 
Erdal et al. 
(2004) Turkish DSM-IV 
Y-BOCS, 
SCID-
I(APA1994) 
59 29±9 21+-7 114 27±6 1.63 
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Table II.6 (h). Descriptive characteristics of the studies (excluding the present study) included in the DRD4 48bp VNTR meta-
analysis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
aGender index= (female cases/male cases)/(female controls/male controls). Abbreviations: DSM: Diagnostic and Statistical Manual; SADS-L: Structured Clinical Interview for 
Affective Disorders and Schizophrenia-Lifetime Version ; SCID-P: Structured Clinical Interview for DSM-IV Patient Version; DIGS: Diagnostic Interview for Genetic Studies; 
KIDDIE-SADS-E: Schedule for Affective Disorders and Schizophrenia for school Age Children-Epidemiological Version ;Y-BOCS: Yale-Brown Obsessive-Compulsive Scale 
Dashes indicate missing or insufficient data.
Reference Ethnicity 
Diagnostic 
System 
Used 
Method of 
Assessment 
n 
(OCD) 
Mean age 
OCD 
subjects (y) 
Mean age 
at onset (y) 
n 
(control) 
Mean age 
control 
subjects (y) 
Gender 
Indexa 
Frisch et al. 
(2000) 
Ashkenazi 
Jew DSM-IV 
SADS-L, 
SCID-P 39 - - 112 - 0.92 
Frisch et al. 
(2000) 
non-
Ashkenazi 
Jew 
DSM-IV SADS-L, SCID-P 36 - - 60 - 0.70 
Millet et al. 
(2003) French DSM-IV 
DIGS, 
KIDDIE-
SADS, Y-
BOCS 
55 23.5+-10 12.9±6 63 34.8±9.7 0.74 
 158
II.7.5.4. Statistical analysis 
For each polymorphism, a two-by-two table was constructed, in which one dichotomous 
variable represented diagnosis (OCD/control), the other allele type. For each study, the 
strength of the association was summarised as the allelic OR; with the major allele assigned 
as the risk allele in all studies.  
 
To test the heterogeneity of the ORs, the Cochran Q-test was performed (Cochran, 1954). The 
cut-off level of significance for heterogeneity was taken to be 0.1. The random effects OR 
was used to detect any heterogeneity across the studies involving the same polymorphisms. 
This model assumes that the studies under investigation represent a random sample of all 
possible studies, and in doing so, accounts for studies that are not available for inclusion in 
the meta-analyses. The random effects model thus weights each study included in the meta-
analysis according to the variance of effect size for each individual study, and according to 
the variance of effect estimates between studies.  
 
Pooling ORs was performed according to the methods described by DerSimonian and Laird, 
1986, and the corresponding 95% CIs were calculated according to Woolf’s Method 
(Woolf,1955).  
 
II.8. ANALYSIS OF AFRIKANER POPULATION STRUCTURE 
Twenty-three polymorphisms were included in Structure analysis and, as indicated in the 
previous sections, some of these polymorphisms had been included in the case-control 
association studies, namely, 5-HT6; DRD3; DAT; DRD1; 5-HT1Dβ; ESRα; DRD4, DRD2; 5-
HT2A,, INPP-1, and COMT . 
 
The genotyping procedures of those polymorphisms have been described in section II.5. 
 
II.8.1. Structure Inference 
The possibility of population substructure was investigated by employing the Bayesian 
clustering method, Structure (version 2.0) (Pritchard, 2000; http://pritch.bsd.uchicago.edu/). 
In setting up the parameter files for structure, the admixture model was selected as an ancestry 
model. Pritchard et al. (2000) recommend the use of this model, given its flexibility in dealing 
with the complexities present in most real populations. The admixture model posits that each 
individual under investigation has mixed ancestry; that is, an individual would have inherited 
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a fraction of her/his genome from ancestors in population K, which is in contrast with the no 
admixture model in which it is assumed that the individual inherits his/her genome solely 
from ancestors in population K.  
 
Structure was run for 106 iterations of the Gibbs sampler, after an initial burn-in of 50 000 
iterations, implementing a model of correlated allele frequencies. This model assumes that, if 
sub-clusters exist, their allele frequencies are likely to be similar, probably as a result of 
migration or shared ancestry. Prior information regarding population membership to direct 
clustering was not used, and the values of K were varied across runs. The value of K that 
maximised the posterior probability of the data was selected as representing the true number 
of clusters (genetically determined sub-populations) within the Afrikaner population. K was 
varied between one and five, and each analysis was repeated 10 times to assess convergence. 
Default values were used for all other parameter settings. 
 
The individuals included in the analysis were all Afrikaans-speaking individuals, recruited by 
the MRC Unit on Anxiety and Stress Disorders. Although many of the individuals (both OCD 
and control) were included in the genetic association analyses, there remains a subset who 
were not included in the genetic investigations in the present study, but who were genotyped 
for concurrent investigations in OCD genetics. Structure analysis was run for the Afrikaner 
OCD and controls separately, and then as a combined group, using the aforementioned 
parameters.  
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CHAPTER III: RESULTS 
 
III.1. GENOTYPING RESULTS 
All polymorphisms were genotyped as described in Chapter II. The following figures (Figure 
III.1-III.37) depict representative gels for each polymorphism.  
                                                              1      2      3      4 
 
Figure III.1. ASREA of the 5-HT2A -1438A/G (rs6311) polymorphism. Representative 2.5% 
agarose gel showing the fragment sizes generated by PCR and restriction digestion with 
MspI. Lane 1: -1438A/-1438A; Lane 2: -1438G/-1438G; Lane 3: -1438A/-1438G; Lane 4: 
Molecular weight marker X. 
 
                                                       1          2        3     4      5 
 
Figure III.2. ASREA of the 5-HT2A T102C (rs6313) polymorphism. Representative 2.5% 
agarose gel showing the fragment sizes generated by PCR and restriction digestion with 
HpaII. Lanes 1 and 3: C102C; Lane 2: T102C; Lane 4: T102T; Lane 5: Molecular weight 
marker X. 
468bp 
244bp 
224bp 
372bp 
216bp 
156bp 
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                                                          1            2            3           4 
 
Figure III.3. ASREA of the 5-HT1Dβ G861C (rs6296) polymorphism. Representative 2% 
agarose gel showing the fragment sizes generated by PCR and restriction digestion with 
HincII. Lane I: C861C; Lane 2: G861G; Lane 3:G861C; Lane 4: Molecular weight marker X. 
 
 
 
 
                                                         1        2         3         4       5 
 
Figure III.4. ASREA of the 5-HT6 T267C (rs1805054) polymorphism. Representative 2.5% 
agarose gel showing the fragment sizes generated by PCR and restriction digestion with RsaI. 
Lane I: T267T; Lanes 2 and 3: T267C; Lane 4: C267C; Lane 5: Low molecular weight DNA 
ladder. 
 
 
662bp 
482bp 
180bp 
578bp 
449bp 
129bp 
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                                                   1             2         3           4          5         6 
 
Figure III.5. ASREA of the 5-HT2C cys23ser (rs6318) polymorphism. Representative 3% 
agarose gel showing the fragment sizes generated by PCR and restriction digestion with 
NlaIII. Lane I: undigested PCR product (control); Lane 2: ser23ser; Lanes 3 and 4: 
cys23cys; Lane 5: cys23ser; Lane 6: Molecular weight marker X. 
 
                                                           1             2               3          4 
 
Figure III.6. ASREA of the DRD4 -521C/T (rs1800955) polymorphism. Representative 
2.5% agarose gel showing the fragment sizes generated by PCR and restriction digestion with 
FspI. Lane I: -521C/C; Lane 2: -521C/T; Lane 3: -521T/T; Lane 4: Molecular weight marker 
X. 
 
 
 
 
184bp 
150bp 
130bp 
380bp 
228bp 
180bp 
 167
 
                                             1          2           3         4         5        6       7 
 
Figure III.7. PCR amplification of the DRD4 48bp VNTR polymorphism. Representative 
3% agarose gel showing the fragment sizes generated by PCR. Lane 1: A2/A2; Lane 2: 
A4/A4; Lanes 3 and 6: A4/A3; Lane 4: A4/A7; Lane 5: A6/A7; Lane 7: Molecular weight 
marker XIV. (A2=379bp, A3=427bp, A4=475bp, A6=571bp, A7=619bp). 
 
 
 
                                                             1          2            3           4    
 
 
Figure III.8. ASREA of the DRD2 Taq1A (rs1800497) polymorphism. Representative 2.5% 
agarose gel showing the fragment sizes generated by PCR and restriction digestion with 
Taq1A I. Lane 1: CC; Lane 2: CT; Lane 3: TT; Lane 4: Marker XIV 
 
500bp 
130bp 
180bp 
310bp 
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                                                        1              2              3             4 
 
Figure III.9. ASREA of the COMT promoter (rs2097603) polymorphism. Representative 
2.5% agarose gel showing the fragment sizes generated by PCR and restriction digestion with 
HindIII. Lane 1: AG; Lane 2: GG; Lane 3: AA; Lane 4: Molecular weight marker X. 
 
 
                                                              1            2          3        4 
 
 
Figure III.10. ASREA of the COMT val158met (rs4680) polymorphism. Representative 
12% polyacrylamide gel showing the fragment sizes generated by PCR and restriction 
digestion with NlaIII. Lane 1: AA (met158met); Lane 2: GG (val158val); Lane 3: AG 
(val158met); Lane 4: Molecular weight marker λPst. 
 
306bp 
271bp 
75bp 
82bp 
68bp 
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                                                           1       2           3             4 
 
Figure III.11. ASREA of the COMT exon 6 (rs362204) polymorphism. Representative 
2.5% agarose gel showing the fragment sizes generated by PCR and restriction digestion with 
BglI. Lane 1: ID (C+/C-); Lane 2: DD (C-/C-); Lane 3: II (C+/C+); Lane 4: Molecular 
weight marker λPst. 
 
                                                         1                2                  3 
 
 
Figure III.12. ASREA of the DRD3 ser9gly (rs6280) polymorphism. Representative 3% 
agarose gel showing the fragment sizes generated by PCR and restriction digestion with 
MscI. Lane 1: AA (ser9ser); Lane 2: AG (gly9ser) Lane 3: Molecular weight marker XIV. 
The visible constitutive fragments (at 47bp and 146bp) are marked with an asterisk.  
GG (gly9gly) is not indicated on the gel. 
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82bp 
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98bp 
47bp** 
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                                                   1            2           3              4            5 
 
Figure III.13. ASREA of the DRD1 A-48G polymorphism. Representative 2.5% agarose gel 
showing the fragment sizes generated by PCR and restriction digestion with DdeI. Lane 1: -
48G/-48G; Lane 2: -48A/-48G; Lane 3: -48A/-48A; Lane 4: undigested PCR product; Lane 
5: Molecular weight marker X.  
The constitutive fragment (at 146bp) is marked with an asterisk. 
 
                                                           1                   2            3 
 
Figure III.14. ASREA of the BDNF val66met (rs6265) polymorphism. Representative 3% 
agarose gel showing the fragment sizes generated by PCR and restriction digestion with 
NlaIII. Lane 1: GG (val66val); Lane 2: GA (val66met); Lane 3: Molecular weight marker 
XIV.  
The constitutive fragment (at 57bp) is marked with an asterisk. 
AA (met66met) is not indicated on this gel. 
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Figure III.15. ASREA of the ESRα rs9430799 polymorphism. Representative 1.5% agarose 
gel showing the fragment sizes generated by PCR and restriction digestion with XbaI. Lane 1: 
AA; Lanes 2 and 3: AG; Lane 4: GG; Lane 5: Molecular weight marker λPst. 
 
 
 
                                                1                 2               3              4 
 
Figure III.16. ASREA of the ESRα rs2234693 polymorphism. Representative 1.5% agarose 
gel showing the fragment sizes generated by PCR and restriction digestion with PvuII. Lane 
1: TT; Lane 2: CC; Lane 3: TC; Lane 4: Molecular weight marker XIV. 
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Figure III.17. ASREA of the INPP-1 rs1882891 polymorphism. Representative 2.5% 
agarose gel showing the fragment sizes generated by PCR and restriction digestion with 
DdeI. Lane 1: AA; Lane 2: CC; Lane 3: CA; Lane 4: Molecular weight marker VI. 
 
                                                       1         2         3         4          5 
 
Figure III.18. ASREA of the PLC-γ1 rs8192707 polymorphism. Representative 2.5% 
agarose gel showing the fragment sizes generated by PCR and restriction digestion with BlpI. 
Lane 1: GA (gly279ser); Lanes 2 and 3: AA (ser279ser); Lane 4: GG (gly279gly); Lane 5: 
Molecular weight marker XIV.  
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Figure III.19. ASREA of the DLX int1C/T polymorphism. Representative 2% agarose gel 
showing the fragment sizes generated by PCR and restriction digestion with ApoI. Lane 1: 
CC; Lane 2: CT; Lane 3: TT; Lane 4: Molecular weight marker λPst. 
 
 
 
                                                       1              2              3           4 
 
Figure III.20. ASREA of the ADRA1C cys492arg polymorphism. Representative 2% 
agarose gel showing the fragment sizes generated by PCR and restriction digestion with PstI. 
Lane 1: CT (cys492arg); Lane 2: TT (arg492arg); Lane 3: CC (cys492cys); Lane 4: 
Molecular weight marker XIV. 
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Figure III.21. ASREA of the SNAP25 MnlI polymorphism. Representative 2% agarose gel 
showing the fragment sizes generated by PCR and restriction digestion with MnlI. Lanes 1 
and 2: TG; Lane 3-6: TT. Lane 7: Low molecular weight marker.  
 
 
                                                           1               2                   3 
 
 
Figure III.22. ASREA of the GNAS FokI (rs7121) polymorphism. Representative 2.5% 
agarose gel showing the fragment sizes generated by PCR and restriction digestion with FokI. 
Lane 1: TC; Lane 2: CC; Lane 3: Marker X (indicating fragment sizes from 154bp to 517bp). 
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Figure III.23. ASREA of the ABCG1 G2457A polymorphism. Representative 2% agarose 
gel showing the fragment sizes generated by PCR and restriction digestion with HhaI. Lane 1: 
GG; Lane 2: AA; Lane 3: AG; Lane 4: Molecular weight marker VI.  
 
 
                                                           1            2          3           4 
 
Figure III.24. ASREA of the SNAP29 C56T polymorphism. Representative 12% 
polyacrylamide gel showing the fragment sizes generated by PCR and restriction digestion 
with DdeI. Lane 1: CC; Lane 2: CT; Lane 3: TT; Lane 4: Molecular weight marker λPst. The 
108bp constitutive fragment is marked with an asterisk. 
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Figure III.25. PCR amplification of the DAT 40bp VNTR polymorphism. Representative 
2% agarose gel showing the fragment sizes generated by PCR. Lane 1: A9/A9; Lanes 2 and 
5: A9/A10; Lane 3: A10/A11; Lanes 4 and 6: A10/A10; Lane 7: Molecular weight marker 
XIV. (A9=440bp, A10=480bp, A11=520bp). 
 
                                                     1      2        3     4       5       6       7 
 
Figure III.26. PCR amplification of the FXIIIB Alu ins/del polymorphism. Representative 
2% agarose gel showing the fragment sizes generated by PCR. Lanes 1 and 2: I/D; Lanes 3, 4 
and 5: I/I; Lane 6: D/D; Lane 7: Low Molecular weight DNA ladder. (I=insertion allele; 
D=deletion allele). 
 
795bp 
501bp 
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Figure III.27. PCR amplification of the YaNBC182 Alu ins/del polymorphism. 
Representative 2% agarose gel showing the fragment sizes generated by PCR. Lane 1: I/I; 
Lane 2: D/D; Lane 3: I/D; Lane 4: Low Molecular weight DNA ladder. 
(I=insertion allele; D=deletion allele). 
 
 
    
                                                             1          2        3           4 
 
Figure III.28. PCR amplification of the TPA25 Alu ins/del polymorphism. Representative 
2.5% agarose gel showing the fragment sizes generated by PCR. Lane 1: I/D; Lane 2: I/I; 
Lane 3: D/D; Lane 4: Low Molecular weight DNA ladder. 
(I=insertion allele; D=deletion allele). 
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Figure III.29. PCR amplification of the YaNBC241 Alu ins/del polymorphism. 
Representative 3% agarose gel showing the fragment sizes generated by PCR. Lane 1: I/D; 
Lane 2: D/D; Lane 3: I/I; Lane 4: Molecular weight marker X. 
(I=insertion allele; D=deletion allele). 
 
                                                     1                   2                   3            4 
 
Figure III.30. PCR amplification of the PV92 Alu ins/del polymorphism. Representative 
2.5% agarose gel showing the fragment sizes generated by PCR. Lane 1: I/I; Lane 2: D/D; 
Lane 3: I/D; Lane 4: Molecular weight marker λPst. 
(I=insertion allele; D=deletion allele). 
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Figure III.31. PCR amplification of the 5-HTT 44bp VNTR polymorphism. Representative 
12% polyacrylamide gel showing the fragment sizes generated by PCR. Lane 1: L/L; Lane 2: 
L/S; Lane 3:S/S; Lane 4: Molecular weight marker λPst. 
(L refers to the “long” allele, S refers to the “short” allele). 
 
 
                                                        1               2            3              4 
 
 
Figure III.32. PCR amplification of the ACE Alu ins/del polymorphism. Representative 2% 
agarose gel showing the fragment sizes generated by PCR. Lane 1: I/I; Lane 2: I/D; Lane 3: 
D/D; Lane 4: Molecular weight marker λPst. 
(I=insertion allele; D=deletion allele). 
 
534bp 
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Figure III.33. SNaPshot results for the BDNF rs2049046 polymorphism. (A): 
representative snapshot result for the TT-genotype, (B): representative SNaPshot result for 
the AA-genotype and (C): representative snapshot result for the TA-genotype. 
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Figure III.34. SNaPshot results for the BDNF rs988748 polymorphism. (A): representative 
snapshot result for the CC-genotype, (B): representative snapshot result for the GG-genotype 
and (C): representative snapshot result for the GC-genotype. 
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Figure III.35. SNaPshot results for the HOXB8 rs2303486 polymorphism. (A): 
representative snapshot result for the AA-genotype, (B): representative snapshot result for 
the TT-genotype and (C): representative snapshot result for the AT-genotype. 
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Figure III.36. SNaPshot results for the GRIN2B rs1806191 polymorphism. (A): 
representative snapshot result for the AA-genotype, (B): representative snapshot result for 
the GG-genotype and (C): representative snapshot result for the GA-genotype. 
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                       A                                           B                                                  C 
 
Figure III.37. SNaPshot results for the GRIN2B rs890 polymorphism. (A): representative 
snapshot result for the AA-genotype, (B): representative snapshot result for the CC-genotype 
and (C): representative snapshot result for the AC-genotype. 
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III.2. INVESTIGATING SUB-STRUCTURE WITHIN THE AFRIKANER 
POPULATION 
 
A total of 137 (76 controls and 61 OCD patients) Afrikaner subjects were selected for 
genotyping for inclusion in the determination of population substructure in the present study. 
These individuals were genotyped for 23 unlinked autosomal polymorphisms, selected on the 
basis of location. The polymorphisms, their exact HWE values and heterozygosities are 
portrayed in Table III.1. The mean heterozygosity for all 23 polymorphisms was 0.446. All of 
the polymorphisms were found to obey HWE (Table III.1). 
 
This data was then analysed for population structure using the Structure program (version 2.0) 
(Pritchard et al., 2000; available on the Pritchard Lab website: 
http://pritch.bsd.uchicago.edu/). The posterior probability values of K, assuming a uniform 
prior on K between 1 and 5, are provided in Table III.2. These posterior probability values 
provide one with the probability that individuals will occupy a particular cluster (sub-
population), given the observed genotypes. These values were obtained as described in 
“Inference for the number of populations” from the Structure user’s manual (Pritchard and 
Wen, July 13 2004) (http://pritch.bsd.uchicago.edu). It is important to stress that these values 
serve only as rough guides as to the most parsimonious model, rather than accurate estimates 
of posterior probabilities. 
 
The posterior probabilities favoured a K of 1 in the total population, and also when the sample 
was stratified according to diagnosis (i.e. control and OCD subjects) (Table III.2). This is 
indicative of an absence of population structure within the Afrikaner population utilised in the 
present study. This result is corroborated by the examining the membership coefficients (Q) 
for each individual for each value of K: the proportion of the population assigned to each 
cluster is symmetric for K=2 to K=5, as indicated by the bar plots in Figure III.38.  
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Table III.1. Genetic markers used in “Structure” analysis, indicating the chromosomal 
location, major allele frequency and HWE and heterozygosity values for each variant. 
 
Abbreviations: HWE: Hardy-Weinberg equilibrium; 5-HT6: serotonin receptor 6; FXIIIB: Factor 13B; INPP-1: inositol polyphosphate-
phosphatase;  DRD3: dopamine receptor 3; DRD1: dopamine receptor 1; DAT: dopamine transporter; 5-HT1Dβ: serotonin receptor 1Dβ; 
ESRα: estrogen receptor α; DLX6: Distal-less like homeobox 6; YaNBC182:Ya subfamily Alu insertion sequence NBC182; TPA25: Tissue 
plasminogen activator Alu insertion;  ADRA1C: Adrenergic receptor α1C; DBH: Dopa-β hydroxylase; DRD4: dopamine receptor 4; DRD2: 
dopamine receptor 2; 5-HT2A: serotonin receptor 2A; YaNBC241: Ya subfamily of Alu insertion repeats; PV92: predicted variant Alu 
insertion repeat; 5-HTT: serotonin transporter; SNAP25: Synaptosomal-associated protein 25kDa; GNAS: guanine nucleotide-binding α 
subunit of G; SNAP29: Synaptosomal-associated protein 29kDa; COMT: catechol-O-methyltransferase; VNTR: variable number of tandem 
repeats. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HWE exact p-value Heterozygosity 
Marker Location Polymorphism 
All Controls OCD All Controls OCD 
5-HT6 1p35-36 rs1805054 0.736 1.000 1.000 0.272 0.221 0.348 
FXIIIB 1q31-32 Alu ins/del 0.353 0.804 0.084 0.453 0.531 0.358 
INPP-1 2q32 rs1882891 0.689 1.000 1.000 0.224 0.220 0.228 
DRD3 3q13.3 rs6280 (ser9gly) 0.701 1.000 0.362 0.457 0.500 0.404 
DRD1 5p35.1 rs4532 0.355 0.445 0.783 0.496 0.514 0.475 
DAT 5p15.3 40bp VNTR 0.847 0.494 0.792 0.350 0.316 0.393 
5-HT1Dβ 6q13 rs6296 (G861C) 0.290 0.173 0.742 0.393 0.405 0.377 
ESRα 6q25.1 rs2234693 0.412 1.000 0.485 0.537 0.508 0.583 
DLX 7q21.3 DLX int1C/T 0.658 0.577 0.162 0.482 0.549 0.375 
YaNBC182 7 Alu ins/del 0.726 0.139 0.291 0.512 0.597 0.417 
TPA25 8p12 Alu ins/del 0.862 0.450 0.591 0.492 0.462 0.527 
ADRA1C 8p21 cys492arg 1.000 0.617 0.585 0.504 0.537 0.463 
DBH 9q34 Insertion/deletion 0.726 1.000 0.664 0.464 0.556 0.421 
DRD4 11p15.5 rs1800955 0.211 0.148 0.792 0.538 0.589 0.475 
DRD2 11q23.2 rs1800497(Taq1A) 0.820 0.560 1.000 0.382 0.352 0.417 
5-HT2A 
13q14-
21 
rs6311 (-
1438A/G) 0.042 0.082 0.388 0.391 0.389 0.393 
YaNBC241 15 Alu ins/del 0.288 0.811 0.325 0.450 0.464 0.435 
PV92 16q24 Alu ins/del 0.800 1.000 0.439 0.346 0.328 0.367 
5-HTT 17q11 44bp VNTR 0.269 0.330 0.592 0.441 0.429 0.455 
SNAP25 20p12 SNAP25 MnlI 0.633 0.697 0.776 0.467 0.457 0.474 
GNAS 20q13.2 rs7121 0.409 0.497 0.790 0.466 0.459 0.475 
SNAP29 22q11.21 C56T 0.085 1.000 1.000 0.582 0.676 0.511 
COMT 22q11.2 rs4680 (val158met) 0.431 0.453 0.453 0.567 0.565 0.569 
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Table III.2. Estimated posterior probabilities of K for the total, control and OCD samples.  
 
 
aThe probability that an individual will occupy a particular cluster (sub-population), given the observed genotype data 
Abbreviation: OCD: Obsessive-compulsive disorder. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
     
Total Sample Control OCD 
K 
ln P (X|K)a 
Posterior 
Probability 
(P[K|X]) a 
ln P (X|K) 
Posterior 
Probability 
(P[K|X]) a 
ln P (X|K) 
Posterior 
Probability
(P[K|X]) a 
1 -3330.73 0.98 -1783.86 0.72 -1552.31 0.97 
2 -3334.64 0.02 -1785.33 0.17 -1555.71 0.03 
3 -3340.5 0.00 -1786.71 0.04 -1560.22 0.00 
4 -3340.53 0.00 -1786.29 0.06 -1561.54 0.00 
5 -3345.68 0.00 -1787.98 0.01 -1558.80 0.00 
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K=2 
 
K=3 
 
K=4 
 
K=5 
 
Figure III.38. Bar plot of estimates of membership co-efficient (Q) for K=2 to K=5 for 
Afrikaners. The x-axis represents the Afrikaner individuals included in Structure analysis, 
whilst the y-axis indicates the proportion of each individual’s genome that is assigned to a 
cluster (for the number of clusters K=2 to K=5). 
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III.3. DESCRIPTIVE OVERVIEW OF THE POLYMORPHISMS INVESTIGATED  
 
III.3.1. Bi-allelic Loci 
Exact tests of HWE were performed on case and control individuals separately for each bi-
allelic polymorphism (Table III.3[a]). All bi-allelic polymorphisms were found to obey HWE, 
in both the case and control populations.  
 
Tables III.3(b), 3(c) and 3(d) provide a descriptive overview of the bi-allelic polymorphisms 
investigated in the present study, in the entire sample (Table III.3[b]), and stratified according 
to gender (males: Table III.3[c]; females: Table III.3[d]). In the control population, no bi-
allelic polymorphisms had a minor allele with a frequency of below 10%, and five (21%) had 
a minor allele frequency between 10% and 20%. 
 
III.3.2. Multi-allelic Loci 
 
III.3.2.1. DRD4 48bp VNTR 
The counts and associated frequencies of the DRD4 48bp VNTR genotypes and alleles in the 
control and OCD samples are presented in Tables III.4 (a) and (b), respectively. A total of 151 
controls and 89 OCD subjects were genotyped at this locus. The 4-repeat allele (A4) was 
found to be the most common allele amongst both the case and control individuals, with a 
frequency of 0.69 in controls and 0.64 in OCD patients (Table III.4[b]). Both the OCD and 
control populations are in HWE at this locus (p = 0.999 and p = 0.112, respectively). The 
overall heterozygosity at the locus was found to be 0.513.  
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Table III.3(a). Exact Hardy-Weinberg equilibrium p-values for the control and OCD 
populations, and heterozygosity statistics for the bi-allelic candidate loci. 
HWE exact p-value 
Gene Variant 
Controls OCD 
Heterozygosity 
5-HT2A rs6311 0.39 0.31 0.47 
 rs6313 0.33 0.07 0.48 
5-HT1Dβ rs6296 0.68 1.00 0.38 
5-HT6 rs1805054 1.00 0.73 0.32 
5-HT2C* rs6318 0.13 0.42 0.34 
DRD4 rs1800955 1.00 1.00 0.49 
DRD2 rs1800497 0.50 1.00 0.38 
COMT rs2097603 0.50 0.30 0.51 
 rs4680 0.38 0.15 0.50 
 rs362204 0.68 0.48 0.38 
DRD3 rs6280 0.24 0.04 0.41 
DRD1 rs4532 0.71 0.66 0.46 
GRIN2B rs1806191 0.54 0.78 0.51 
 rs890] 0.76 0.42 0.49 
BDNF rs6265 0.37 0.38 0.32 
 rs2049046 0.80 0.78 0.50 
 rs988748 0.67 0.47 0.39 
HOXB8 rs2303486 0.55 0.37 0.50 
ESRα rs9340799 0.20 0.32 0.45 
 rs2234693 0.27 0.80 0.50 
INPP-1 rs1882891 0.65 1.00 0.22 
PLCγ1 rs8192707 0.78 0.77 0.35 
ACE Ins/del 0.69 0.07 0.48 
 
* HWE calculated using the female population.; Abbreviations: HWE: Hardy-Weinberg Equilibrium; 5-HT2A: serotonin receptor 2A; 5-
HT1Dβ: serotonin receptor 1Dβ; 5-HT6: serotonin receptor 6; 5-HT2C: serotonin receptor 2C; DRD4: dopamine receptor 4; DRD2: dopamine 
receptor 2; COMT: Catechol-O-methyltransferase; DRD3: dopamine receptor 3; DRD1: dopamine receptor 1; GRIN2B: glutamate receptor 
subunit 2B; BDNF: brain-derivedneurotrophic factor; HOXB8: homeobox gene B8;  ESRα: estrogen receptor α; INPP-1: inositol 
polyphosphate-phosphatase 1; PLC-γ1: phospholipase-gamma; ACE: Angiotensin-converting enzyme. 
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Table III.3(b). Genotype and allele scores and frequencies of bi-allelic candidate polymorphisms in control and OCD subjects. 
 
an1 refers to the major allele, n2 refers to the minor allele. bHemizygous males were grouped with females homozygous for the ser23(C) or cys23(G) alleles for descriptive purposes only 
Abbreviations: 5-HT2A: serotonin receptor 2A; 5-HT1Dβ: serotonin receptor 1Dβ; 5-HT6: serotonin receptor 6; 5-HT2C: serotonin receptor 2C; DRD4: dopamine receptor 4; DRD2: dopamine receptor 2; COMT: 
Catechol-O-methyltransferase; DRD3: dopamine receptor 3; DRD1: dopamine receptor 1; GRIN2B: glutamate receptor subunit 2B; BDNF: brain-derived neurotrophic factor; HOXB8: homeobox gene B8;  ESRα: 
estrogen receptor α; INPP-1: inositol polyphosphate-phosphatase 1; PLC-γ1: phospholipase-gamma; ACE: Angiotensin-converting enzyme 
Control OCD 
Genotype Alleles Genotype Alleles Gene Variant n1/n2a 
n11 % n12 % n22 % 
Total 
n1 % n2 % n11 % n12 % n22 % 
Total 
n1 % n2 % 
rs6311 G/A 57 39.0 64 43.8 25 17.1 146 178 61.0 114 39.0 44 40.7 46 42.6 18 16.7 108 134 62.0 82 38.0 
5-HT2A 
rs6313 C/T 66 40.2 71 43.3 27 16.5 164 203 61.9 125 38.1 45 41.7 42 38.9 21 19.4 108 132 61.1 84 38.9 
5-HT1Dβ rs6296 G/C 95 57.6 59 35.8 11 6.7 165 249 75.5 81 24.5 55 52.9 41 39.4 8 7.7 104 151 72.6 57 27.4 
5-HT6 rs1805054 C/T 80 72.7 29 26.4 1 0.9 110 189 85.9 31 14.1 53 63.1 29 34.5 2 2.4 84 135 80.4 33 19.6 
5-HT2Cb rs6318 G/C 100 68.5 35 24.0 11 7.5 146 200 78.1 56 21.9 68 69.4 15 15.3 15 15.3 98 113 76.9 34 23.1 
DRD4 rs1800955 T/C 39 28.5 69 50.4 29 21.2 137 147 53.6 127 46.4 32 35.2 45 49.5 14 15.4 91 109 59.9 73 40.1 
DRD2 rs1800497 C/T 74 56.1 48 36.4 10 7.6 132 196 74.2 68 25.8 57 55.3 40 38.8 6 5.8 103 154 74.8 52 25.2 
rs2097603 A/G 28 35.4 36 45.6 15 19.0 79 92 58.2 66 41.8 16 27.1 25 42.4 18 30.5 59 57 48.3 61 51.7 
rs4680 G/A 32 25.0 69 53.9 27 21.1 128 133 52.0 123 48.0 16 17.2 54 58.1 23 24.7 93 86 46.2 100 53.8 COMT 
rs362204 D/I 42 40.0 51 48.6 12 11.4 105 135 64.3 75 35.7 28 53.8 22 42.3 2 3.8 52 78 75.0 26 25.0 
DRD3 rs6280 A/G 51 42.5 51 42.5 18 15.0 120 153 63.8 87 36.3 54 56.3 30 31.3 12 12.5 96 138 71.9 54 28.1 
DRD1 A-48G A/G 47 36.2 65 50.0 18 13.8 130 159 61.2 101 38.8 40 40.0 49 49.0 11 11.0 100 129 64.5 71 35.5 
rs1806191 G/A 10 25.0 23 57.5 7 17.5 40 43 53.8 37 46.3 22 39.3 25 44.6 9 16.1 56 69 61.6 43 38.4 GRIN2B 
rs890 A/C 12 29.3 22 53.7 7 17.1 41 46 56.1 36 43.9 18 31.6 31 54.4 8 14.0 57 67 58.8 47 41.2 
rs6265 G/A 95 67.9 43 30.7 2 1.4 140 233 83.2 47 16.8 73 65.2 33 29.5 6 5.4 112 179 79.9 45 20.1 
rs2049046 A/T 19 30.2 33 52.4 11 17.5 63 71 56.3 55 43.7 12 24.0 24 48.0 14 28.0 50 48 48.0 52 52.0 BDNF 
rs988748 C/G 39 63.9 21 34.4 1 1.6 61 99 81.1 23 18.9 25 51.0 22 44.9 2 4.1 49 72 73.5 26 26.5 
HOXB8 rs2303486 T/A 10 23.8 24 57.1 8 19.0 42 44 52.4 40 47.6 10 20.4 20 40.8 19 38.8 49 40 40.8 58 59.2 
rs9340799 A/G 57 42.5 55 41.0 22 16.4 134 169 63.1 99 36.9 39 47.6 32 39.0 11 13.4 82 110 67.1 54 32.9 
ESRα 
rs2234693 T/C 32 27.8 52 45.2 31 27.0 115 112 48.7 118 51.3 19 31.1 29 47.5 13 21.3 61 67 54.9 55 45.1 
INPP-1 rs1882891 C/A 94 79.0 23 19.3 2 1.7 119 211 88.7 27 11.3 71 74.0 24 25.0 1 1.0 96 166 86.5 26 13.5 
PLC-γ1 rs8192707 A/G 73 62.4 40 34.2 4 3.4 117 186 79.5 48 20.5 56 60.9 31 33.7 5 5.4 92 143 77.7 41 22.3 
ACE Alu ins/del D/I 63 47.0 59 44.0 12 9.0 134 185 69.0 83 31.0 44 40.4 43 39.4 22 20.2 109 131 60.1 87 39.9 
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Table III.3(c). Genotype and allele scores and frequencies of bi-allelic candidate polymorphisms in male control and OCD subjects. 
Control OCD 
Genotype  Alleles Genotype Alleles (%) Gene Variant 
 
n1/n2a 
 n11 % n12 % n22 % 
Total 
n1 % n2 % n11 % n12 % n22 % 
Total 
n1 % n2 % 
rs6311 G/A 15 41.7 15 41.7 6 16.7 36 45 62.5 27 37.5 27 49.1 21 38.2 7 12.7 55 75 68.2 35 31.8 
5-HT2A 
rs6313 C/T 14 35.0 20 50.0 6 15.0 40 48 60.0 32 40.0 26 47.3 19 34.5 10 18.2 55 71 64.5 39 35.5 
5-HT1Dβ rs6296 G/C 26 63.4 14 34.1 1 2.4 41 66 80.5 16 19.5 34 64.2 15 28.3 4 7.5 53 83 78.3 23 21.7 
5-HT6 rs1805054 C/T 15 60.0 10 40.0 0 0.0 25 40 80.0 10 20.0 23 59.0 15 38.5 1 2.6 39 61 78.2 17 21.8 
5-HT2C rs6318 G/C 35 97.2 0 0.0 1 2.8 36 35 97.2 1 2.8 38 77.6 0 0.0 11 22.4 49 38 77.6 11 22.4 
DRD4 rs1800955 T/C 15 45.5 14 42.4 4 12.1 33 44 66.7 22 33.3 16 34.8 23 50.0 7 15.2 46 55 59.8 37 40.2 
DRD2 rs1800497 C/T 12 41.4 13 44.8 4 13.8 29 37 63.8 21 36.2 28 58.3 17 35.4 3 6.3 48 73 76.0 23 24.0 
rs2097603 A/G 4 26.7 8 53.3 3 20.0 15 16 53.3 14 46.7 9 33.3 10 37.0 8 29.6 27 28 51.9 26 48.1 
rs4680 G/A 13 37.1 18 51.4 4 11.4 35 44 62.9 26 37.1 9 19.6 28 60.9 9 19.6 46 46 50.0 46 50.0 COMT   
rs362204 D/I 8 32.0 15 60.0 2 8.0 25 31 62.0 19 38.0 15 65.2 8 34.8 0 0.0 23 38 82.6 8 17.4 
DRD3 rs6280 A/G 11 44.0 12 48.0 2 8.0 25 34 68.0 16 32.0 29 61.7 10 21.3 8 17.0 47 68 72.3 26 27.7 
DRD1 A-48G A/G 11 34.4 20 62.5 1 3.1 32 42 65.6 22 34.4 20 39.2 27 52.9 4 7.8 51 67 65.7 35 34.3 
rs1806191 G/A 4 26.7 8 53.3 3 20.0 15 16 53.3 14 46.7 10 33.3 17 56.7 3 10.0 30 37 61.7 23 38.3 GRIN2B 
  rs890 A/C 8 32.0 13 52.0 4 16.0 25 29 58.0 21 42.0 7 23.3 18 60.0 5 16.7 30 32 53.3 28 46.7 
rs6265 G/A 25 75.8 8 24.2 0 0.0 33 58 87.9 8 12.1 33 57.9 19 33.3 5 8.8 57 85 74.6 29 25.4 
rs2049046 A/T 5 35.7 6 42.9 3 21.4 14 16 57.1 12 42.9 8 28.6 13 46.4 7 25.0 28 29 51.8 27 48.2 BDNF   
rs988748 C/G 5 38.5 8 61.5 0 0.0 13 18 69.2 8 30.8 16 57.1 10 35.7 2 7.1 28 42 75.0 14 25.0 
HOXB8 rs2303486 T/A 3 30.0 5 50.0 2 20.0 10 11 55.0 9 45.0 5 17.9 11 39.3 12 42.9 28 21 37.5 35 62.5 
rs9340799 A/G 13 44.8 12 41.4 4 13.8 29 38 65.5 20 34.5 19 46.3 16 39.0 6 14.6 41 54 65.9 28 34.1 ESRα 
  rs2234693 T/C 6 25 11 45.8 7 29.2 24 23 47.9 25 52.1 19 31.1 29 47.5 13 21.3 61 67 54.9 55 45.1 
INPP-1 rs1882891 C/A 20 74.1 7 25.9 0 0.0 27 47 87.0 7 13.0 35 74.5 12 25.5 0 0.0 47 82 87.2 12 12.8 
PLC-γ1 rs8192707 A/G 15 57.7 9 34.6 2 7.7 26 39 75.0 13 25.0 29 64.4 14 31.1 2 4.4 45 72 80.0 18 20.0 
ACE Ins/del D/I 14 46.7 15 50.0 1 3.3 30 43 71.7 17 28.3 21 37.5 20 35.7 15 26.8 56 62 55.4 50 44.6 
an1  refers to the major allele, n2  refers to the minor allele 
Abbreviations: 5-HT2A: serotonin receptor 2A; 5-HT1Dβ: serotonin receptor 1Dβ; 5-HT6: serotonin receptor 6; 5-HT2C: serotonin receptor 2C; DRD4: dopamine receptor 4; DRD2: dopamine receptor 2; COMT: Catechol-O-
methyltransferase; DRD3: dopamine receptor 3; DRD1: dopamine receptor 1; GRIN2B: glutamate receptor subunit 2B; BDNF: brain-derivedneurotrophic factor; HOXB8: homeobox gene B8;  ESRα: estrogen receptor α; 
 193
 
Table III.3(d). Genotype and allele scores and frequencies of bi-allelic candidate polymorphisms in female control and OCD subjects. 
 
an1  refers to the major allele, n2  refers to the minor allele.  
Abbreviations: 5-HT2A: serotonin receptor 2A; 5-HT1Dβ: serotonin receptor 1Dβ; 5-HT6: serotonin receptor 6; 5-HT2C: serotonin receptor 2C; DRD4: dopamine receptor 4; DRD2: dopamine receptor 2; 
COMT: Catechol-O-methyltransferase; DRD3: dopamine receptor 3; DRD1: dopamine receptor 1; GRIN2B: glutamate receptor subunit 2B; BDNF: brain-derived neurotrophic factor; HOXB8: homeobox 
gene B8;  ESRα: estrogen receptor α; INPP-1: inositol polyphosphate-phosphatase 1; PLCγ1: phospholipase-gamma; ACE: Angiotensin-converting enzyme. 
Control OCD 
  
Genotype Alleles Genotype Alleles 
Gene 
 
 
Variant n1/n2a 
n11 % n12 % n22 % 
Total 
n1 % n2 % n11 % n12 % n22 % 
Total
n1 % n2 % 
rs6311 G/A 42 38.2 49 44.5 19 17.3 110 133 60.5 87 39.5 17 32.1 25 47.2 11 20.8 53 59 55.7 47 44.3 
5-HT2A 
rs6313 C/T 52 41.9 51 41.1 21 16.9 124 155 62.5 93 37.5 19 35.8 23 43.4 11 20.8 53 61 57.5 45 42.5 
5-HT1Dβ rs6296 G/C 69 55.6 45 36.3 10 8.1 124 183 73.8 65 26.2 21 41.2 26 51.0 4 7.8 51 68 66.7 34 33.3 
5-HT6 rs1805054 C/T 65 76.5 19 22.4 1 1.2 85 149 87.6 21 12.4 30 66.7 14 31.1 1 2.2 45 74 82.2 16 17.8 
5-HT2C rs6318 G/C 65 59.1 35 31.8 10 9.1 110 165 75.0 55 25.0 30 61.2 15 30.6 4 8.2 49 75 76.5 23 23.5 
DRD4 rs1800955 T/C 24 23.1 55 52.9 25 24.0 104 103 49.5 105 50.5 16 35.6 22 48.9 7 15.6 45 54 60.0 36 40.0 
DRD2 rs1800497 C/T 62 60.2 35 34.0 6 5.8 103 159 77.2 47 22.8 29 52.7 23 41.8 3 5.5 55 81 73.6 29 26.4 
rs2097603 A/G 24 37.5 28 43.8 12 18.8 64 76 59.4 52 40.6 7 21.9 15 46.9 10 31.3 32 29 45.3 35 54.7 
rs4680 G/A 19 20.4 51 54.8 23 24.7 93 89 47.8 97 52.2 7 14.9 26 55.3 14 29.8 47 40 42.6 54 57.4 COMT 
rs362204 D/I 34 42.5 36 45.0 10 12.5 80 104 65.0 56 35.0 13 44.8 14 48.3 2 6.9 29 40 69.0 18 31.0 
DRD3 rs6280 A/G 40 42.1 39 41.1 16 16.8 95 119 62.6 71 37.4 25 51.0 20 40.8 4 8.2 49 70 71.4 28 28.6 
DRD1 A-48G A/G 36 36.7 45 45.9 17 17.3 98 117 59.7 79 40.3 20 40.8 22 44.9 7 14.3 49 62 63.3 36 36.7 
rs1806191 G/A 6 24.0 15 60.0 4 16.0 25 27 54.0 23 46.0 12 46.2 8 30.8 6 23.1 26 32 61.5 20 38.5 
GRIN2B 
rs890 A/C 4 25.0 9 56.3 3 18.8 16 17 53.1 15 46.9 11 40.7 13 48.1 3 11.1 27 35 64.8 19 35.2 
rs6265 G/A 70 65.4 35 32.7 2 1.9 107 175 81.8 39 18.2 40 72.7 14 25.5 1 1.8 55 94 85.5 16 14.5 
rs2049046 A/T 13 28.3 25 54.3 8 17.4 46 51 55.4 41 44.6 4 18.2 11 50.0 7 31.8 22 19 43.2 25 56.8 BDNF 
rs988748 C/G 33 73.3 11 24.4 1 2.2 45 77 85.6 13 14.4 9 42.9 12 57.1 0 0.0 21 30 71.4 12 28.6 
HOXB8 rs2303486 T/A 7 21.9 19 59.4 6 18.8 32 33 51.6 31 48.4 5 23.8 9 42.9 7 33.3 21 19 45.2 23 54.8 
rs9340799 A/G 44 41.9 43 41.0 18 17.1 105 131 62.4 79 37.6 20 48.8 16 39.0 5 12.2 41 56 68.3 26 31.7 
ESRα 
rs2234693 T/C 26 28.6 41 45.1 24 26.4 91 89 48.9 93 51.1 6 22.2 14 51.9 7 25.9 27 26 48.1 28 51.9 
INPP-1 rs1882891 C/A 74 80.4 16 17.4 2 2.2 92 164 89.1 20 10.9 36 73.5 12 24.5 1 2.0 49 84 85.7 14 14.3 
PLCγ1 rs8192707 A/G 58 63.7 31 34.1 2 2.2 91 147 80.8 35 19.2 27 57.4 17 36.2 3 6.4 47 71 75.5 23 24.5 
ACE Alu Ins/del D/I 49 47.1 44 42.3 11 10.6 104 142 68.3 66 31.7 23 43.4 23 43.4 7 13.2 53 69 65.1 37 34.9 
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Table III.4(a). Descriptive overview of the DRD4 48bp VNTR polymorphism, indicating the 
genotype counts and frequencies in the total OCD and control populations, and stratified by 
gender. 
 
Control OCD 
Total Male Female Total Male Female Genotype 
n % n % n % n % n % n % 
A4/A4 79 52.3 18 47.4 61 54.0 34 38.2 13 30.2 21 45.7 
A4/A7 24 15.9 8 21.1 16 14.2 21 23.6 13 30.2 8 17.4 
A4/A2 15 9.9 2 5.3 13 11.5 15 16.9 5 11.6 10 21.7 
A7/A7 12 7.9 5 13.2 7 6.2 5 5.6 1 2.3 4 8.7 
A4/A3 9 6.0 2 5.3 7 6.2 9 10.1 7 16.3 2 4.3 
A2/A2 5 3.3 0 0.0 5 4.4 1 1.1 1 2.3 0 0.0 
A4/A6 2 1.3 2 5.3 0 0.0 0 0.0 0 0.0 0 0.0 
A7/A3 2 1.3 1 2.6 1 0.9 1 1.1 1 2.3 0 0.0 
A2/A3 1 0.7 0 0.0 1 0.9 0 0.0 0 0.0 0 0.0 
A3/A3 1 0.7 0 0.0 1 0.9 0 0.0 0 0.0 0 0.0 
A7/A6 1 0.7 0 0.0 1 0.9 0 0.0 0 0.0 0 0.0 
A3/A6 0 0.0 0 0.0 0 0.0 1 1.1 1 2.3 0 0.0 
A7/A2 0 0.0 0 0.0 0 0.0 2 2.2 1 2.3 1 2.2 
A2=2-repeat allele; A3=3-repeat allele A4=4-repeat allele; A6=6-repeat allele; A7=7-repeat allele.  
Abbreviations: OCD: obsessive-compulsive disorder. 
 
 
Table III.4(b). Descriptive overview of the DRD4 48bp VNTR polymorphism, indicating the 
allele counts and frequencies  in the total OCD and control populations, and stratified by 
gender. 
 
Control OCD 
Total Male Female Total Male Female Allele 
n % n % n % n % n % n % 
A4 208 68.9 50 65.8 158 69.9 113 63.5 51 59.3 62 67.4 
A7 51 16.9 19 25.0 32 14.2 34 19.1 17 19.8 17 18.5 
A2 26 8.6 2 2.6 24 10.6 19 10.7 8 9.3 11 12.0 
A3 14 4.6 3 3.9 11 4.9 11 6.2 9 10.5 2 2.2 
A6 3 1.0 2 2.6 1 0.4 1 0.6 1 1.2 0 0.0 
 
A2=2-repeat allele; A3=3-repeat allele A4=4-repeat allele; A6=6-repeat allele; A7=7-repeat allele. 
Abbreviations: OCD: obsessive-compulsive disorder. 
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III.3.2.2. DAT 40bp VNTR 
The counts and associated frequencies of the DAT 40bp VNTR genotypes and alleles in the 
control and OCD samples are presented in Tables III.5 (a) and (b), respectively. A total of 180 
controls and 110 OCD subjects were genotyped for this polymorphism. The 10-repeat allele 
(A10) was found to be the most abundant amongst both case and control individuals (with 
frequencies of 73.6% and 74.4%, respectively) (Table III.5[b]). Both case and control 
individuals were found to be in HWE for this polymorphism (p=0.07 and p=0.84, 
respectively). The overall heterozygosity at this locus was found to be 0.401.  
 
Table III.5(a). Descriptive overview of the DAT 40bp VNTR polymorphism, indicating the 
genotype counts and frequencies  in the total OCD and control populations, and stratified by 
gender. 
 
A2=2-repeat allele; A9=9-repeat allele; A10=10-repeat allele; A11=11-repeat allele. 
Abbreviations: OCD: obsessive-compulsive disorder 
 
 
Table III.5(b). Descriptive overview of the DAT 40bp VNTR polymorphism, indicating the 
allele counts and frequencies in the total OCD and control populations, and stratified by 
gender. 
 
 
A2=2-repeat allele; A9=9-repeat allele; A10=10-repeat allele; A11=11-repeat allele. 
Abbreviations: OCD: obsessive-compulsive disorder 
 
 
Control OCD 
Total Male Female Total Male Female Genotype 
n % n % n % n % n % n % 
A10/A10 106 58.9 29 63.0 77 57.5 60 54.5 32 56.1 28 52.8 
A10/A9 54 30.0 10 21.7 44 32.8 38 34.5 18 31.6 20 37.7 
A9/A9 17 9.4 6 13.0 11 8.2 8 7.3 3 5.3 5 9.4 
A10/A11 2 1.1 1 2.2 1 0.7 3 2.7 3 5.3 0 0.0 
A10/A2 0 0.0 0 0.0 0 0.0 1 0.9 1 1.8 0 0.0 
A9/A11 1 0.6 0 0.0 1 0.7 0 0.0 0 0.0 0 0.0 
Control OCD 
Total Male Female Total Male Female Genotype 
n % n % n % n % n % n % 
A10 268 74.4 69 75 199 74.3 162 73.6 86 75.4 76 71.7 
A9 89 24.7 22 23.9 67 25 54 24.5 24 21.1 30 28.3 
A11 3 0.8 1 1.1 2 0.7 3 1.4 3 2.6 0 0 
A2 0 0 0 0 0 0 1 0.5 1 0.9 0 0 
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III.3.3. Linkage Disequilibrium 
LD analyses were performed for those candidate genes for which two or more variants were 
genotyped. These genes included: 5-HT2A, DRD4, COMT, GRIN2B and BDNF and ESRα. 
Table III.6 depicts the D’ and r2 values obtained when the variants were investigated for 
pairwise LD.  
 
A high degree of LD was observed between the 5-HT2A SNPs (-1438 A/G [rs6313] and T102C 
[rs6311]) (D’= 0.861; r2= 0.737), consistent with information obtained from previous 
literature (Masellis et al., 1998). On the other hand, very little pairwise LD was observed 
between the DRD4 -521 C/T (rs1800955) and exon 3 VNTR polymorphisms (D’= 0.140; r2= 
0.028). Pairwise LD was observed between the COMT val158met (rs4680) polymorphism and 
rs362204 (D’= 0.545; r2= 0.138), but not between val158met and rs2097603, or rs362204 and 
rs2097603.  
 
The GRIN2B polymorphisms under investigation in the present study (rs1806191 and rs890) 
were found to be in strong, although not complete, LD with one another. This is to be 
expected, given the relatively short distance of 1.3kb between them (D’= 0.545; r2 = 0.285). 
For BDNF, a high degree of pairwise LD was observed between all the variants (BDNF 
rs6265, rs2049046 and rs988748) studied, consistent with results from previous studies (Hall 
et al., 2003; Sklar et al.,2002). A relatively high degree of pairwise LD was also noted 
between the two ESRα polymorphisms (rs9340799 and rs2234693) investigated (D’= 0.887; 
r2 = 0.476).  
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Table III.6. Pairwise LD values for SNPs occurring within the same gene for the whole 
dataset used in the present study. 
Gene Variant 1 Variant2 |D'| r2 
5-HT2A rs6311 rs6313 0.861 0.737 
DRD4 rs1800995 48bp VNTR 0.140 0.028 
rs2097603 rs4680 0.214 0.014 
rs4680 rs362204 0.545 0.138 COMT  
rs2097603 rs362204 0.420 0.072 
GRIN2B rs1806191 rs890 0.545 0.285 
rs6265 rs2049046 0.810 0.430 
rs6265 rs988748 0.920 0.818 BDNF  
rs2049046 rs988748 0.805 0.204 
ESRα rs9340799 rs2234693 0.887 0.476 
 
Abbreviations: 5-HT2A: serotonin receptor 2A; DRD4: dopamine receptor 4; COMT: Catechol-O-
methyltransferase; GRIN2B: glutamate receptor subunit 2B; BDNF: brain-derived neurotrophic factor; 
ESRα: estrogen receptor α. 
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III.4. CLINICAL AND GENETIC ANALYSES OF DATA 
The following sections pertain to the analysis of clinical and genetic data, stratified and 
analysed according to: 
i. gender 
ii. severity (as measured by total Y-BOCS score) 
iii. age at onset of OCD 
iv. the presence or absence of co-morbid disorders (MDD and tics) 
v. symptom dimensions (hoarding, symmetry/ordering, sexual/religious, 
contamination/washing and aggressive symptoms).  
 
Since numbers become particularly small when stratifying the dataset according to the 
selected criterion, haplotype analyses were only conducted for the case-control, severity and 
age at onset analyses. Moreover, as haplotype counts were reduced further when stratifying 
for gender, only whole group comparisons were performed for these three analyses.  
 
III.4.1. Stratification by gender 
One hundred and thirty two Afrikaner OCD subjects (71 (54%) male and 61 (46%) female) 
and 218 Afrikaner control subjects (56 (26%) male and 162 (74%) female) were utilised in the 
present study. The proportion of each gender was found to differ significantly between the 
OCD and control subgroups (p< 0.001).   
 
III.4.1.1.  Age at interview 
The median age at interview for the OCD subjects was 27 years (95% CI: 24.5-34.2), and for 
the control subjects was 36 years (95% CI: 29.5-37.9). Age at time of interview for both the 
OCD and control subjects, stratified according to gender, is represented by the box plot in 
Figure III.39. From this figure, it is evident that the distributions of the ages are skewed 
within the groups; this was confirmed by the Shapiro-Wilks test for normality. It was found 
that taking the natural logs of the ages transformed them to symmetry. The variances are, 
however, still very different, as confirmed by Bartlett’s test. Nonparametric tests were thus 
used throughout the present study. 
 
The median age for males in the control group (43 years [95% CI: 39-47]) is significantly 
higher than for any of the other three groups (p< 0.001). The median ages of the females 
differ by 3.5 years, and the difference is thus not statistically significant. There was also no 
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statistically significant difference between the median age at interview of males and females 
within the OCD subset (p = 0.091), although the males were on average slightly younger than 
the females. 
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Figure III.39. Boxplot representing distribution and means of age at interview (in years) of 
OCD and control individuals included in the present study. 
 
III.4.1.2. Clinical characteristics of males and females within the OCD sample 
The demographic and clinical characteristics, stratified by gender, of the 132 Afrikaner OCD 
patients used in the study are depicted in Table III.7. Quantitative data are represented as 
medians with 95% confidence intervals (CI), whilst categorical data are represented by counts 
and percentage of group. 
 
Total Y-BOCS scores were recorded in 129 (97.7 %) of the OCD patients; the median  
Y-BOCS score was 21 (95% CI: 19.7-22.3). No statistically significant differences in  
Y-BOCS were observed between male and female subjects (p=0.548) (Table III.7). Age at 
onset of OCD was recorded for 119 (90.2%) of the OCD subjects, with the median age at 
onset of OCD found to be 14 years (95% CI: 12-15). Although the median age at onset of 
OCD was lower in males compared to females (14 [95% CI: 12-15] and 15 [95% CI: 12-18] 
years, respectively), the difference was not significant (p = 0.182) (Table III.7).  
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Table III.7.  Demographic and clinical characteristics of male and female OCD subjects 
included in the present study. 
 
  Male Female  Clinical 
Characteristic n % median 95% CI median 95% CI p-value 
Age at interview 131 99.2 27 24-30 32 27-36 0.091 
Y-BOCS score 129 97.7 20 18-22 21 19-23 0.548 
Age of OCD onset 119 90.2 14 12-15 15 12-18 0.182 
Family history na % n % n % p-value 
Family history of OCD 20 25.0 11 25.6 9 24.3 0.897 
Family history of OCS 37 46.3 23 53.5 14 37.8 0.235 
Family history of tics 6 7.5 3 7.0 3 8.1 0.848 
Primary symptom 
dimensions n
b % n % n % p-value 
Hoarding/collecting 23 25.3 7 16.7 16 32.7 0.091 
Symmetry/ordering 53 58.2 26 61.9 27 55.1 0.530 
Sex/religion 38 41.8 24 57.1 14 28.6 0.010 
Contamination/washing 55 60.4 26 61.9 29 59.2 0.830 
Aggression 46 50.5 20 47.6 26 53.1 0.670 
Miscellaneous 56 61.5 26 61.9 30 61.2 1.000 
Comorbidity nc % n % n % p-value 
MDD 82 64.6 42 61.8 40 67.8 0.580 
SIB 24 18.9 12 17.6 12 20.3 0.820 
Dysthymia 20 15.7 12 17.6 8 13.6 0.630 
Tics 18 14.2 13 19.1 5 8.5 0.126 
Specific phobia 18 14.2 5 7.4 13 22.0 0.022 
GAD 16 12.6 8 11.8 8 13.6 0.800 
PD 13 10.2 4 5.9 9 15.3 0.140 
Social phobia 13 10.2 6 8.8 7 11.9 0.770 
TTM 12 9.4 4 5.9 8 13.6 0.220 
IED 12 9.4 6 8.8 6 10.2 1.000 
BDD 10 7.9 6 8.8 4 6.8 0.750 
TS 7 5.5 4 5.9 3 5.1 1.000 
Anorexia 5 3.9 0 0.0 5 8.5 0.020 
Hypochondriasis 5 3.9 3 4.4 2 3.4 1.000 
 
a(n=80: male=43, female=37 ) b(n=91: male=42, female=49) c(n=127: male=68, female=59) 
Abbreviations: 95% CI: 95% confidence intervals; Y-BOCS: Yale-Brown Obsessive-Compulsive Score; OCD: Obsessive-
compulsive disorder; OCS: obsessive-compulsive symptoms; MDD: major depressive disorder; SIB: self-injurious behaviour; 
GAD: generalised anxiety disorder; PD: panic disorder; TTM: Trichotillomania; IED: intermittent explosive disorder; BDD: body 
dysmorphic disorder; TS: Tourette Syndrome.  
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When the family history of OCD and OCS were considered, no significant differences were 
noted between male and female OCD patients (p = 0.897 and p = 0.235, respectively). 
Likewise, no significant differences in family history of tics was observed between male and 
female patients (p = 0.848) (Table III.7).  
 
Data on primary symptoms are available for 91 patients, 49 female and 42 male (Table III.7). 
It is interesting to note that contamination and washing represents the major primary symptom 
subtype, with 60.4% of the patients exhibiting this symptom with no significant difference 
between the genders (p = 0.830) (Figure III.40). However, significantly more males were 
found to suffer from sexual/ religious symptoms (57.1% of the male OCD subset compared to 
28.6% of the female OCD sample; p = 0.010). No other statistically significant differences 
were observed when the remaining symptom subtypes were stratified according to gender 
(Table III.7 and Figure III.40). 
 
Table III.7 and Figure III.41 indicate the proportions of males and females presenting with 
selected co-morbid disorders. The most common co-morbid disorder observed amongst the 
OCD subjects was major depressive disorder (MDD), diagnosed in 82 (64.6%) of the patients, 
with no difference in lifetime prevalence observed between males and females (61.8% and 
67.8% in the male and female subsets, respectively; p = 0.580). When lifetime prevalence of 
other selected co-morbid disorders was compared between male and female OCD subjects, a 
significantly greater number of females were found to suffer from co-morbid specific phobia 
(7.4% versus 22.0%, for the male and female OCD subsets, respectively; p = 0.022) and 
anorexia nervosa (0% and 8.5%, for male and female subsets, respectively; p = 0.020). 
 
III.4.1.3. Single locus case-control genetic association analysis 
 
III.4.1.3.1. Single locus analysis of bi-allelic polymorphisms 
The results of the single locus case-control genetic association analyses for bi-allelic data in 
the whole sample are depicted in Table III.8. Tables III.9 and III.10 represent the separate 
statistical analyses for bi-allelic loci for males and females, respectively. When the genotype 
frequencies were compared between the case and control subjects, a statistically significant 
difference was noted in the distribution of the ACE Alu Ins/del genotype (p = 0.037; OR = 
0.38 [95% CI: 0.16-0.91]) (Table III.8), with the DD- and DI-genotypes over-represented in 
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the control sample (Table III.3[b]). However, when the distribution of the allele frequencies 
was compared between the case and control individuals, no significant difference was 
observed (p = 0.057; OR = 0.69 [95% CI: 0.47-1.10]) (Table III.8), indicating that the genetic 
model involved in conferring protection to OCD may be dominant.  
 
Interestingly, when the dataset was stratified according to gender, the association with ACE 
was maintained when genotype distribution of the Alu ins/del polymorphism was compared 
between male OCD subjects and controls (p = 0.020; OR = 0.10 [95% CI: 0.00-0.83]). A 
nominally significant association was observed when ACE allele distribution was compared 
between male OCD and control subjects (p = 0.049; OR = 0.49 [95% CI: 0.23-1.00]) (Table 
III.9), with the D-allele once again representing the protective allele. However, neither 
genotypic nor allelic association was observed in the female subset (p = 0.814 and p = 0.612, 
respectively) (Table III.10). 
 
Comparing the allelic frequencies of the 5-HT2C cys23ser (rs6318) polymorphism, statistically 
significant differences were observed between male OCD and control subjects (p<0.001; 
OR=0.10 [95% CI: 0.01-0.44]), indicating that the G-allele (forming part of the codon that 
encodes cys23) represents the protective allele (Table III.9). No statistically significant 
differences were observed when the same SNP was investigated in the female population 
(Table III.10).  
 
Further significant differences between male OCD and control subjects were observed with 
regard to the COMT rs362204 and BDNF val66met (rs6265) allelic distributions (p=0.040 and 
p=0.036, respectively). For the COMT rs362204 polymorphism, the resultant allelic OR of 
2.88 (95% CI: 1.03-8.70) indicates that the allele characterised by the deletion of a cytosine 
base (denoted as the D-allele in the present study) increases the risk of developing the 
disorder, compared to the C-insertion allele (denoted as the I-allele in the present study). 
When the genotypic distribution of the variant was considered, the OCD subjects presented 
with a higher frequency of DD-genotypes compared to controls;  although this difference 
represented only a trend towards association (p = 0.071 [Table III.9]), it supports the notion 
that the D-allele may represent a risk factor in the development of OCD. 
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Figure III.40. Bar graph indicating the proportions of male and female OCD subjects 
experiencing certain obsessions and/or compulsions. 
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Figure III.41. Bar graph indicating the proportions of male and female OCD subjects 
presenting with selected co-morbid disorders. 
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Abbreviations: MDD: major depressive disorder; SIB: self-injurious behaviour; GAD: generalised anxiety disorder; PD: panic 
disorder; TTM: Trichotillomania; IED: intermittent explosive disorder; BDD: body dysmorphic disorder; TS: Tourette 
Syndrome.  
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Table III.8. Association analysis investigating the differences in genotype and allele 
distributions between OCD and control individuals in bi-allelic loci, with p-values, OR’s, 
95% CIs and corresponding post-test power. 
 
 
Significant p-values are indicated in red, bold font. 
an1 refers to the major allele, n2 refers to the minor allele bgenotypic OR is calculated with the major genotype representing the risk 
genotype; callelic OR is calculated assuming the major allele to be the risk allele;dlower boundary of the 95% CI; eUpper boundary of the 
95% CI; fMale and female subsets were analysed separately (dashes indicate that the variant was not analysed in the whole population). 
Abbreviations: OR: Odds ratio; CI: confidence interval; 5-HT2A: serotonin receptor 2A; 5-HT1Dβ: serotonin receptor 1Dβ; 5-HT6: 
serotonin receptor 6; 5-HT2C: serotonin receptor 2C; DRD4: dopamine receptor 4; DRD2: dopamine receptor 2; COMT: Catechol-O-
methyltransferase; DRD3: dopamine receptor 3; DRD1: dopamine receptor 1; GRIN2B: glutamate receptor subunit 2B; BDNF: brain-
derived neurotrophic factor; HOXB8: homeobox gene B8;  ESRα: estrogen receptor α; INPP-1: inositol polyphosphate-phosphatase 1; 
PLC-γ1: phospholipase-gamma; ACE: Angiotensin-converting enzyme. 
Genotype Allele  
95% CI 95% CI   
Gene 
  
  
Variant 
  
  
n1/n2a 
  
p-
value OR
b 
LBd UBe 
Power p-value OR
c 
LBd UBe 
Power 
rs6311 G/A 0.985 1.04 0.48 2.28 0.051 0.927 1.03 0.71 1.50 0.050 
5-HT2A 
rs6313 C/T 0.686 0.85 0.41 1.79 0.060 0.858 0.96 0.66 1.38 0.053 
5-HT1Dß rs6296 G/C 0.738 0.79 0.27 2.41 0.060 0.480 0.87 0.57 1.31 0.098 
5-HT6 rs1805054 C/T 0.289 0.64 0.05 9.10 0.050 0.170 0.68 0.38 1.19 0.259 
5-HT2Cf rs6318 G/C - - - - - - - - - - 
DRD4 rs1800955 T/C 0.479 1.61 0.69 3.88 0.170 0.250 1.26 0.85 1.87 0.194 
DRD2 rs1800497 C/T 0.769 1.37 0.42 4.82 0.060 0.916 1.05 0.68 1.55 0.051 
rs2097603 A/G 0.275 0.49 0.16 1.30 0.290 0.116 0.67 0.40 1.10 0.348 
rs4680 G/A 0.372 1.72 0.70 4.19 0.190 0.249 1.26 0.85 1.90 0.193 COMT 
rs362204 D/I 0.164 3.80 0.76 38.86 0.310 0.074 1.64 0.95 2.88 0.409 
DRD3 rs6280 A/G 0.173 1.58 0.65 3.94 0.150 0.101 1.43 0.93 2.20 0.368 
DRD1 A-48G A/G 0.792 1.33 0.50 3.62 0.070 0.562 1.13 0.76 1.69 0.083 
rs1806191 G/A 0.373 1.76 0.45 6.89 0.082 0.252 1.40 0.76 2.56 0.137 
GRIN2B 
rs890 A/C 0.548 1.49 0.37 6.03 0.059 0.569 1.19 0.65 2.16 0.066 
rs6265 G/A 0.237 0.25 0.02 1.47 0.290 0.421 0.82 0.51 1.31 0.121 
rs2049046 A/T 0.420 0.50 0.15 1.64 0.180 0.229 0.72 0.41 1.25 0.200 BDNF 
rs988748 C/G 0.350 0.33 0.01 6.60 0.060 0.194 0.65 0.32 1.28 0.224 
HOXB8 rs2303486 T/A 0.159 2.08 0.55 8.10 0.160 0.183 1.52 0.81 2.84 0.242 
rs9340799 A/G 0.785 1.32 0.54 3.37 0.070 0.471 1.17 0.76 1.80 0.100 
ESRα 
rs2234693 T/C 0.807 1.29 0.50 3.34 0.070 0.578 1.14 0.72 1.81 0.075 
INPP-1 rs1882891 C/A 1.000 1.46 0.08 87.52 0.059 0.559 0.82 0.45 1.52 0.083 
PLC-γ1 rs8192707 A/G 0.596 0.61 0.12 2.97 0.070 0.722 0.92 0.56 1.51 0.057 
ACE Alu ins/del D/I 0.037 0.38 0.16 0.91 0.600 0.057 0.69 0.47 1.02 0.465 
 205
The allelic OR for the BDNF val66met SNP was 0.41 (95% CI: 0.15-0.99), indicating that, in 
the male population, the G-allele (encoding for part of the val66 codon) represents the 
protective allele. When the genotypic distribution of BDNF val66met was considered, a 
greater number of OCD patients carrying at least one A-allele was observed compared to 
controls, although this represented only a trend towards significant association (p = 0.059) 
(Table III.9). 
 
No statistically significant differences were observed when the genotype and allele 
frequencies of the female OCD and control subjects were compared (Table III.10).  
 
III.4.1.3.2. Single locus analysis of multi-allelic loci 
 
i. DRD4 48bp VNTR 
No statistically significant differences were observed when the distribution of DRD4 48bp 
VNTR genotypes and alleles were compared between OCD subjects and controls (p = 0.059 
and p = 0.679, respectively). Likewise, when the sample was stratified according to gender, 
no statistically significant differences in genotype or allele distributions were observed in 
either the male (p = 0.104 and p = 0.082, respectively) or the female (p = 0.595 and p = 0.721, 
respectively) (genotype and allele scores for the DRD4 48bp VNTR are provided in Tables 
III.4[a] and 4[b]) 
 
ii. DAT 40bp VNTR 
When the genotype and allele distributions of the DAT 40bp VNTR were compared between 
the entire OCD and control samples, no statistically significant differences were observed (p = 
0.584 and p = 0.711, respectively). Moreover, when the sample was stratified according to 
gender, no significant differences were noted in genotype or allele distributions in the male (p 
= 0.512 and p = 0.649, respectively) or female (p = 0.934 and p = 0.768, respectively) subsets 
(genotype and allele scores for the DAT 40bp VNTR are provided in Tables III.5[a] and [b]). 
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Table III.9. Association analysis investigating the differences in genotype and allele 
distributions between male OCD and control individuals in bi-allelic loci, with p-values, 
OR’s, 95% CIs and corresponding post-test power. 
 
 
 
Significant p-values are indicated in red, bold font. 
an1 refers to the major allele, n2 refers to the minor allele bgenotypic OR is calculated with the major genotype representing the risk genotype; 
callelic OR is calculated assuming the major allele to be the risk allele;dlower boundary of the 95% CI; eUpper boundary of the 95% CI; fdue to 
hemizygosity at the 5-HT2C locus, only allele frequencies were compared. 
Abbreviations: OR: Odds ratio; CI: confidence interval; 5-HT2A: serotonin receptor 2A; 5-HT1Dβ: serotonin receptor 1Dβ; 5-HT6: serotonin 
receptor 6; 5-HT2C: serotonin receptor 2C; DRD4: dopamine receptor 4; DRD2: dopamine receptor 2; COMT: Catechol-O-methyltransferase; 
DRD3: dopamine receptor 3; DRD1: dopamine receptor 1; GRIN2B: glutamate receptor subunit 2B; BDNF: brain-derivedneurotrophic 
factor; HOXB8: homeobox gene B8;  ESRα: estrogen receptor α; INPP-1: inositol polyphosphate-phosphatase 1; PLC-γ1: phospholipase-
gamma; ACE: Angiotensin-converting enzyme. 
Genotype Allele 
95% CI 95% CI Gene Variant n1/n2a p-
value OR
b 
LBd UBe 
Power p-value OR
c 
LBd UBe 
Power 
rs6311 G/A 0.802 1.53 0.35 6.48 0.06 0.519 1.27 0.64 2.49 0.09 
5-HT2A 
rs6313 C/T 0.332 1.11 0.27 4.28 0.05 0.546 1.21 0.64 2.29 0.08 
5-HT1Dß rs6296 G/C 0.564 0.35 0.01 3.77 0.08 0.857 0.90 0.41 1.95 0.05 
5-HT6 rs1805054 C/T 1.000 0.10 0.00 0.78 0.06 0.822 0.83 0.29 2.20 0.05 
5-HT2Cf rs6318 G/C - <0.001 0.10 0.01 0.44 0.92 
DRD4 rs1800955 T/C 0.672 0.62 0.11 3.04 0.06 0.408 0.74 0.36 1.51 0.11 
DRD2 rs1800497 C/T 0.263 3.03 0.44 23.98 0.16 0.140 1.79 0.83 3.89 0.30 
rs2097603 A/G 0.660 0.85 0.09 6.86 0.06 1.000 0.94 0.35 2.53 0.05 
rs4680 G/A 0.183 0.32 0.05 1.59 0.25 0.113 0.59 0.30 1.17 0.31 COMT 
rs362204 D/I 0.071 9.12 0.39 212.66 0.18 0.040 2.88 1.03 8.70 0.52 
DRD3 rs6280 A/G 0.072 0.66 0.06 4.13 0.05 0.701 1.23 0.54 2.75 0.06 
DRD1 A-48G A/G 0.669 0.46 0.01 5.50 0.05 1.000 1.00 0.49 2.03 0.05 
rs1806191 G/A 0.538 3.07 0.16 61.74 0.06 0.435 1.60 0.51 5.04 0.08 
GRIN2B 
rs890 A/C 0.569 0.26 0.00 4.40 0.08 0.439 0.59 0.18 1.83 0.10 
rs6265 G/A 0.059 0.12 0.01 2.26 0.29 0.036 0.41 0.15 0.99 0.49 
rs2049046 A/T 0.918 0.70 0.08 5.28 0.05 0.817 0.81 0.29 2.21 0.06 BDNF 
rs988748 C/G 0.435 0.60 0.03 14.52 0.07 0.601 1.33 0.41 4.14 0.08 
HOXB8 rs2303486 T/A 0.516 3.38 0.29 52.57 0.11 0.251 2.12 0.60 7.81 0.18 
rs9340799 A/G 1.000 0.98 0.17 5.11 0.06 1.000 1.02 0.47 2.18 0.05 
ESRα 
rs2234693 T/C 0.694 1.82 0.34 10.08 0.08 0.448 1.39 0.62 3.15 0.11 
INPP-1 rs1882891 C/A 1.000 1.73 0.03 90.61 0.05 1.000 1.02 0.32 3.04 0.06 
PLC-γ1 rs8192707 A/G 0.777 1.91 0.13 28.74 0.05 0.530 1.33 0.54 3.23 0.08 
ACE Alu ins/del D/I 0.020 0.10 0.00 0.83 0.56 0.049 0.49 0.23 1.01 0.49 
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Table III.10. Association analysis investigating the differences in genotype and allele 
distributions between female OCD and control individuals in bi-allelic loci, with p-values, 
OR’s, 95% CIs and corresponding post-test power. 
 
 an1 refers to the major allele, n2 refers to the minor allele bgenotypic OR is calculated with the major genotype representing the risk 
genotype; callelic OR is calculated assuming the major allele to be the risk allele;dlower boundary of the 95% CI; eUpper boundary of the 
95% CI. 
 Abbreviations: OR: Odds ratio; CI: confidence interval; 5-HT2A: serotonin receptor 2A; 5-HT1Dβ: serotonin receptor 1Dβ; 5-HT6: 
serotonin receptor 6; 5-HT2C: serotonin receptor 2C; DRD4: dopamine receptor 4; DRD2: dopamine receptor 2; COMT: Catechol-O-
methyltransferase; DRD3: dopamine receptor 3; DRD1: dopamine receptor 1; GRIN2B: glutamate receptor subunit 2B; BDNF: brain-
derivedneurotrophic factor; HOXB8: homeobox gene B8;  ESRα: estrogen receptor α; INPP-1: inositol polyphosphate-phosphatase 1; 
PLC-γ1: phospholipase-gamma; ACE: Angiotensin-converting enzyme. 
Genotype Allele 
95% CI 95% CI Gene Variant n1/n2a p-
value OR
b 
LBd UBe 
Power p-value OR
c 
LBd UBe 
Power 
rs6311 G/A 0.685 0.70 0.25 2.00 0.08 0.471 0.82 0.50 1.35 0.11 
5-HT2A 
rs6313 C/T 0.694 0.70 0.26 1.92 0.09 0.406 0.81 0.50 1.33 0.12 
5-HT1Dß rs6296 G/C 0.191 0.76 0.19 3.68 0.05 0.193 0.71 0.42 1.21 0.23 
5-HT6 rs1805054 C/T 0.378 1.15 0.30 5.45 0.05 0.264 0.65 0.30 1.42 0.17 
5-HT2C rs6318 G/C 1.000 0.47 0.01 37.43 0.06 0.888 1.09 0.60 2.00 0.05 
DRD4 rs1800955 T/C 0.228 2.35 0.75 8.03 0.28 0.102 1.53 0.90 2.61 0.34 
DRD2 rs1800497 C/T 0.598 0.94 0.18 6.19 0.06 0.492 0.83 0.47 1.47 0.09 
rs2097603 A/G 0.207 0.36 0.09 1.34 0.31 0.090 0.57 0.30 1.09 0.39 
rs4680 G/A 0.672 1.64 0.49 5.85 0.10 0.447 1.24 0.73 2.11 0.11 COMT 
rs362204 D/I 0.824 1.89 0.33 20.08 0.07 0.630 1.20 0.60 2.43 0.07 
DRD3 rs6280 A/G 0.326 2.48 0.69 11.35 0.24 0.151 1.49 0.86 2.64 0.27 
DRD1 A-48G A/G 0.869 1.34 0.44 4.51 0.06 0.613 1.16 0.69 1.99 0.08 
rs1806191 G/A 1.000 1.32 0.19 8.53 0.05 0.541 1.34 0.56 3.25 0.07 
GRIN2B 
rs890 A/C 0.656 2.03 0.26 18.44 0.06 0.532 1.40 0.57 3.43 0.08 
rs6265 G/A 0.717 1.14 0.06 69.06 0.08 0.439 1.31 0.67 2.65 0.10 
rs2049046 A/T 0.401 0.36 0.06 1.99 0.17 0.203 0.61 0.28 1.34 0.21 BDNF 
rs988748 C/G 0.62 0.85 0.03 22.63 0.40 0.054 0.43 0.17 1.03 0.52 
HOXB8 rs2303486 T/A 0.526 1.38 0.21 9.33 0.05 0.688 1.21 0.51 2.90 0.06 
rs9340799 A/G 0.706 1.63 0.49 6.41 0.09 0.416 1.30 0.73 2.34 0.13 
ESRα 
rs2234693 T/C 0.816 0.79 0.19 3.21 0.05 0.758 0.89 0.46 1.71 0.06 
INPP-1 rs1882891 C/A 0.672 0.97 0.05 58.96 0.09 0.444 0.73 0.33 1.65 0.10 
PLCγ1 rs8192707 A/G 0.431 0.31 0.02 2.92 0.13 0.350 0.74 0.39 1.41 0.14 
ACE Alu ins/del D/I 0.814 0.74 0.23 2.56 0.06 0.612 0.87 0.51 1.47 0.07 
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III.4.1.4. Haplotype analyses  
 
III.4.1.4.1. 5-HT2A haplotype analysis 
Investigating the frequencies of the haplotypes at the 5-HT2A locus (Table III.11), it was found 
that the G-allele from the promoter SNP (-1438 A/G, or rs6311) and the C-allele from the 
SNP in exon 2 (T102C, or rs6313) almost always appear together, comprising more than 50% 
of the total haplotypes observed in the combined Afrikaner OCD and control populations. The 
haplotype A-T represents the second most common haplotype in the population, with G-T and 
A-C haplotypes representing roughly equivalent proportions in the total population. No 
statistically significant differences were observed when either the individual haplotype 
frequencies were compared between OCD and control subjects (represented by the 
corresponding individual p-values in Table III.11) or when the haplotypes were compared 
globally between the case and control individuals (p = 0.778). 
 
III.4.1.4.2. DRD4 haplotype analysis 
Ten haplotypes were observed in the present study, but only the haplotypes with a frequencies 
of >1% are presented in Table III.12. Only weakly significant differences in the overall 
haplotype distribution was observed between OCD subjects and controls (global p = 0.08). 
However, when the individual haplotypes were analysed, significantly more controls were 
found to carry the C-A4 haplotype compared to cases (individual p = 0.049) (Table III.12). 
Moreover, a significantly increased number of T-A2 haplotypes were observed in the OCD, 
compared to control population (individual p = 0.026).  
 
III.4.1.4.3. COMT haplotype analysis 
When the global test for association was considered, no statistically significant differences 
between OCD and control subjects were observed (p = 0.355). Likewise, no statistically 
significant differences in individual haplotype frequencies between OCD and control subjects 
(Table III.13). 
III.4.1.4.4. GRIN2B haplotype analysis 
When the variants were investigated as a haplotype, no statistically significant differences in 
haplotype frequencies were observed between case and control subjects (global p = 0.324) 
(Table III.14). 
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III.4.1.4.5. BDNF haplotype analysis 
The limited degree of haplotypic diversity indicates a high degree of LD between the SNPs 
investigated in the present study In the present study, the first three haplotypes, indicated in 
Table III.15, accounted for 97% of the observed haplotypes.  No statistically significant 
differences in haplotype frequencies were observed between the OCD and control 
populations, with a global p-value equivalent to 0.487. 
III.4.1.4.6. ESRα haplotype analysis 
Linkage disequilibrium was observed between rs2234693 and rs9340779 (D’= 0.911, r2 = 
0.492, p<0.0001), with the first three haplotypes comprising approximately 98% of those 
observed in the entire population. However, no statistically significant differences were noted 
when the haplotype frequencies were compared between OCD and control populations (global 
p = 0.599) (Table III.16). 
Table III.11.Haplotype distribution of 5-HT2A SNPs -1438 A/G (rs6311) and T102C (rs6311) 
in OCD and control individuals. 
Variant Haplotype Frequencies 
rs6311 rs6313 Control (n= 145) OCD (n= 104) Total (n= 249) 
Haplotype 
Score 
Individual 
p-value 
G C 0.575 0.601 0.586 0.563 0.520 
A T 0.350 0.346 0.349 -0.092 0.914 
G T 0.037 0.029 0.034 -0.502 0.601 
A C 0.037 0.024 0.032 -0.803 0.453 
Global p= 0.778 
Abbreviations: OCD: obsessive-compulsive disorder. 
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Table III.12. Haplotype distribution of DRD4 polymorphisms the SNP in the promoter region 
(-521C/T [rs1800955]) and the 48bp VNTR in OCD and control individuals. 
Variant Haplotype Frequencies 
Control OCD Total 
rs1800955 
48bp 
VNTR (n= 124) (n=70) (n= 194) 
Haplotype 
Score 
Individual p-
value 
T A4 0.357 0.385 0.359 0.03 0.974 
C A4 0.329 0.207 0.293 -2.03 0.049 
T A7 0.136 0.123 0.137 0.29 0.791 
C A7 0.045 0.105 0.062 1.55 0.134 
C A2 0.043 0.057 0.047 0.66 0.536 
T A2 0.030 0.072 0.046 2.16 0.026 
C A3 0.034 0.037 0.034 -0.05 0.968 
T A3 0.014 0.013 0.015 0.26 0.845 
Global p=0.08 
Abbreviations: OCD: Obsessive-compulsive disorder; VNTR: variable number of tandem repeats polymorphism; A4: 4-repeat 
allele of DRD4 48bp VNTR; A7: 7-repeat allele of DRD4 48bp VNTR; A2: 2-repeat allele of DRD4 48bp VNTR. 
 
 
Table III.13. Haplotype distribution of the COMT promoter (rs2097603), val158met 
(rs4680)and rs362204 polymorphisms  in OCD and control individuals. 
 
Variant 
  Haplotype Frequencies 
rs2097603 rs4680 rs362204 Control (n= 48) 
OCD 
(n= 31) 
Total 
 (n=79) 
Haplotype 
Score 
Individual p-
value 
G A D 0.230 0.328 0.259 1.977 0.054 
A G I 0.233 0.154 0.200 -1.451 0.131 
A A D 0.124 0.203 0.163 0.995 0.346 
A G D 0.196 0.093 0.151 -1.57 0.116 
G G D 0.096 0.118 0.111 0.224 0.841 
G G I 0.048 0.038 0.044 -0.223 0.843 
A A I 0.051 0.018 0.037 -0.626 0.557 
G A I 0.023 0.048 0.036 0.720 0.481 
Global p=0.355 
Haplotypes with a frequency of <0.03 are not indicated. 
Abbreviations: OCD: obsessive-compulsive disorder. 
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Table III.14. Haplotype distribution of GRIN2B SNPs rs1806191 and rs890 in OCD and 
control individuals. 
 
Variant 
 Haplotype Frequencies 
Control OCD Total 
rs1806191 rs890 
(n= 40) (n= 55) (n= 95) 
Haplotype 
Score 
Individual p-
value 
G A 0.468 0.467 0.466 0.290 0.786 
A C 0.362 0.261 0.306 -1.365 0.169 
G C 0.080 0.148 0.118 1.314 0.187 
A A 0.091 0.124 0.110 0.458 0.650 
Global p=0.324 
Abbreviations: OCD: obsessive-compulsive disorder. 
 
Table III.15. Haplotype distribution of BDNF SNPs rs6265, rs2049046 and rs988748 in 
OCD and control individuals. 
Global p=0.487 
 Abbreviations: OCD: obsessive-compulsive disorder. 
 
 
 
 
Table III.16. Haplotype distribution of the ESRα SNPs, rs93407999 and rs2234693 in 
OCD and control individuals. 
 
 
Global p=0.599 
Abbreviations: OCD: obsessive-compulsive disorder. 
 
 
 
 
 
Variant 
  Haplotype Frequencies 
rs6256 rs2049046 rs988748 Control (n=37) 
OCD 
(n=36) Total (n=72) 
Haplotype 
Score 
Individual 
p-value 
G A C 0.527 0.458 0.493 -0.848 0.320 
G T C 0.284 0.250 0.267 -0.449 0.677 
A T G 0.162 0.250 0.205 1.378 0.156 
Variant 
 Haplotype Frequencies 
Control OCD Total 
rs9340799 rs2234693 
(n= 110) (n= 56) (n= 166) 
Haplotype Score Individual p-value 
A T 0.500 0.518 0.506 0.299 0.747 
G C 0.350 0.339 0.346 -0.186 0.897 
A C 0.132 0.134 0.133 0.055 1.000 
 212
III.4.2. Stratification by symptom severity (total Y-BOCS score)  
III.4.2.1. Analysis of clinical variables 
The relationships between selected clinical variables with symptom severity, as represented 
by total Y-BOCS, are presented in Table III.17. No statistically significant differences in total 
Y-BOCS score were noted for OCD patients with or without family history of OCD (p = 
0.084), OCS (p = 0.694) or tics (p = 0.604). Those OCD patients experiencing aggressive 
obsessions and compulsions were found to have lower total Y-BOCS scores compared to 
those who did not experience aggressive symptoms (median Y-BOCS scores = 18 [95% CI: 
15.7-20.3] and 22.5 [95% CI: 20.5-24.5], respectively; p = 0.050). 
When the presence or absence of co-morbid disorders was investigated with regard to total Y-
BOCS score (Table III.17) statistically significant differences were observed for self-injurious 
behaviour (p = 0.005), specific phobia (p = 0.018) and anorexia nervosa (p = 0.012). For all 
three of these disorders, the presence of the co-morbid disorder was associated with a higher 
total Y-BOCS score (24 [95% CI: 22.3-25.7] vs. 19.5 [95% CI: 17.8-21.2] for the presence 
and absence of co-morbid SIB, respectively; 23.5 [95% CI: 19.4-27.6] vs. 20.5 [95% CI: 
19.0-22.0] for the presence and absence of co-morbid social phobia, respectively and 28 [95% 
CI: 21.0-35.1] vs. 21[95% CI: 19.6-22.5] for the presence and absence of co-morbid anorexia 
nervosa, respectively).  Due to low numbers, the sample was not stratified, or analysed, 
according to gender for clinical analyses. 
  
III.4.2.2. Single locus analysis of clinical severity 
III.4.2.2.1. Single locus analysis of bi-allelic polymorphisms 
The results from the Wilcoxon test for differences in medians, employed to determine 
whether genotype or allele distribution influenced Y-BOCS score, are presented in Tables 
III.18[a] to [d]. Significant differences in the distribution of Y-BOCS scores between the 
genotypes of the DRD1 SNP, A-48G, were noted in male OCD subjects (p = 0.045) (Table 
III.18[b]). Males homozygous for the G-allele exhibited higher total Y-BOCS scores (median 
Y-BOCS score = 27.5 [95% CI: 22.4-32.6]) than those who were either heterozygous or 
homozygous for the A-allele (18.5 [95% CI: 15.4-21.6] and 18 [95% CI: 13.4-22.6], 
respectively) (Table III.18[b]). 
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Similarly, the CC-genotype of the GRIN2B rs890 was found to be associated with an 
increased severity of the disorder, as indicated by the higher total Y-BOCS score (median Y-
BOCS score = 26 [95% CI: 20.1-31.9]) (Table III.18[c]). When the sample was stratified 
according to gender, both male and female individuals carrying the CC-genotype attained 
higher Y-BOCS scores compared to individuals homozygous for the A-allele or heterozygous 
individuals, although these differences did not reach statistical significance (p = 0.118 and 
p=0.053 for males and females, respectively).  
 
In the female OCD subset, a nominally statistically significant difference was found in the 
distribution of total Y-BOCS scores amongst genotypes comprising the BDNF val66met 
(rs6265) polymorphism (p = 0.045) (Table III.18[c]). Since no conclusions could be drawn 
about the AA (met66met)-genotype and OCD severity (only one female subject was found to 
carry this genotype), the AA-carrying female was grouped with the heterozygous females. 
When the median Y-BOCS scores of the AA+AG combined group was compared to 
GG(val66val)-carrying females, those homozygous for the G-allele had significantly higher 
Y-BOCS scores (median Y-BOCS scores=23 [95% CI: 21-25] and 16 [95% CI: 11.7-21], 
respectively; p=0.013). No similar association was noted in the male OCD subset (p=0.677). 
 
III.4.2.2.2. Single locus analysis of multi-allelic polymorphisms 
 
i. DRD4 
Due to the large number of DRD4 48bp VNTR genotypes observed in the present study, it 
was decided to group them according to the presence or absence of at least one A4-allele, as 
suggested by Wang et al. (2004) (section I.6.1.2.1[i]) (Table III.19). No statistically 
significant differences in median Y-BOCS scores were observed when the total OCD 
population was investigated (p=0.851), or when the data was stratified into male (p=0.273) 
and female (p=0.335) subsets. 
 
 ii. DAT 
No statistically significant differences were observed in median Y-BOCS scores between the 
genotypes comprising the DAT 40bp VNTR in the total OCD population (p=0.207), or in the 
gender-stratified subsets (p=0.340 for males, p=0.142 for females) (Table III.20).  
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Table III.17. Clinical variables in the OCD patient subset according to symptom severity 
(as measured by total Y-BOCS score). 
 
 
 
Significant p-values are indicated in red, bold font. 
Abbreviations: OCD: Obsessive-compulsive disorder; OCS: Obsessive-compuslive symptoms; MDD: major depressive disorder; 
SIB: self-injurious behaviour; GAD: generalised anxiety disorder; PD: panic disorder; TTM: Trichotillomania; IED: intermittent 
explosive disorder; BDD: body dysmorphic disorder; TS: Tourette Syndrome; CI: confidence interval.
Clinical Variable Present Absent 
Family History n % Median 95% CI n % Median 95% CI 
p-
value 
Family history of OCD 19 24.0 23.0 21.0-25.0 60 76.0 18.0 16.0-20.0 0.084 
Family history of OCS 36 47.0 21.0 18.6-23.4 41 53.0 21.0 16.8-21.2 0.694 
Family history of tics  6 7.6 21.0 15.9-21.1 73 92.0 19.0 19.2-22.8 0.604 
Primary symptom 
dimensions           
Hoarding/collecting 22 25.0 22.0 19.7-24.3 67 75.0 21.0 19.2-22.8 0.394 
Symmetry/ordering 53 59.0 23.0 21.0-25.0 37 41.0 19.0 16.9-21.1 0.156 
Sex /religion 37 42.0 21.0 18.4-23.6 52 58.0 22.0 19.3-23.7 0.266 
Contamination/washing  54 60.0 22.0 20.3-23.7 36 40.0 19.0 15.8-22.2 0.123 
Aggressive symptoms 45 51.0 18.0 15.7-20.3 44 49.0 22.5 20.5-24.5 0.050 
Co-morbidity          
MDD 79 63.0 22.0 20.2-23.8 46 37.0 20.0 17.9-22.1 0.515 
SIB  22 18.0 24.0 22.3-25.7 103 82.0 19.5 17.8-21.2 0.005 
Dysthymic disorder  20 16.0 23.5 20.5-26.5 105 84.0 21.0 19.5-22.5 0.289 
Tics  17 14.0 18.0 14.9-21.1 108 86.0 22.0 20.4-23.6 0.476 
Specific phobia 18 14.0 23.5 19.4-27.6 107 86.0 20.5 19.0-22.0 0.018 
GAD 14 11.2 21.0 19.6-22.4 111 88.8 23.0 17.5-28.5 0.707 
PD 13 10.0 22.0 15.4-28.6 112 90.0 21.0 19.6-22.3 0.313 
Social Phobia  11 8.8 23.0 20.6-25.4 114 91.0 21.0 19.5-22.5 0.225 
TTM  12 9.6 22.5 16.1-28.9 113 90.0 21.0 19.7-22.3 0.472 
IED  11 8.8 21.0 13.8-28.2 114 91.0 21.0 19.7-22.3 0.628 
BDD  10 8.0 24.5 21.5-27.5 115 92.0 21.0 19.7-22.3 0.266 
TS  7 5.6 22.0 18.1-25.9 118 94.0 21.0 19.5-22.5 0.591 
Anorexia nervosa  5 4.0 28.0 21.0-35.1 120 96.0 21.0 19.6-22.5 0.012 
Hypochondriasis  4 3.2 13.5 5.6-21.4 121 97.0 21.0 19.7-22.3 0.340 
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Table III.18 (a). Quantitative analyses indicating the relationship between total Y-BOCS score and genotype in serotonergic candidate 
genes. 
 
a Total OCD sample for whom total Y-BOCS was recorded;  bLB: lower boundary of the 95% CI; cUB:upper boundary of the 95% CI; ddue to male hemizygosity at the 5-HT2C locus, genders were analysed 
separately. Dashes indicate that no data was generated for the whole sample for this locus. 
Abbreviations: OCD: Obsessive-compulsive disorder; CI: confidence interval; 5-HT2A: serotonin receptor 2A; 5-HT1Dβ: serotonin receptor 1Dβ; 5-HT6: serotonin receptor 6; 5-HT2C: serotonin receptor 2C.
Total OCD samplea Male Female 
95% CI 95% CI 95% CI Gene  Variant Genotype n % median 
LBb UBc 
p-
value n % median 
LBb UBc 
p-
value n % median 
LBb UBc 
p-
value 
A/A 16 15.2 20.5 15.8 25.2 6 11.3 19.0 7.39 30.6 10 19.2 21.5 16.5 26.5 
G/A 45 42.9 21.0 19.1 22.9 20 37.7 20.0 16.6 23.4 25 48.1 21.0 18.5 23.5 rs6311 
G/G 44 41.9 24.0 21.7 26.3 
0.390 
27 50.9 23.0 19.8 26.2 
0.747 
17 32.7 24.0 19.8 28.2 
0.399 
C/C 45 42.5 22.0 19.4 24.6 26 49.1 21.5 18.1 24.9 19 35.8 22.0 17.8 26.2 
C/T 42 39.6 20.5 18.6 22.5 19 35.8 19.0 15.6 22.4 23 43.4 21.0 18.5 23.5 
5-HT2A 
rs6313 
T/T 19 17.9 24.0 19.8 28.2 
0.210 
8 15.1 22.5 14.4 30.6 
0.587 
11 20.8 24.0 19.2 28.8 
0.37 
C/C 8 7.9 17.5 13.0 22.0 4 7.8 15.5 10.0 21 4 8.0 23.5 16.4 30.6 
G/C 39 38.6 21.0 18.0 24.0 14 27.5 21.5 18.1 24.9 25 50.0 21.0 15.9 26.1 5-HT1Dß rs6296 
G/G 54 53.5 21.0 18.9 23.2 
0.515 
33 64.7 20.0 16.7 23.3 
0.131 
21 42.0 22.0 19.9 24.1 
0.784 
C/C 53 63.9 23.0 21.3 24.7 23 59.0 23.0 20.2 25.8 30 68.2 22.0 19.7 24.3 
C/T 28 33.7 21.5 18.7 24.3 15 38.5 19.0 15.3 22.7 13 29.5 22.0 18.5 25.5 5-HT6 rs1805054 
T/T 2 2.4 24.0 1.7 46.3 
0.828 
1 2.6 14.0 - - 
0.522 
1 2.3 34.0 - - 
0.342 
G/G 36 76.6 20.0 17.0 23.0 30 61.2 19.0 15.8 22.2 
G/C 0 - - - - 15 30.6 22.0 18.9 25.1 5-HT2C
d rs6318 
C/C 
- - 
11 23.4 19.0 15.9 22.1 
0.435 
4 8.2 25.0 21.4 28.6 
0.224 
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 Table III.18 (b). Quantitative analyses indicating the relationship between total Y-BOCS score and genotype in dopaminergic candidate 
genes. 
 
Significant values are represented in red, bold font.  
 *Total OCD sample for whom total Y-BOCS was recorded. bLB: lower boundary of the 95% CI; cUB:upper boundary of the 95% CI 
Abbreviations: OCD: Obsessive-compulsive disorder; CI: confidence interval; DRD4: dopamine receptor 4; DRD2: dopamine receptor 2; COMT: Catechol-O-methyltransferase; DRD3: dopamine 
receptor 3; DRD1: dopamine receptor 1. 
Total OCD samplea Male Female 
95% CI 95% CI 95% CI 
  
Gene 
  
  
Variant 
  
Genotype 
n % median 
LBb UBc 
p-
value n % median 
LBb UBc 
p-
value n % median 
LBb UBc 
p-
value 
C/C 12 13.6 22.5 19.5 25.5 6 13.6 21.5 17 26 6 13.6 22.5 19.3 25.7 
T/C 45 51.1 18.0 15.2 20.8 23 52.3 18.0 14.2 21.8 22 50.0 19.5 14.8 24.2 DRD4 rs1800995 
T/T 31 35.2 22.0 19.5 24.6 
0.275 
15 34.1 24.0 19.5 28.5 
0.543 
16 36.4 22.0 17.3 26.7 
 
0.527 
C/C 57 56.4 22.0 20.1 23.9 28 59.6 22.0 19.3 24.7 29 53.7 22.0 19.1 24.9 
C/T 39 38.6 22.0 19.5 24.5 17 36.2 24.0 20.2 27.8 22 40.7 21.5 18.5 24.5 DRD2 rs1800497 
T/T 5 5.0 20.0 9.4 30.6 
0.923 
2 4.3 7.5 4.79 19.8 
0.126 
3 5.6 28.0 23.9 32.1 
 
0.460 
A/A 16 27.6 18.0 13.5 22.5 9 33.3 18.0 12.7 23.3 7 22.6 18.0 11.4 24.6 
A/G 24 41.4 21.5 18.8 24.2 10 37.0 19.5 15.5 23.5 14 45.2 23.0 18.8 27.2 DRD3 rs2097603 
G/G 18 31.0 23.0 20.0 26.0 
0.590 
8 29.6 23.5 16.8 30.2 
0.614 
10 32.3 23.0 20.0 26.0 
 
0.720 
A/A 22 24.2 21.0 18.3 23.7 8 18.2 21.0 15.7 26.3 14 29.8 21.0 18.5 23.5 
A/G 53 58.2 22.0 19.2 24.8 27 61.4 20.0 16.4 23.6 26 55.3 23.0 18.7 27.3 rs4680 
G/G 16 17.6 17.5 14.0 21.1 
0.330 
9 20.5 18.0 12.2 23.8 
0.950 
7 14.9 17.0 14.3 19.7 
 
0.198 
D/D 27 52.9 21.0 18.1 23.9 14 63.6 20.0 14.5 25.5 13 44.8 22.0 17.2 26.8 
D/I 22 43.1 23.5 20.1 26.9 8 36.4 19.5 13.1 25.9 14 48.3 24.0 16.4 31.6 rs362204 
I/I 2 3.9 27.0 24.8 29.2 
0.437 
0 0.0 - - - 
0.608 
2 6.9 27.0 24.8 29.2 
 
0.657 
A/A 53 55.8 22.0 20.1 24.0 29 61.7 23.0 20.4 25.6 24 50.0 22.0 19.6 24.4 
A/G 30 31.6 22.0 18.5 25.5 10 21.3 23.5 16.5 30.5 20 41.7 21.0 17.1 24.9 
 
COMT 
rs6280 
G/G 12 12.6 22.0 18.4 25.7 
0.931 
8 17.0 19.0 13.7 24.3 
0.615 
4 8.3 25.0 17.5 32.5 
 
0.534 
A/A 40 40.8 21.5 18.3 24.8 20 40.0 18.0 13.4 22.6 20 41.7 22.0 17.1 26.9 
A/G 47 48.0 20.0 17.9 22.1 26 52.0 18.5 15.4 21.6 21 43.8 23.0 19.9 26.1 DRD1 
A-48G 
 
G/G 11 11.2 25.0 22.1 27.9 
0.172 
4 8.0 27.5 22.4 32.6 
0.045 
7 14.6 24.0 18.9 29.1 
 
0.833 
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Table III.18 (c). Quantitative analyses indicating the relationship between total Y-BOCS score and genotype in GRIN2B, HOXB8 and 
BDNF candidate genes. 
 
Significant values are represented in red, bold font.  
 aTotal OCD sample for whom total Y-BOCS was recorded. bLB: lower boundary of the 95% CI; cUB:upper boundary of the 95% CI 
Abbreviations: OCD: Obsessive-compulsive disorder; CI: confidence interval; GRIN2B: glutamate receptor subunit 2B; BDNF: brain-derivedneurotrophic factor; HOXB8: homeobox gene B8. 
Total OCD samplea Male Female 
95% CI 95% CI 95% CI Gene Variant Genotype 
n % median 
LBb UBc 
p-
value n % median LBb UBc 
p-
value n % median LBb UBc 
p-
value 
A/A 9 16.4 24.0 21.9 26.1 3 10.0 26.0 18.7 33.3 6 24.0 24.0 21.4 26.6 
A/G 25 45.5 21.0 18.5 23.5 17 56.7 21.0 17.6 24.5 8 32.0 20.0 16.7 23.4 rs1806191 
G/G 21 38.2 19.0 15.6 22.5 
0.230 
10 33.3 20.0 14.0 26.0 
0.408 
11 44.0 19.0 16.1 21.9 
0.373 
A/A 18 32.1 19.0 14.9 23.1 7 23.3 21.0 15.9 26.1 11 42.3 18.0 14.7 21.3 
A/C 30 53.6 20.5 17.9 23.1 18 60.0 19.5 15.4 23.6 12 46.2 21.0 18.0 24.0 
GRIN2B 
rs890 
C/C 8 14.3 26.0 20.1 31.9 
0.013 
5 16.7 26.0 31.7 31.9 
0.118 
3 11.5 26.0 20.1 31.9 
0.053 
A/A 6 5.5 18.5 13.3 23.7 5 8.9 18.0 12.3 23.7 1 1.9 19 - - 
G/A 32 29.1 18.0 14.9 21.1 18 32.1 20.5 16.8 24.2 14 25.9 16.0 10.9 21.1 
G/G 72 65.5 22.5 20.9 24.1 
0.103 
33 58.9 21.0 17.7 24.3 
0.899 
39 72.2 23.0 21.0 25.0 
0.045 
rs6265 
A/A + 
G/A 38 34.5 18.0 15.2 20.8 0.036 23 41.1 18.0 14.9 21.1 0.677 15 27.8 16.0 11.7 21.0 0.013 
A/A 12 24.0 17.0 13.6 20.4 8 28.6 16.5 11.8 21.2 4 18.2 17.5 10.0 25.0 
A/T 24 48.0 24.0 20.0 28.0 13 46.4 24.0 19.2 28.8 11 50.0 24.0 19.0 29.0 rs2049046 
T/T 14 28.0 21.0 17.2 24.8 
0.317 
7 25.0 20.0 13.1 26.9 
0.251 
7 31.8 22.0 18.7 25.3 
0.919 
C/C 25 51.0 23.0 19.8 26.2 16 57.1 23.0 19.1 26.9 9 42.9 22.0 18.3 25.7 
C/G 22 44.9 17.0 13.6 20.4 10 35.7 17.0 11.0 23.0 12 57.1 19.5 15.2 23.8 
BDNF 
rs988748 
G/G 2 4.1 18.0 0.1 35.9 
0.532 
2 7.1 18.0 0.1 35.9 
0.452 
0 0.0 - - - 
0.668 
A/A 19 38.8 22.0 18.9 25.1 12 42.9 20.5 15.9 25.1 7 33.3 24.0 19.8 28.2 
A/T 20 40.8 19.5 16.3 22.7 11 39.3 18.0 13.2 22.8 9 42.9 21.0 17.3 24.7 HOXB8 rs2303486 
T/T 10 20.4 20.0 17.0 23.0 
0.797 
5 17.9 21.0 17.5 24.5 
0.91 
5 23.8 19.0 14.8 23.2 
0.384 
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Table III.18 (d). Quantitative analyses indicating the relationship between total Y-BOCS score and genotype in ESRα, INPP-1,  
PLC-γ1 and ACE candidate genes. 
 
*Total OCD sample for whom total Y-BOCS was recorded. bLB: lower boundary of the 95% CI; cUB:upper boundary of the 95% CI. 
Abbreviations: OCD: Obsessive-compulsive disorder; CI: confidence interval; ESRα: estrogen receptor α; INPP-1: inositol polyphosphate-phosphatase 1; PLCγ1: phospholipase-gamma; ACE: 
Angiotensin-converting enzyme. 
Total OCD samplea Male Female 
95% CI 95% CI 95% CI Gene Variant Genotype 
n % median 
LBb UBc 
p-
value n % median LBb UBc 
p-
value n % median LBb UBc 
p-
value 
A/A 38 47.5 21.5 17.7 25.3 18 46.2 22.0 17.5 26.5 20 48.8 21.5 16.4 26.6 
A/G 31 38.8 20.0 17.6 22.4 15 38.5 20.0 16.1 23.9 16 39.0 20.5 17.5 23.5 rs9340799 
G/G 11 13.8 24.0 19.5 28.5 
0.647 
6 15.4 15.0 9.8 20.2 
0.209 
5 12.2 25.0 19.3 30.7 
0.094 
C/C 13 22.0 24.0 21.4 26.6 6 18.8 21.5 14.4 28.6 7 25.9 24.0 19.2 28.8 
T/C 28 47.5 16.5 12.6 20.4 14 43.8 17.0 11.1 22.9 14 51.9 16.0 10.5 21.5 
ESRα 
rs2234693 
T/T 18 30.5 21.0 16.5 25.5 
0.229 
12 37.5 17.0 12.4 21.6 
0.792 
6 22.2 25.0 19.8 30.2 
0.241 
A/A 1 1.1 17.0 17.0 17.0 0 0.0 - - - 1 2.1 17.0 - - 
C/A 23 24.7 23.0 19.7 26.3 11 24.4 21.0 15.3 26.7 12 25.0 24.0 18.1 29.9 INPP-1 rs1882891 
C/C 69 74.2 22.0 20.3 23.7 
0.531 
34 75.6 22.0 19.0 25.0 
0.968 
35 72.9 22.0 19.7 24.3 
0.355 
A/A 55 61.1 24.0 22.0 26.0 28 63.6 22.0 18.4 25.6 27 58.7 24.0 21.0 27.0 
A/G 30 30.3 19.0 16.7 21.3 14 31.8 19.5 16.1 22.9 16 34.8 18.5 15.5 21.5 PLC-γ1 rs8192707 
G/G 5 5.1 22.0 14.9 29.1 
0.302 
2 4.5 18.0 6.8 29.2 
0.795 
3 6.5 22.0 11.1 32.9 
0.151 
D/D 43 40.2 21.0 19.0 23.1 20 36.4 18.5 14.8 22.2 23 44.2 21.0 18.0 24.0 
D/I 42 39.3 22.0 20.3 23.7 20 36.4 20.0 16.5 23.5 22 42.3 22.0 20.3 23.7 ACE Alu ins/del 
I/I 22 20.6 23.0 16.3 29.7 
0.566 
15 27.3 23.0 18.5 27.5 
0.558 
7 13.5 19.0 1.4 36.6 
0.660 
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Table III.19. Quantitative analyses indicating the relationship between total Y-BOCS score 
and genotypes, categorised by DRD4 48bp VNTR A4-allele status. 
 
Total OCD population 
95% CIa Genotype 
n % Median 
LBb UBc 
A4/A4 33 37.5 22.0 19.2 24.8 
A4/other 45 51.1 21.0 18.6 23.4 
other/other 10 11.4 21.0 14.0 28.0 
  Male 
A4/A4 12 28.6 24.5 21.5 27.5 
A4/other 25 59.5 19.0 15.5 22.5 
other/other 5 11.9 16.0 6.1 25.9 
  Female 
A4/A4 21 45.7 19.0 15.6 22.4 
A4/other 20 43.5 21.0 18.0 24.0 
other/other 5 10.9 25.0 15.8 34.2 
 
p = 0.851 for whole OCD sample, p = 0.273 for males, p = 0.335 for females. 
A4 = 4-repeat allele; “other” alleles comprise A2, A3, A7and A6 alleles. 
aconfidence interval; blower boundary of 95% CI; c upper boundary of 95% CI. 
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Table III.20. Quantitative analyses indicating the relationship between total Y-BOCS score 
and genotypes in the DAT 40bp VNTR. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
p = 0.207 for whole OCD sample, p = 0.340 for males, p = 0.142 for females. 
A9 = 9-repeat allele; A10 = 10-repeat allele; A11 = 11-repeat allele;. 
aconfidence interval; blower boundary of 95% CI; c upper boundary of 95% CI. 
Total OCD population 
95% CI Genotype 
n % Median 
LB UB 
A10/A10 60 55.0 19.0 16.7 21.3 
A10/A9 38 34.9 23.5 21.2 25.8 
A9/A9 8 7.3 17.5 9.4 25.6 
A10/A11 3 2.8 23.0 19.8 26.2 
 Male 
A10/A10 32 56.1 19.0 16.1 21.9 
A10/A9 18 31.6 21.5 17.4 25.6 
A9/A9 3 5.3 24.0 13.1 34.9 
A10/A11 3 5.3 23.0 19.8 26.2 
 Female 
A10/A10 28 52.8 21.0 17.8 24.2 
A10/A9 20 37.7 24.0 22.4 25.6 
A9/A9 5 9.4 26.0 11.1 20.9 
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III.4.2.3. Haplotype analyses of symptom severity (total Y-BOCS score) 
 
III.4.2.3.1. 5-HT2A haplotype analysis 
No statistically significant associations were observed between the haplotypes of the 5-HT2A -
1438A/G (rs6311) and T102C (rs6313) SNPs and total Y-BOCS score, with a global p-value 
of 0.212 (Table III.21). It should, however, be mentioned that the haplotype G-T did show a 
trend towards association with a higher total Y-BOCS score (and thus with increased 
severity), by the generation of a haplotype score of 1.917 and individual p-value of 0.050.  
 
III.4.2.3.2. DRD4 haplotype analysis 
When the distribution of total Y-BOCS scores was investigated in the DRD4 haplotypes 
formed by the C/T SNP located at promoter position -521 (rs1800955) and the 48bp VNTR 
located in exon 3, no statistically significant differences were observed (p = 0.636) (Table 
III.22).  
 
III.4.2.3.3. COMT haplotype analysis 
When the distribution of Y-BOCS scores amongst COMT polymorphism haplotypes was 
investigated, no significant differences, either individually or globally (global p-value = 
0.980), were noted for the haplotypes formed by the promoter polymorphism rs2097603, the 
functional val158met (rs4680) polymorphism, or the C insertion/deletion polymorphism in the 
sixth exon (rs362204) (Table III.23). 
 
III.4.2.3.4. GRIN2B haplotype analysis 
When comparing the differences in Y-BOCS score distribution between haplotypes 
comprised of the GRIN2B rs1806191 and rs890 polymorphisms, statistically significant 
differences were noted (global p = 0.032) (Table III.24). Closer inspection of the Y-BOCS 
score distribution amongst the individual haplotypes revealed that OCD patients carrying the 
G-A haplotype presented with a less severe form of the disorder, as they tended to have 
significantly lower Y-BOCS scores, indicated by the negative haplotype score of -2.371 
(individual haplotype p-value = 0.021) (Table III.24). On the other hand, those subjects 
carrying the A-C haplotype presented with a more severe form of the disorder, indicated by 
higher total Y-BOCS scores (haplotype score = 2.274; individual p value = 0.022).  
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III.4.2.3.5. BDNF haplotype analysis 
The distribution of Y-BOCS scores amongst the BDNF rs890-rs1806191 haplotypes 
investigated in the present study are depicted in Table III.25. No statistically significant 
differences in Y-BOCS score were noted, either within individual haplotypes, or when all the 
haplotypes were considered globally (p = 0.408). 
 
III.4.2.3.6. ESRα haplotype analysis 
No statistically significant differences in Y-BOCS score were noted for the haplotypes formed 
by the two intronic ESRα SNPs, rs1799732 and rs1800497, with a global p-value of 0.713 
being attained (Table III.26). 
 
Table III.21. Distribution of total Y-BOCS score within 5-HT2A haplotypes comprising the -
1438 A/G (rs6311) and T102C (rs6313) variants. 
 
 
Variants 
rs6311 rs6313 
Haplotype Frequency 
(n=103) Haplotype Score Individual p-value 
G C 0.612 0.002 0.996 
A T 0.338 -0.287 0.780 
A C 0.025 -0.989 0.328 
G T 0.025 1.917 0.050 
Global p=0.212 
 
 
 
Table III.22. Distribution of total Y-BOCS score within haplotypes comprising the 
DRD4 promoter polymorphism (-521C/T [rs1800955]) and the 48bp VNTR in OCD 
individuals. 
 
Global p=0.636 
A4: 4-repeat allele of DRD4 48bp VNTR; A7: 7-repeat allele of DRD4 48bp VNTR; A3: 3-repeat allele of DRD4 48bp VNTR 
A2: 2-repeat allele of DRD4 48bp VNTR. 
Variants 
rs1800955 48bp VNTR 
Haplotype Frequency 
(n=69) Haplotype Score Individual p-value 
T A4 0.396 1.09 0.271 
C A4 0.191 -1.10 0.269 
T A7 0.122 0.09 0.922 
C A7 0.110 -0.37 0.691 
T A2 0.071 0.26 0.821 
C A2 0.059 0.63 0.528 
C A3 0.039 -0.70 0.479 
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Table III.23. Distribution of total Y-BOCS score within haplotypes comprising the COMT 
promoter (rs2097603), val158met (rs4680) and rs362204 polymorphisms in OCD 
individuals. 
 
Variants 
rs2097603 rs4680 rs362204 
Haplotype Frequency 
(n=31) Haplotype Score Individual p-value 
G A D 0.323 0.375 0.717 
A A D 0.203 -0.29 0.787 
A G I 0.149 0.096 0.932 
G G D 0.124 -0.084 0.928 
A G D 0.092 -0.127 0.917 
Global p=0.980 
 
 
Table III.24. Distribution of total Y-BOCS score within haplotypes comprising the GRIN2B 
rs890 and rs1806191 polymorphisms  in OCD individuals. 
 
Significant p-values are indicated in red, bold font. 
Global p=0.032 
 
Table III.25. Distribution of total Y-BOCS score within haplotypes comprising the BDNF 
val66met (rs6265), rs2049046 and rs988748 polymorphisms in OCD individuals. 
 
Variants 
rs6265 rs2049046 rs988748 
Haplotype Frequency 
(n=36) 
Haplotype 
Score Individual p-value 
G A C 0.458 1.136 0.279 
A T G 0.25 -1.699 0.098 
G T C 0.25 0.076 0.948 
 
Global p=0.480 
 
 
 
Variants 
rs1806191 rs890 
Haplotype Frequency 
(n=54) Haplotype Score Individual p-value 
G A 0.464 -2.371 0.021 
A C 0.270 2.274 0.022 
G C 0.138 1.015 0.306 
A A 0.128 -1.045 0.294 
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Table III.26. Distribution of total Y-BOCS score within haplotypes comprising the ESRα 
rs9340799 and rs2234693 polymorphisms in OCD individuals. 
 
Variants 
rs9340799 rs2234693 
Haplotype Frequency 
(n=55) 
Haplotype 
Score Individual p-value 
A T 0.508 -0.266 0.794 
G C 0.341 0.905 0.363 
A C 0.140 -0.772 0.388 
Global p=0.713 
 
III.4.3. Stratification by age at onset of OCD 
 
III.4.3.1. Analysis of clinical variables 
OCD subjects with a positive family history of OCD were found to exhibit an earlier age at 
onset compared to those patients without a family history of the disorder (p < 0.001; median 
ages of onset = 10 years [95% CI: 4.5-16] and 15 years [95% CI: 13-19], respectively) (Table 
III.27). No other statistically significant differences in age at onset of OCD were observed for 
presence or absence of family history of OCS or tics. Likewise, when symptom dimensions 
were analysed, no statistically significant differences were observed in age at onset between 
those subjects experiencing selected symptoms and those not experiencing the symptom 
(Table III.27). 
 
When age at onset and co-morbidity were investigated, patients diagnosed with co-morbid TS 
were found to exhibit an earlier age at onset compared to those who were not diagnosed with 
TS (median age at onset=8 years [95% CI: 5.0-11.0]) and 14 years [95% CI: 12.3-15.7]), 
respectively; p = 0.025) (Table III.27). Moreover, the age at onset of OCD patients presenting 
with co-morbid specific phobia was lower than those who did not exhibit co-morbid specific 
phobia (median ages of 10 years[95% CI: 7.5-12.5] and 15 [95% CI: 13.4-16.6] years, 
respectively) although this difference did not reach statistical significance (p = 0.053).  
 
III.4.3.2. Single locus analysis of age of onset 
 
III.4.3.2.1. Single locus analysis of bi-allelic loci 
The results of the Kaplan-Meier logrank tests for age at onset are depicted in Tables III.28 (a) 
to (d).  
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Table III.27. Clinical variables in the OCD patient subset according to age at onset of OCD. 
 
 
 
 
Significant p-values are indicated in red, bold font. 
Abbreviations: OCD: Obsessive-compulsive disorder; OCS: Obsessive-compuslive symptoms; MDD: major depressive disorder; SIB: 
self-injurious behaviour; GAD: generalised anxiety disorder; PD: panic disorder; TTM: Trichotillomania; IED: intermittent explosive 
disorder; BDD: body dysmorphic disorder; TS: Tourette Syndrome; CI: confidence interval. 
Clinical Variable Present Absent 
Family History n % Median 95% CI n % Median 95% CI 
p-
value 
Family history of OCD 17 22.7 10.0 4.5-16.0 58 77.3 15.0 13.0-19.0 <0.001 
Family history of OCS 33 45.2 13.5 10.0-18.0 40 54.8 15.0 13.0-19.0 0.567 
Family history of tics 5 6.7 16.0 15.0-α 70 93.3 14.0 13.0-17.0 0.343 
Primary symptom 
dimensions          
Hoarding/collecting 20 23.8 13.0 10.9-15.1 64 76.2 14.0 11.5-16.5 0.846 
Symmetry/ordering 51 60.0 14.0 11.6-16.4 34 40.0 13.0 10.9-15.1 0.570 
Sex/religion 34 40.5 13.0 10.3-15.7 50 59.5 15.5 13.3-17.7 0.236 
Contamination/washing 51 60.0 13.0 10.9-15.1 34 40.0 15.0 11.7-18.3 0.276 
Aggression 43 51.2 13.0 10.9-15.1 41 48.8 14.0 10.5-17.5 0.809 
Co-morbidity          
MDD 75 64.7 14.0 12.2-15.8 41 35.3 15.0 12.8-17.2 0.337 
SIB 21 18.1 13.0 9.9-16.1 95 81.9 14.0 12.2-15.8 0.802 
Dysthymic disorder 20 17.2 13.5 9.1-17.9 96 82.8 14.0 12.4-15.6 0.832 
Tics 16 13.8 10.0 5.9-14.1 100 86.2 14.0 12.3-15.7 0.100 
Specific phobia 14 12.1 10.0 7.5-12.5 102 87.9 15.0 13.4-16.6 0.053 
GAD 13 11.2 13.0 8.2-17.8 103 88.8 14.0 12.3-15.7 0.483 
PD 11 9.5 14.0 9.0-19.0 105 90.5 14.0 12.4-15.6 0.713 
Social Phobia 11 9.5 12.0 9.4-14.6 105 90.5 14.0 12.4-15.6 0.331 
TTM 8 6.9 13.0 5.2-20.8 108 93.1 14.0 12.5-15.5 0.523 
IED 11 9.5 16.0 12.2-19.8 105 90.5 14.0 12.5-15.5 0.436 
BDD 10 8.6 14.5 11.0-18.0 106 91.4 14.0 12.5-15.5 0.922 
TS 7 6.0 8.0 5.0-11.0 109 94.0 14.0 12.3-15.7 0.025 
Anorexia nervosa 5 4.3 21.0 10.4-31.6 111 95.7 14.0 12.5-15.5 0.484 
Hypochondriasis 4 3.4 16.0 4.9-27.1 112 96.6 14.0 12.5-15.5 0.617 
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Table III.28 (a). Kaplan-Meier estimates of age at onset of OCD according to genotypes of markers within serotonergic genes. 
 
 
Significant p-values are indicated in red, bold font. 
α = infinity; a Total population for  whom age at onset was recorded.; bLB: lower boundary of the 95% CI; cUB:upper boundary of the 95% CI; ddue to male hemizygosity at the 5-HT2C locus, genders were 
analysed separately. Dashes indicate that no data was generated for the whole sample for this locus. 
Abbreviations: 5-HT2A: serotonin receptor 2A; 5-HT1Dβ: serotonin receptor 1Dβ; 5-HT6: serotonin receptor 6; 5-HT2C: serotonin receptor 2C 
Total OCD samplea Male Female 
95% CI 95% CI 95% CI 
 
Gene 
 
 
Variant 
 
Genotype 
n % median 
LBb UBc 
p-
value n % median LBb UBc 
p-
value n % median LBb UBc 
p-
value 
A/A 14 14.3 12.5 10.0 25.0 5 10 12.0 10.0 α 9 18.8 13.0 10.0 α 
G/A 44 44.9 16.0 13.0 19.0 19 38 15.0 13.0 20.0 25 52.1 16.0 13.0 24.0 rs6311 
G/G 40 40.8 14.5 13.0 20.0 
0.381 
26 52 14.0 13.0 20.0 
0.140 
14 29.2 18.0 10.0 30.0 
0.770 
C/C 42 43.3 15.5 13.0 20.0 25 51 14.0 13.0 23.0 17 35.4 17.0 10.0 24.0 
C/T 39 40.2 15.0 14.0 19.0 17 34.7 10.0 13.0 20.0 22 45.8 16.5 13.0 24.0 
5-HT2A 
rs6313 
T/T 16 16.5 10.0 9.0 18.0 
0.118 
7 14.3 10.0 7.0 α 
0.015 
9 18.8 10.0 9.0 α 
0.645 
C/C 6 6.4 13.0 10.0 α 3 6.4 14.0 4.5 α 3 6.4 12.0 10.0 α 
G/C 38 40.4 14.5 13.0 17.0 14 29.8 13.5 12.0 17.0 24 51.1 16.5 13.0 21.0 5-HT1Dß rs6296 
G/G 50 53.2 14.0 13.0 18.0 
0.505 
30 63.8 14.5 13.0 20.0 
0.194 
20 42.6 13.5 10.0 25.0 
0.830 
C/C 48 62.3 14.0 13.0 19.0 22 59.5 14.0 13.0 20.0 26 65 14.5 10.0 24.0 
C/T 28 36.4 15.0 11.0 19.0 14 37.8 12.0 10.0 17.0 14 35 18.5 13.0 30.0 5-HT6 rs1805054 
T/T 1 1.3 20.0 - - 
0.595 
1 2.7 20.0 - - 
0.121 
0 0.0 0.0 0.0 0.0 
0.966 
G/G 34 77.3 14.5 13.0 19.0 26 59.1 14.5 10.0 19.0 
G/C 0 0 - - - 15 34.1 18.0 10.0 33.0 5-HT2Cd rs6318 
C/C 
- - 
10 22.7 15.5 10.0 α 
0.688 
3 6.8 24.0 4.0 α 
0.237 
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Amongst the serotonergic candidate genes investigated, significant differences in age at onset 
were seen only between genotypes comprising the T102C (rs6313) polymorphism in 5-HT2A 
(p=0.015), and only in male OCD subjects (Table III.28[a]; Figure III.42). Here, male 
individuals homozygous for the 5-HT2A T102-allele exhibited earlier ages at onset (median 
age at onset=10 years [95% CI: 7-α]) compared to those who were homozygous for the C102-
allele, or T102C-heterozygotes (median ages at onset=14 years for both [95% CIs: 13-23 and 
13-20, respectively]).  
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Figure III.42. Kaplan-Meier estimation of time to age at onset of OCD, according to 5-
HT2A T102C genotype in males. TT homozygotes demonstrated a significantly earlier age at 
onset than heterozygotes or CC homozygotes. 
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The relationship between dopaminergic candidates investigated in the present study and age at 
onset of OCD is depicted in Table III.28(b). An association between age at onset and the 
COMT polymorphism, rs362204, was observed in the male population. No OCD patients for 
whom age at onset had been recorded were found to carry the I/I genotype. Consequently, a 
pairwise comparison was made between age at onset of OCD subjects who were homozygous 
for the D-allele, and heterozygous D/I carriers. Males carrying the D/D-genotype exhibited 
significantly lower ages at onset (median age at onset = 14 years [95% CI: 13-20]) compared 
to heterozygotes (median age at onset = 20years [95% CI: 16-α]) (Table III.28[b] and Figure 
III.43). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure III.43. Kaplan-Meier estimation of time to age at onset of OCD, according to 
COMT rs362204 genotype in males. DD homozygotes showed a significantly earlier age at 
onset compared to DI heterozygotes, while no II homozygotes were observed. 
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For the DRD3 ser9gly polymorphism, heterozygous male subjects presented with earlier ages 
at onset (median age at onset =11 years [95% CI: 6-α]) compared to those who were 
homozygous for either the A (ser9)-allele or G (gly9) allele (median ages at onset = 15 years 
[95% CI: 13-19] and 17 years [95% CI: 13- α], respectively) (Table III.28[b] and Figure 
III.44). In females, however, the GG (gly9gly) homozygotes showed a weakly significant 
tendency for earlier age of onset (p = 0.068). 
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Figure III.44. Kaplan-Meier estimation of time to age at onset of OCD, according to DRD3 
ser9gly genotype in males. AG (ser9gly) heterozygotes experienced significantly lower ages 
at onset compared to AA (ser9ser)- or GG (gly9gly)-homozygotes. 
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Table III.28(b). Kaplan-Meier estimates of age at onset of OCD according to genotypes of markers within dopaminergic candidate genes.  
 
 
Significant p-values are indicated in red, bold font; α = infinity; a Total population for  whom age at onset was recorded.; bLB: lower boundary of the 95% CI; cUB:upper boundary of the 95% CI 
Abbreviations: DRD4: dopamine receptor 4; DRD2: dopamine receptor 2; COMT: Catechol-O-methyltransferase; DRD3: dopamine receptor 3; DRD1: dopamine receptor 1. 
Total OCD samplea Male Female 
95% CI 95% CI 95% CI Gene Variant Genotype 
n % median 
LBb UBc 
p-
value n % median LBb UBc 
p-
value n % median LBb UBc 
p-
value 
C/C 14 16.9 14.0 13.0 24.0 7 17.1 15.0 13.0 α 7 16.7 13.0 7.0 α 
T/C 41 49.4 14.0 13.0 19.0 20 48.8 14.0 13.0 20.0 21 50.0 16.0 10.0 27.0 DRD4 rs1800995 
T/T 28 33.7 14.0 12.0 19.0 
0.376 
14 34.1 13.0 10.0 20.0 
0.519 
14 33.3 18.0 13.0 α 
0.304 
C/C 52 54.7 14.0 13.0 17.0 26 57.8 13.5 13.0 17.0 26 52.0 16.0 13.0 24.0 
C/T 37 38.9 15.0 13.0 19.0 16 35.6 14.5 9.0 25.0 21 42.0 17.0 10.0 21.0 DRD2 rs1800497 
T/T 6 6.3 17.5 12.0 α 
0.614 
3 6.7 15.0 12.0 α 
0.573 
3 6.0 30.0 9.0 α 
0.632 
A/A 14 25.5 13.0 10.0 30.0 8 30.8 13.0 12.0 α 6 20.7 12.5 9.0 α 
A/G 24 43.6 16.0 13.0 24.0 10 38.5 14.0 9.0 α 14 48.3 22.0 13.0 30.0 rs2097603 
G/G 17 30.9 13.0 11.0 20.0 
0.597 
8 30.8 13.5 12.0 α 
0.897 
9 31.0 13.0 10.0 α 
0.625 
A/A 22 26.5 13.0 10.0 18.0 8 20 11.0 6.0 α 14 32.6 15.5 10.0 37.0 
A/G 47 56.6 15.0 14.0 18.0 25 62.5 15.0 14.0 18.0 22 51.2 15.0 13.0 23.0 rs4680 
G/G 14 16.9 17.0 13.0 30.0 
0.564 
7 17.5 19.0 13.0 α 
0.223 
7 16.3 12.0 5.0 α 
0.880 
D/D 26 56.5 14.5 13.0 20.0 14 66.7 14.0 13.0 20.0 12 48.0 17.0 13.0 α 
COMT 
rs362204 
D/I 20 43.5 19.5 14.0 25.0 
0.578 
7 33.3 20.0 16.0 α 
0.040 
13 52.0 16.0 9.0 α 
0.536 
A/A 51 58.0 15.0 13.0 19.0 29 64.4 15.0 13.0 19.0 22 51.2 15.0 10.0 21.0 
A/G 26 29.5 14.5 13.0 24.0 8 17.8 11.0 6.0 α 18 41.9 20.5 13.0 33 DRD3 rs6280 
G/G 11 12.5 14.0 10.0 α 
0.655 
8 17.8 17.0 13.0 α 
0.022 
3 7.0 10.0 7.0 α 
0.068 
A/A 37 40.2 16.0 14.0 19.0 19 40.4 14.0 13.0 19.0 18 40.0 17.5 13.0 30.0 
A/G 45 48.9 14.0 13.0 19.0 25 53.2 14.0 13.0 20.0 20 44.4 14.5 10.0 23.0 DRD1 rs4532 
G/G 10 10.9 13.5 9.0 α 
0.341 
3 6.4 13.0 5.0 α 
0.431 
7 15.6 14.0 9.0 α 
0.510 
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The relationship between age at onset of OCD and variants situated in GRIN2B, BDNF and 
HOXB8 are presented in Table III.28(c). Male OCD subjects carrying the GRIN2B rs890 AA-
genotype were found to experience a later age at onset (median age at onset=22 years [95% 
CI: 15-α]), compared to those who were heterozygous or homozygous for the C-allele 
(median ages at onset=13 years [95% CI: 9-19] and 10 years [95% CI: 7- α], respectively) 
(p=0.012) (Table III.28[c] and Figure III.45]). Females showed no difference in the age of 
onset for any of these genotypes. 
 
In contrast, in the female subset, OCD subjects carrying the GRIN2B rs1806191 GG 
genotypes were found to have later ages at onset (median age at onset=19 years [95% CI: 
13.0- α], compared to those who were heterozygous or homozygous for the A-allele (median 
ages at onset=11.5 years [95% CI: 7- α] and 10 years [95% CI: 10- α], respectively) (Figure 
III.46). However, this difference was found to be at the borderline of significance, with a p-
value of 0.049. In the male subset, those individuals homozygous for the rs1806191 AA-
genotype also experienced earlier ages at onset, compared to those who heterozygous or 
homozygous for the G-allele, although this difference did not reach statistical significance 
(p=0.087) (Table III.28[c]).  
 
In addition, males homozygous for the BDNF val66met (rs6265) met66-allele (the A-allele) 
experienced earlier age at onset (median age at onset=5 years [95% CI: 4.5-α]), compared to 
those who are heterozygous or homozygous for the G (val66)-allele (median ages at onset=13 
years [95% CI: 12-20] and 15 years [95% CI: 14-19], respectively) (p=0.028) (Table III.28[c] 
and Figure III.47). 
 
An association between age at onset of OCD and HoxB8 was also observed: females carrying 
the HoxB8 rs2303486 AA-genotype exhibited much earlier ages at onset (median age at 
onset=9 years [95% CI: 7-α]) compared to those subjects who were either homozygous for the 
T-allele, or heterozygous (median ages at onset=25 years [95% CI: 10- α] and 16 years [95% 
CI: 13- α], respectively) (p=0.024) (Table III.28[c] and Figure III.48); however, no effect was 
observed in males. 
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Table III.28(c). Kaplan-Meier estimates of age at onset of OCD according to genotypes of markers within GRIN2B, BDNF and HOXB8 
candidate polymorphisms. 
 
Significant p-values are indicated in red, bold font. 
α = infinity; a Total population for  whom age at onset was recorded.; bLB: lower boundary of the 95% CI; cUB:upper boundary of the 95% CI. 
Abbreviations: OCD: Obsessive-compulsive disorder; CI: confidence interval; GRIN2B: glutamate receptor subunit 2B; BDNF: brain-derivedneurotrophic factor; HOXB8: homeobox gene B8
Total OCD samplea Male Female 
95% CI 95% CI 95% CI 
 
Gene 
 
 
Variant 
 
Genotype 
n % median 
LBb UBc 
p-
value n % median LBb UBc 
p-
value n % median LBb UBc 
p-
value 
A/A 8 15.1 10.0 7.0 α 3 10.3 4.0 1.4 α 5 20.8 10.0 10.0 α 
G/A 25 47.2 13.0 10.0 19.0 17 58.6 13.0 12.0 22.0 8 33.3 11.5 7.0 α rs1806191 
G/G 20 37.7 14.5 13.0 30.0 
0.090 
9 31.0 13.0 11.0 α 
0.087 
11 45.8 19.0 13.0 α 
0.049 
A/A 18 33.3 18.5 15.0 30.0 7 24.1 22.0 15.0 α 11 44.0 18.0 14.0 α 
A/C 28 51.9 13.0 10.0 15.0 17 58.6 13.0 9.0 19.0 11 44.0 13.0 10.0 α 
GRIN2B 
rs890 
C/C 8 14.8 10.0 7.0 α 
0.051 
5 17.2 10.0 7.0 α 
0.012 
3 12.0 10.0 7.0 α 
0.897 
A/A 6 5.9 9.5 4.5 α 5 9.4 5.0 4.5 α 1 2.0 45.0 α α 
G/A 31 30.4 14.0 13.0 20.0 17 32.1 13.0 12.0 20.0 14 28.6 16.0 13.0 30.0 rs6265 
G/G 65 63.7 15.0 14.0 18.0 
0.937 
31 58.5 15.0 14.0 19.0 
0.028 
34 69.4 15.5 12.0 21.0 
0.148 
A/A 11 24.4 13.0 13.0 α 7 28.0 13.0 11.0 α 4 20.0 17.0 10.0 α 
A/T 20 44.4 13.5 10.0 22.0 11 44.0 13.0 9.0 α 9 45.0 14.0 10.0 α rs2049046 
T/T 14 31.1 11.0 7.0 30.0 
0.964 
7 28.0 13.0 5.0 α 
0.908 
7 35.0 8.0 7.0 α 
0.993 
C/C 23 52.3 13.0 11.0 23.0 15 60.0 13.0 13.0 25.0 8 42.1 12.0 10.0 α 
BDNF 
rs988748 
G/G+C/G 21 47.7 13.0 9.0 23.0 
0.966 
10 40.0 10.5 5.0 α 
0.572 
11 57.9 14.0 10.0 α 
0.939 
A/A 18 40.0 14.0 9.0 21.0 12 46.2 15.0 13.0 α 6 31.6 9.0 7.0 α 
A/T 17 37.8 13.0 13.0 23.0 9 34.6 13.0 10.0 α 8 42.1 16.0 13.0 α HOXB8 rs2303486 
T/T 10 22.2 12.0 7.0 α 
0.923 
5 19.2 11.0 5.0 α 
0.253 
5 26.3 25.0 10.0 α 
0.024 
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Figure III.45. Kaplan-Meier estimation of time to age at onset of OCD, according to 
GRIN2B rs890 genotype in males. Those carrying at least one C-allele experienced 
significantly earlier ages at onset compared to those homozygous for the A-allele. 
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Figure III.46 Kaplan-Meier estimation of time to age at onset of OCD, according to 
GRIN2B rs1806191 genotype in females. Those carrying at least one A-allele experienced 
significantly earlier ages at onset compared to GG-homozygotes. 
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Figure III.47. Kaplan-Meier estimation of time to age at onset of OCD, according to BDNF 
val66met genotype in males. AA(met66met)-homozygotes experienced significantly earlier 
ages at onset compared to AG(val66met) - or GG(val66val)- carriers. 
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Figure III.48. Kaplan-Meier estimation of time to age at onset of OCD, according to 
HOXB8 rs2303486 genotype in females. AA-carriers experienced significantly earlier ages 
at onset compared to AT- or TT-carriers. 
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When the unstratified OCD group was investigated, a significant association was noted 
between the PLC-γ1 ser279gly variant (rs8192707) and age at onset (p=0.008) (Table 
III.28[d]; Figure 49[a]). Here, subjects homozygous for the A (ser279)-allele were found to 
exhibit a later age at onset (median age at onset=16 years [95% CI: 14-20]), compared to 
those who were heterozygous, or homozygous for the G (gly279)-allele (median ages at 
onset=13 years [95% CI: 10-17] and 10 years [95% CI: 10- α], respectively).  
 
Because the numbers within the genotype groups were reduced to below 5 when the sample 
was stratified according to gender, individuals carrying the GG (gly279gly)- or GA 
(gly279ser)-genotypes were grouped together in their respective gender subsets. Once again, 
when the total OCD sample was considered with this genotype-grouping, individuals carrying 
at least one G(ser279)-allele were found to experience significantly lower ages at onset 
(median=13 years [95% CI: 10-15] compared to those who were homozygous for the 
A(gly279)-allele (p=0.005) (Table III.28[d]; Figure 49[b]). When the grouped genotype 
dataset was stratified according to gender, both male and female individuals homozygous for 
the A(ser279)-allele were found to present with later ages at onset (median ages at onset=15 
[95%CI: 14-20] and 18.5 years [95% CI: 13-24], respectively), compared to those who carried 
at least one copy of the G-allele (median ages at onset=13 years for both male and female, 
with male 95% CI: 9-16 and female 95% CI: 10-23) (Table III.28[d]; Figures III.49 [c] and 
[d]).  
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Table III.28(d). Kaplan-Meier estimates of age at onset of OCD according to genotypes of markers within bi-allelic ESRα, INPP-1 and PLC-γ1 
candidate polymorphisms. 
 
 
Significant p-values are indicated in red, bold font; α = infinity 
a Total population for  whom age at onset was recorded.; bLB: lower boundary of the 95% CI; cUB:upper boundary of the 95% CI; dGG and AG were grouped together for this analysis. 
Abbreviations: OCD: Obsessive-compulsive disorder; CI: confidence interval; ESRα: estrogen receptor α; INPP-1: inositol polyphosphate-phosphatase 1; PLCγ1: phospholipase-gamma; ACE: Angiotensin-
converting enzyme. 
Total OCD samplea Male Female 
95% CI 95% CI 95% CI 
 
Gene 
 
 
Variant 
 
Genotype 
n % median 
LBb UBc 
p-
value n % median LBb UBc 
p-
value n % median LBb UBc 
p-
value 
A/A 35 47.3 17.0 14.0 19.0 17 47.2 15.0 14.0 23.0 18 47.4 17.0 13.0 22.0 
A/G 30 40.5 13.0 10.0 17.0 15 41.7 14.0 13.0 18.0 15 39.5 10.0 9.0 27.0 rs9340799 
G/G 9 12.2 16.0 12.0 α 
0.646 
4 11.1 17.0 12 α 
0.284 
5 13.2 16.0 10.0 α 
0.928 
C/C 13 23.2 15.0 13.0 α 6 20.0 14.5 14.0 α 7 26.9 16.0 8.0 α 
T/C 26 46.4 13.5 10.0 16.0 13 43.3 14.0 13.0 α 13 50.0 13.0 7.0 α 
ESRα 
rs2234693 
T/T 17 30.4 19.0 16.0 24.0 
0.389 
11 36.7 17.0 16.0 α 
0.740 
6 23.1 21.5 13.0 α 
0.547 
C/A 24 27.0 14.5 13.0 23.0 12 26.7 13.5 12.0 α 12 27.3 20.0 13.0 α 
INPP-1 rs1882891 
C/C 65 73.0 15.0 13.0 17.0 
0.708 
33 73.3 15.0 14.0 20.0 
0.783 
32 72.7 14.0 10.0 21.0 
0.848 
PLC-γ1 rs8192707 A/A 51 60.0 16.0 14.0 20.0 27 64.3 15.0 14.0 20.0 24 55.8 18.5 13.0 24.0 
  A/G 29 34.1 13.0 10.0 17.0 13 31.0 13.0 9.0 α 16 37.2 14.0 7.0 25.0 
  G/G 5 5.9 10.0 10.0 α 
0.008 
2 4.8 8.5 1.0 α 
0.091 
3 7.0 10.0 10.0 α 
0.075 
  GG+AGd 34 40.0 13.0 10.0 15.0 0.005 15 35.7 13.0 9.0 16.0 0.030 19 44.2 13.0 10.0 23.0 0.039 
D/D 40 40.4 19.0 15.0 22.0 19 36.5 17.0 15.0 25.0 21 44.7 19.0 13.0 25.0 
D/I 38 38.4 13.0 10.0 18.0 19 36.5 14.0 13.0 20.0 19 40.4 10.0 10.0 24.0 ACE Alu ins/del 
I/I 21 21.2 14.0 13.0 16.0 
0.296 
14 26.9 14.0 13.0 16.0 
0.225 
7 14.9 14.0 7.0 α 
0.371 
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Figure III.49(a). Kaplan-Meier estimation of time to age at onset of OCD, according to 
PLC-γ1 genotype, in the whole OCD sample. GG (gly279gly) and AG (ser279gly)- carriers 
experienced significantly earlier ages at onset compared to AA (ser279ser)-carriers. 
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Figure III.49(b): Kaplan-Meier estimation of time to age at onset, according to the presence or 
absence of the G(gly279) PLC-γ1 allele in the whole OCD sample. Subjects carrying at least 
one G (gly279)-allele were found to experience lower ages at onset compared to those carrying 
the AA (ser279ser)-genotype (X refers to either the G or A alleles). 
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Figure III.49(c). Kaplan-Meier estimation of time to age at onset of OCD in males, grouped 
according to the presence or absence of the G (gly279) allele. Males carrying at least one G 
(ser279)-allele experienced significantly earlier ages at onset compared to those homozygous 
for the A-allele (X refers to either the G or A alleles). 
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Figure III.49 (d). Kaplan-Meier estimation of time to age at onset of OCD in females, 
grouped according to the presence or absence of the G (gly279) allele. Females carrying at 
least one G(gly279)-allele experienced significantly earlier ages at onset compared to those 
homozygous for the A-allele (X refers to either G or A). 
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III.4.3.2.2. Single locus analysis of multi-allelic loci 
 
 i. DRD4 
A large number of genotypes (9 in total) were observed for the DRD4 48bp VNTR 
polymorphism amongst OCD subjects for whom age at onset was recorded, at least two thirds 
of which could be considered rare (<10%) in the present study. The 95% CIs corresponding to 
the median ages at onset in individuals carrying the rare genotypes are thus very wide, with 
the result that very little reliable information can be derived from them. Consequently, as for 
the Y-BOCS analyses (section III.4.2.2.2[i]), it was decided to group the genotypes 
according to the presence of at least one A4-allele (Table III.29). However, the analyses was 
not found to yield a statistically significant result when the whole OCD population was 
considered (p = 0.917), or when stratified by gender (p = 0.963 and p = 0.838 for males and 
females, respectively).  
 
ii. DAT 
Five genotypes were observed in the total OCD sample for whom age at onset was recorded. 
As one of these, the A10/A2 genotype, was observed in only one person, it was decided that 
this genotype should be excluded from the analysis; the age at onset of this individual had 
been 12 years.  
 
Results generated for the remaining genotypes are presented, with the caution that they should 
be viewed as preliminary. OCD subjects carrying the A10/A11 genotypes experienced 
significantly earlier ages at onset (p < 0.001) compared to those homozygous for either the 
A10 or A9-alleles, and A9/A10 heterozygotes (Table III.30; Figure III.50[a]). Upon 
stratification, however, this association was only observed in the male population (p < 0.001) 
(Figure III.50 [b]) and not in the female population (p=0.860).  
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Table III.29. Kaplan-Meier estimates of the ages at onset of OCD according to DRD4 
48bp VNTR genotypes, grouped according to the presence or absence of at least one 
A4-allele. 
 
Total OCD samplea 
95% CIa Genotype 
n % median 
LBb UBc 
A4/A4 30 36.6 14.0 13 22 
A4/other 43 52.4 15.0 13 18 
other/other 9 11.0 23.0 12 α 
 Male 
A4/A4 12 28.6 15.0 13 α 
A4/other 23 59.5 15.0 13 20 
other/other 5 11.9 13.0 4 α 
 Female 
A4/A4 21 45.7 13.5 10 25 
A4/other 20 43.5 16.5 13 24 
other/other 5 10.9 23.5 12 α 
 
Total p = 0.917; males p = 0.963 female p = 0.838 
α=infinity 
A4 = 4-repeat allele; “other” alleles comprise A2, A3, A7and A6 alleles 
aconfidence interval; blower boundary of 95% CI; c upper boundary of 95% CI. 
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Table III.30 Kaplan-Meier estimates of the ages at onset of OCD according to DAT 
40bp VNTR genotypes. 
 
Total OCD samplea 
95% CIa Genotype 
n % median 
LBb UBc 
A10/A10 50 50.5 16.0 14.0 18.0 
A10/A9 38 38.4 14.0 12.0 19.0 
A9/A9 8 8.1 11.0 7.0 α 
A10/A11 4 3.0 7.3 1.0 α 
 Male 
A10/A10 26.0 52.0 16.5 14.0 20.0 
A10/A9 18.0 36.0 13.5 13.0 16.0 
A9/A9 3.0 6.0 13.0 9.0 α 
A10/A11 3.0 6.0 7.3 1.0 α 
 Female 
A10/A10 24.0 49.0 15.5 13.0 18.0 
A10/A9 20.0 40.8 19.0 10.0 25.0 
A9/A9 5.0 10.2 7.0 5.0 α 
 
Total p < 0.001; male p < 0.001; female p = 0.860 
A9 = 9-repeat allele; A10 = 10-repeat allele; A11 = 11-repeat allele 
aconfidence interval; blower boundary of 95% CI; c upper boundary of 95% CI. 
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Figure III.50(a). Kaplan-Meier estimation of time to age at onset of OCD, according to 
DAT 40bp VNTR genotypes observed in the present sample (excluding A10/A2). 
Individuals carrying the A10/A11 genotype experienced significantly earlier ages at onset. 
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Figure III.50(b). Kaplan-Meier estimation of time to age at onset of OCD in males, 
according to DAT 40bp VNTR genotypes observed in the present sample (excluding 
A10/A2). Individuals carrying the A10/A11 genotype experienced significantly earlier ages 
at onset.
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III.4.3.3. Haplotype analyses: age at onset 
 
III.4.3.3.1. 5-HT2A haplotype analysis 
When the haplotypes comprising the SNPs genotyped in 5-HT2A were analysed for any 
differences in median ages at onset, the global p-value of 0.443 indicated that no significant 
differences were present (Table III.31).  
 
III.4.3.3.2. DRD4 haplotype analysis 
Haplotype frequencies for the two DRD4 polymorphisms investigated are presented in Table 
III.32. No statistically significant differences were observed, with a global p-value of 0.319. 
 
III.4.3.3.3. COMT haplotype analysis 
The results from the age at onset haplotype analysis involving the three COMT variants 
genotyped are represented in Table III.33. No statistically significant differences in age at 
onset between haplotypes were noted, with global p-value of 0.850. 
 
III.4.3.3.4. GRIN2B haplotype analysis 
Although the global p-value indicated only a trend towards significant differences in age at 
onset (p = 0.060) between the four possible haplotypes comprising the GRIN2B rs890 and 
rs1806191 variants, it was found that those OCD patients carrying the G-A haplotype 
experienced significantly later onset compared to those carrying the remaining haplotypes 
(haplotype score=2.541; individual p-value = 0.011). Conversely, those OCD patients 
carrying the A-C haplotype exhibited significantly earlier ages at onset (haplotype score =       
-2.382; individual p-value = 0.018) (Table III.34). 
 
III.4.3.3.5. BDNF haplotype analysis 
Although the BDNF val66met (rs6265) variant was found to be associated with age at onset of 
OCD in males when single loci were analysed (Table III.28[c]), no statistically significant 
differences were observed when haplotype analysis of the three BDNF markers, val66met 
(rs6265), rs2049046 and rs988748 was conducted (global p-value = 0.584) (Table III.35). 
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III.4.3.3.6. ESRα haplotype analysis 
No statistically significant differences in age at onset between haplotypes formed by the ESRα 
intronic SNPs, rs9340799 and rs2234693, was noted, with global p-value of 0.829 (Table 
III.36).  
 
 
Table III.31. Haplotype analysis of candidate markers within 5-HT2A and age at onset  
distribution. 
 
Variants 
rs6311 rs6313 
Haplotype Frequency 
(n=95) Haplotype Score Individual p-value 
G C 0.622 0.992 0.320 
A T 0.329 -0.862 0.409 
A C 0.027 0.669 0.503 
Global p=0.443 
 
 
Table III.32. Haplotype analysis of candidate markers within DRD4 and age at onset  
distribution. 
 
Global p=0.319 
A4=4-repeat allele; A2=2-repeat allele; A3=3-repeat allele; A7=7-repeat allele 
 
 
 
 
 
 
 
Variants 
rs1800955 48bp VNTR 
Haplotype 
Frequency  
(n=65) 
Haplotype Score Individual p-value 
T A4 0.396 1.09 0.271 
C A4 0.191 -1.10 0.269 
T A7 0.122 0.09 0.922 
C A7 0.110 -0.37 0.691 
T A2 0.071 0.26 0.821 
C A2 0.059 0.63 0.528 
C A3 0.039 -0.70 0.479 
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Table III.33. Haplotype analysis of candidate markers within COMT and age at onset 
distribution. 
Global p=0.850 
 
 
Table III.34. Haplotype analysis of candidate markers within GRIN2B and age at onset 
distribution. 
 
Variants 
rs1806191 rs890 
Haplotype Frequency 
(n=52) Haplotype Score Individual p-value 
G A 0.475 2.541 0.011 
A C 0.273 -2.382 0.018 
G C 0.131 -0.137 0.902 
A A 0.122 0.110 0.916 
Global p=0.060 
Significant p-values are indicated in red, bold font. 
 
 
 
Table III.35. Haplotype analysis of candidate markers within BDNF and age at onset 
distribution. 
 
Variants 
rs6265 rs2049046 rs988748 
Haplotype Frequency 
(n=32) 
Haplotype 
Score 
Individual p-
value 
G A C 0.453 0.486 0.631 
A T G 0.266 -1.112 0.266 
G T C 0.250 0.664 0.509 
Global p=0.584 
 
 
 
 
 
Variants 
rs2097603 rs4680 rs362204 
Haplotype 
Frequency (n=29) Haplotype Score Individual p-value 
G A D 0.363 0.516 0.630 
A A D 0.194 0.209 0.833 
A G I 0.132 -0.503 0.631 
G G D 0.132 0.433 0.682 
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Table III.36. Haplotype analysis of candidate markers within ESRα and age at onset 
distribution. 
 
Variants 
rs9340799 rs2234693 
Haplotype Frequency 
(n=55) Haplotype Score Individual p-value 
A T 0.510 0.614 0.556 
G C 0.343 -0.270 0.761 
A C 0.147 -0.519 0.643 
Global p=0.829 
 
III.4.4. Stratification by co-morbidity 
 
The OCD sample was also stratified according to the presence or absence of selected co-
morbid disorder. Since the sample sizes become small after stratification of the OCD sample, 
genetic analyses were conducted using the most common co-morbid disorders observed in the 
present study; namely, co-morbid major depressive disorder (MDD), and the presence or 
absence of tics. Following this logic, haplotype analyses were not conducted, due to the 
reduced numbers after stratification for co-morbidity. 
 
III.4.4.1. Major depressive disorder (MDD) 
 
III.4.4.1.1. Analysis of clinical variables  
Major depressive disorder (MDD) has been found to be the most prevalent disorder occurring 
co-morbidly with OCD: in the present study, 64.6% of the OCD patients presented with co-
morbid MDD (Table III.7). For this reason, it was of interest to determine whether OCD 
patients exhibiting co-morbid MDD (OCD+MDD) differed genetically or clinically from 
those patients who did not exhibit MDD (OCD-MDD).  
 
Initial comparisons were made between the two groups of patients and selected demographic 
and clinical factors, and certain aspects of a family history of psychiatric disorders (Table 
III.37). Male OCD patients presenting with co-morbid MDD were, on average, younger than 
female OCD patients with co-morbid MDD, although this difference did not reach statistical 
significance (median ages at onset=13 years [95% CI: 12-15] and 16 years [95% CI: 13-21] 
for males and females, respectively; p=0.198). No statistically significant differences were 
observed when gender (p = 0.580 [Table III.7]), total Y-BOCS score (p = 0.515 [Table 
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III.17]) or age at onset of OCD (p = 0.337 [Table III.27]) were compared between the two 
patient groups. Moreover, no significant differences in presence or absence of family history 
of OCD (p = 0.182), OCS (p = 0.062) or tics (p = 0.605) were noted between the groups 
(Table III.37). 
 
However, when the frequencies of symptom subtypes were compared between the groups, 
significantly more patients with MDD experienced sexual/religious symptoms compared to 
those without MDD (50.0% versus 25.8%, respectively; p = 0.042) (Table III.37).   
 
III.4.4.1.2. Single locus analysis according to the presence or absence of co-morbid MDD 
 
III.4.4.1.2.1. Single locus analysis of bi-allelic polymorphisms 
The genotype and allele scores and their corresponding frequencies for each bi-allelic 
polymorphism investigated are represented in Table III.38. The results of the genetic 
association analyses comparing genotype and allele frequencies between OCD patients with 
MDD and those without, are depicted in Table III.39(a), and between OCD patients exhibiting 
co-morbid MDD and controls are presented in Table III.39(b). 
 
Two significant associations were observed: firstly, the C-allele of the 5-HT6 SNP, 
rs1805054, was found to be significantly overrepresented in the OCD-MDD group (p=0.004; 
OR=0.22 [95% CI: 0.05-0.68]) (Tables III.38 and III.39[a]), and in the control group 
(p=0.008; OR=0.47 [95% CI: 0.27-0.83]) (Tables III.3[b], III.38 and III.39[b]), indicating that 
this allele may confer protection against the development of co-morbid MDD. 
 
Secondly, when the genotypic distribution of the COMT promoter SNP, rs2097603, was 
compared between the two OCD subsets, significantly more OCD-MDD patients possessed 
the AA-genotype compared to OCD+MDD patients (p = 0.038; OR = 0.21 [95% CI: 0.04-
0.97]) indicating that this genotype may confer protection against the development of co-
morbid MDD.  The allelic distribution was also found to differ significantly between 
OCD+MDD and the OCD-MDD subsets (p = 0.035; OR = 0.43 [95% CI: 0.18-0.98]) (Table 
III.39[a]). The OR value of the aforementioned association indicates that the A-allele may 
represent a protective allele.  
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Table III.37. Clinical characteristics in the OCD patient subset according to the presence 
(OCD+MDD) or absence of MDD (OCD-MDD) as a co-morbid disorder. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
an(OCD+MDD)=50; n(OCD-MDD)=30; bn(OCD+MDD)=58; n(OCD-MDD)=31 
Abbreviations: MDD: Major depressive disorder OCD: obsessive-compulsive disorder; OCS: Obsessive-
compulsive symptoms. 
Clinical Variables OCD+MDD OCD-MDD 
Family Historya 
 n % n % 
p-value 
  
Family history of OCD 10 20.0 10 33.3 0.182 
Family history of OCS 19 38.0 18 60.0 0.062 
Family history of tics  4 8.0 2 6.7 0.605 
Primary Symptom 
Dimensions b      
Hoarding 14 24.1 8 25.8 0.862 
Symmetry/ ordering 36 62.1 17 54.8 0.571 
Sexual/religious 29 50.0 8 25.8 0.042 
Contamination 37 63.8 17 54.8 0.469 
Aggression 31 53.4 14 45.2 0.456 
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Table III.38. Genotype and allele scores and frequencies in bi-allelic candidate polymorphisms in OCD patients presenting with co-morbid 
MDD (OCD+MDD) and those without co-morbid MDD (OCD-MDD).  
 
 
an1  refers to the major allele, n2  refers to the minor allele.  
Abbreviations: 5-HT2A: serotonin receptor 2A; 5-HT1Dβ: serotonin receptor 1Dβ; 5-HT6: serotonin receptor 6;  DRD4: dopamine receptor 4; DRD2: dopamine receptor 2; COMT: Catechol-O-methyltransferase; DRD3: 
dopamine receptor 3; DRD1: dopamine receptor 1; GRIN2B: glutamate receptor subunit 2B; BDNF: brain-derivedneurotrophic factor; HOXB8: homeobox gene B8;  ESRα: estrogen receptor α; INPP-1: inositol 
polyphosphate-phosphatase 1; PLCγ1: phospholipase-gamma; ACE: Angiotensin-converting enzyme.
OCD+MDD OCD-MDD 
Genotype  Alleles Genotype Alleles Gene Variant n1/n2a 
n11 % n12 % n22 % 
Total 
n1 % n2 % n11 % n12 % n22 % 
Total 
n1 % n2 % 
rs6311 G/A 26 37.7 32 46.4 11 15.9 69 84 60.9 54 39.1 17 45.9 13 35.1 7 18.9 37 47 63.5 27 36.5 
5-HT2A 
rs6313 C/T 26 39.4 27 40.9 13 19.7 66 79 59.8 53 40.2 18 48.6 12 32.4 7 18.9 37 48 64.9 26 35.1 
5-HT1Dβ rs6296 G/C 29 46.0 30 47.6 4 6.3 63 88 69.8 38 30.2 23 63.9 10 27.8 3 8.3 36 56 77.8 16 22.2 
5-HT6 rs1805054 C/T 29 51.8 25 44.6 2 3.6 56 83 74.1 29 25.9 24 85.7 4 14.3 0 0.0 28 52 92.9 4 7.1 
DRD4 rs1800955 T/C 20 35.1 28 49.1 9 15.8 57 68 59.6 46 40.4 10 31.3 17 53.1 5 15.6 32 37 57.8 27 42.2 
DRD2 rs1800497 C/T 39 59.1 25 37.9 2 3.0 66 103 78.0 29 22.0 18 50.0 15 41.7 3 8.3 36 51 70.8 21 29.2 
rs2097603 A/G 8 21.1 15 39.5 15 39.5 38 31 40.8 45 59.2 8 38.1 10 47.6 3 14.3 21 26 61.9 16 38.1 
rs4680 A/G 14 25.9 29 53.7 11 20.4 54 57 52.8 51 47.2 9 26.5 21 61.8 4 11.8 34 39 57.4 29 42.6 COMT 
rs362204 D/I 16 44.4 18 50.0 2 5.6 36 50 69.4 22 30.6 12 75.0 4 25.0 0 0.0 16 28 87.5 4 12.5 
DRD3 rs6280 A/G 36 56.3 22 34.4 6 9.4 64 94 73.4 34 26.6 17 54.8 8 25.8 6 19.4 31 42 67.7 20 32.3 
DRD1 A-48G A/G 22 33.8 37 56.9 6 9.2 65 81 62.3 49 37.7 17 50.0 12 35.3 5 14.7 34 46 67.6 22 32.4 
rs1806191 G/A 14 41.2 15 44.1 5 14.7 34 43 63.2 25 36.8 8 40.0 8 40.0 4 20.0 20 24 60.0 16 40.0 
GRIN2B 
rs890 A/C 12 35.3 18 52.9 4 11.8 34 42 61.8 26 38.2 6 28.6 12 57.1 3 14.3 21 24 57.1 18 42.9 
rs6265 G/A 44 60.3 26 35.6 3 4.1 73 114 78.1 32 21.9 27 73.0 7 18.9 3 8.1 37 61 82.4 13 17.6 
rs2049046 T/A 8 26.7 16 53.3 6 20.0 30 32 53.3 28 46.7 6 30.0 8 40.0 6 30.0 20 20 50.0 20 50.0 BDNF 
rs988748 C/G 14 45.2 17 54.8 0 0.0 31 45 72.6 17 27.4 11 61.1 5 27.8 2 11.1 18 27 75.0 9 25.0 
HOXB8 rs2303486 A/T 11 37.9 12 41.4 6 20.7 29 34 58.6 24 41.4 8 40.0 8 40.0 4 20.0 20 24 60.0 16 40.0 
rs9340799 A/G 24 48.0 19 38.0 7 14.0 50 67 67.0 33 33.0 15 48.4 13 41.9 3 9.7 31 43 69.4 19 30.6 
ESRα 
rs2234693 T/C 12 33.3 18 50.0 6 16.7 36 42 58.3 30 41.7 7 28.0 11 44.0 7 28.0 25 25 50.0 25 50.0 
INPP-1 rs1882891 C/A 45 76.3 13 22.0 1 1.7 59 103 87.3 15 12.7 25 69.4 11 30.6 0 0.0 36 61 84.7 11 15.3 
PLC-γ1 rs8192707 A/G 34 59.6 18 31.6 5 8.8 57 86 75.4 28 24.6 21 63.6 12 36.4 0 0.0 33 54 81.8 12 18.2 
ACE Alu Ins/del D/I 29 40.8 25 35.2 17 23.9 71 83 58.5 59 41.5 13 36.1 18 50.0 5 13.9 36 44 61.1 28 38.9 
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Table III.39(a). Association analyses investigating the differences in genotype and allele 
distributions between OCD subjects with co-morbid MDD and those without co-morbid 
MDD in bi-allelic loci, with corresponding p-values, ORs and 95% CIs. 
Significant p-values are indicated in red, bold font. 
an1 refers to the major allele, n2 refers to the minor allele bgenotypic OR is calculated with the major genotype representing the risk 
genotype; callelic OR is calculated assuming the major allele to be the risk allele;dlower boundary of the 95% CI; eUpper boundary of the 
95% CI 
Abbreviations: OR: Odds ratio; CI: confidence interval; 5-HT2A: serotonin receptor 2A; 5-HT1Dβ: serotonin receptor 1Dβ; 5-HT6: 
serotonin receptor 6; DRD4: dopamine receptor 4; DRD2: dopamine receptor 2; COMT: Catechol-O-methyltransferase; DRD3: 
dopamine receptor 3; DRD1: dopamine receptor 1; GRIN2B: glutamate receptor subunit 2B; BDNF: brain-derivedneurotrophic factor; 
HOXB8: homeobox gene B8; ESRα: estrogen receptor α; INPP-1: inositol polyphosphate-phosphatase 1; PLC-γ1: phospholipase-
gamma; ACE: Angiotensin-converting enzyme 
 
 
Genotype Allele 
95% CI 95% CI Gene Variant n1/n2a p-
value OR
b 
LBd UBe 
Power p-value OR
c 
LBd UBe 
Power 
rs6311 G/A 1.000 0.97 0.26 3.42 0.054 0.768 0.89 0.48 1.66 0.054 
5-HT2A 
rs6313 C/T 0.784 0.78 0.22 2.62 0.052 0.551 0.81 0.43 1.51 0.075 
5-HT1Dß rs6296 G/C 1.000 0.95 0.13 6.22 0.059 0.250 0.66 0.31 1.35 0.140 
5-HT6 rs1805054 C/T 0.499 0.00 0.00 6.87 0.073 0.004 0.22 0.05 0.68 0.667 
DRD4 rs1800955 T/C 1.000 1.11 0.23 4.98 0.053 0.874 1.08 0.55 2.10 0.051 
DRD2 rs1800497 C/T 0.325 3.18 0.33 41.20 0.101 0.307 1.46 0.72 2.95 0.128 
rs2097603 A/G 0.038 0.21 0.04 0.97 0.313 0.035 0.43 0.18 0.98 0.417 
rs4680 A/G 0.501 0.57 0.10 2.79 0.065 0.641 0.83 0.43 1.60 0.065 COMT 
rs362204 D/I 0.503 0.00 0.00 8.01 0.065 0.054 0.33 0.08 1.10 0.317 
DRD3 rs6280 A/G 0.319 2.09 0.48 9.15 0.107 0.493 1.31 0.64 2.67 0.083 
DRD1 A-48G A/G 1.000 1.08 0.22 5.07 0.054 0.533 0.79 0.40 1.53 0.077 
rs1806191 G/A 0.704 1.39 0.21 8.75 0.050 0.838 1.15 0.47 2.75 0.051 
GRIN2B 
rs890 A/C 0.673 1.48 0.16 12.30 0.050 0.691 1.21 0.51 2.84 0.056 
rs6265 G/A 0.673 1.62 0.20 13.00 0.052 0.485 0.76 0.34 1.62 0.076 
rs2049046 T/A 1.000 1.32 0.22 8.15 0.050 0.839 1.14 0.48 2.75 0.051 BDNF 
rs988748 C/G 0.222 α 0.21 α 0.100 1.000 0.88 0.30 2.46 0.050 
HOXB8 rs2303486 A/T 1.000 0.92 0.14 5.54 0.056 1.000 0.95 0.38 2.31 0.050 
rs9340799 A/G 0.726 0.69 0.10 3.64 0.051 0.863 0.90 0.43 1.86 0.051 
ESRα 
rs2234693 T/C 0.473 1.96 0.38 10.60 0.077 0.460 1.40 0.64 3.08 0.092 
INPP-1 rs1882891 C/A 1.000 0.00 0.00 71.70 0.057 0.666 1.24 0.48 3.10 0.056 
PLC-γ1 rs8192707 A/G 0.152 0.00 0.00 1.97 0.178 0.357 0.68 0.29 1.53 0.102 
ACE Alu ins/del D/I 0.568 0.66 0.16 2.43 0.062 0.769 0.90 0.48 1.66 0.054 
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Table III.39(b). Association analyses investigating the differences in genotype and allele 
distributions between OCD subjects with co-morbid MDD and controls in bi-allelic loci, with 
corresponding p-values, ORs and 95% CIs. 
 
 
Significant p-values are indicated in red, bold font. 
an1 refers to the major allele, n2 refers to the minor allele bgenotypic OR is calculated with the major genotype representing the risk 
genotype; callelic OR is calculated assuming the major allele to be the risk allele;dlower boundary of the 95% CI; eUpper boundary of the 
95% CI;  
 Abbreviations: OR: Odds ratio; CI: confidence interval; 5-HT2A: serotonin receptor 2A; 5-HT1Dβ: serotonin receptor 1Dβ; 5-HT6: 
serotonin receptor 6; DRD4: dopamine receptor 4; DRD2: dopamine receptor 2; COMT: Catechol-O-methyltransferase; DRD3: dopamine 
receptor 3; DRD1: dopamine receptor 1; GRIN2B: glutamate receptor subunit 2B; BDNF: brain-derivedneurotrophic factor; HOXB8: 
homeobox gene B8;  ESRα: estrogen receptor α; INPP-1: inositol polyphosphate-phosphatase 1; PLC-γ1: phospholipase-gamma; ACE: 
Angiotensin-converting enzyme 
 
 
Genotype Allele 
95% CI 95% CI Gene Variant n1/n2a p-
value OR
b 
LBd UBe 
Power p-value ORc 
LBd UBe 
Power 
rs6311 G/A 0.623 0.82 0.37 1.83 0.050 0.684 0.92 0.61 1.39 0.050 
5-HT2A 
rs6313 C/T 0.933 1.04 0.44 2.42 0.062 0.985 1.00 0.66 1.51 0.068 
5-HT1Dß rs6296 G/C 0.777 0.84 0.25 2.84 0.189 0.222 0.75 0.48 1.19 0.246 
5-HT6 rs1805054 C/T 0.126 0.18 0.02 2.08 0.660 0.008 0.47 0.27 0.83 0.770 
DRD4 rs1800955 T/C 0.283 1.65 0.66 4.15 0.148 0.278 1.28 0.82 1.99 0.192 
DRD2 rs1800497 C/T 0.210 2.64 0.55 12.63 0.111 0.408 1.23 0.75 2.02 0.140 
rs2097603 A/G 0.012 0.49 0.28 0.86 0.572 0.018 0.29 0.10 0.83 0.684 
rs4680 G/A 0.390 0.66 0.26 1.70 0.111 0.409 0.83 0.53 1.30 0.141 COMT 
rs362204 D/I 0.302 2.29 0.46 11.37 0.097 0.426 1.26 0.71 2.25 0.120 
DRD3 rs6280 A/G 0.143 2.12 0.77 5.86 0.340 0.060 1.57 0.98 2.52 0.452 
DRD1 A-48G A/G 0.526 1.40 0.49 4.03 0.154 0.825 1.05 0.68 1.62 0.058 
rs1806191 G/A 0.345 1.96 0.48 7.99 0.617 0.243 1.48 0.77 2.87 0.736 
GRIN2B 
rs890 A/C 0.452 1.75 0.40 7.58 0.092 0.483 1.26 0.66 2.44 0.105 
rs6265 G/A 0.184 0.31 0.05 1.91 0.256 0.195 0.72 0.44 1.19 0.267 
rs2049046 A/T 0.201 0.43 0.12 1.58 0.183 0.216 0.68 0.37 1.26 0.228 BDNF 
rs988748 C/G 0.550 1.10 0.04 28.53 0.404 0.183 0.62 0.30 1.26 0.265 
HOXB8 rs2303486 T/A 0.229 0.44 0.11 1.70 0.345 0.197 0.64 0.33 1.26 0.252 
rs9340799 A/G 0.573 1.32 0.50 3.51 0.080 0.483 1.19 0.73 1.93 0.096 
ESRα 
rs2234693 T/C 0.233 1.94 0.65 5.81 0.180 0.242 1.38 0.81 2.35 0.199 
INPP-1 rs1882891 C/A 0.972 0.96 0.09 10.84 0.067 0.706 0.88 0.45 1.72 0.070 
PLC-γ1 rs8192707 A/G 0.146 0.37 0.09 1.48 0.207 0.391 0.79 0.47 1.35 0.160 
ACE Alu ins/del D/I 0.245 0.50 0.15 1.65 0.701 0.203 0.71 0.41 1.21 0.566 
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Indeed, when the allele and genotype frequencies of the same SNP were compared between 
the OCD+MDD and control samples (Table III.3[b], Table III.38 and Table III.39[b]), 
significant differences in both the genotypic (p = 0.012; OR = 0.49 [95% CI: 0.28-0.86]) and 
allelic (p = 0.018; OR = 0.29 [95% CI: 0.10-0.83]) (Table III.39[b]) distributions were 
observed, re-inforcing the assumption that the rs2097603 AA-genotype confers protection 
against the development of co-morbid MDD.  
 
III.4.4.1.2.2. Single locus analysis of multi-allelic polymorphisms 
 
 i. DRD4 
The genotype and allele counts for the DRD4 48bp VNTR in OCD+MDD and OCD-MDD 
subgroups are provided in Tables III.40 (a) and (b). No statistically significant differences in 
genotype (p = 0.884) or allele (p = 0.976) were observed between the two OCD subsets.  
 
Likewise, when the genotype and allele frequencies were compared between OCD+MDD and 
control samples, no statistically significant differences were observed (p = 0.384 and p = 
0.851 for genotype and allele analyses, respectively (Tables III.4[a] and [b] and III.40[a] and 
[b]). 
 
 ii. DAT 
Genotype and allele counts and frequencies for the DAT 40bp VNTR in the OCD patients 
presenting with co-morbid MDD, and those not, are provided in Tables III.41[a] and [b]), no 
statistically significant differences could be observed between OCD patients with co-morbid 
MDD and those without (p = 0.388 and p = 0.253, respectively). 
 
Likewise, when the DAT 40bp VNTR genotype and allele frequencies were compared 
between the OCD+MDD and control samples, no statistically significant differences were 
observed (p = 0.367 and p = 0.378 for genotype and allele analyses, respectively) (Tables 
III.5[a] and [b] and III.41[a] and [b]).  
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Table III.40(a). The genotype counts and associated frequencies in the DRD4 48bp VNTR 
OCD subjects presenting with co-morbid MDD (OCD+MDD) and those without co-morbid 
MDD (OCD-MDD). 
 
OCD+MDD OCD-MDD Genotype 
n % n % 
A4/A4 21 40.4 11 32.4 
A4/A7 11 21.2 10 29.4 
A4/A2 8 15.4 7 20.6 
A4/A3 6 11.5 3 8.8 
A7/A7 3 5.8 1 2.9 
A2/A2 1 1.9 0 0.0 
A3/A6 1 1.9 0 0.0 
A7/A2 1 1.9 1 2.9 
A7/A3 0 0.0 1 2.9 
p=0.884 
A4=4-repeat allele; “other” alleles comprise A2, A3, A7and A6 alleles 
Abbreviations: OCD: obsessive-compulsive disorder; MDD: major 
depressive disorder 
 
 
 
Table III.40(b). The allele counts and associated frequencies in the DRD4 48bp VNTR in 
OCD subjects presenting with co-morbid MDD (OCD+MDD) and those without co-morbid 
MDD (OCD-MDD). 
 
OCD+MDD OCD-MDD 
Allele 
n % n % 
A4 67 64.4 42 61.8 
A7 18 17.3 14 20.6 
A2 11 10.6 8 11.8 
A3 7 6.7 4 5.9 
A6 1 1.0 0 0.0 
p = 0.976 
A4 = 4-repeat allele; “other” alleles comprise A2, A3, A7and A6 alleles 
Abbreviations: OCD: obsessive-compulsive disorder; MDD: major 
depressive disorder 
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Table III.41(a). The genotype counts and associated frequencies in the DAT 40bp VNTR 
OCD subjects presenting with co-morbid MDD (OCD+MDD) and those without co-morbid 
MDD (OCD-MDD). 
 
OCD+MDD OCD-MDD 
Genotype 
n % n % 
A10/A10 34 48.6 23 97.1 
A9/A10 27 38.6 9 77.1 
A9/A9 6 8.6 2 17.1 
A10/A11 2 2.9 1 5.7 
A2/A10 1 1.4 0 2.9 
 
p = 0.388  
A2 = 2-repeat allele; A9 = 9-repeat allele; A10 = 10-repeat allele; A11 = 11-repeat allele 
Abbreviations: OCD: obsessive-compulsive disorder; MDD: major depressive disorder 
 
 
 
Table III.41(b). The allele counts and associated frequencies in the DAT 40bp VNTR in OCD 
subjects presenting with co-morbid MDD (OCD+MDD) and those  without co-morbid MDD 
(OCD-MDD). 
 
OCD+MDD OCD-MDD 
Allele 
n % n % 
A10 98 70.0 56 80.0 
A9 39 27.9 13 18.6 
A11 2 1.4 1 1.4 
A2 1 0.7 0 0.0 
 
p = 0.253 
A2= 2-repeat allele; A9 = 9-repeat allele; A10 = 10-repeat allele; A11 = 11-repeat allele;  
Abbreviations: OCD: obsessive-compulsive disorder; MDD: major depressive disorder 
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III.4.4.2. Co-morbid tics 
 
III.4.4.2.1. Clinical variables 
Although more males did present with co-morbid tics compared to female OCD subjects 
(19.1% versus 8.5%), this difference did not reach statistical significance (p = 0.126) (Table 
III.7 and Figure III.41). In addition, no significant differences in total Y-BOCS score were 
observed (p = 0.476 [Table III.17]). Although the OCD subjects exhibiting co-morbid tics did 
experience, on average, earlier ages at onset than those subjects who were not diagnosed with 
co-morbid tic disorders, this difference was not statistically significant (median ages at 
onset=10 years [95% CI: 5.9-14.1] and 14 years [95% CI: 12.3-15.7], respectively; p=0.100 
[Table III.27]). 
 
The family history and symptom dimensions of OCD subjects with co-morbid tics 
(OCD+tics) and those without (OCD-tics) are presented in Table III.42. When the family 
history of OCD, OCS and tics was considered, no significant differences were observed with 
regard to the frequency of co-morbid tic disorders. When the frequency of co-morbid tics 
amongst patients with certain symptom dimensions was investigated, significantly more 
patients with contamination symptoms presented with tics, compared to those subjects 
without contamination symptoms (90.9% versus 57.5%, respectively; p=0.045).  
 
III.4.4.2.2. Single locus analysis according to the presence or absence of co-morbid tics 
Since the maximum number of OCD patients presenting with co-morbid tics amounted to 18 
(i.e. 14% of the population), only those variants for which more than 60 subjects had been 
genotyped were utilised in the genetic analyses. 
 
III.4.4.2.2.1. Single locus analysis of bi-allelic polymorphisms  
The genotype and allele distributions of the selected variants in the OCD+tics and OCD-tics 
subsets are represented in Table III.43. The results of the association analyses between the 
two OCD subsets are represented in Table III.44(a), whilst those for the genetic analyses 
between the OCD+tics and control samples are presented in Table III.44(b) (the genotype and 
allele distributions of the control subjects are represented in Table II.3[b]).  
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Table III.42. Clinical characteristics in the OCD patient subset according to  
the presence (OCD+tics) or absence (OCD-tics) of tics. 
 
 
 
 
 
 
 
 
 
 
 
an(OCD+tics) =12, n(OCD-tics) =68; bn (OCD+tics)=11, n(OCD-tics) =80.  
Abbreviations: OCD: Obsessive-compulsive disorder; OCS: Obsessive-compulsive symptoms 
 
 
A statistically significant difference in genotype and allele distribution between the two OCD 
subgroups was observed for the COMT val158met (rs4680) polymorphism (p=0.026; 
OR=0.10 [95% CI: 0.00-0.86] and p = 0.004; OR = 0.30 [95% CI: 0.11-0.74]) (Table 
III.44[a]), with the G (val158)-allele assumed to confer protection against the development of 
co-morbid tics. When the genotype and allele frequencies between the OCD+tics and control 
samples were compared, differences in frequencies were also observed (p=0.006; OR=0.08 
[95% CI: 0.01-0.70]) and p = 0.002; OR = 0.29 [95% CI: 0.12-0.65], respectively) (Table 
III.44[b]). Once again, the G (val158)-allele was found to be underrepresented amongst the 
OCD+tics group, and thus might be assumed to confer protection against the development of 
this subtype. 
 
The BDNF val66met (rs6265) polymorphism was also found to exhibit significantly different 
genotype frequencies in the two OCD subsets under investigation (p = 0.035; OR = 0.13 [95% 
CI: 0.02-1.16]) (Table III.44[a]), with an increase in AA homozygotes in the OCD+tics group 
indicating that the possession of the G(val66)-allele confers protection against developing co-
morbid tics. When the BDNF val66met allele frequencies were analysed, the frequency of the 
A(met66)-allele was greater amongst the OCD+tics subset, although this difference did not 
reach statistical significance (p=0.059; OR=0.45 [95% CI: 0.18-1.18]). When the allele and 
Clinical Variable OCD+tics OCD-tics 
Family Historya n % n % 
p-value 
Family history of OCD  5 41.7 15 22.1 0.163 
Family history of OCS  5 41.7 32 47.1 1.000 
Family history of tics  2 16.7 4 5.9 0.219 
Primary Symptom 
Dimensionsb      
Hoarding  3 27.3 20 25.0 1.000 
Symmetry/ ordering 7 63.6 47 58.8 1.000 
Sexual/religious  5 45.5 33 41.3 1.000 
Contamination  10 90.9 46 57.5 0.045 
Aggression  6 54.5 41 51.3 1.000 
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genotype frequencies in the OCD+tics and control samples were compared, significant 
differences in both the allele and genotype distributions were observed (p=0.026; OR=0.40 
[95% CI: 0.18-0.92] and p<0.001; OR=0.06 [95% CI: 0.01-0.39] for allele and genotype 
association analyses, respectively) (Table III.44[b]). Once again, the G(val66)-allele was 
found at a lower frequency in the OCD+tics group, and implying that it confers protection 
against the development of co-morbid tics.  
 
No further significant differences in genotype or allele distributions were observed between 
the two OCD subsets, or between the OCD+tics subset and controls. 
 
III.4.4.2.2.2. Single locus analysis of multi-allelic polymorphisms 
 
 i. DRD4 
Tables III.45 (a) and (b) depicts the genotype and allele frequencies, respectively, in OCD 
patients presenting with co-morbid tic disorder and those without, for the DRD4 48bp VNTR 
polymorphism. When the two OCD subsets were analysed, no statistically significant 
differences in genotype (p = 0.427) or allele (p = 0.513) frequencies were detected  
 
When the genotype and allele frequencies of the VNTR were compared between the 
OCD+tics and control samples, no statistically significant differences in distribution for either 
were observed (p = 0.224 and p = 0.292 for genotype and allele analyses, respectively ) 
(Tables III.4[a] and [b] and III.45[a] and [b]). 
 
 ii. DAT 
The genotype and allele counts and frequencies for the DAT 40bp VNTR are presented in 
Tables 46(a) and (b), respectively. No statistically significant differences were observed for 
genotype or allele frequencies when the two OCD subsets were investigated (p = 0.747 and p 
= 0.900, respectively. Likewise, when the OCD+tics and control samples were compared, no 
significant distributions in DAT 40bp VNTR genotype or allele frequencies were observed (p 
= 0.550 and p = 0.527, respectively) (Tables III.5[a] and [b] and III.46[a] and [b]) .  
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Table III.43 Genotype and allele scores and frequencies in bi-allelic candidate polymorphisms in OCD patients presenting with co-morbid 
tics (OCD+tics) and those without co-morbid tics (OCD-tics).  
 
OCD+tics OCD-tics 
Genotype  Alleles Genotype Alleles Gene Variant n1/n2a 
n11 % n12 % n22 % 
Total 
n1 % n2 % n11 % n12 % n22 % 
Total 
n1 % n2 % 
rs6311 G/A 9 50.0 6 33.3 3 16.7 18 24 66.7 12 33.3 34 38.6 39 44.3 15 17.0 88 107 60.8 69 39.2 
5-HT2A 
rs6313 C/T 8 44.4 7 38.9 3 16.7 18 23 63.9 13 36.1 36 42.4 32 37.6 17 20.0 85 104 61.2 66 38.8 
5-HT1Dβ rs6296 G/C 13 72.2 4 22.2 1 5.6 18 30 83.3 6 16.7 39 48.1 36 44.4 6 7.4 81 114 70.4 48 29.6 
5-HT6 rs1805054 C/T 8 72.7 3 27.3 0 0.0 11 19 86.4 3 13.6 45 61.6 26 35.6 2 2.7 73 116 79.5 30 20.5 
DRD4 rs1800955 T/C 5 33.3 7 46.7 3 20.0 15 17 56.7 13 43.3 25 33.8 38 51.4 11 14.9 74 88 59.5 60 40.5 
DRD2 rs1800497 C/T 6 46.2 7 53.8 0 0.0 13 19 73.1 7 26.9 51 57.3 33 37.1 5 5.6 89 135 75.8 43 24.2 
COMT rs4680 G/A 1 5.9 6 35.3 10 58.8 17 8 23.5 26 76.5 14 19.7 44 62.0 13 18.3 71 72 50.7 70 49.3 
DRD3 rs6280 A/G 5 41.7 3 25.0 4 33.3 12 13 54.2 11 45.8 48 57.8 27 32.5 8 9.6 83 123 74.1 43 25.9 
DRD1 A-48G A/G 5 33.3 9 60.0 1 6.7 15 19 63.3 11 36.7 34 40.5 40 47.6 10 11.9 84 108 64.3 60 35.7 
BDNF rs6265 G/A 8 53.3 4 26.7 3 20.0 15 20 66.7 10 33.3 63 66.3 29 30.5 3 3.2 95 155 81.6 35 18.4 
rs9340799 A/G 7 53.8 4 30.8 2 15.4 13 18 69.2 8 30.8 32 47.1 28 41.2 8 11.8 68 92 67.6 44 32.4 
ESRα 
rs2234693 T/C 5 41.7 5 41.7 2 16.7 12 15 62.5 9 37.5 14 28.6 24 49.0 11 22.4 49 52 53.1 46 46.9 
INPP-1 rs1882891 C/A 12 80.0 3 20.0 0 0.0 15 27 90.0 3 10.0 58 72.5 21 26.3 1 1.3 80 137 85.6 23 14.4 
PLC-γ1 rs8192707 A/G 10 71.4 4 28.6 0 0.0 14 24 85.7 4 14.3 45 59.2 26 34.2 5 6.6 76 116 76.3 36 23.7 
ACE Alu Ins/del D/I 6 37.5 7 43.8 3 18.8 16 19 59.4 13 40.6 36 39.6 36 39.6 19 20.9 91 108 59.3 74 40.7 
 
an1  refers to the major allele, n2  refers to the minor allele. Abbreviations: 5-HT2A: serotonin receptor 2A; 5-HT1Dβ: serotonin receptor 1Dβ; 5-HT6: serotonin receptor 6; 5-HT2C: serotonin receptor 2C; 
DRD4: dopamine receptor 4; DRD2: dopamine receptor 2; COMT: Catechol-O-methyltransferase; DRD3: dopamine receptor 3; DRD1: dopamine receptor 1; GRIN2B: glutamate receptor subunit 2B; 
BDNF: brain-derivedneurotrophic factor; HOXB8: homeobox gene B8;  ESRα: estrogen receptor α; INPP-1: inositol polyphosphate-phosphatase 1; PLC-γ1: phospholipase-gamma; ACE: Angiotensin-
converting enzyme. 
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Table III.44(a). Association analysis investigating the differences in genotype and allele 
distributions between OCD subjects with co-morbid tics (OCD+tics) and those without co-
morbid tics (OCD-tics) in bi-allelic loci, with corresponding p-values, ORs and 95% CIs. 
 
Significant p-values are indicated in red, bold font. 
an1 refers to the major allele, n2 refers to the minor allele bgenotypic OR is calculated with the major genotype representing the risk 
genotype; callelic OR is calculated assuming the major allele to be the risk allele;dlower boundary of the 95% CI; eUpper boundary of the 
95% CI.  
Abbreviations: OR: Odds ratio; CI: confidence interval; 5-HT2A: serotonin receptor 2A; 5-HT1Dβ: serotonin receptor 1Dβ; 5-HT6: 
serotonin receptor 6; DRD4: dopamine receptor 4; DRD2: dopamine receptor 2; COMT: Catechol-O-methyltransferase; DRD3: dopamine 
receptor 3; DRD1: dopamine receptor 1; BDNF: brain-derivedneurotrophic factor; ESRα: estrogen receptor α; INPP-1: inositol 
polyphosphate-phosphatase 1; PLC-γ1: phospholipase-gamma; ACE: Angiotensin-converting enzyme. 
 
Genotype Allele 
95% CI 95% CI Gene Variant n1/n2a p-
value OR
b 
LBd UBe 
Power p-value OR
c 
LBd UBe 
Power 
rs6311 G/A 1.000 1.32 0.27 8.63 0.050 0.575 1.29 0.58 3.02 0.067 
5-HT2A 
rs6313 C/T 1.000 1.25 0.26 8.26 0.050 0.851 1.12 0.50 2.59 0.051 
5-HT1Dß rs6296 G/C 1.000 1.98 0.21 99.00 0.052 0.148 2.10 0.79 6.57 0.215 
5-HT6 rs1805054 C/T 0.552 0.72 0.04 14.58 0.064 0.573 1.63 0.44 9.18 0.067 
DRD4 rs1800955 T/C 0.695 0.74 0.12 5.60 0.050 0.840 0.89 0.38 2.16 0.051 
DRD2 rs1800497 C/T 0.445 1.39 0.07 28.11 0.050 0.808 0.87 0.32 2.61 0.050 
COMT rs4680 G/A 0.026 0.10 0.00 0.86 0.445 0.004 0.30 0.11 0.74 0.663 
DRD3 rs6280 A/G 0.052 0.22 0.04 1.32 0.312 0.054 0.42 0.16 1.11 0.338 
DRD1 A-48G A/G 1.000 1.46 0.14 76.40 0.053 1.000 0.96 0.40 2.39 0.051 
BDNF rs6265 G/A 0.035 0.13 0.02 1.16 0.414 0.059 0.45 0.18 1.18 0.291 
rs9340799 A/G 1.000 0.88 0.13 10.20 0.057 1.000 1.08 0.41 3.09 0.050 
ESRα 
rs2234693 T/C 0.670 1.92 0.25 23.90 0.057 0.495 1.47 0.54 4.20 0.079 
INPP-1 rs1882891 C/A 1.000 1.06 0.23 4.70 0.114 0.772 1.51 0.41 8.40 0.059 
PLC-γ1 rs8192707 A/G 0.296 2.54 0.13 45.57 0.063 0.331 1.86 0.58 7.85 0.109 
ACE Alu ins/del D/I 1.000 1.05 0.20 7.24 0.057 1.000 1.00 0.44 2.35 0.053 
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Table III.44(b). Association analysis investigating the differences in genotype and allele 
distributions between OCD subjects with co-morbid tics (OCD+tics)  and controls, with 
corresponding p-values, ORs and 95% CIs. 
 
Significant p-values are indicated in red, bold font. 
an1 refers to the major allele, n2 refers to the minor allele bgenotypic OR is calculated with the major genotype representing the risk 
genotype; callelic OR is calculated assuming the major allele to be the risk allele;dlower boundary of the 95% CI; eUpper boundary of the 
95% CI.  
Abbreviations: OR: Odds ratio; CI: confidence interval; 5-HT2A: serotonin receptor 2A; 5-HT1Dβ: serotonin receptor 1Dβ; 5-HT6: 
serotonin receptor 6; DRD4: dopamine receptor 4; DRD2: dopamine receptor 2; COMT: Catechol-O-methyltransferase; DRD3: dopamine 
receptor 3; DRD1: dopamine receptor 1; BDNF: brain-derivedneurotrophic factor; ESRα: estrogen receptor α; INPP-1: inositol 
polyphosphate-phosphatase 1; PLC-γ1: phospholipase-gamma; ACE: Angiotensin-converting enzyme. 
 
Genotype Allele 
95% CI 95% CI Gene Variant n1/n2a p-
value OR
b 
LBd UBe 
Power p-value OR
c 
LBd UBe 
Power 
rs6311 G/A 0.904 1.09 0.27 4.43 0.173 0.815 1.09 0.53 2.23 0.098 
5-HT2A 
rs6313 C/T 0.697 1.32 0.33 5.28 0.085 0.506 1.28 0.62 2.66 0.056 
5-HT1Dß rs6296 G/C 0.705 1.51 0.18 12.64 0.197 0.292 1.63 0.65 4.05 0.174 
5-HT6 rs1805054 C/T 0.751 0.32 0.01 8.40 0.070 1.000 1.04 0.29 3.72 0.050 
DRD4 rs1800955 T/C 0.780 1.24 0.27 5.61 0.060 0.753 1.13 0.53 2.42 0.062 
DRD2 rs1800497 C/T 0.370 1.83 0.10 34.94 0.202 0.896 0.94 0.38 2.34 0.052 
COMT rs4680 G/A 0.006 0.08 0.01 0.70 0.832 0.002 0.29 0.12 0.65 0.877 
DRD3 rs6280 A/G 0.249 0.44 0.11 1.83 0.423 0.354 0.67 0.29 1.56 0.153 
DRD1 A-48G A/G 0.559 1.92 0.21 17.54 0.141 0.816 1.10 0.50 2.40 0.055 
BDNF rs6265 G/A <0.001 0.06 0.01 0.39 0.791 0.026 0.40 0.18 0.92 0.604 
rs9340799 A/G 0.719 1.35 0.26 7.01 0.154 0.532 1.32 0.55 3.14 0.094 
ESRα 
rs2234693 T/C 0.299 2.42 0.44 13.43 0.219 0.260 1.64 0.69 3.89 0.251 
INPP-1 rs1882891 C/A 0.645 0.56 0.03 12.36 0.064 0.555 0.77 0.25 2.38 0.053 
PLC-γ1 rs8192707 A/G 0.461 1.29 0.06 25.63 0.113 0.435 1.55 0.51 4.68 0.122 
ACE Alu ins/del D/I 0.217 0.38 0.08 1.74 0.175 0.268 0.66 0.31 1.39 0.193 
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Table III.45 (a). Genotype frequencies in the DRD4 48bp VNTR polymorphism for OCD 
patients presenting with co-morbid tic disorder (OCD+tics) and those without co-morbid tic 
disorder (OCD-tics).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
p=0.427 
A2=2-repeat allele; A9=9-repeat allele; A10=10-repeat allele; A11=11-repeat allele;  
Abbreviations: OCD: Obsessive-compulsive disorder. 
 
 
 
Table III.45 (b). Genotype frequencies in the DRD4 48bp VNTR polymorphism for OCD 
patients presenting with co-morbid tic disorder (OCD+tics) and those without co-morbid tic 
disorder (OCD-tics).  
 
OCD+tics OCD-tics 
Allele 
n % n % 
A4 11 55.0 98 64.5 
A7 6 30.0 26 17.1 
A2 3 15.0 16 10.5 
A3 0 0.0 11 7.2 
A6 0 0.0 1 0.7 
p = 0.513 
A2 = 2-repeat allele; A9 = 9-repeat allele; A10 = 10-repeat allele; A11 = 11-repeat allele;  
Abbreviations: OCD: Obsessive-compulsive disorder 
 
 
 
 
OCD+tics OCD-tics 
Genotype 
n % n % 
A4/A7 4 40.0 17 22.4 
A4/A2 3 30.0 12 15.8 
A4/A4 2 20.0 30 39.5 
A7/A7 1 10.0 3 3.9 
A2/A2 0 0.0 1 1.3 
A3/A6 0 0.0 1 1.3 
A4/A3 0 0.0 9 11.8 
A7/A2 0 0.0 2 2.6 
A7/A3 0 0.0 1 1.3 
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Table III.46 (a). Genotype frequencies in the DAT 40bp VNTR polymorphism for OCD 
patients presenting with co-morbid tic disorder (OCD+tics) and those without co-morbid tic 
disorder (OCD-tics).  
 
 
 
 
 
 
 
 
p = 0.747 
A2 = 2-repeat allele; A9 = 9-repeat allele; A10 = 10-repeat allele; A11 = 11-repeat allele;  
Abbreviations: OCD: Obsessive-compulsive disorder 
 
 
 
 
 
 
 
Table III.46(b). Allele counts and frequencies in the DAT 40bp VNTR polymorphism for 
OCD patients presenting with co-morbid tic disorder (OCD+tics) and those without co-
morbid tic disorder (OCD-tics).  
 
OCD+tics OCD-tics 
Allele 
n % n % 
A10 28 77.8 126 72.4 
A9 7 19.4 45 25.9 
A11 1 2.8 2 1.1 
A2 0 0.0 1 0.6 
 
p = 0.900 
A2 = 2-repeat allele; A9 = 9-repeat allele; A10 = 10-repeat allele; A11 = 11-repeat allele;  
Abbreviations: OCD: Obsessive-compulsive disorder 
 
 
OCD+tics OCD-tics 
Genotype 
n % n % 
A10/A10 11 61.1 46 0.5 
A9/A10 5 27.8 31 0.4 
A9/A9 1 5.6 7 0.1 
A10/A11 1 5.6 2 0.0 
A10/A2 0 0.0 1 0.0 
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III.4.5.  Stratification by primary symptom dimension 
 
The OCD population was also stratified according to primary symptom subtype. Clinical 
variables and genotype and allele frequencies were investigated in, and compared between, 
those OCD patients experiencing a particular symptom subtype, and those who did not 
experience the particular symptom subtype. The symptom subtypes that were investigated 
were:  
i. Hoarding and collecting obsessions and/or compulsions 
ii. Symmetry and ordering obsessions and/or compulsions 
iii. Sexual/ religious obsessions and/or compulsions 
iv. Contamination and washing obsessions and/or compulsions 
v. Aggression obsessions and/or compulsions  
 
III.4.5.1.  Hoarding symptoms 
 
III.4.5.1.1. Analysis of clinical variables 
No statistically significant differences were observed in the frequency of hoarders between 
male and female subjects (p=0.091 [Table III.7]), although more females were found to 
present with the hoarding subtype (32.7% females versus 16.7% males). Moreover, no 
statistically significant differences were observed with regard to severity (total Y-BOCS 
score) (p=0.394 [Table III.17]) or age at onset (p=0.846 [Table III.27]). 
 
When family history was investigated, those OCD patients experiencing hoarding obsessions 
and/or compulsions had more family members with OCD compared to those patients who did 
not experience hoarding symptoms (58.3% and 19.0%, respectively, p=0.008) (Table III.47). 
No statistically significant differences with regard to family history of OCS and family 
history of tics was observed (p=0.752 and p=0.266, respectively) (Table III.47). When the 
lifetime prevalence of co-morbid disorders was investigated, it was found that significantly 
more subjects with co-morbid SIB and BDD experienced hoarding symptomatology (p=0.034 
and p=0.011, respectively) (Table III.47).  
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Table III.47. Clinical characteristics in the OCD patient subset according to  
the presence or absence of hoarding symptoms. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Statistically significant differences are indicated in red, bold font. a n(hoarding present) = 12, n(hoarding absent) = 
58;  b n(hoarding present) = 23, n(hoarding absent) = 68.  
Abbreviations: OCD: Obsessive-compulsive disorder; OCS: obsessive-compulsive symptoms; MDD: major 
depressive disorder; SIB: self-injurious behaviour; GAD: generalised anxiety disorder; PD: panic disorder; TTM: 
Trichotillomania; IED: intermittent explosive disorder; BDD: body dysmorphic disorder; TS: Tourette Syndrome.  
 
 
 
 
HOARDING 
Present Absent Family historya 
n % n % 
p-value 
Family history of OCD 7 58.3 11 19.0 0.008 
Family history of OCS 7 58.3 28 48.3 0.752 
Family history of tics 2 16.7 4 6.9 0.266 
Co-morbidityb      
MDD 15 65.2 44 64.7 0.965 
SIB 6 26.1 6 8.8 0.034 
Dysthymia 5 21.7 11 16.2 0.545 
OCD + tics 3 13.0 8 11.8 0.871 
Specific phobia 6 26.1 8 11.8 0.177 
GAD 4 17.4 5 7.4 0.163 
Panic disorder 3 13.0 6 8.8 0.558 
Social phobia 2 8.7 6 8.8 0.985 
TTM 2 8.7 4 5.9 0.638 
IED 2 8.7 5 7.4 0.835 
BDD 5 21.7 3 4.4 0.011 
TS 2 8.7 2 2.9 0.245 
Anorexia 1 4.3 4 5.9 0.78 
Hypochondriasis 1 4.3 1 1.5 0.416 
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III..4.5.1.2. Single locus analysis of hoarding symptomatology 
As for the genetic analyses in the previous section, only OCD subjects for whom more than 
60 samples were genotyped per variant were included in the analyses.  
 
III.4.5.1.2.1. Single locus genetic investigation of bi-allelic polymorphisms 
For each candidate marker investigated, the genotype and allele counts and frequencies of 
OCD subjects experiencing hoarding symptoms, and those not, are presented in Table III.48. 
Control genotype and allele frequencies for each variant are presented in Table III.3b. The 
results from the association analyses, whereby the genotype and allele frequencies of 
individual markers were compared between hoarders and non-hoarders are presented in Table 
III.49(a), and between hoarders and control individuals in Table III.49(b). 
 
The alleles of the DRD4 -521C/T promoter polymorphism (rs1800955) were found to differ 
significantly in frequency between hoarders and non-hoarders (p=0.043), with an OR of 2.86 
(95% CI: 0.99-9.53) indicating that the -521T-allele may represent a risk allele for developing 
hoarding symptoms (Table III.49[a]). A similar association was noted when the genotype and 
allele frequencies of the variant were compared between hoarders and controls (p = 0.047; OR 
= 6.69 [95% CI: 0.80-55.82] for the genotype analysis, and p = 0.011; OR = 3.17 [95% CI: 
1.25-8.06] for the allele analysis) (Tables III.3[b], III.48 and III.49[b]). One should, however, 
not dismiss the relatively wide 95% CI that was obtained for the genotype analysis, indicating 
that chance could have played a factor in the observed result.  
 
In addition, statistically significant differences in both genotypic and allelic frequencies 
between hoarders and non-hoarders were observed for the COMT val158met (rs4680) variant 
(p = 0.008; OR = 0.04 [95% CI: 0.00-0.86] and p = 0.006; OR = 0.29 [95% CI: 0.10-0.77], 
respectively). The OR of below zero suggests that the G(val158)-allele possesses a protective 
effect (Table III.49[a]). Indeed, when the genotype and allele frequencies were compared 
between the hoarding and control samples, the G (val158)-allele was once again found to 
confer protection against the development of hoarding obsessions and compulsions (p=0.004; 
OR=0.05 [95% CI: 0.00-0.90] for the genotype analysis, and p=0.004; OR=0.31 [95% CI: 
0.13-0.71] for the allele analysis) (Tables III.3[b], III.48 and III.49[b]). 
 
Interestingly, both of the ESRα variants investigated (rs9340799 and rs2234693) produced 
significant differences in genotypic frequency between OCD patients experiencing hoarding 
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symptoms and those not (p = 0.004 and p = 0.041, respectively) (Table III.49[a]). The 
distribution of alleles in rs9340799 was also found to differ significantly between hoarders 
and non-hoarders (p = 0.002) (Table III.49[a]). However, no significant association was noted 
when the genotype and allele frequencies of the two ESRα variants were compared between 
the hoarding and control samples (Table III.49[b]), indicating that the variants may play a role 
in the development of a characteristic specific to the non-hoarding OCD group. Indeed, when 
both of the variants were compared between the OCD non-hoarding and control samples, 
statistically significant differences in genotype and allele frequencies for both the ESRα 
rs9340799 and rs2234693 polymorphisms were generated (Table III.49[c]).  
 
III.4.5.1.2.2. Single locus analysis of multi-allelic loci 
 
 i. DRD4 
The genotype and allele frequencies and scores, respectively, for the hoarding and non-
hoarding subsets are presented in Table III.50(a) and (b). No statistically significant 
differences were noted between hoarders and non-hoarders (p = 0.341 and p = 0.282 for 
genotype and allele analyses, respectively), or between hoarders and controls (p = 0.339 and p 
= 0.673 for genotype and allele analyses, respectively) (Tables III.4[a] and [b] and III.50[a] 
and [b]). 
 
 ii. DAT 
No statistically significant differences in the genotypic or allelic distribution of the DAT 40bp 
VNTR were observed when OCD patients with hoarding symptoms were compared to those 
without hoarding symptoms (p = 0.833 and p = 0.796, respectively). (Tables III.51[a] and 
[b]). Likewise, no significant differences in the genotypic or allelic frequencies were observed 
when the distribution of the VNTR was compared between hoarders and controls (p = 0.634 
and p = 0.604 for genotype and allele analyses, respectively) (Tables III.5[a] and [b] and 
III.51[a] and [b]). 
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Table III.48. Genotype and allele scores and frequencies in bi-allelic candidate polymorphisms in OCD patients presenting hoarding 
symptoms and those without.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
an1  refers to the major allele, n2  refers to the minor allele. Abbreviations: 5-HT2A: serotonin receptor 2A; 5-HT1Dβ: serotonin receptor 1Dβ; 5-HT6: serotonin receptor 6; DRD4: dopamine receptor 4; DRD2: 
dopamine receptor 2; COMT: Catechol-O-methyltransferase; DRD3: dopamine receptor 3; DRD1: dopamine receptor 1; GRIN2B: glutamate receptor subunit 2B; BDNF: brain-derivedneurotrophic factor; 
HOXB8: homeobox gene B8;  ESRα: estrogen receptor α; INPP-1: inositol polyphosphate-phosphatase 1; PLCγ1: phospholipase-gamma; ACE: Angiotensin-converting enzyme.
Hoarding No hoarding 
Genotype  Alleles Genotype Alleles Gene Variant n1/n2* 
n11 % n12 % n22 % 
Total 
n1 % n2 % n11 % n12 % n22 % 
Total 
n1 % n2 % 
rs6311 G/A 10 47.6 7 33.3 4 19.0 21 27 64.3 15 35.7 20 39.2 24 47.1 7 13.7 51 64 62.7 38 37.3 5-
HT2A rs6313 C/T 11 52.4 7 33.3 3 14.3 21 29 69.0 13 31.0 21 42.9 20 40.8 8 16.3 49 62 63.3 36 36.7 
5-
HT1Dβ 
rs6296 G/C 12 63.2 7 36.8 0 0.0 19 31 81.6 7 18.4 21 44.7 21 44.7 5 10.6 47 63 67.0 31 33.0 
5-HT6 rs1805054 C/T 11 68.8 5 31.3 0 0.0 16 27 84.4 5 15.6 28 65.1 15 34.9 0 0.0 43 71 82.6 15 17.4 
DRD4 rs1800955 T/C 9 64.3 4 28.6 1 7.1 14 22 78.6 6 21.4 12 28.6 23 54.8 7 16.7 42 47 56.0 37 44.0 
DRD2 rs1800497 C/T 10 52.6 7 36.8 2 10.5 19 27 71.1 11 28.9 31 59.6 19 36.5 2 3.8 52 81 77.9 23 22.1 
COMT rs4680 G/A 0 0.0 8 50.0 8 50.0 16 8 25.0 24 75.0 11 28.2 20 51.3 8 20.5 39 42 53.8 36 46.2 
DRD3 rs6280 A/G 10 52.6 6 31.6 3 15.8 19 26 68.4 12 31.6 28 57.1 16 32.7 5 10.2 49 72 73.5 26 26.5 
DRD1 A-48G A/G 7 35.0 9 45.0 4 20.0 20 23 57.5 17 42.5 19 41.3 25 54.3 2 4.3 46 63 68.5 29 31.5 
BDNF rs6265 G/A 16 72.7 6 27.3 0 0.0 22 38 86.4 6 13.6 33 62.3 16 30.2 4 7.5 53 82 77.4 24 22.6 
rs9340799 A/G 2 13.3 10 66.7 3 20.0 15 14 46.7 16 53.3 20 60.6 13 39.4 0 0.0 33 53 80.3 13 19.7 
ESRα 
rs2234693 T/C 1 10.0 6 60.0 3 30.0 10 8 40.0 12 60.0 9 40.9 12 54.5 1 4.5 22 30 68.2 14 31.8 
INPP-
1 rs1882891 C/A 16 84.2 3 15.8 0 0.0 19 35 92.1 3 7.9 32 69.6 13 28.3 1 2.2 46 77 83.7 15 16.3 
PLC-
γ1 rs8192707 A/G 13 72.2 3 16.7 2 11.1 18 29 80.6 7 19.4 25 56.8 17 38.6 2 4.5 44 67 76.1 21 23.9 
ACE Ins/del D/I 10 50.0 7 35.0 3 15.0 20 27 67.5 13 32.5 22 40.7 21 38.9 11 20.4 54 65 60.2 43 39.8 
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Table III.49(a). Association analysis investigating the differences in genotype and allele 
distributions between OCD subjects with hoarding symptoms and those without, indicating 
corresponding p-values, ORs and 95% CIs. 
 
Significant p-values are indicated in red, bold font. 
 an1 refers to the major allele, n2 refers to the minor allele bgenotypic OR is calculated with the major genotype representing the risk 
genotype; callelic OR is calculated assuming the major allele to be the risk allele;dlower boundary of the 95% CI; eUpper boundary of the 
95% CI.  
Abbreviations: OR: Odds ratio; CI: confidence interval; 5-HT2A: serotonin receptor 2A; 5-HT1Dβ: serotonin receptor 1Dβ; 5-HT6: 
serotonin receptor 6; DRD4: dopamine receptor 4; DRD2: dopamine receptor 2; COMT: Catechol-O-methyltransferase; DRD3: dopamine 
receptor 3; DRD1: dopamine receptor 1; BDNF: brain-derivedneurotrophic factor; ESRα: estrogen receptor α; INPP-1: inositol 
polyphosphate-phosphatase 1; PLC-γ1: phospholipase-gamma; ACE: Angiotensin-converting enzyme. 
 
 
 
 
 
 
 
 
Genotype Allele 
95% CI 95% CI Gene Variant n1/n2a p-
value OR
b 
LBd UBe 
Power p-value OR
c 
LBd UBe 
Power 
rs6311 G/A 1.000 0.88 0.17 5.09 0.053 1.000 1.07 0.48 2.45 0.050 
5-HT2A 
rs6313 C/T 1.000 1.39 0.26 9.75 0.050 0.566 1.29 0.57 3.07 0.067 
5-HT1Dß rs6296 G/C 0.103 6.39 0.32 125.64 0.154 0.094 2.18 0.86 5.50 0.238 
5-HT6 rs1805054 C/T 1.000 0.40 0.01 21.60 0.054 1.000 1.14 0.38 4.40 0.056 
DRD4 rs1800955 T/C 0.124 5.00 0.49 50.64 0.152 0.043 2.86 0.99 9.53 0.382 
DRD2 rs1800497 C/T 0.286 0.33 0.02 5.13 0.070 0.505 0.70 0.28 1.80 0.080 
COMT rs4680 G/A 0.008 0.04 0.00 0.86 0.553 0.006 0.29 0.10 0.77 0.621 
DRD3 rs6280 A/G 0.669 0.60 0.10 4.59 0.053 0.670 0.78 0.32 1.96 0.061 
DRD1 A-48G A/G 0.148 0.20 0.01 1.71 0.214 0.239 0.63 0.27 1.45 0.136 
BDNF rs6265 G/A 0.303 4.43 0.29 87.33 0.102 0.265 1.85 0.66 5.99 0.138 
rs9340799 A/G 0.004 0.00 0.00 0.45 0.748 0.002 0.22 0.08 0.61 0.795 
ESRα 
rs2234693 T/C 0.041 0.06 0.00 1.29 0.337 0.054 0.32 0.09 1.06 0.363 
INPP-1 rs1882891 C/A 1.000 1.52 0.01 39.50 0.061 0.271 2.26 0.59 13.00 0.130 
PLC-γ1 rs8192707 A/G 0.608 0.53 0.03 8.07 0.051 0.645 1.30 0.46 4.02 0.057 
ACE Alu ins/del D/I 0.724 1.65 0.33 11.20 0.058 0.451 1.37 0.60 3.23 0.081 
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Table III.49(b). Association analysis investigating the differences in genotype and allele 
distributions between OCD subjects with hoarding symptoms and controls, indicating 
corresponding p-values, ORs and 95% CIs. 
 
 
Significant p-values are indicated in red, bold font. 
an1 refers to the major allele, n2 refers to the minor allele bgenotypic OR is calculated with the major genotype representing the risk 
genotype; callelic OR is calculated assuming the major allele to be the risk allele;dlower boundary of the 95% CI; eUpper boundary of 
the 95% CI.  Abbreviations: OR: Odds ratio; CI: confidence interval; 5-HT2A: serotonin receptor 2A; 5-HT1Dβ: serotonin receptor 
1Dβ; 5-HT6: serotonin receptor 6; DRD4: dopamine receptor 4; DRD2: dopamine receptor 2; COMT: Catechol-O-methyltransferase; 
DRD3: dopamine receptor 3; DRD1: dopamine receptor 1; BDNF: brain-derived neurotrophic factor; ESRα: estrogen receptor α; 
INPP-1: inositol polyphosphate-phosphatase 1; PLC-γ1: phospholipase-gamma; ACE: Angiotensin-converting enzyme. 
 
 
Table III.49(c). Association analysis investigating the differences in genotype and allele 
distributions in the ESRα rs9340799 and rs2234693 polymorphisms between OCD subjects 
without hoarding symptoms and controls, indicating corresponding p-values, ORs and 95% 
CIs. 
 
 
 
Significant p-values are indicated in red, bold font. 
an1 refers to the major allele, n2 refers to the minor allele bgenotypic OR is calculated with the major genotype representing the risk 
genotype; callelic OR is calculated assuming the major allele to be the risk allele;dlower boundary of the 95% CI; eUpper boundary of 
the 95% CI. Abbreviations: ESRα: estrogen receptor α. 
Genotype Allele 
95% CI 95% CI Gene Variant n1/n2a p-
value OR
b 
LBd UBe 
Power p-value OR
c 
LBd UBe 
Power 
rs6311 G/A 0.555 1.50 0.39 5.80 0.06 0.366 1.37 0.69 2.74 0.07 
5-HT2A 
rs6313 C/T 0.885 1.10 0.31 3.82 0.07 0.678 1.15 0.59 2.26 0.11 
5-HT1Dß rs6296 G/C 0.242 3.01 0.17 54.29 0.12 0.402 3.01 0.61 3.40 0.19 
5-HT6 rs1805054 C/T 0.711 0.43 0.02 11.16 0.06 0.789 0.89 0.32 2.47 0.11 
DRD4 rs1800955 T/C 0.047 6.69 0.80 55.82 0.72 0.011 3.17 1.25 8.06 0.67 
COMT rs4680 G/A 0.004 0.05 0.00 0.90 0.76 0.004 0.31 0.13 0.71 0.82 
DRD3 rs6280 A/G 0.819 1.18 0.29 4.76 0.08 0.576 1.23 0.59 2.56 0.08 
DRD1 A-48G A/G 0.557 0.67 0.18 2.57 0.05 0.659 0.86 0.44 1.69 0.08 
BDNF rs6265 G/A 0.562 0.86 0.04 18.82 0.07 0.599 1.28 0.51 3.19 0.08 
rs9340799 A/G 0.127 0.26 0.04 1.65 0.63 0.081 1.51 0.24 1.10 0.42 
ESRα 
rs2234693 T/C 0.317 0.32 0.03 3.27 0.15 0.371 0.66 0.26 1.66 0.11 
INPP-1 rs1882891 C/A 0.561 0.87 0.04 19.02 0.05 0.781 1.49 0.43 5.19 0.08 
PLC-γ1 rs8192707 A/G 0.243 0.36 0.06 2.15 0.05 0.882 1.07 0.44 2.59 0.05 
ACE Alu ins/del D/I 0.531 0.64 0.15 2.65 0.05 0.845 0.93 0.46 1.90 0.05 
Genotype Allele 
95% CI 95% CI Gene Variant n1/n2a 
p-value ORb 
LBd UBe 
p-
value OR
c 
LBd UBe 
rs9340799 A/G <0.001 0.02 0.00 0.45 <0.001 0.22 0.08 0.55 
ESRα 
rs2234693 T/C 0.016 0.04 0.002 0.80 0.033 0.31 0.10 0.93 
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Table III.50(a). Genotype counts and frequencies in the DRD4 48bp VNTR polymorphism for 
OCD patients presenting with hoarding symptoms  and those without.  
 
 
 
 
 
 
 
 
 
 
 
p = 0.341 
A2 = 2-repeat allele; A3 = 3-repeat allele; A4 = 4-repeat allele; A6 = 6-
repeat allele; A7 = 7-repeat allele. 
 
 
Table III.50(b). Allele counts and frequencies in the DRD4 48bp VNTR 
polymorphism for OCD patients presenting with hoarding symptoms  and those 
without.  
 
 
 
 
 
 
 
 
p = 0.282 
A2 = 2-repeat allele; A3 = 3-repeat allele; A4 = 4-repeat allele; A6 = 6-
repeatallele; A7 = 7-repeat allele. 
 
 
 
Hoarding No Hoarding 
Genotype 
n % n % 
A4/A4 7 43.8 17 40.5 
A4/A7 5 31.3 8 19.0 
A4/A2 4 25.0 5 11.9 
A2/A2 0 0.0 1 2.4 
A3/A6 0 0.0 1 2.4 
A4/A3 0 0.0 6 14.3 
A7/A2 0 0.0 1 2.4 
A7/A3 0 0.0 1 2.4 
A7/A7 0 0.0 2 4.8 
Hoarding No Hoarding 
Allele 
n % n % 
A4 23 71.9 53 63.1 
A7 5 15.6 14 16.7 
A2 4 12.5 8 9.5 
A3 0 0.0 8 9.5 
A6 0 0.0 1 1.2 
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Table III.51(a). Genotype counts and frequencies in the DAT 40bp VNTR polymorphism for 
OCD patients presenting with hoarding symptoms  and those without.  
 
 
 
 
 
 
 
 
 
p=0.833 
A2=2-repeat allele; A9=9-repeat allele; A10=10-repeat allele; A11=11-repeat allele. 
 
 
 
 
Table III.51(b). Allele counts and  frequencies in the DAT 40bp VNTR polymorphism for 
OCD patients presenting with hoarding symptoms  and those without.  
 
 
 
 
 
 
p=0.796 
A2=2-repeat allele; A9=9-repeat allele; A10=10-repeat allele; A11=11-repeat allele. 
 
 
 
 
Hoarding No Hoarding 
Genotype 
n % n % 
A10/A10 10 47.6 23 46.9 
A9/A10 9 42.9 18 36.7 
A9/A9 2 9.5 5 10.2 
A10/A11 0 0.0 2 4.1 
A2/A10 0 0.0 1 2.0 
Hoarding No Hoarding 
Allele 
n % n % 
A10 29 69.0 67 68.4 
A9 13 31.0 28 28.6 
A2 0 0.0 1 1.0 
A11 0 0.0 2 2.0 
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III.4.5.2. Symmetry and ordering symptoms 
 
III.4.5.2.1. Analysis of clinical variables 
No statistically significant differences between male and female OCD subjects were noted in 
the frequency of symmetry/ordering obsessions and compulsions (p = 0.530 [Table III.7]; 
Figure III.40). In addition, no differences in Y-BOCS (p = 0.156 [Table III.17]) or age at 
onset (p = 0.570 [Table III.27]) were observed between those subjects presenting with 
symmetry/ordering symptoms and those that did not. 
 
A comparison of clinical variables (family history of OCD, OCS and tics, and the prevalence 
of selected co-morbid disorders) is presented in Table III.52. Those OCD patients with a 
positive family history of tics were found to experience significantly more symmetry/ordering 
symptoms than those without a family history of tics (2.3% versus 17.9%, p = 0.032). 
Investigating the prevalence of certain co-morbid disorders, fewer of the OCD subjects who 
also experienced symmetry/ordering symptom dimensions were diagnosed with co-morbid 
social phobia (3.7%), compared to those patients who did not present with symmetry/ordering 
symptoms (18.4%) (p = 0.019) (Table III.52). There were no other statistically significant 
differences in the prevalence of the remaining co-morbid disorders. 
 
III.4.5.2.2. Single locus analysis of hoarding behaviour symmetry/ordering symptomatology 
 
III.4.5.2.2.1. Single locus genetic investigation of bi-allelic polymorphisms 
The genotypic and allele counts and frequencies of those OCD patients experiencing 
symmetry/ordering symptoms, and those who did not, are presented in Table III.53. No 
statistically significant differences in genotypic or allelic frequencies were observed between 
the two OCD subsets (Table III.54[a]). A marginally significant difference in the ACE Alu 
ins/del genotype distribution was observed when the symmetry/ordering OCD subset was 
compared to controls (p = 0.048; OR = 0.38 [95% CI: 0.14-1.01]) (Table III.3[b], Table III.53 
and Table III.54[b]). Here, an increased number of individuals carrying at least one D-allele 
were observed in the control sample compared to OCD subset (91.0% and 78.8%), suggesting 
that this genotype may represent a protective factor against the development of the 
symmetry/ordering symptom subtype, probably in a dominant manner.  
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III.4.5.2.2.2. Single locus analysis of multi-allelic polymorphisms 
 
i. DRD4 
The genotype and allele scores and frequencies in OCD patients experiencing 
symmetry/ordering and those not are presented in Table III.55(a) and (b) respectively. No 
statistically significant differences in either genotype or allele frequencies were observed (p = 
0.066 and p = 0.726 for genotype and allele analyses, respectively). Likewise, no statistically 
significant differences in genotype or allele frequencies were noted between the 
symmetry/ordering OCD group and control subjects (p = 0.067 and p = 0.885 for genotype 
and allele analyses, respectively. 
 
 ii. DAT 
The genotype and allele scores and frequencies, respectively, in OCD patients experiencing 
symmetry/ordering and those not are presented in Tables III.56(a) and (b). No statistically 
significant differences in the genotype or allele distributions between OCD patients with 
symmetry/ordering obsessions and compulsions and those without were observed (p = 0.496 
and p = 0.811, respectively). Also, no statistically significant differences were observed when 
the DAT VNTR genotype and allele frequencies were compared between the 
symmetry/ordering OCD subset and control subjects (p = 0.576 and p = 0.302 for genotype 
and allele analyses, respectively. 
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Table III.52. Clinical characteristics in the OCD patient subset according to  
the presence or absence of symmetry/ ordering symptoms. 
 
 
 
 
 
Statistically significant differences are indicated in red, bold font. 
 a n(symmetry/ordering present) = 43, n(symmetry/ordering absent) = 28;  b n(symmetry/ordering 
present) = 54, n(hoarding absent) = 38.  
Abbreviations: OCD: Obsessive-compulsive disorder; OCS: obsessive-compulsive symptoms; MDD: 
major depressive disorder; SIB: self-injurious behaviour; GAD: generalised anxiety disorder; PD: 
panic disorder; TTM: Trichotillomania; IED: intermittent explosive disorder; BDD: body dysmorphic 
disorder; TS: Tourette Syndrome.  
 
SYMMETRY / ORDERING 
Clinical Variable 
Present Absent 
Family historya n % n % 
p-value 
Family history of OCD 11 25.6 7 25.0 0.592 
Family history of OCS 22 51.2 13 46.4 1.000 
Family history of tics 1 2.3 5 17.9 0.032 
Co-morbidityb    
MDD 37 68.5 23 60.5 0.428 
SIB 6 11.1 7 18.4 0.322 
Dysthymia 12 22.2 4 10.5 0.145 
OCD + tics 7 13.0 4 10.5 0.723 
Specific phobia 6 11.1 8 21.1 0.191 
GAD 5 9.3 4 10.5 0.840 
Panic disorder 7 13.0 2 5.3 0.221 
Social phobia 2 3.7 7 18.4 0.019 
TTM 4 7.4 3 7.9 0.931 
IED 6 11.1 2 5.3 0.327 
BDD 5 9.3 3 7.9 0.819 
TS 2 3.7 2 5.3 0.718 
Anorexia 5 9.3 0 0.0 0.054 
Hypochondriasis 0 0.0 2 5.3 0.088 
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Table III.53. Genotype and allele scores and frequencies in bi-allelic candidate polymorphisms in OCD patients presenting with 
symmetry/ordering symptoms and those without. 
 
 
 
an1  refers to the major allele, n2  refers to the minor allele. 
Abbreviations: 5-HT2A: serotonin receptor 2A; 5-HT1Dβ: serotonin receptor 1Dβ; 5-HT6: serotonin receptor 6; DRD4: dopamine receptor 4; DRD2: dopamine receptor 2; COMT: Catechol-O-methyltransferase; 
DRD3: dopamine receptor 3; DRD1: dopamine receptor 1; BDNF: brain-derivedneurotrophic factor; ESRα: estrogen receptor α; INPP-1: inositol polyphosphate-phosphatase 1; PLCγ1: phospholipase-gamma; 
ACE: Angiotensin-converting enzyme. 
 
Symmetry/ordering symptoms No symmetry/ordering symptoms 
Genotype  Alleles Genotype Alleles Gene Variant n1/n2a 
n1
1 
% n12 % n22 % 
Total 
n1 % n2 % n11 % n12 % n22 % 
Total 
n1 % n2 % 
rs6311 G/A 20 45.5 18 40.9 6 13.6 44 58 65.9 30 34.1 10 34.5 14 48.3 5 17.2 29 34 58.6 24 41.4 
5-HT2A 
rs6313 C/T 21 48.8 16 37.2 6 14.0 43 58 67.4 28 32.6 11 39.3 12 42.9 5 17.9 28 34 60.7 22 39.3 
5-HT1Dβ rs6296 G/C 22 55.0 16 40.0 2 5.0 40 60 75.0 20 25.0 11 40.7 13 48.1 3 11.1 27 35 64.8 19 35.2 
5-HT6 rs1805054 C/T 25 64.1 14 35.9 0 0.0 39 64 82.1 14 17.9 14 66.7 7 33.3 0 0.0 21 35 83.3 7 16.7 
DRD4 rs1800955 T/C 14 41.2 15 44.1 5 14.7 34 43 63.2 25 36.8 7 30.4 13 56.5 3 13.0 23 27 58.7 19 41.3 
DRD2 rs1800497 C/T 27 58.7 17 37.0 2 4.3 46 71 77.2 21 22.8 15 57.7 9 34.6 2 7.7 26 39 75.0 13 25.0 
COMT rs4680 A/G 7 21.9 19 59.4 6 18.8 32 33 51.6 31 48.4 9 37.5 10 41.7 5 20.8 24 28 58.3 20 41.7 
DRD3 rs6280 A/G 28 60.9 13 28.3 5 10.9 46 69 75.0 23 25.0 11 47.8 9 39.1 3 13.0 23 31 67.4 15 32.6 
DRD1 A-48G A/G 14 35.0 20 50.0 6 15.0 40 48 60.0 32 40.0 12 44.4 15 55.6 0 0.0 27 39 72.2 15 27.8 
BDNF rs6265 G/A 31 66.0 14 29.8 2 4.3 47 76 80.9 18 19.1 19 65.5 8 27.6 2 6.9 29 46 79.3 12 20.7 
rs9340799 A/G 14 46.7 14 46.7 2 6.7 30 42 70.0 18 30.0 8 42.1 9 47.4 2 10.5 19 25 65.8 13 34.2 
ESRα 
rs2234693 T/C 5 23.8 12 57.1 4 19.0 21 22 52.4 20 47.6 5 41.7 6 50.0 1 8.3 12 16 66.7 8 33.3 
INPP-1 rs1882891 C/A 31 73.8 10 23.8 1 2.4 42 72 85.7 12 14.3 18 75.0 6 25.0 0 0.0 24 42 87.5 6 12.5 
PLC-γ1 rs8192707 A/G 22 55.0 16 40.0 2 5.0 40 60 75.0 20 25.0 17 73.9 4 17.4 2 8.7 23 38 82.6 8 17.4 
ACE Alu Ins/del D/I 20 42.6 17 36.2 10 21.3 47 57 60.6 37 39.4 12 42.9 11 39.3 5 17.9 28 35 62.5 21 37.5 
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Table III.54(a). Association analysis investigating the differences in genotype and allele 
distributions between OCD subjects with symmetry/ordering symptoms and those without, 
indicating corresponding p-values, ORs and 95% CIs. 
 
Significant p-values are indicated in red, bold font. 
an1 refers to the major allele, n2 refers to the minor allele bgenotypic OR is calculated with the major genotype representing the risk 
genotype; callelic OR is calculated assuming the major allele to be the risk allele;dlower boundary of the 95% CI; eUpper boundary of the 
95% CI.  
Abbreviations: OR: Odds ratio; CI: confidence interval; 5-HT2A: serotonin receptor 2A; 5-HT1Dβ: serotonin receptor 1Dβ; 5-HT6: 
serotonin receptor 6; DRD4: dopamine receptor 4; DRD2: dopamine receptor 2; COMT: Catechol-O-methyltransferase; DRD3: 
dopamine receptor 3; DRD1: dopamine receptor 1; BDNF: brain-derivedneurotrophic factor; ESRα: estrogen receptor α; INPP-1: 
inositol polyphosphate-phosphatase 1; PLC-γ1: phospholipase-gamma; ACE: Angiotensin-converting enzyme. 
 
 
 
 
 
 
Genotype Allele 
95% CI 95% CI Gene Variant n1/n2a p-
value OR
b 
LBd UBe 
Power p-value OR
c 
LBd UBe 
Power 
rs6311 G/A 0.491 1.65 0.31 8.42 0.059 0.387 1.36 0.65 2.85 0.091 
5-HT2A 
rs6313 C/T 0.719 1.57 0.31 7.89 0.057 0.473 1.34 0.62 2.86 0.082 
5-HT1Dß rs6296 G/C 0.337 2.91 0.29 39.70 0.084 0.246 1.62 0.71 3.70 0.148 
5-HT6 rs1805054 C/T 1.000 1.76 0.03 93.42 0.052 1.000 0.92 0.29 2.70 0.054 
DRD4 rs1800955 T/C 1.000 1.19 0.14 8.49 0.054 0.696 1.21 0.52 2.79 0.057 
DRD2 rs1800497 C/T 0.619 1.78 0.12 26.80 0.050 0.839 1.13 0.46 2.66 0.051 
COMT rs4680 A/G 0.704 0.66 0.11 3.90 0.052 0.566 0.76 0.33 1.73 0.071 
DRD3 rs6280 A/G 0.680 1.51 0.20 9.44 0.051 0.419 1.45 0.61 3.36 0.094 
DRD1 A-48G A/G 0.061 0.00 0.00 1.25 0.291 0.196 0.58 0.25 1.29 0.189 
BDNF rs6265 G/A 0.638 1.62 0.11 24.00 0.050 0.836 1.10 0.44 2.67 0.050 
rs9340799 A/G 0.625 1.71 0.11 28.00 0.050 0.663 1.21 0.46 3.14 0.053 
ESRα 
rs2234693 T/C 0.580 0.27 0.00 4.25 0.074 0.308 0.56 0.17 1.74 0.111 
INPP-1 rs1882891 C/A 1.000 0.00 0.00 69.30 0.057 1.000 0.86 0.25 2.69 0.050 
PLC-γ1 rs8192707 A/G 1.000 1.29 0.09 19.40 0.056 0.379 0.63 0.22 1.69 0.097 
ACE Alu ins/del D/I 1.000 0.84 0.18 3.54 0.050 0.864 0.93 0.44 1.92 0.050 
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Table III.54(b). Association  analysis investigating the differences in genotype and allele 
distributions between OCD subjects with symmetry/ordering symptoms and controls, 
indicating corresponding p-values, ORs and 95% CIs. 
 
 
Significant p-values are indicated in red, bold font. 
an1 refers to the major allele, n2 refers to the minor allele bgenotypic OR is calculated with the major genotype representing the risk 
genotype; callelic OR is calculated assuming the major allele to be the risk allele;dlower boundary of the 95% CI; eUpper boundary 
of the 95% CI.  
Abbreviations: OR: Odds ratio; CI: confidence interval; 5-HT2A: serotonin receptor 2A; 5-HT1Dβ: serotonin receptor 1Dβ; 5-
HT6: serotonin receptor 6; DRD4: dopamine receptor 4; DRD2: dopamine receptor 2; COMT: Catechol-O-methyltransferase; 
DRD3: dopamine receptor 3; DRD1: dopamine receptor 1; BDNF: brain-derivedneurotrophic factor; ESRα: estrogen receptor α; 
INPP-1: inositol polyphosphate-phosphatase 1; PLC-γ1: phospholipase-gamma; ACE: Angiotensin-converting enzyme. 
 
 
Genotype Allele 
95% CI 95% CI Gene Variant n1/n2a p-
value OR
b 
LBd UBe 
Power p-value OR
c 
LBd UBe 
Power 
rs6311 G/A 0.467 1.46 0.524 4.08 0.108 0.401 1.24 0.751 2.04 0.135 
5-HT2A 
rs6313 C/T 0.485 1.43 0.521 3.94 0.109 0.342 1.28 0.77 2.11 0.137 
5-HT1Dß rs6296 G/C 0.763 1.27 0.26 6.16 0.051 0.932 0.98 0.56 1.72 0.051 
5-HT6 rs1805054 C/T 0.576 0.95 0.04 24.06 0.105 0.413 0.75 0.38 1.50 0.131 
DRD4 rs1800955 T/C 0.197 2.08 0.67 6.44 0.217 0.155 1.49 0.86 2.57 0.282 
DRD2 rs1800497 C/T 0.450 1.82 0.38 8.86 0.080 0.576 1.17 0.67 2.05 0.093 
COMT rs4680 G/A 0.597 0.72 0.22 2.41 0.075 0.615 0.87 0.34 1.01 0.088 
DRD3 rs6280 A/G 0.216 1.98 0.66 5.90 0.381 0.051 1.71 0.99 2.93 0.479 
DRD1 A-48G A/G 0.841 0.89 0.30 2.68 0.052 0.853 0.95 0.57 1.59 0.052 
BDNF rs6265 G/A 0.250 0.33 0.04 2.42 0.650 0.601 0.85 0.47 1.56 0.073 
rs9340799 A/G 0.198 2.70 0.57 12.87 0.134 0.310 1.37 0.75 2.50 0.172 
ESRα 
rs2234693 T/C 0.789 1.21 0.30 4.93 0.065 0.817 1.08 0.56 2.09 0.072 
INPP-1 rs1882891 C/A 0.735 0.66 0.06 7.53 0.092 0.478 0.77 0.37 1.59 0.113 
PLC-γ1 rs8192707 A/G 0.570 0.60 0.10 3.51 0.095 0.400 0.77 0.43 1.41 0.116 
ACE Alu ins/del D/I 0.048 0.38 0.14 1.01 0.226 0.137 0.70 0.42 1.13 0.294 
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Table III.55(a). Genotype counts and frequencies in the DRD4 48bp VNTR polymorphism for 
OCD patients presenting with symmetry/ordering symptoms and those without.  
 
 
 
 
 
 
 
 
 
 
 
p = 0.066 
A2 = 2-repeat allele; A3 = 3-repeat allele; A4 = 4-repeat allele; A6 = 6-repeat 
allele; A7 = 7-repeat allele. 
 
 
Table III.55(b). Allele counts and frequencies in the DRD4 48bp VNTR polymorphism for OCD 
patients presenting with symmetry/ordering symptoms  and those without.  
 
 
 
 
 
 
 
p = 0.726 
A2 = 2-repeat allele; A3 = 3-repeat allele; A4 = 4-repeat allele; A6 = 6-repeat allele; 
A7 = 7-repeat allele. 
 
 
Symmetry/ordering No Symmetry/ordering 
Genotype 
n % n % 
A2/A2 0 0.0 1 3.7 
A3/A6 0 0.0 1 3.7 
A4/A2 4 12.5 5 18.5 
A4/A3 4 12.5 2 7.4 
A4/A4 11 34.4 13 48.1 
A4/A7 12 37.5 2 7.4 
A7/A2 1 3.1 0 0.0 
A7/A3 0 0.0 1 3.7 
A7/A7 0 0.0 2 7.4 
Symmetry/ordering No Symmetry/ordering 
Allele 
n % n % 
A4 42 65.6 35 64.8 
A7 13 20.3 7 13.0 
A2 5 7.8 7 13.0 
A3 4 6.3 4 7.4 
A6 0 0.0 1 1.9 
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Table III.56(a). Genotype counts and frequencies in the DAT 40bp VNTR polymorphism for 
OCD patients presenting with symmetry/ordering symptoms and those without.  
 
 
 
 
 
 
 
 
 
p = 0.496 
A2 = 2-repeat allele; A9 = 9-repeat allele; A10 = 10-repeat allele; A11 = 11-repeat allele 
 
 
 
Table III.56(b). Allele counts and  frequencies in the DAT 40bp VNTR polymorphism for 
OCD patients presenting with symmetry/ordering symptoms and those without.  
 
Symmetry/ordering No symmetry ordering Allele 
n % n % 
A10 56 66.7 42 72.4 
A9 27 32.1 14 24.1 
A11 1 1.2 1 1.7 
A2 0 0.0 1 1.7 
 
p = 0.811. 
A2 = 2-repeat allele; A9 = 9-repeat allele; A10 = 10-repeat allele; A11 = 11-repeat allele. 
 
Symmetry/ordering No symmetry ordering 
Genotype 
n % n % 
A10/A10 20 47.6 14 48.3 
A9/A10 15 35.7 12 41.4 
A9/A9 6 14.3 1 3.4 
A10/A11 1 2.4 1 3.4 
A10/A2 0 0.0 1 3.4 
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III.4.5.3. Sexual and religious symptoms 
 
III.4.5.3.1. Analysis of clinical variables 
When the frequency of sexual/religious symptoms was compared between male and female 
OCD subjects, significantly more males were found to experience this group of symptoms 
(57.1% versus 28.6%; p = 0.010 [Table III.7). No significant differences in median Y-BOCS 
score (Table III.17) or age at onset of OCD (Table III.27) were observed between those 
patients experiencing the symptoms and those not (p = 0.266 and 0.236, respectively).  
 
Table III.57 shows the comparison of clinical variables between OCD subjects experiencing 
sexual/religious symptoms and those not. No significant differences in proportion of family 
members suffering from OCD, OCS or tics was noted. However, when the proportion of 
patients diagnosed with selected co-morbid disorders was investigated, statistically significant 
differences were observed for MDD (p = 0.017), dysthymic disorder (p = 0.016) and BDD (p 
= 0.019). Significantly more OCD patients with sexual and religious symptoms were 
diagnosed with co-morbid MDD and dysthymic disorder compared to those OCD subjects 
who did not exhibit sexual/religious symptomatology (78.9% versus 54.7% and 28.9% versus 
9.4%, respectively). On the other hand, a greater proportion of OCD subjects without 
sexual/religious symptoms were diagnosed with BDD compared to those with sexual/religious 
symptoms (15.1% versus 0%, respectively). 
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Table III.57. Clinical characteristics in the OCD patient subset according to  
the presence or absence of sexual/religious symptoms. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Statistically significant differences are indicated in red, bold font. a n(sexual/religious symptoms 
present) = 29, n(sexual/religious symptoms absent) =42;  b n(sexual/religious symptoms present) = 38, 
n(sexual/religious symptoms absent) = 53.  Abbreviations: OCD: Obsessive-compulsive disorder; 
OCS: obsessive-compulsive symptoms; MDD: major depressive disorder; SIB: self-injurious 
behaviour; GAD: generalised anxiety disorder; PD: panic disorder; TTM: Trichotillomania; IED: 
intermittent explosive disorder; BDD: body dysmorphic disorder; TS: Tourette Syndrome.  
 
 
 
 
 
 
 
 
 
Sexual/religious symptoms 
Clinical Variable 
Present Absent 
  Family historya n % n % 
p-value 
Family history of OCD 5 17.2 13 31.0 0.269 
Family history of OCS 12 41.4 23 54.8 0.332 
Family history of tics  4 13.8 2 4.8 0.218 
Co-morbidityb    
MDD 30 78.9 29 54.7 0.017 
SIB 4 10.5 8 15.1 0.755 
Dysthymia 11 28.9 5 9.4 0.016 
OCD + tics  5 13.2 6 11.3 1.000 
Specific phobia 4 10.5 10 18.9 0.381 
GAD 2 5.3 7 13.2 0.295 
Panic disorder 5 13.2 4 7.5 0.483 
Social phobia 5 13.2 3 5.7 0.271 
TTM 2 5.3 4 7.5 1.000 
IED 4 10.5 3 5.7 0.446 
BDD 0 0.0 8 15.1 0.019 
TS 1 2.6 3 5.7 0.638 
Anorexia 1 2.6 4 7.5 0.396 
Hypochondriasis 0 0.0 2 3.8 0.508 
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III.4.5.3.2. Single locus analysis of sexual/religious symptomatology 
 
III.4.5.3.2.1. Single locus genetic investigation of bi-allelic polymorphisms  
Table III.58 represents the genotypic and allelic counts in selected markers, in those OCD 
subjects experiencing sexual/religious symptoms and those who did not. Table III.59(a) 
depicts the resultant p-values and the corresponding ORs after comparing the distribution of 
these genotypic and allelic frequencies between the two groups, whilst Table III.59(b) 
presents the p-values and ORs obtained when the genotype and allele frequencies were 
compared between OCD patients experiencing sexual/religious symptoms and controls.  
 
No statistically significant differences in genotype or allele distribution were observed when 
the two OCD subsets were analysed (Table III.59[a]). However, when the OCD subset with 
sexual/religious symptoms was compared to the control sample, significant differences in the 
BDNF val66met (rs6265) genotype distribution (Table III.59[b]). Here, OCD patients 
experiencing sexual/religious symptoms exhibited a significantly higher frequency of the 
AA(met66met)–genotype compared to controls (10% versus 1.4%, respectively; p=0.015 
[Table III.3(b), Table III.58 and Table III.59(b)]). Although not statistically significant, the 
same pattern was noted when the two OCD subsets were analysed (Table III.58), with the 
frequency of AA (met66met6) carriers in the OCD subset characterised by no sexual/religious 
symptoms amounting to only 2.2%.  
 
Furthermore, significantly more controls were found to carry the ACE Alu ins/del DD-
genotype compared to OCD patients who experienced sexual/religious symptoms (p = 0.021; 
OR = 0.27 [95% CI: 0.09-0.85]) (Tables III.3[b], III.58 and III.59[b]). Significant differences 
in allelic distribution were also observed between the two samples (p = 0.042; OR = 0.55 
[95% CI: 0.31-0.99]) (Tables III.3[b], III.58 and III.59[b]), indicating that the D-allele may be 
functioning in a dominant manner in conferring protection against the development of 
sexual/religious symptoms .  
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Table III.58. Genotype and allele counts and frequencies in bi-allelic candidate polymorphisms  in OCD patients presenting with 
sexual/religious symptoms and those without. 
 
 
an1  refers to the major allele, n2  refers to the minor allele. Abbreviations: 5-HT2A: serotonin receptor 2A; 5-HT1Dβ: serotonin receptor 1Dβ; 5-HT6: serotonin receptor 6; DRD4: dopamine receptor 4; DRD2: 
dopamine receptor 2; COMT: Catechol-O-methyltransferase; DRD3: dopamine receptor 3; DRD1: dopamine receptor 1; BDNF: brain-derivedneurotrophic factor; ESRα: estrogen receptor α; INPP-1: inositol 
polyphosphate-phosphatase 1; PLC-γ1: phospholipase-gamma; ACE: Angiotensin-converting enzyme. 
 
Sexual/religious symptoms No sexual/religious symptoms 
Genotype  Alleles Genotype Alleles Gene Variant n1/n2a 
n11 % n12 % n22 % 
Total 
n1 % n2 % n11 % n12 % n22 % 
Total 
n1 % n2 % 
rs6311 G/A 14 48.3 13 44.8 2 6.9 29 41 70.7 17 29.3 16 37.2 18 41.9 9 20.9 43 50 58.1 36 41.9 
5-HT2A 
rs6313 C/T 14 51.9 10 37.0 3 11.1 27 38 70.4 16 29.6 18 41.9 17 39.5 8 18.6 43 53 61.6 33 38.4 
5-HT1Dβ rs6296 G/C 14 56.0 9 36.0 2 8.0 25 37 74.0 13 26.0 19 46.3 19 46.3 3 7.3 41 57 69.5 25 30.5 
5-HT6 rs1805054 C/T 15 57.7 11 42.3 0 0.0 26 41 78.8 11 21.2 24 72.7 9 27.3 0 0.0 33 57 86.4 9 13.6 
DRD4 rs1800955 T/C 8 36.4 11 50.0 3 13.6 22 27 61.4 17 38.6 13 38.2 16 47.1 5 14.7 34 42 61.8 26 38.2 
DRD2 rs1800497 C/T 15 55.6 10 37.0 2 7.4 27 40 74.1 14 25.9 26 59.1 16 36.4 2 4.5 44 68 77.3 20 22.7 
COMT rs4680 A/G 7 35.0 8 40.0 5 25.0 20 22 55.0 18 45.0 9 25.7 20 57.1 6 17.1 35 38 54.3 32 45.7 
DRD3 rs6280 A/G 17 58.6 8 27.6 4 13.8 29 42 72.4 16 27.6 21 53.8 14 35.9 4 10.3 39 56 71.8 22 28.2 
DRD1 A-48G A/G 11 40.7 16 59.3 0 0.0 27 38 70.4 16 29.6 15 38.5 18 46.2 6 15.4 39 48 61.5 30 38.5 
BDNF rs6265 G/A 19 63.3 8 26.7 3 10.0 30 46 76.7 14 23.3 30 66.7 14 31.1 1 2.2 45 74 82.2 16 17.8 
rs9340799 A/G 6 33.3 10 55.6 2 11.1 18 22 61.1 14 38.9 16 53.3 13 43.3 1 3.3 30 45 75.0 15 25.0 
ESRα 
rs2234693 T/C 2 18.2 6 54.5 3 27.3 11 10 45.5 12 54.5 8 38.1 12 57.1 1 4.8 21 28 66.7 14 33.3 
INPP-1 rs1882891 C/A 20 74.1 7 25.9 0 0.0 27 47 87.0 7 13.0 28 73.7 9 23.7 1 2.6 38 65 85.5 11 14.5 
PLC-γ1 rs8192707 A/G 11 52.4 9 42.9 1 4.8 21 31 73.8 11 26.2 27 65.9 11 26.8 3 7.3 41 65 79.3 17 20.7 
ACE Ins/del D/I 10 34.5 12 41.4 7 24.1 29 32 55.2 26 44.8 22 48.9 16 35.6 7 15.6 45 60 66.7 30 33.3 
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Table III.59(a). Association analysis investigating the differences in genotype and allele 
distributions between OCD subjects experiencing sexual/religious symptoms, and those not, 
in bi-allelic loci, with corresponding p-values, ORs and 95% CIs. 
 
 
 
Significant p-values are indicated in red, bold font. 
an1 refers to the major allele, n2 refers to the minor allele bgenotypic OR is calculated with the major genotype representing the risk 
genotype; callelic OR is calculated assuming the major allele to be the risk allele;dlower boundary of the 95% CI; eUpper boundary of 
the 95% CI. 
Abbreviations: OR: Odds ratio; CI: confidence interval; 5-HT2A: serotonin receptor 2A; 5-HT1Dβ: serotonin receptor 1Dβ; 5-HT6: 
serotonin receptor 6; DRD4: dopamine receptor 4; DRD2: dopamine receptor 2; COMT: Catechol-O-methyltransferase; DRD3: 
dopamine receptor 3; DRD1: dopamine receptor 1; BDNF: brain-derived neurotrophic factor; ESRα: estrogen receptor α; INPP-1: 
inositol polyphosphate-phosphatase 1; PLC-γ1: phospholipase-gamma; ACE: Angiotensin-converting enzyme. 
 
 
 
 
 
 
 
 
Genotype Allele 
95% CI 95% CI Gene Variant n1/n2a p-
value OR
b 
LBd UBe 
Power p-value OR
c 
LBd UBe 
Power 
rs6311 G/A 0.152 3.82 0.63 42.10 0.195 0.159 1.73 0.81 3.79 0.210 
5-HT2A 
rs6313 C/T 0.480 2.04 0.39 14.20 0.079 0.363 1.47 0.68 3.30 0.112 
5-HT1Dß rs6296 G/C 1.000 1.10 0.11 14.90 0.061 0.693 1.25 0.53 3.01 0.060 
5-HT6 rs1805054 C/T 1.000 0.63 0.01 33.56 0.149 0.328 0.59 0.20 1.73 0.193 
DRD4 rs1800955 T/C 1.000 1.02 0.15 8.45 0.062 1.000 0.98 0.42 2.32 0.052 
DRD2 rs1800497 C/T 0.626 0.58 0.04 8.84 0.050 0.689 0.84 0.36 2.01 0.054 
COMT rs4680 A/G 1.000 0.94 0.16 5.74 0.057 1.000 1.03 0.44 2.42 0.051 
DRD3 rs6280 A/G 1.000 0.81 0.13 5.07 0.051 1.000 1.03 0.45 2.38 0.051 
DRD1 A-48G A/G 0.071 9.65 0.68 189.11 0.247 0.354 1.48 0.67 3.36 0.110 
BDNF rs6265 G/A 0.295 0.22 0.00 2.93 0.114 0.413 0.71 0.29 1.74 0.081 
rs9340799 A/G 0.231 0.20 0.00 4.55 0.090 0.173 0.53 0.20 1.41 0.174 
ESRα 
rs2234693 T/C 0.095 0.11 0.00 2.05 0.202 0.116 0.42 0.13 1.36 0.215 
INPP-1 rs1882891 C/A 1.000 2.16 0.08 55.68 0.053 1.000 1.14 0.37 3.73 0.050 
PLC-γ1 rs8192707 A/G 1.000 1.22 0.09 69.90 0.063 0.504 0.74 0.29 1.97 0.066 
ACE Alu ins/del D/I 0.321 0.46 0.10 2.01 0.113 0.169 0.62 0.30 1.28 0.180 
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Table III.59(b). Association analysis investigating the differences in genotype and allele 
distributions between OCD subjects experiencing sexual/religious symptoms and controls in 
bi-allelic loci, with corresponding p-values, ORs and 95% CIs. 
 
Genotype Allele 
95% CI 95% CI Gene Variant n1/n2a p-
value OR
b 
LBd UBe 
Power p-value OR
c 
LBd UBe 
Power 
rs6311 G/A 0.332 1.91 0.51 7.18 0.30 0.23 1.46 0.78 2.73 0.23 
5-HT2A 
rs6313 C/T 0.141 3.07 0.65 14.53 0.20 0.162 1.55 0.84 2.85 0.16 
5-HT1Dß rs6296 G/C 0.798 0.81 0.16 4.05 0.06 0.824 0.93 0.47 1.83 0.09 
5-HT6 rs1805054 C/T 0.665 0.58 0.02 14.85 0.24 0.205 0.61 0.28 1.32 0.19 
DRD4 rs1800955 T/C 0.335 1.98 0.48 8.13 0.15 0.339 1.37 0.72 2.63 0.12 
DRD2 rs1800497 C/T 0.987 1.01 0.20 5.10 0.05 0.979 0.99 0.51 1.93 0.05 
COMT rs4680 G/A 0.426 0.60 0.17 2.12 0.13 0.413 0.76 0.39 1.48 0.10 
DRD3 rs6280 A/G 0.511 1.50 0.45 5.05 0.23 0.213 1.49 0.79 2.81 0.17 
DRD1 A-48G A/G 0.045 8.96 0.50 159.86 0.24 0.202 1.51 0.80 2.85 0.18 
BDNF rs6265 G/A 0.015 0.13 0.02 0.85 0.20 0.230 0.66 0.34 1.30 0.15 
rs9340799 A/G 0.863 1.16 0.22 6.18 0.06 0.820 0.92 0.45 1.88 0.05 
ESRα 
rs2234693 T/C 0.642 0.65 0.10 4.13 0.06 0.655 0.82 0.34 1.97 0.06 
INPP-1 rs1882891 C/A 0.514 1.10 0.05 23.45 0.06 0.738 0.86 0.35 2.09 0.07 
PLC-γ1 rs8192707 A/G 0.660 0.60 0.06 5.90 0.14 0.408 0.73 0.34 1.55 0.11 
ACE Alu ins/del D/I 0.021 0.27 0.09 0.86 0.54 0.042 0.55 0.31 0.99 0.43 
 
Significant p-values are indicated in red, bold font. 
an1 refers to the major allele, n2 refers to the minor allele bgenotypic OR is calculated with the major genotype representing the risk 
genotype; callelic OR is calculated assuming the major allele to be the risk allele;dlower boundary of the 95% CI; eUpper boundary of 
the 95% CI.  
Abbreviations: OR: Odds ratio; CI: confidence interval; 5-HT2A: serotonin receptor 2A; 5-HT1Dβ: serotonin receptor 1Dβ; 5-HT6: 
serotonin receptor 6; DRD4: dopamine receptor 4; DRD2: dopamine receptor 2; COMT: Catechol-O-methyltransferase; DRD3: 
dopamine receptor 3; DRD1: dopamine receptor 1; BDNF: brain-derived neurotrophic factor; ESRα: estrogen receptor α; INPP-1: 
inositol polyphosphate-phosphatase 1; PLC-γ1: phospholipase-gamma; ACE: Angiotensin-converting enzyme. 
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III.4.5.3.2.2. Single locus analysis of multi-allelic polymorphisms  
i. DRD4 
The genotypic and allelic distributions of the DRD4 48bp are presented in Tables III.60(a) and 
(b). No statistically significant differences in genotype or allele distribution were noted for 
either of the investigations (p = 0.891 and p = 0.524 for genotype and allele analyses, 
respectively). Likewise, when the genotype and allele frequencies were compared between  
OCD patients with sexual/religious symptoms and the control group, no significant 
differences were observed (p = 0.647 and p = 0.563 for genotype and allele analyses, 
respectively) (Tables III.4[a] and [b] and III.60[a] and [b]).  
 
ii. DAT 
The genotype and allele counts and frequencies for the DAT 40bp VNTR in OCD subjects 
experiencing sexual/religious symptoms and those who did not, are represented in Tables 
III.61(a) and (b). No significant differences in either genotype or allele distribution between 
the two subsets was observed (p = 0.648 and p = 0.786, respectively). Likewise, when the 
genotype and allele distributions were compared between OCD patients with sexual/religious 
symptoms and the control group, no significant differences were observed (p = 0.253 and p = 
0.151 for genotype and allele analyses, respectively) (Tables III.5[a] and [b] and III.61[a] and 
[b]). 
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Table III.60(a). Genotype counts and frequencies in the DRD4 40bp VNTR 
polymorphism for OCD patients presenting with sexual/ religious symptoms and 
those without.  
 
 
 
 
 
 
 
 
 
 
 
 
p=0.891 
A2=2-repeat allele; A3=3-repeat allele; A4=4-repeat allele; A6=6-repeat allele; A7=7-
repeat allele. 
 
 
 
Table III.60(b). Allele counts and frequencies in theDRD4 40bp VNTR 
polymorphism for OCD patients presenting with sexual/ religious symptoms and 
those without.  
 
                              
 
 
 
 
 
 
p=0.524 
A2=2-repeat allele; A3=3-repeat allele; A4=4-repeat allele; A6=6-repeat allele; A7=7-
repeat allele. 
Sexual/religious 
symptoms 
No sexual/religious 
symptoms Genotype 
n % n % 
A4/A4 9 42.9 15 40.5 
A4/A7 4 19.0 9 24.3 
A4/A2 3 14.3 6 16.2 
A4/A3 3 14.3 3 8.1 
A2/A2 1 4.8 0 0.0 
A3/A6 1 4.8 0 0.0 
A7/A2 0 0.0 1 2.7 
A7/A3 0 0.0 1 2.7 
A7/A7 0 0.0 2 5.4 
Sexual/religious 
symptoms No sexual/religious symptoms Allele 
n % n % 
A4 28 66.7 48 64.9 
A7 4 9.5 15 20.3 
A2 5 11.9 7 9.5 
A3 4 9.5 4 5.4 
A6 1 2.4 0 0.0 
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Table III.61(a). Genotype counts and frequencies in the DAT 40bp VNTR polymorphism for 
OCD patients presenting with sexual/ religious symptoms and those without.  
 
 
 
 
 
 
 
 
p=0.648 
A9=9-repeat allele; A10=10-repeat allele; A11=11-repeat allele. 
 
 
 
 
 
Table III.61(b). Allele counts and frequencies in the DAT 40bp VNTR polymorphism for 
OCD patients presenting with sexual/religious symptoms and those without.  
 
 
 
 
 
 
 
 
p=0.786 
A9=9-repeat allele; A10=10-repeat allele; A11=11-repeat allele. 
 
 
Sexual/religious 
symptoms 
No sexual/religious 
symptoms Allele 
n % n % 
A10 38 67.9 58 69.0 
A9 16 28.6 25 29.8 
A2 1 1.8 0 0.0 
A11 1 1.8 1 1.2 
Sexual/religious 
symptoms 
No sexual/religious 
symptoms Genotype 
n % n % 
A10/A10 14 50.0 19 45.2 
A9/A10 8 28.6 19 45.2 
A9/A9 4 14.3 3 7.1 
A10/A11 1 3.6 1 2.4 
A10/A2 1 3.6 0 0.0 
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III.4.5.4. Contamination Symptoms 
 
III.4.5.4.1. Analysis of clinical variables 
Contamination obsessions and washing compulsions (comprising the contamination/washing 
symptom dimension) were found to be the most common symptom subtype experienced in 
the present study, with 60.4% of the patients reporting these obsessions and compulsions 
(Table III.7). No significant differences were observed with regard to gender (p = 0.830 
[Table III.7]). Moreover, no significant differences in median total Y-BOCS scores or median 
ages at onset were observed between subjects experiencing contamination/washing symptoms 
and those not (p = 0.123 [Table III.17] and p = 0.276 [Table III.27], respectively). 
 
The comparison of selected clinical variables is presented in Table III.62. No significant 
differences were observed when family history of OCD, OCS or tics was considered. When 
selected co-morbid disorders were investigated, significantly more patients experiencing 
contamination/washing symptoms were found to be diagnosed with tics, compared to those 
OCD subjects who did not experience contamination fears (17.9% versus 2.8%, respectively, 
p = 0.045). 
 
III.4.5.4.2. Single locus analysis of contamination symptomatology 
 
III.4.5.4.2.1. Single locus analysis of bi-allelic polymorphisms 
Table III.63 presents the genotypic and allelic counts of the candidate polymorphisms in OCD 
subjects with contamination fears and those without. No statistically significant differences in 
either genotypic or allelic counts were noted when the two OCD subsets were compared 
(Table III.64[a]). When the OCD subset characterised by contamination symptoms and the 
control sample were compared, a statistically significant difference in the genotypic frequency 
of the ACE Alu ins/del variant was observed (p = 0.038; OR = 0.36 [95% CI: 0.14-0.97]), with 
an overrepresentation of the DD- and DI-genotypes amongst control individuals compared to 
contamination/washing OCD subset (91% versus 78.7%, respectively) (Tables III.3[b], III.63 
and III.64[b]). No significant differences in allele distribution were noted, indicating that the 
D allele may be functioning in a dominant manner to confer protection against the 
development of contamination symptoms 
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Table III.62. Clinical characteristics in the OCD patient subset according to the presence or 
absence of contamination symptoms. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Statistically significant differences are indicated in red, bold font. 
an(contamination symptoms present)=44, n(contamination symptoms absent)=27;  
bn(contamination symptoms present)=56, n(contamination symptoms absent)=36.  
Abbreviations: OCD: Obsessive-compulsive disorder; OCS: obsessive-compulsive 
symptoms; MDD: major depressive disorder; SIB: self-injurious behaviour; GAD: 
generalised anxiety disorder; PD: panic disorder; TTM: Trichotillomania; IED: intermittent 
explosive disorder; BDD: body dysmorphic disorder; TS: Tourette Syndrome.  
 
 
 
 
 
 
 
Contamination symptoms 
Present Absent Family historya 
n % n % 
p-value 
Family history of OCD 13 29.5 5 18.5 0.403 
Family history of OCS 21 47.7 14 51.9 1.000 
Family history of tics 4 9.1 2 7.4 1.000 
Co-morbidityb    
MDD 38 67.9 22 61.1 0.512 
SIB 9 16.1 4 11.1 0.558 
Dysthymia 13 23.2 3 8.3 0.092 
Tics 10 17.9 1 2.8 0.045 
Specific phobia 8 14.3 6 16.7 0.773 
GAD 5 8.9 4 11.1 0.733 
Panic disorder 3 5.4 6 16.7 0.147 
Social phobia 5 8.9 4 11.1 0.733 
TTM 6 10.7 1 2.8 0.245 
IED 6 10.7 2 5.6 0.475 
BDD 4 7.1 4 11.1 0.707 
TS 4 7.1 0 0.0 0.153 
Anorexia 4 7.1 1 2.8 0.645 
Hypochondriasis 0 0.0 2 5.6 0.151 
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Table III.63. Genotype and allele counts and frequencies in bi-allelic candidate markers in OCD patients presenting with contamination 
symptoms and those without. 
 
 
an1  refers to the major allele, n2  refers to the minor allele. 
Abbreviations: 5-HT2A: serotonin receptor 2A; 5-HT1Dβ: serotonin receptor 1Dβ; 5-HT6: serotonin receptor 6; DRD4: dopamine receptor 4; DRD2: dopamine receptor 2; COMT: Catechol-O-
methyltransferase; DRD3: dopamine receptor 3; DRD1: dopamine receptor 1; BDNF: brain-derivedneurotrophic factor; ESRα: estrogen receptor α; INPP-1: inositol polyphosphate-phosphatase 1; PLC-γ1: 
phospholipase-gamma; ACE: Angiotensin-converting enzyme. 
 
Contamination symptoms No contamination symptoms 
Genotype  Alleles Genotype Alleles Gene Variant n1/n2a 
n11 % n12 % n22 % 
Total 
n1 % n2 % n11 % n12 % n22 % 
Total 
n1 % n2 % 
rs6311 G/A 19 41.3 20 43.5 7 15.2 46 58 63.0 34 37.0 11 40.7 12 44.4 4 14.8 27 34 63.0 20 37.0 
5-HT2A 
rs6313 C/T 19 42.2 20 44.4 6 13.3 45 58 64.4 32 35.6 13 50.0 8 30.8 5 19.2 26 34 65.4 18 34.6 
5-HT1Dβ rs6296 G/C 21 50.0 17 40.5 4 9.5 42 59 70.2 25 29.8 12 48.0 12 48.0 1 4.0 25 36 72.0 14 28.0 
5-HT6 rs1805054 C/T 22 61.1 14 38.9 0 0.0 36 58 80.6 14 19.4 17 70.8 7 29.2 0 0.0 24 41 85.4 7 14.6 
DRD4 rs1800955 T/C 13 36.1 16 44.4 7 19.4 36 42 58.3 30 41.7 8 38.1 12 57.1 1 4.8 21 28 66.7 14 33.3 
DRD2 rs1800497 C/T 27 62.8 14 32.6 2 4.7 43 68 79.1 18 20.9 15 51.7 12 41.4 2 6.9 29 42 72.4 16 27.6 
COMT rs4680 A/G 10 27.8 17 47.2 9 25.0 36 37 51.4 35 48.6 6 30.0 12 60.0 2 10.0 20 24 60.0 16 40.0 
DRD3 rs6280 A/G 24 57.1 11 26.2 7 16.7 42 59 70.2 25 29.8 15 55.6 11 40.7 1 3.7 27 41 75.9 13 24.1 
DRD1 A-48G A/G 16 38.1 22 52.4 4 9.5 42 54 64.3 30 35.7 10 40.0 13 52.0 2 8.0 25 33 66.0 17 34.0 
BDNF rs6265 G/A 33 70.2 13 27.7 1 2.1 47 79 84.0 15 16.0 17 58.6 9 31.0 3 10.3 29 43 74.1 15 25.9 
rs9340799 A/G 12 38.7 15 48.4 4 12.9 31 39 62.9 23 37.1 10 55.6 8 44.4 0 0.0 18 28 77.8 8 22.2 
ESRα 
rs2234693 T/C 6 27.3 11 50.0 5 22.7 22 23 52.3 21 47.7 4 36.4 7 63.6 0 0.0 11 15 68.2 7 31.8 
INPP-1 rs1882891 C/A 33 80.5 8 19.5 0 0.0 41 74 90.2 8 9.8 16 64.0 8 32.0 1 4.0 25 40 80.0 10 20.0 
PLC-γ1 rs8192707 A/G 24 61.5 12 30.8 3 7.7 39 60 76.9 18 23.1 15 62.5 8 33.3 1 4.2 24 38 79.2 10 20.8 
ACE Ins/del D/I 19 40.4 18 38.3 10 21.3 47 56 59.6 38 40.4 13 46.4 10 35.7 5 17.9 28 36 64.3 20 35.7 
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Table III.64(a). Association analysis investigating the differences in genotype and allele 
distributions between OCD subjects experiencing contamination symptoms, and those not, 
in bi-allelic loci, with corresponding p-values, ORs and 95% CIs. 
 
Significant p-values are indicated in red, bold font. 
an1 refers to the major allele, n2 refers to the minor allele bgenotypic OR is calculated with the major genotype representing the risk 
genotype; callelic OR is calculated assuming the major allele to be the risk allele;dlower boundary of the 95% CI; eUpper boundary 
of the 95% CI.  
Abbreviations: OR: Odds ratio; CI: confidence interval; 5-HT2A: serotonin receptor 2A; 5-HT1Dβ: serotonin receptor 1Dβ; 5-HT6: 
serotonin receptor 6; DRD4: dopamine receptor 4; DRD2: dopamine receptor 2; COMT: Catechol-O-methyltransferase; DRD3: 
dopamine receptor 3; DRD1: dopamine receptor 1; BDNF: brain-derived neurotrophic factor; ESRα: estrogen receptor α; INPP-1: 
inositol polyphosphate-phosphatase 1; PLC-γ1: phospholipase-gamma; ACE: Angiotensin-converting enzyme 
 
 
 
Genotype Allele 
95% CI 95% CI Gene Variant n1/n2a p-
value OR
b 
LBd UBe 
Power p-value OR
c 
LBd UBe 
Power 
rs6311 G/A 0.985 1.10 0.24 4.26 0.050 0.992 1.00 0.50 2.00 0.050 
5-HT2A 
rs6313 C/T 0.779 1.22 0.31 4.84 0.051 0.910 0.96 0.47 1.96 0.052 
5-HT1Dß rs6296 G/C 0.472 2.29 0.23 22.87 0.055 0.828 1.09 0.50 2.63 0.057 
5-HT6 rs1805054 C/T 1.000 1.29 0.02 68.08 0.086 0.492 0.71 0.26 1.91 0.104 
DRD4 rs1800955 T/C 0.182 4.31 0.44 41.82 0.158 0.377 1.43 0.65 3.20 0.124 
DRD2 rs1800497 C/T 0.572 1.80 0.23 14.11 0.118 0.356 1.44 0.66 3.13 0.150 
COMT rs4680 A/G 0.281 0.37 0.06 2.32 0.112 0.380 0.71 0.32 1.54 0.141 
DRD3 rs6280 A/G 0.158 0.23 0.03 2.05 0.082 0.465 0.75 0.34 1.63 0.098 
DRD1 A-48G A/G 0.815 0.80 0.12 5.20 0.054 0.841 0.93 0.44 1.94 0.055 
BDNF rs6265 G/A 0.102 5.82 0.56 60.3 0.243 0.136 1.83 0.82 4.11 0.319 
rs9340799 A/G 0.090 0.13 0.01 2.75 0.258 0.127 0.48 0.19 1.24 0.338 
ESRα 
rs2234693 T/C 0.100 7.62 0.33 175.10 0.180 0.217 1.96 0.68 5.70 0.234 
INPP-1 rs1882891 C/A 0.159 6.10 0.24 157.80 0.279 0.096 2.31 0.85 6.32 0.366 
PLC-γ1 rs8192707 A/G 0.595 1.87 0.18 19.72 0.055 0.770 1.14 0.50 2.73 0.058 
ACE Alu ins/del D/I 0.631 1.37 0.38 5.00 0.068 0.570 1.22 0.62 2.42 0.078 
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Table III.64(b). Association analysis investigating the differences in genotype and allele 
distributions between OCD subjects experiencing contamination symptoms and controls in 
bi-allelic loci, with corresponding p-values, ORs and 95% CIs. 
 
 
Significant p-values are indicated in red, bold font. 
an1 refers to the major allele, n2 refers to the minor allele bgenotypic OR is calculated with the major genotype representing the risk 
genotype; callelic OR is calculated assuming the major allele to be the risk allele;dlower boundary of the 95% CI; eUpper boundary of 
the 95% CI.  
Abbreviations: OR: Odds ratio; CI: confidence interval; 5-HT2A: serotonin receptor 2A; 5-HT1Dβ: serotonin receptor 1Dβ; 5-HT6: 
serotonin receptor 6; DRD4: dopamine receptor 4; DRD2: dopamine receptor 2; COMT: Catechol-O-methyltransferase; DRD3: 
dopamine receptor 3; DRD1: dopamine receptor 1; BDNF: brain-derived neurotrophic factor; ESRα: estrogen receptor α; INPP-1: 
inositol polyphosphate-phosphatase 1; PLC-γ1: phospholipase-gamma; ACE: Angiotensin-converting enzyme. 
 
Genotype Allele 
95% CI 95% CI Gene Variant n1/n2a p-
value OR
b 
LBd UBe 
Power p-value OR
c 
LBd UBe 
Power 
rs6311 G/A 0.620 1.30 0.47 3.60 0.06 0.657 1.12 0.69 1.81 0.06 
5-HT2A 
rs6313 C/T 0.728 1.19 0.44 3.19 0.06 0.721 1.09 0.67 1.77 0.07 
5-HT1Dß rs6296 G/C 0.383 0.60 0.17 2.00 0.16 0.271 0.74 0.44 1.26 0.20 
5-HT6 rs1805054 C/T 0.601 0.84 0.03 21.29 0.14 0.275 0.68 0.34 1.36 0.18 
DRD4 rs1800955 T/C 0.542 1.38 0.49 3.89 0.08 0.477 1.21 0.72 2.05 0.09 
DRD2 rs1800497 C/T 0.450 1.82 0.38 8.86 0.12 0.367 1.31 0.73 2.36 0.15 
COMT rs4680 G/A 0.902 0.94 0.33 2.64 0.07 0.932 0.98 0.58 1.65 0.07 
DRD3 rs6280 A/G 0.708 1.21 0.45 3.28 0.13 0.282 1.34 0.80 2.30 0.17 
DRD1 A-48G A/G 0.492 1.53 0.45 5.20 0.07 0.607 1.14 0.67 1.91 0.08 
BDNF rs6265 G/A 0.768 0.70 0.06 7.91 0.06 0.852 1.06 0.56 2.00 0.05 
rs9340799 A/G 0.815 1.20 0.34 3.98 0.05 0.982 0.99 0.56 1.76 0.05 
ESRα 
rs2234693 T/C 0.818 1.16 0.32 4.20 0.06 0.823 1.08 0.56 2.05 0.07 
INPP-1 rs1882891 C/A 0.405 1.77 0.08 37.87 0.05 0.691 1.18 0.52 2.72 0.06 
PLC-γ1 rs8192707 A/G 0.291 0.44 0.09 2.10 0.08 0.631 0.86 0.46 1.59 0.09 
ACE Alu ins/del D/I 0.038 0.36 0.14 0.97 0.33 0.100 0.66 0.41 1.08 0.42 
 299
III.4.5.4.2.2. Single locus analysis of multi-allelic polymorphisms 
 
i. DRD4 
The genotype and allele scores and frequencies for the DRD4 48bp VNTR are provided in 
Tables III.65[a] and [b], respectively. Statistically significant differences in distribution were 
noted for the genotype analysis (p = 0.015), but not for the allele analysis (p = 0.076). When 
the genotype combinations were combined according to the presence of at least one A4 allele, 
it was found that significantly more OCD patients carrying the A4/A4 genotype did not 
experience contamination symptoms, compared to those who did (58.3% versus 28.6%, 
respectively; p = 0.035) (Table III.65[c]). 
 
This association was, however, only observed when the genotype frequencies were compared 
between the two OCD subsets. When the frequencies of the A4-allele were compared between 
the subsets, no statistically significant differences were observed (p = 0.172) (Table III.65[d]). 
 
Likewise, when the genotype and allele frequencies of the ungrouped DRD4 48bp VNTR 
were compared between OCD patients presenting with contamination symptoms and controls, 
statistically significant differences were noted with regard to genotype distribution (p = 
0.042), but not for allele distribution (p = 0.392) (Tables III.4[a] and [b] and III.65[a] and [b]). 
Moreover, when the genotypes were combined according to the presence or absence of at 
least one A4-allele, the control subjects presented with a significantly higher frequency of 
A4/A4 genotypes (52.3% versus 28.6%; p = 0.005) (Table III.65[e]). Again, when the 
frequency of A4-alleles were compared against non-A4-alleles, however, no statistically 
significant differences were observed (p = 0.158) (Table III.65[f]). 
 
ii. DAT 
Tables III.66(a) and (b) provide the genotype and allele counts and frequencies for the DAT 
40bp VNTR polymorphism in OCD subjects with contamination symptoms and those 
without. No significant differences in either the genotype or allele distributions were noted 
between the two OCD patient subsets (p = 0.348 and p = 0.743, respectively). 
 
Similarly, no statistically significant differences in either genotype (p = 0.121) or allele (p = 
0.207) frequencies were observed when the OCD patients experiencing contamination 
symptoms were compared to controls. 
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Table III.65(a). Genotype scores and frequencies in the DRD4 48bp VNTR polymorphism for 
OCD patients presenting with contamination symptoms and those without.  
 
 
 
 
 
 
 
 
 
 
 
 
p=0.015 
A2=2-repeat allele; A3=3-repeat allele; A4=4-repeat allele; A6=6-repeat allele; A7=7-
repeat allele. 
 
 
 
 
Table III.65(b). Allele counts and frequencies in the DRD4 48bp VNTR polymorphism for 
OCD patients presenting with contamination symptoms and those without.  
 
 
 
 
 
p= 0.076 
 A2 = 2-repeat allele; A3 = 3-repeat allele; A4 = 4-repeat allele; A6 = 6-repeat allele; A7 = 7-repeat 
allele 
.
 
 
 
 
 
 
Contamination 
symptoms 
No contamination 
symptoms Genotype 
n % n % 
A4/A7 12 34.3 2 8.3 
A4/A4 10 28.6 14 58.3 
A4/A2 7 20.0 2 8.3 
A4/A3 3 8.6 3 12.5 
A7/A7 2 5.7 0 0.0 
A2/A2 1 2.9 0 0.0 
A3/A6 0 0.0 1 4.2 
A7/A2 0 0.0 1 4.2 
A7/A3 0 0.0 1 4.2 
Contamination symptoms No contamination symptoms 
Genotype 
n % n % 
A4/A4 10 28.6 14 58.3 
A4/other 22 62.9 7 29.2 
other/other 3 8.6 3 12.5 
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Table III.65(c). Genotype counts and frequencies in the DRD4 48bp VNTR polymorphism for 
OCD patients presenting with contamination symptoms and those without, according to the 
presence or absence of at least one A4-allele.  
 
 
 
 
 
 
 
 
p= 0.035 
A4 = 4-repeat allele; “other” genotypes comprise A2, A3, A7and A6 alleles. 
 
 
 
 
Table III.65(d). Allele counts and frequencies in the DRD4 48bp VNTR polymorphism for 
OCD patients presenting with contamination symptoms and those without, according to the 
presence or absence of the A4-allele. 
 
 
 
 
 
 
 
p= 0.172 
A4 = 4-repeat allele; “other” alleles comprise A2, A3, A7and A6 allele. 
Contamination 
symptoms 
No contamination 
symptoms Allele 
n % n % 
A4 42 60.0 35 72.9 
A7 16 22.9 4 8.3 
A2 9 12.9 3 6.3 
A3 3 4.3 5 10.4 
A6 0 0.0 1 2.1 
Contamination 
symptoms 
No contamination 
symptoms Allele 
n % n % 
A4 42 60.0 35 72.9 
other 28 40.0 13 27.1 
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Table III.65(e). Genotype counts and frequencies in the DRD4 48bp VNTR polymorphism for 
OCD patients presenting with contamination symptoms and controls, according to the 
presence or absence of at least one A4-allele.  
 
 
 
 
 
 
p= 0.005 
A4 = 4-repeat allele; “other” genotypes comprise A2, A3, A7and A6 alleles 
 
 
 
 
 
 
 
 
Table III.65(f). Allele counts and frequencies in the DRD4 48bp VNTR polymorphism for 
OCD patients presenting with contamination symptoms and controls, according to the 
presence or absence of the A4-allele.  
 
Contamination symptoms Control 
Allele 
n % n % 
A4 42 60.0 208 68.9 
other 28 40.0 94 31.1 
 
p = 0.158 
A4 = 4 -repeat allele; “other” genotypes comprise A2, A3, A7and A6 alleles 
 
 
 
 
Contamination 
symptoms Control Genotype 
n % n % 
A4/A4 10 28.6 79 52.3 
A4/other 22 62.9 50 33.1 
other/other 3 8.6 22 14.6 
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Table III.66(a). Genotype counts and frequencies in the DAT 40bp VNTR polymorphism for 
OCD patients presenting with contamination symptoms and those without.  
 
Contamination symptoms No contaminationsymptoms 
Genotype 
n % n % 
A10/A10 19 42.2 15 57.7 
A9/A10 20 44.4 7 26.9 
A9/A9 4 8.9 3 11.5 
A10/A11 2 4.4 0 0.0 
A2/A10 0 0.0 1 3.8 
 
p = 0.348 
A9 = 9-repeat allele; A10 = 10-repeat allele; A11 = 11-repeat allele. 
 
 
 
 
 
Table III.66(b). Allele counts and frequencies in the DAT 40bp VNTR polymorphism for 
OCD patients presenting with contamination symptoms and those without.  
 
 
Contamination symptoms No contamination symptoms 
Allele 
n % n % 
A10 60 66.7 38 45.2 
A9 28 31.1 13 15.5 
A11 2 2.2 0 0.0 
A2 0 0.0 1 1.2 
 
p = 0.743 
A9 = 9-repeat allele; A10 = 10-repeat allele; A11 = 11-repeat allele. 
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III.4.5.5. Aggressive Symptoms 
 
III.4.5.5.1. Analysis of clinical variables 
No statistically significant differences in the frequency of aggressive symptoms were 
observed amongst males and females (p = 0.670 [Table III.7). Likewise, no significant 
differences in age at onset were observed between those OCD subjects experiencing 
aggressive symptoms and those not (p = 0.809, [Table III.27]).  Interestingly, the subtype was 
found to be nominally associated with Y-BOCS score (Table III.17): those patients 
experiencing aggressive symptoms were found to have a lower Y-BOCS score (decreased 
severity) (median Y-BOCS = 18 [95% CI: 15.7-20.3]) compared to those without these 
symptoms (median Y-BOCS score = 22.5 [95% CI: 20.5-24.5]) (p = 0.050). 
 
The comparison of selected clinical variables between OCD subjects experiencing aggressive 
symptoms and those not, is depicted in Table III.67. No significant differences were observed 
with regard to family history of OCD, OCS or tics, or selected co-morbid disorders.  
 
III.4.5.5.2. Single locus analysis of aggressive symptomatology 
 
III.4.5.5.2.1. Single locus genetic investigation of bi-allelic polymorphisms 
The genotypic and allelic counts of the bi-allelic polymorphisms are represented in Table 
III.68. Table III.69(a) indicates the p-values and corresponding ORs obtained from comparing 
the distributions of genotypes and alleles between the two OCD subsets, and Table III.69(b) 
presents the p-values and corresponding ORs obtained from comparing the genotype and 
allele frequencies between OCD subjects presenting with aggressive symptoms, and controls. 
No statistically significant differences were detected for either of the groups of analyses.  
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Table III.67. Clinical characteristics in the OCD patient subset according to  
the presence or absence of aggressive symptoms. 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Statistically significant differences are indicated in red, bold font. 
 a n(aggression symptoms present)=37, n(aggression symptoms absent)=34;  b n(aggression symptoms present)=47, 
n(aggression symptoms absent)=44.  
Abbreviations: OCD: Obsessive-compulsive disorder; OCS: obsessive-compulsive symptoms; MDD: major 
depressive disorder; SIB: self-injurious behaviour; GAD: generalised anxiety disorder; PD: panic disorder; TTM: 
Trichotillomania; IED: intermittent explosive disorder; BDD: body dysmorphic disorder; TS: Tourette Syndrome.  
 
 
Aggressive symptoms 
Present Absent Family historya 
n % n % 
p-value 
Family history of OCD 12 32.4 6 17.6 0.181 
Family history of OCS 20 54.1 15 44.1 0.473 
Family history of tics 3 8.1 3 8.8 1.000 
Co-morbidityb      
MDD 32 68.1 27 61.4 0.519 
SIB 7 14.9 5 11.4 0.760 
Dysthymia 8 17.0 8 18.2 1.000 
OCD + tics 6 12.8 5 11.4 1.000 
Specific phobia 9 19.1 5 11.4 0.388 
GAD 5 10.6 4 9.1 1.000 
Panic disorder 6 12.8 3 6.8 0.487 
Social phobia 4 8.5 4 9.1 1.000 
TTM 3 6.4 3 6.8 1.000 
IED 4 8.5 3 6.8 1.000 
BDD 5 10.6 3 6.8 0.715 
TS 1 2.1 3 6.8 0.350 
Anorexia 4 8.5 1 2.3 0.362 
Hypochondriasis 1 2.1 1 2.3 1.000 
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Table III.68. Genotype and allele scores and frequencies in bi-allelic candidate polymorphisms in OCD patients presenting with aggressive 
symptoms and those without.  
 
 
an1  refers to the major allele, n2  refers to the minor allele. 
Abbreviations: 5-HT2A: serotonin receptor 2A; 5-HT1Dβ: serotonin receptor 1Dβ; 5-HT6: serotonin receptor 6; DRD4: dopamine receptor 4; DRD2: dopamine receptor 2; COMT: Catechol-O-methyltransferase; 
DRD3: dopamine receptor 3; DRD1: dopamine receptor 1; GRIN2B: glutamate receptor subunit 2B; BDNF: brain-derivedneurotrophic factor; HOXB8: homeobox gene B8;  ESRα: estrogen receptor α; INPP-1: 
inositol polyphosphate-phosphatase 1; PLCγ1: phospholipase-gamma; ACE: Angiotensin-converting enzyme. 
 
 
Aggressive symptoms No aggressive symptoms 
Genotype  Alleles Genotype Alleles Gene Variant n1/n2a 
n11 % n12 % n22 % 
Total 
n1 % n2 % n11 % n12 % n22 % 
Total 
n1 % n2 % 
rs6311 G/A 14 37.8 17 45.9 6 16.2 37 45 60.8 29 39.2 16 45.7 14 40.0 5 14.3 35 46 65.7 24 34.3 
5-HT2A 
rs6313 C/T 15 40.5 15 40.5 7 18.9 37 45 60.8 29 39.2 17 51.5 12 36.4 4 12.1 33 46 69.7 20 30.3 
5-HT1Dβ rs6296 G/C 13 38.2 18 52.9 3 8.8 34 44 64.7 24 35.3 20 62.5 10 31.3 2 6.3 32 50 78.1 14 21.9 
5-HT6 rs1805054 C/T 16 53.3 14 46.7 0 0.0 30 46 76.7 14 23.3 23 79.3 6 20.7 0 0.0 29 52 89.7 6 10.3 
DRD4 rs1800955 T/C 9 31.0 16 55.2 4 13.8 29 34 58.6 24 41.4 12 44.4 11 40.7 4 14.8 27 35 64.8 19 35.2 
DRD2 rs1800497 C/T 16 44.4 18 50.0 2 5.6 36 50 69.4 22 30.6 25 71.4 8 22.9 2 5.7 35 58 82.9 12 17.1 
COMT rs4680 A/G 7 25.0 15 53.6 6 21.4 28 29 51.8 27 48.2 9 33.3 13 48.1 5 18.5 27 31 57.4 23 42.6 
DRD3 rs6280 A/G 21 61.8 10 29.4 3 8.8 34 52 76.5 16 23.5 17 50.0 12 35.3 5 14.7 34 46 67.6 22 32.4 
DRD1 A-48G A/G 14 40.0 18 51.4 3 8.6 35 46 65.7 24 34.3 12 38.7 16 51.6 3 9.7 31 40 64.5 22 35.5 
BDNF rs6265 G/A 26 68.4 11 28.9 1 2.6 38 63 82.9 13 17.1 23 62.2 11 29.7 3 8.1 37 57 77.0 17 23.0 
rs9340799 A/G 10 43.5 12 52.2 1 4.3 23 32 69.6 14 30.4 12 48.0 11 44.0 2 8.0 25 35 70.0 15 30.0 
ESRα 
rs2234693 T/C 7 36.8 11 57.9 1 5.3 19 25 65.8 13 34.2 3 23.1 7 53.8 3 23.1 13 13 50.0 13 50.0 
INPP-1 rs1882891 C/A 28 80.0 7 20.0 0 0.0 35 63 90.0 7 10.0 20 66.7 9 30.0 1 3.3 30 49 81.7 11 18.3 
PLC-γ1 rs8192707 A/G 21 65.6 9 28.1 2 6.3 32 51 79.7 13 20.3 17 56.7 11 36.7 2 6.7 30 45 75.0 15 25.0 
ACE Alu Ins/del D/I 18 46.2 14 35.9 7 17.9 39 50 64.1 28 35.9 14 40.0 14 40.0 7 20.0 35 42 60.0 28 40.0 
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Table III.69(a). Association analysis investigating the differences in genotype and allele 
distributions between OCD subjects experiencing aggressive symptoms, and those not, in 
bi-allelic loci, with corresponding p-values, ORs and 95% CIs. 
  
 
 
Significant p-values are indicated in red, bold font. 
an1 refers to the major allele, n2 refers to the minor allele bgenotypic OR is calculated with the major genotype representing the 
risk genotype; callelic OR is calculated assuming the major allele to be the risk allele;dlower boundary of the 95% CI; eUpper 
boundary of the 95% CI.  
Abbreviations: OR: Odds ratio; CI: confidence interval; 5-HT2A: serotonin receptor 2A; 5-HT1Dβ: serotonin receptor 1Dβ; 5-
HT6: serotonin receptor 6; DRD4: dopamine receptor 4; DRD2: dopamine receptor 2; COMT: Catechol-O-methyltransferase; 
DRD3: dopamine receptor 3; DRD1: dopamine receptor 1; BDNF: brain-derived neurotrophic factor; ESRα: estrogen receptor 
α; INPP-1: inositol polyphosphate-phosphatase 1; PLC-γ1: phospholipase-gamma; ACE: Angiotensin-converting enzyme. 
 
 
 
 
 
 
 
Genotype Allele 
95% CI 95% CI Gene Variant n1/n2a p-
value OR
b 
LBd UBe 
Power p-value OR
c 
LBd UBe 
Power 
rs6311 G/A 0.734 0.74 0.14 3.62 0.051 0.606 0.81 0.39 1.69 0.065 
5-HT2A 
rs6313 C/T 0.488 0.51 0.09 2.50 0.079 0.292 0.68 0.31 1.44 0.120 
5-HT1Dß rs6296 G/C 0.632 0.44 0.03 4.43 0.061 0.123 0.52 0.22 1.19 0.252 
5-HT6 rs1805054 C/T 1.000 0.71 0.01 37.21 0.370 0.085 0.38 0.13 1.17 0.474 
DRD4 rs1800955 T/C 1.000 0.76 0.11 5.30 0.050 0.562 0.77 0.33 1.77 0.068 
DRD2 rs1800497 C/T 1.000 0.65 0.04 9.76 0.051 0.077 0.47 0.19 1.12 0.303 
COMT rs4680 A/G 0.704 0.66 0.11 3.90 0.052 0.572 0.80 0.35 1.81 0.062 
DRD3 rs6280 A/G 0.451 2.03 0.34 15.00 0.071 0.339 1.55 0.68 3.57 0.125 
DRD1 A-48G A/G 1.000 1.16 0.13 10.40 0.056 1.000 1.05 0.48 2.30 0.050 
BDNF rs6265 G/A 0.351 3.32 0.25 185.00 0.074 0.418 1.44 0.60 3.54 0.088 
rs9340799 A/G 1.000 1.63 0.07 108.00 0.054 1.000 0.98 0.37 2.57 0.052 
ESRα 
rs2234693 T/C 0.245 5.99 0.33 417.00 0.122 0.300 1.90 0.62 6.02 0.133 
INPP-1 rs1882891 C/A 0.243 4.17 0.16 107.62 0.052 0.207 2.01 0.66 6.60 0.155 
PLC-γ1 rs8192707 A/G 1.000 1.23 0.08 18.60 0.058 0.668 1.30 0.52 3.34 0.063 
ACE Alu ins/del D/I 0.755 1.28 0.30 5.44 0.050 0.615 1.19 0.58 2.44 0.059 
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Table III.69(b). Association analysis investigating the differences in genotype and allele 
distributions between OCD subjects experiencing aggressive symptom and controls in bi-
allelic loci, with corresponding p-values, ORs and 95% CIs. 
 
 
Significant p-values are indicated in red, bold font. 
an1 refers to the major allele, n2 refers to the minor allele bgenotypic OR is calculated with the major genotype representing the 
risk genotype; callelic OR is calculated assuming the major allele to be the risk allele;dlower boundary of the 95% CI; eUpper 
boundary of the 95% CI.  
Abbreviations: OR: Odds ratio; CI: confidence interval; 5-HT2A: serotonin receptor 2A; 5-HT1Dβ: serotonin receptor 1Dβ; 5-
HT6: serotonin receptor 6; DRD4: dopamine receptor 4; DRD2: dopamine receptor 2; COMT: Catechol-O-methyltransferase; 
DRD3: dopamine receptor 3; DRD1: dopamine receptor 1; BDNF: brain-derived neurotrophic factor; ESRα: estrogen receptor 
α; INPP-1: inositol polyphosphate-phosphatase 1; PLC-γ1: phospholipase-gamma; ACE: Angiotensin-converting enzyme. 
 
 
 
 
 
 
 
 
 
 
 
Genotype Allele 
95% CI 95% CI Gene Variant n1/n2a p-
value OR
b 
LBd UBe 
Power p-value OR
c 
LBd UBe 
Power 
rs6311 G/A 0.966 1.02 0.35 2.97 0.05 0.981 0.99 0.59 1.68 0.05 
5-HT2A 
rs6313 C/T 0.796 0.88 0.32 2.40 0.05 0.863 0.95 0.57 1.60 0.05 
5-HT1Dß rs6296 G/C 0.327 0.50 0.12 2.04 0.37 0.070 0.60 0.34 1.04 0.47 
5-HT6 rs1805054 C/T 0.655 0.62 0.02 38.50 0.31 0.084 0.54 0.27 1.10 0.39 
DRD4 rs1800955 T/C 0.425 1.67 0.47 5.97 0.09 0.489 1.22 0.69 2.17 0.11 
DRD2 rs1800497 C/T 0.924 1.08 0.22 5.42 0.11 0.415 0.78 0.45 1.40 0.14 
COMT rs4680 A/G 0.597 0.72 0.22 2.41 0.07 0.612 0.86 0.48 1.54 0.08 
DRD3 rs6280 A/G 0.170 2.47 0.66 9.28 0.42 0.050 1.85 1.00 3.42 0.52 
DRD1 A-48G A/G 0.398 1.79 0.46 6.96 0.10 0.485 1.22 0.70 2.12 0.12 
BDNF rs6265 G/A 0.623 0.55 0.05 6.23 0.05 0.947 0.98 0.50 1.92 0.05 
rs9340799 A/G 0.182 3.86 0.47 31.95 0.12 0.395 1.34 0.68 2.63 0.15 
ESRα 
rs2234693 T/C 0.050 6.78 0.79 58.38 0.40 0.080 1.89 0.92 3.87 0.50 
INPP-1 rs1882891 C/A 0.441 1.51 0.07 32.33 0.05 0.752 1.15 0.48 1.96 0.05 
PLC-γ1 rs8192707 A/G 0.535 0.58 0.10 3.36 0.05 0.971 1.01 0.51 2.01 0.05 
ACE Alu ins/del D/I 0.185 0.49 0.17 1.43 0.13 0.412 0.80 0.47 1.36 0.11 
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III.4.5.5.2.2. Single locus analysis of multi-allelic polymorphisms 
 
 i .DRD4 
 The DRD4 48bp VNTR genotypic and allelic scores in those OCD patients experiencing 
aggressive symptoms, and those without are presented in Tables III.70(a) and (b). No 
statistically significant differences in either the genotypic (p = 0.267) or allelic (p = 0.616) 
distributions were noted. Similarly, when the OCD subset experiencing aggressive symptoms 
was compared to the control sample, no significant differences in genotypic (p = 0.265) or 
allelic (p = 0.350) distributions were observed (Tables III.4[a] and [b] and III.70[a] and [b]).  
 
 ii. DAT 
The DAT 40bp VNTR genotypic and allelic scores in those OCD patients experiencing 
aggressive symptoms, and those without are presented in Tables III.71(a) and (b). No 
statistically significant differences in either the genotypic (p = 0.638) or allelic (p = 0.612) 
distributions were noted. Similarly, when the OCD subset experiencing aggressive symptoms 
was compared to the control sample, no significant differences in genotypic (p = 0.214) or 
allelic (p = 0.146) distributions were observed (Tables III.5[a] and[b] and III.71[a] and [b]).  
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Table III.70(a). Genotype counts and frequencies in the DRD4 48bp VNTR polymorphism for 
OCD patients presenting with aggressive symptoms and those without.  
 
 
 
 
 
 
 
 
 
 
p = 0.267  
A2 = 2-repeat allele; A3  = 3-repeat allele; A4 = 4-repeat allele; A6 = 6-repeat allele; A7 = 7-
repeat allele 
 
 
Table III.70(b). Allele counts and frequencies in the DRD4 48bp VNTR polymorphism for 
OCD patients presenting with aggressive symptoms and those without.  
 
 
 
 
 
 
 
 
p = 0.616 
A2 = 2-repeat allele; A3 = 3-repeat allele; A4 = 4-repeat allele; A6 = 6-repeat allele; A7 
= 7-repeat allele. 
Aggressive symptoms No aggressive symptoms 
Genotype 
n % n % 
A4/A4 11 37.9 13 44.8 
A4/A2 5 17.2 4 13.8 
A4/A3 5 17.2 1 3.4 
A4/A7 5 17.2 8 27.6 
A7/A7 2 6.9 0 0.0 
A7/A3 1 3.4 0 0.0 
A2/A2 0 0.0 1 3.4 
A3/A6 0 0.0 1 3.4 
A7/A2 0 0.0 1 3.4 
Aggressive symptoms No aggressive symptoms 
Allele 
n % n % 
A4 37 63.8 39 67.2 
A7 10 17.2 9 15.5 
A2 5 8.6 7 12.1 
A3 6 10.3 2 3.4 
A6 0 0.0 1 1.7 
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Table III.71(a). Genotype counts and frequencies in the DAT 40bp VNTR polymorphism for 
OCD patients presenting with aggressive symptoms and those without.  
 
Aggressive symptoms No aggressive symptoms 
Genotype 
n % n % 
A10/A10 15 40.5 18 54.5 
A9/A10 16 43.2 11 33.3 
A9/A9 4 10.8 3 9.1 
A10/A11 2 5.4 0 0.0 
A2/A10 0 0.0 1 3.0 
 
p = 0.638 
A2 = 2-repeat allele; A9 = 9-repeat allele; A10 = 10-repeat allele; A11 = 11-repeat allele. 
 
 
 
 
Table III.71(b). Allele counts and frequencies in the DAT 40bp VNTR polymorphism for 
OCD patients presenting with aggressive symptoms and those without.  
 
Aggressive symptoms No aggressive symptoms 
Allele 
n % n % 
A10 48 64.9 48 72.7 
A9 24 32.4 17 25.8 
A2 0 0.0 1 1.5 
A11 2 2.7 0 0.0 
 
p = 0.612 
A2 = 2-repeat allele; A9 = 9-repeat allele; A10 = 10-repeat allele; A11 = 11-repeat allele. 
 
 312
III.5. META-ANALYSES 
 
III.5.1. 5-HT2A -1438 A/G (rs6311) 
Four studies, including the present one, were included in the meta-analysis investigating the 
role that the 5-HT2A promoter polymorphism, -1438 A/G (rs6311), may play in mediating the 
development of OCD. The total number of OCD patients and controls amounted to 322 and 
444, respectively. The frequencies of the -1438G-allele in the control and OCD subjects in 
each included study are represented in Table III.72. All of the studies were in HWE, and no 
heterogeneity of ORs across the studies could be detected (Q = 6.37, 3df, p = 0.100).  
 
Figure III.51 presents a Forest Plot of the individual and summary ORs. Although a 
significant association was detected by Enoch et al. (2001), implicating the G-allele as a 
protective factor (therefore, the A-allele is assumed to represent the risk factor in their study), 
the summary OR generated by the present analysis indicates that no association exists 
between the variant and OCD (summary OR= 0.83 [95% CI: 0.62-1.11]).   
 
III.5.2. 5-HT2A T102C (rs6313) 
The five studies included in the meta-analysis of the 5-HT2A polymorphism T102C 
represented six independent samples and effect sizes, with an aggregate of 387 OCD patients 
and 657 controls. All studies were found to be in HWE. The frequency of the most prevalent 
allele, C102, in each study included in the meta-analysis is indicated in Table III.73.  
 
The individual and summary ORs and their corresponding 95% CIs are presented in Figure 
III.52, with neither the individual studies nor the meta-analysis achieving statistical 
significance (summary OR=0.97 [95% CI: 0.79-1.20]). There was no evidence for 
heterogeneity of ORs across the studies (Q = 6.36, 5df, p = 0.273).  
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Table III.72. Frequency of the 5-HT2A -1438G-allele in case and control subjects in each of 
the studies included in the meta-analysis. 
 
 
 
 
 
 
 
 
Abbreviations: OCD: obsessive-compulsive disorder. 
 
 
 
0.50 0.79 1.26 2.00  
 
                   Odds ratio 
 
Figure III.51. Forest plot of the association between the G-allele of the 5-HT2A 
 -1438A/G (rs6311) variant and OCD. Each study is indicated by the reference, OR point 
estimate and 95% CI. The summary refers to the meta-analysis OR by random effects model. 
Studies are ordered by year of publication.  
Frequency of -1438G 
Reference 
OCD Control 
Enoch et al. (2001)  0.50 0.62 
Tot et al. (2003) 0.54 0.51 
Walitza et al. (2004) 0.51 0.60 
Present Study 0.62 0.61 
95% CI OR 
LB UB 
0.61 0.42 0.87 
1.09 0.68 1.76 
0.70 0.46 1.07 
1.03 0.71 1.50 
   
   
0.83 0.62 1.11 
Enoch et al.(2001) 
Tot et al. (2003) 
Walitza et al. (2004) 
Present Study 
 
 
Summary 
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Table III.73. Frequency of the 5-HT2A C102-allele in case and control subjects in each of the 
studies included in the meta-analysis. 
 
 
 
 
 
 
 
 
Abbreviations: OCD: obsessive-compulsive disorder. 
 
 
 
 
0.50 0.79 1.26 2.00
)
 
Odds Ratio 
 
1Ashkenazi Jews, 2non-Ashkenazi Jews. 
 
Figure III.52. Forest plot of the association between the C-allele of the  5-HT2A T102C 
(rs6313) variant and OCD. Each study is indicated by the reference, OR point estimate and 
95% CI. The summary refers to the meta-analysis OR by random effects model. Studies are 
ordered by year of publication.  
Frequency of 5-HT2A C102 Reference 
OCD Control 
Nicolini et al. (1996) 0.61 0.69 
Frisch et al. (2000) 1 0.45 0.55 
Frisch et al. (2000) 2 0.53 0.43 
Tot et al. (2003) 0.51 0.48 
Meira-Lima et al. (2004) 0.55 0.52 
Present Study 0.61 0.62 
95% CI 
OR LBa UBb 
0.69 0.41 1.17 
0.67 0.40 1.12 
1.47 0.81 2.65 
1.14 0.71 1.83 
1.10 0.76 1.60 
0.96 0.66 1.38 
  
  
0.97 0.79 1.20
Nicolini et al. (1996) 
Frisch et al. (2000)1 
Frisch et al. (2000)2 
Tot et al. (2003) 
Meira-Lima et al. (2004) 
Present Study 
 
 
Summary 
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III.5.3. 5-HT2C  cys23ser (rs6318) 
Three studies were included in the 5-HT2C cys23ser meta-analysis, yielding a total of 281 
OCD patients (135 males, 146 females) and 425 (162 males, 263 females) controls. All 
studies were found to be in HWE, and no heterogeneity was observed across the ORs (Q = 
5.05, 3df; p = 0.17 for males and Q = 0.25, 3df; p = 0.97 for females). Given the location of 5-
HT2C on the X-chromosome, male and female meta-analyses were conducted separately.  
 
The frequencies of the cys23-allele (the G-allele) in the male and female case and control 
samples for each study included in the meta-analysis are presented in Table III.74. The 
individual and summary ORs and their corresponding 95% CIs pertaining to the male subsets 
in each analysis are presented in Figure III.53(a). Although a significant association between 
the variant and OCD was observed in the present study (section III.4.1.3.1.), no overall 
significance was detected when the studies were combined (OR = 0.85 [95% CI: 0.36-0.82]. 
As for the male subset, no statistically significant differences were noted for the female subset 
(OR = 1.09 [95% CI: 0.76-1.57]) (Figure III.53[b]). 
 
III.5.4 DAT 40bp VNTR 
Two studies (Frisch et al., 2000 and the present study) were included in the meta-analysis, and 
only the two most common alleles (A10 and A9) were used to construct the summary OR. 
One study was excluded due to inconsistencies in the data (Billet et al., 1998). The meta-
analysis comprised a total of 181 OCD patients and 349 controls. The A10-allele was found to 
be most prevalent in both studies included in the meta-analysis. The frequencies of this allele 
in the case and control populations of the included studies are provided in Table III.75.  
 
The individual and summary ORs and their 95% CIs are provided in Figure III.54. The 
summary OR and its 95% CI indicate the lack of association between the DAT 40bp VNTR 
and OCD. No heterogeneity across the ORs was noted(Q = 0.38, 2df, p = 0.826).  
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Table III.74. Frequency of the 5-HT2C  cys23-allele in male and female case and control 
subjects in each of the studies included in the meta-analysis. 
Male Female 
Reference 
OCD Control OCD Control 
Cavallini et al. 0.85 0.83 0.82 0.79 
Frisch et al. (2000) 1 0.76 0.71 0.83 0.84 
Frisch et al. (2000) 2 0.75 0.69 0.83 0.81 
Present Study 0.78 0.97 0.77 0.75 
1Ashkenazi Jews, 2non-Ashkenazi Jews. 
 
 
 
 
 
0.03 0.10 0.32 1.00 3.16 10.00
)
)
       Odds Ratio 
1Ashkenazi Jews, 2non-Ashkenazi Jews. 
 
Figure III.53(a). Forest plot of the association between the cys23-allele of the 5-HT2c 
cys23ser (rs6318) variant and male OCD subjects. Each study is indicated by the reference, 
OR point estimate and 95% CI. The summary refers to the meta-analysis OR by random 
effects model. Studies are ordered by year of publication.  
 
95% CI 
OR LB UB 
1.17 0.42 3.22
1.27 0.41 3.86
1.30 0.26 6.38
0.14 0.02 0.82
  
  
  
0.85 0.36 2.00
Cavallini et al. (1998) 
Frisch et al. (2000)1 
Frisch et al. (2000)2 
Present Study 
 
 
 
Summary 
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0.16 0.40 1.00 2.51 6.31
 
1Ashkenazi Jews, 2non-Ashkenazi Jews. 
 
Figure III.53(b). Forest plot of the association between the cys23-allele of the 5-HT2c 
cys23ser (rs6318) variant and female OCD subjects. Each study is indicated by the 
reference, OR point estimate and 95% CI. The summary refers to the meta-analysis OR by 
random effects model. Studies are ordered by year of publication.  
 
 
 
 
 
 
 
 
 
95% CI 
OR LB UB 
1.21 0.63 2.35
0.90 0.33 2.41
1.11 0.45 2.75
1.08 0.62 1.87
  
  
1.09 0.76 1.57
  
Cavallini et al. (1998) 
Frisch et al. (2000)1 
Frisch et al. (2000)2 
Present Study 
 
 
Summary 
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Table III.75. Frequency of the DAT A10-allele in male and female case and control subjects 
in each of the studies included in the meta-analysis. 
 
 
 
 
 
 
 
 
 
 
1Ashkenazi Jews, 2non-Ashkenazi Jews. 
 
 
0.50 0.79 1.26 2.00  
Odds Ratio 
1Ashkenazi Jews, 2non-Ashkenazi Jews. 
 
Figure III.54. Forest plot of the association between the A10-allele of the DAT 40bp 
VNTR variant and OCD. Each study is indicated by the reference, OR point estimate and 
95% CI. The summary refers to the meta-analysis OR by random effects model. Studies are 
ordered by year of publication.  
 
 
 
 
 
Frequency of A10 
Reference 
OCD Control 
Frisch et al. (2000) 1 0.61 0.65 
Frisch et al. (2000) 2 0.67 0.65 
Present Study 0.75 0.75 
Frisch et al. (2000)1 
Frisch et al. (2000)2 
Present Study 
 
 
 
Summary 
95% CI 
OR LB UB 
0.84 0.49 1.45
1.10 0.58 2.07
0.97 0.65 1.43
 
 
 
0.95 0.72 1.27
 319
III.5.5. DRD2 Taq1A (rs1800497) 
Two studies (Nicolini et al., 1996 and the present study) were included in the meta-analysis 
investigating the role that the DRD2 Taq1A polymorphism (rs1800497) may play in the 
development of OCD. Data presented by Billet et al. (1998) was excluded, due to 
inconsistencies. The total number of OCD patients amounted to 173, whilst the controls 
reached 231. The frequencies of the C-allele in the case and control populations of each study 
included in the meta-analysis are presented in Table III.76.  
 
The individual and summary ORs and 95% CIs are presented in Figure III.55. The 95% CIs 
indicate that no statistically significant associations were observed, either in the individual 
studies, or the meta-analysis. No heterogeneity across ORs was noted (Q = 0.84, 1df, p = 
0.361), and both studies were in HWE.   
 
No statistically significant differences were noted in DRD2 Taq1A C-allele frequency 
between the pooled case and control subjects (summary OR = 1.18 [95% CI: 0.86-1.63]). 
 
III.5.6. DRD3 ser9gly 
Data from three studies were included in the meta-analysis (Catalano et al., 1994; Nicolini et 
al., 1996, and the present study). Data from one study (Billet et al., 1998) was excluded due to 
inconsistencies in their data. The total number of OCD and control subjects amounted to 260 
and 275, respectively. The frequencies of the A (ser9)- allele in the OCD and control samples 
of each study included in the meta-analysis are represented in Table III.77. All studies were in 
HWE, and no heterogeneity across the individual ORs (presented in Figure III.56) was 
detected (Q = 1.92, 2 df, p = 0.382).  
 
Although none of the included studies reported a significant association between the variant 
and OCD, the summary OR (OR = 1.30 [95% CI: 1.01-1.68]; Figure III.56) indicates a 
significant association between the DRD3 ser9gly variant, with the A (ser9)-allele 
representing a risk factor in the development of OCD.  
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Table III.76. Frequency of the DRD2 C(A1)-allele in male and female case and control 
subjects in each of the studies included in the meta-analysis. 
 
 
 
 
 
 
 
 
 
 
0.63 1.00 1.58 2.51
)
 
Odds Ratio 
 
Figure III.55. Forest plot of the association between the C-allele of the DRD2 Taq1A 
(rs180094) variant and OCD. Each study is indicated by the reference, OR point estimate 
and 95% CI. The summary refers to the meta-analysis OR by random effects model. Studies 
are ordered by year of publication. 
Frequency of C 
(A1) Reference 
OCD Control 
Nicolini et al. (1996) 0.56 0.47 
Present 0.75 0.74 
Nicolini et al. (1996) 
Present Study 
 
 
Summary 
95% CI 
OR LB UB 
1.42 0.85 2.35
1.05 0.68 1.55
 
 
1.18 0.86 1.63
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Table III.77. Frequency of the DRD3 A (ser9)-allele in case and control subjects in each of 
the studies included in the meta-analysis. 
 
 
 
 
 
 
 
 
 
0.63 1.00 1.58
)
 
Odds Ratio 
 
Figure III.56. Forest plot of the association between the ser9-allele of the DRD3 ser9gly 
(rs6280) variant and OCD. Each study is indicated by the reference, OR point estimate and 
95% CI. The summary refers to the meta-analysis OR by random effects model. Studies are 
ordered by year of publication.  
 
 
Frequency of ser9 
Reference 
OCD Control 
Catalano et al. (1994) 0.66 0.57 
Nicolini et al. (1996) 0.59 0.60 
Present Study 0.72 0.64 
95% CI 
OR LB UB 
1.45 0.96 2.18
0.94 0.56 1.59
1.43 0.95 2.14
  
  
1.30 1.01 1.68
Catalano et al. (1994) 
Nicolini et al. (1996) 
Present Study 
Summary 
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III.5.7 COMT val158met (rs4680) meta-analysis 
Five studies, including the present, were pooled in the COMT val158met (rs4680) meta-
analysis, amounting to 321 OCD patients and 727 controls. No heterogeneity was detected 
across the ORs of the individual studies (Q = 5.46; 4df; p = 0.24). All studies were in HWE. 
Table III.78 presents the G(val158)-allele frequencies in the OCD and control populations in 
each of the studies. No evidence of association between the val158met variant and OCD was 
observed in the meta-analysis (summary OR = 0.81 [95% CI: 0.65-1.02]) (Figure III.57[a]). 
 
Since previously reported associations between the COMT val158met variant and OCD have 
been found to be gender dimorphic (Karayiourgou et al., 1997; 1999; Alsobrook et al., 2002), 
it was of interest to stratify the sample according to gender. Unfortunately, due to the inability 
to extract gender data from some of the investigations, only the present study and that by 
Karayiorgou et al. (1997) could be included in the gender-specific meta-analyses. Table 
III.78(b) presents the frequency of the G(val158)-allele in male OCD and control subjects in 
these two investigations, which included a total of 88 male OCD and 110 male control 
individuals were included in the meta-analysis. No significant heterogeneity across ORs was 
noted (Q=1.43; 1df; p=0.23). The meta-analysis revealed a significant difference in allelic 
distribution of the variant, with the G(val158)-allele conferring protection against developing 
the disorder (Figure III.57[b]).  
 
The genotype data from a total of 78 female OCD and 166 female control subjects was 
available for inclusion in the meta-analysis of the female subset. No significant differences in 
ORs between the two studies included in the meta-analysis were detected (Q=0.45; 1df; 
p=0.50). The G(val158)-allele frequency in the female OCD and control subsets in both 
studies is provided in Table III.78(c). From the Forest plot (Figure III.57[c], it is clear that, in 
contrast to the male subset, no significant differences in allele frequency were observed in the 
pooled female subset (summary OR = 0.90 [95% CI:0.62-1.35]). 
 
 323
Table III.78(a). Frequency of the COMT G(val158)-allele in case and control subjects in 
each of the studies included in the meta-analysis.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                           Odds Ratio 
 
 
 
 
Figure III.57(a). Forest plot of the association between the val158-allele of the COMT 
val158met (rs4680) variant and OCD. Each study is indicated by the reference, OR point 
estimate and 95% CI. The summary refers to the meta-analysis OR by random effects model. 
Studies are ordered by year of publication. 
Frequency of met158 (G) 
Reference 
OCD Control 
Karayiorgou et al. (1997) 0.44 0.58 
Ohara et al. (1998) 0.62 0.65 
Meira-Lima et al. (2003) 0.59 0.62 
Erdal et al. (2004) 0.60 0.57 
Present Study 0.46 0.52 
95% CI 
OR LB UB 
0.57 0.38 0.85 
0.87 0.42 1.79 
0.86 0.59 1.25 
1.16 0.74 1.81 
0.8 0.55 1.16 
   
   
0.81 0.65 1.02 
Karayiorgou et al. (1997) 
Ohara et al. (1998) 
Meira-Lima et al. (2003) 
Erdal et al. (2004) 
Present Study 
 
 
Average 
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Table III.78(b). Frequency of the COMT G(val158)-allele in male case and control subjects 
in each of the studies included in the meta-analysis.  
 
 
 
 
 
 
 
 
 
 
0.16 0.40 1.00
7)
 
           Odds Ratio 
 
Figure III.57(b). Forest plot of the association between the val158-allele of the COMT 
val158met (rs4680) variant and OCD in males. Each study is indicated by the reference, OR 
point estimate and 95% CI. The summary refers to the meta-analysis OR by random effects 
model. Studies are ordered by year of publication.  
Frequency of met158 (G) 
Reference 
OCD Control 
Karayiorgou et al. (1997) 0.32 0.57 
Present Study 0.50 0.63 
95% CI 
OR LBa UBb 
0.36 0.20 0.62
0.60 0.32 1.12
 
 
 
0.45 0.27 0.74
Karayiorgou et al. (1997) 
Present Study 
 
 
 
Summary 
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Table III.78(c). Frequency of the COMT G(val158)-allele in female case and control subjects 
in each of the studies included in the meta-analysis.  
 
 
 
 
 
 
 
 
 
 
 
       
 
 
 
 
 
                                                                      Odds Ratio 
 
 
Figure III.57(c). Forest plot of the association between the val158-allele of the COMT 
val158met (rs4680) variant and OCD in females. Each study is indicated by the reference, 
OR point estimate and 95% CI. The summary refers to the meta-analysis OR by random 
effects model. Studies are ordered by year of publication.  
Frequency of met158 (G) 
Reference 
OCD Control 
Karayiorgou et al. (1997) 0.60 0.58 
Present Study 0.43 0.48 
Karayiorgou et al. (1997) 
Present Study 
 
 
Average 
95% CI 
OR 
LBa UBb 
1.06 0.58 1.93 
0.81 0.49 1.33 
   
   
0.90 0.62 1.32 
0.50 0.79 1.26 2.00
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III.5.8. DRD4 48bp VNTR 
Three studies were included in the present meta-analysis of the DRD4 VNTR polymorphism, 
amounting to 209 OCD and 386 control subjects. The effects of the three most prevalent 
alleles, A2, A4 and A7, were investigated in separate analyses. The A4-allele was found to be 
the most prevalent in all of the included studies. The frequencies of the A2, A4 and A7-alleles 
in the OCD and control samples of all studies included in the meta-analyses are presented in 
Table III.79.  
 
All studies were in HWE, and no heterogeneity across the individual ORs were detected when 
the meta-analyses were conducted according to the presence or absence of the A4-allele (Q = 
5.76, 3df, p = 0.12). However, a significant amount of heterogeneity was noted between the 
studies when data was grouped according to the presence or absence of the A2- and A7-alleles 
(Q = 6.63, 3df, p = 0.08 for the A2-analysis; Q = 11.88; 3df, p=0.01 for the A7-analysis). 
Meta-analyses were thus not performed according to the presence or absence of either DRD4 
A2 or A7-alleles.  
 
Figure III.58 represents the ORs and corresponding 95% CIs for the individual studies 
included in the meta-analysis to determine whether the A4-allele conferred an increased risk 
to the development of OCD. The pooled OR and corresponding 95% CIs indicate that the A4-
allele did not play a role in the mediating the development of OCD (OR = 1.05 [95% CI: 
0.72-1.54]. 
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Table III.79. Frequency of the DRD4 48bp VNTR A2, A4 and A7 alleles in case and control 
subjects in each of the studies included in the meta-analysis. 
 
1Ashkenazi Jews, 2non-Ashkenazi Jews. 
 
0.32 0.50 0.79 1.26 2.00 3.16  
Odds Ratio 
 1Ashkenazi Jews, 2non-Ashkenazi Jews. 
 
Figure III.58. Forest plot of the association between the A4-allele of the DRD4 48bp 
VNTR and OCD. Each study is indicated by the reference, OR point estimate and 95% CI. 
The summary refers to the meta-analysis OR by random effects model. Studies are ordered by 
year of publication.  
 
A2-allele A4-allele A7-allele 
Reference 
OCD Control OCD Control OCD Control 
Frisch et al. (2000) 1 0.08 0.04 0.67 0.71 0.20 0.21 
Frisch et al. (2000) 2 0.11 0.09 0.76 0.65 0.09 0.23 
Millet et al. (2003) 0.02 0.10 0.80 0.72 0.10 0.01 
Present Study 0.11 0.09 0.63 0.69 0.19 0.17 
95% CI 
OR LB UB 
0.81 0.47 1.41 
1.66 0.85 3.24 
1.49 0.80 2.77 
0.79 0.53 1.16 
   
   
1.05 0.72 1.54 
Frisch et al. (2000)1 
Frisch et al. (2000)2 
Millet et al. (2003) 
Present Study 
 
 
Summary 
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CHAPTER IV: DISCUSSION 
 
“The difficulty lies, not in the new ideas, but in escaping the old ones” 
John Maynard Keynes, English economist 
 
OCD represents a psychiatric disorder with a complex multifactorial inheritance. Presently, it 
is believed that individual susceptibility to the disorder is governed by the conjoint effects of 
variation at an, as of yet, undetermined number of genes, and the collective effect of various 
environmental exposures encountered during an individual’s life. Case-control association 
studies represent an important tool in dissecting the genetic aetiology of complex disorders. 
Over the last decade, a large number of association studies have been dedicated to 
disentangling the genetic components that may be involved in the aetiology of OCD. 
However, numerous potential caveats limit the success of case-control association studies; not 
surprisingly, very few of the initially exciting positive findings in the OCD field have been 
replicated, with inconsistent results between studies. The paucity of robust findings is 
probably the result of a mixture of a lack of sufficient phenotypic resolution to identify 
genetic risk factors, and the lack of application of the appropriate statistical methodology.  
 
The aim of the present study was thus two-fold: firstly, to assess the factors that may 
confound case-control genetic association studies of complex disorders, and secondly, to 
investigate the genetic aetiology of OCD, a complex psychiatric disorder, and clinically-
defined OCD-related subtypes, avoiding the identified pitfalls. 
 
IV.1. POPULATION STRATIFICATION 
Generally, in this type of study, it is customary for subjects to be classified as being of a 
particular ancestral grouping based on self-reported ancestry: in this study, following 
convention, at least three of their four grandparents had to be of Afrikaner descent (section 
II.1). This self-reported ancestry method is thought by some investigators to be adequate to 
prevent stratification (Morton and Collins, 1998), but others have disagreed (Freedman et al., 
2004).  
 
The Afrikaner population has often been used in case-control association studies, as the 
Afrikaner is thought to be a homogeneous group. However, until now, no empirical data 
existed to support the absence of cryptic subpopulations within the Afrikaner population that 
may confound an association study. Recently, proof of substructure in populations originally 
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thought to be genetically homogeneous has been reported, for example, the Icelandic 
population (Helgason et al., 2005). Hence, to a priori assess the absence of population 
stratification and thus the validity of using the Afrikaner population in a case-control 
association study, Structure, a model-based clustering algorithm that identifies clusters of 
related individuals from multilocus genotypes, was implemented in the present study. The 
number of clusters, which was chosen by the author to vary from K=1 to K=5, was based on 
the reported ancestry of the Afrikaners: the population has been proposed to originate from 
five Northern European populations: Dutch, German, French, Belgian and British (Botha and 
Beighton, 1983).  
 
No evidence was observed for cryptic population substructure in either the Afrikaner OCD or 
control population used in the current genetic analyses: classification of the Afrikaner 
individuals into clusters demonstrated symmetry, with roughly the same proportion of each 
individual’s genome assigned to each cluster (Table III.2). Varying K to larger values (up to 
12) had no effect on the result (results not shown). The evidence thus suggested that cases and 
controls were ethnically and genetically matched, and not subject to population stratification 
with respect to each other, supporting the use of at least these particular samples in case-
control association studies.   
 
Of course, Structure does not represent the only means by which one can detect and control 
for population structure in genetic association studies. Other methods, each with their 
respective merits, do exist, for example the GC method (section I.4.1.1.3[ii]). However, 
Structure was chosen over the GC method in the present study, largely because it provides 
one with a more meaningful characterisation of individuals into specific subpopulations (if 
they exist), which could not only be used in subsequent genetic investigations, but may also 
aid consequent genealogical investigations. The GC method, on the other hand, provides one 
with only an average correction factor that can be implemented in subsequent genetic 
association studies. 
 
A limiting factor to detecting population substructure in the present investigation is that, if 
substructure within the Afrikaner population does exist, it is likely to be very subtle, given 
their past geographical and cultural isolation, and derivation from geographically closely 
related Northern European groups. Detection of such subtle substructure may require the use 
of many more markers, increasing the amount and cost of genotyping to a very large degree. 
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It should also be noted that the most informative marker to use when investigating whether 
population stratification exists would be those that possess large frequency differences 
between the proposed subpopulations (Campbell et al., 2005). It is thought that the so-called 
ancestry-informative markers that are currently available will not be sufficient to detect 
structure in closely related populations: identification of such markers in the Afrikaner 
population will entail assessing the frequencies of a large number of variants across the 
proposed contributing sub-populations. However, even if, as yet undetected subtle population 
substructure amongst Afrikaners does exist, it is unlikely that the frequency of OCD between 
these subpopulations will be significantly different, decreasing the potential for confounding 
by population stratification.  
 
IV.2. GENETIC ANALYSES 
OCD is a clinically heterogeneous disorder: many clinical subtypes of the disorder, which 
may be mediated by different aetiological mechanisms, have been reported (Ball et al., 1996; 
Mataix-Cols et al., 2000; Ravindran et al., 1999). These subtypes may thus represent 
intermediate phenotypes that are more proximal to a particular genetic substrate than the 
higher order construct of the disorder, and may therefore provide a stronger genetic signal, 
with correspondingly greater effect size.  
 
However, although the phenotypic heterogeneity of OCD is fast becoming recognised, and 
indeed utilised, in genetic association studies (as discussed in the forthcoming sections), the 
formal, dichotomous diagnosis of OCD may still provide insight into which genes play a role 
in contributing to the overall aetiology, and may provide important clues with regard to the 
pathophysiology of the disorder. The following sections highlight important findings from the 
present population-based genetic association study, beginning with the overall case-control 
association analyses, and moving onto the various subtype analyses performed.  
 
IV.2.1. Unstratified Case-control Association Analyses 
No statistically significant associations were noted when any of the candidate markers were 
analysed in a single locus context in the unstratified sample. However, when the DRD4 
VNTR and -521C/T (rs1800955) variants were analysed as a haplotype, significantly more 
controls were found to carry the -521C/T-VNTR C-A4 haplotype (p = 0.049). Moreover, 
significantly more cases were found to carry the T-A2 haplotype compared to controls (p = 
0.026) (Table III.12).  
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It is interesting to note that both polymorphisms possess proposed functionality, with the 
alleles implicated in susceptibility to OCD depressing the functionality of the DRD4 receptor: 
the T-allele of the -521C/T SNP has been found to result in a decrease in expression of DRD4 
by as much as 40% in comparison to the C-allele (Okuyama et al., 1999), while, compared to 
the A4-allele, the VNTR A2-allele has been found to possess a blunted cAMP response 
(Asghari et al., 1995) (section I.6.1.2.1[i]). As neither of the alleles was found to contribute to 
OCD when analysed separately, the haplotypic association may be due to cis-interaction 
between the alleles in the promoter variant and the exon 3 VNTR. This points to a threshold 
effect, where OCD susceptibility is increased when available DRD4s are reduced both in 
number and in function.  
 
One should, however, bear in mind that, whilst haplotype-based analyses may represent a 
somewhat statistically more robust model compared to single locus analysis, the unambiguous 
construction of haplotypes from genotypic population-based data is not possible, especially 
for heterozygotes. Consequently, the eventual reverse classification into haplotype-based 
diplotypes is approximate, based on haplotype estimates and posterior probabilities. It is thus 
likely that the eventual statistical significance may be overstated, signifying the requirement 
for independent replication of the present observation. 
 
IV.2.2. Subtype Analyses 
One of the main reasons for lack of replication amongst association studies investigating 
complex disorders such as OCD may be the phenotypic heterogeneity of the disorder. 
Subtyping according to clinically-defined variables reduces background “noise” and 
consequently increases the power to detect small effects. In the present investigation, OCD 
was subtyped according to gender, severity of the symptoms (assessed using the total Y-
BOCS score), age at onset of the disorder, co-morbidity (MDD and tics) and symptom 
dimensions (hoarding, symmetry/ordering, sexual/religious, contamination and aggressive 
symptoms).  
 
IV.2.2.1. Stratification by gender 
Although epidemiological studies have indicated that the male:female ratio in OCD is 
approximately 1:1 (section I.2.1), it has been hypothesised that OCD may exhibit features of 
gender dimorphism, particularly with regard to symptomatology and co-morbidity 
(Karayiorgou et al., 1999; Bogetto et al., 1999; Castle et al., 1995; Enoch et al., 2001; Baer et 
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al., 1993). Clinically, male OCD patients in previous studies have often been found to have a 
higher frequency of co-morbid social phobia, alcohol abuse and tic disorders, whilst females 
have been found to experience a higher frequency of co-morbid eating disorders and MDD 
(Bogetto et al., 1999). As far as symptomatology is concerned, prominent sexual, exactness 
and symmetry obsessions have previously been found to be more prominent amongst male 
OCD patients (Lensi et al., 1996), whilst female OCD subjects have been found to exhibit 
more frequent contamination and washing rituals compared to male OCD patients (Castle et 
al., 1995; Minichiello et al., 1990; Rasmussen and Eisen, 1990). Indeed, in the present study, 
significantly more males were found to exhibit sexual and religious obsessions, corroborating 
results from previous studies (Lensi et al., 1996), whilst females were found to experience 
significantly higher frequencies of specific phobia and anorexia as co-morbid disorders 
(section III.4.1.2; Table III.7).  
 
It has been proposed that such gender differences may be due to epigenetic hormonal 
influences that affect the manifestation of the disorder (Karayiorgou et al., 1999) and are 
apparent at a genetic level as well. Indeed, sexually dimorphic effects have been noted in 
genetic association studies of the role of COMT (Karayiorgou et al., 1997; 1999), MAO-A 
(Camarena et al., 1998; 2001; Karayiorgou et al., 1999) and 5-HT2A (Enoch et al., 2001). In 
the present study, when the total sample was stratified by gender, differences in genotype and 
allele frequencies of the 5-HT2C cys23ser (rs6318), COMT rs362204, BDNF val66met 
(rs6265) and ACE Alu ins/del variants were noted between male OCD and control individuals; 
these findings are discussed below.  
 
IV.2.2.1.1. 5-HT2C cys23ser  
In the present study, the X-linked 5-HT2C cys23ser (rs6318) G (cys23)-allele was found to 
confer protection against the development of OCD in males (Table III.9). This gene has been 
proposed to play a role in grooming behaviour (Heisler and Tecott, 1999; Graf et al., 2003), 
and in the manifestation of compulsive-like syndromes (Chou-Green et al., 2003).  
 
Contradictory results have been obtained with regard to the functionality of the cys23ser 
variant: it has been found to increase CSF MHPG (the major metabolite of norepinephrine) in 
Finnish males carrying the C (ser23)-allele (Lappalainen et al., 1999), but this result was not 
replicated in a more recent study conducted on a Swedish sample (Jonsson et al., 2004) 
(section I.6.1.1.1[iib]). On the other hand, a recent functional analysis suggest that the 5-
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HT2C receptor containing the C (ser23)-allele may be constitutively more active than one 
containing the G (cys23)-allele (Okada et al., 2004). 
 
In the light of the uncertainty regarding the functionality of the variant, the reasons for the 
gender-biased effects require speculation, although it is tempting to consider that the 5-HT2C 
gene being X-linked may play a role. Indeed, previous studies have indicated a sexually 
dimorphic effect between another X-linked gene, MAO-A, and OCD in males (Camarena et 
al., 1998; Karayiorgou et al., 1999). Although in general, X-linked genes undergo random X-
inactivation in females, a mechanism which is proposed to increase similarity amongst males 
and females, recent evidence suggests that at least one out of every five X-linked genes 
escapes X-inactivation (Carrel et al., 1999), which could result in differences between the 
sexes due to the imbalanced expression of the gene product. Therefore, one could hypothesise 
that, if 5-HT2C does indeed harbour the disease susceptibility variant (assumed to decrease 
expression of the gene), and it represents one of the genes that escapes X-inactivation, 
females carrying the disease susceptibility variant may express sufficient amounts of the 
product due to the presence of two copies of the gene. On the other hand, males carrying the 
disease susceptibility variant may express lower levels of 5-HT2C, which, in conjunction with 
other environmental and genetic factors, may deem them more susceptible to OCD than their 
female counterparts.  
 
The present finding does contradict results from two previous case-control association studies, 
where no evidence to support a role for the variant in mediating the development of OCD was 
found (Cavallini et al., 1998; Frisch et al., 2000). The inconsistencies could be due to a 
number of factors, including ethnic differences: Cavallini et al. (1998) utilised an Italian 
population, whilst Frisch et al. (2000) utilised non-Ashkenazi and Ashkenazi Jewish 
populations). Given the present uncertainty regarding the functionality of the variant, a 
possible explanation for the discrepancies in the genetic findings is that the cys23ser variant is 
not the causal variant, but may be in LD with the susceptibility variant in the 5-HT2C gene, or 
one nearby, in the Afrikaner population, but not in the Italian or Jewish populations. 
 
One cannot, of course, dismiss the possibility that the present observation represents a Type I 
error, due to the relatively small number of male control subjects. On the other hand, the 
possibility does also exist that the two negative associations (Cavallini et al., 1998; Frisch et 
al., 2000) were not sufficiently powered to accept the null hypothesis with certainty. In an 
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attempt to resolve the discrepancies regarding the results of the association studies, at the 
same time increasing the power of the study, a meta-analysis was conducted, the results of 
which indicated no role for the variant in mediating the development of OCD, in either males 
or females. However, it would be unwise to completely dismiss the association, as again, the 
meta-analysis comprises a relatively small sample size, and thus probably does not possess 
the power to reject the alternative hypothesis with absolute certainty. The results can thus best 
be described as inconclusive: a suggestion would be to perform independent studies using 
larger samples of males and females, and to eventually pool the data appropriately in a meta-
analysis that does possess sufficient power to refute or accept the null hypothesis.  
 
IV.2.2.1.2. COMT val158met and rs362204 
The allelic distribution of the COMT rs362204 insertion/deletion polymorphism was found to 
be significantly different in male cases and controls. Specifically, the D-allele (characterised 
by the deletion of a cytosine base) was found to confer an increased risk to developing OCD 
in males (OR = 2.88) (Table III.9). The rs362204 variant has thus far not been found to be 
functional (DeMille et al., 2002), although it is situated immediately 3’ to the stop codon in 
exon 6, and as such, may affect gene transcription. Moreover, in the present study, the D-
allele was found to exhibit a measure of pairwise LD with the val158met A-allele, which has 
been found to be associated with an increased susceptibility OCD in males in previous studies 
(Karayiorgou et al., 1997; 1999), and in a meta-analysis performed in the present study.  
T
 
Disappointingly, however, haplotype analyses involving the COMT val158met, rs362204 and 
promoter rs2097603 variants yielded no statistically significant differences (p = 0.355) (Table 
III.13), although the frequency of the val158met-rs362204 A(met158)-D-haplotype was found 
to be increased in the OCD population compared to controls (32.8% versus 23%, respectively) 
(data not shown). It may thus be that the sample size included in the haplotype analysis is too 
small to attain sufficient power to reject the null hypothesis completely. On the other hand, 
the lack of complete LD between the val158met and rs362204 variants with the promoter 
variant (rs2097603), which was also included in the haplotype analysis, could result in the 
“dilution” of any association the COMT val158met-rs362204 haplotype has with OCD. 
However, haplotype analysis involving only the latter two variants also yielded no statistically 
significant results, although, once again, the frequency of the val158met-rs362204 A-D 
variant was higher in the OCD, compared to the control, population (data not shown). 
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Therefore further investigation, in a dataset large enough to retain optimal power after 
stratifying according to gender and haplotype, is warranted. 
 
The COMT val158met (rs4680) variant has, to date, been one of the most extensively 
genotyped COMT polymorphism in psychiatric association studies, including studies of OCD. 
The present study represents an extension of an original investigation involving the val158met 
polymorphism and OCD in an Afrikaner population (Niehaus et al., 2001). In the latter, an 
association was observed between the heterozygous val158met genotype and the disorder. In 
the present study, however, this association disappears; no statistically significant differences 
in allele or genotype frequency were observed between the OCD subjects and controls of 
either gender. A possible reason for the discrepant results may be the preliminary nature of 
the Niehaus et al. (2001) investigation: only 54 OCD and 54 control subjects were included in 
the study (compared to 93 OCD and 128 controls in the present study (Table III.3[b]). This 
indicates, as the authors themselves stated, the possibility that the results may represent a 
spurious association between the COMT val158met variant and OCD. 
 
Indeed, two recently conducted meta-analyses (one based on available case-control 
information, one based on available family-based information) yielded little evidence for the 
involvement of the COMT val158met polymorphism in the development of OCD (Azzam et 
al., 2003). However, it should be mentioned that those authors did note an association 
between the A(met158)-allele and OCD in the case-control meta-analysis, but only when 
using the less conservative fixed-effects model (Azzam et al., 2003). Due to the extra data 
obtained from the present study, and two studies investigating the relationship between the 
COMT val158met variant and OCD, being published subsequent to the publication of the 
meta-analysis by Azzam et al. (2003) (Erdal et al., 2003; Meira-Lima et al., 2004), a case-
control meta-analysis was conducted in the present study.  
 
As was found by Azzam et al. (2003), when the data was analysed in its entirety, no 
statistically significant differences were observed, although the present meta-analysis did 
result in narrower 95% CIs than were obtained by Azzam et al. (2003). In view of the fact that 
gender bias that has often been noted in associations between COMT val158met and OCD, the 
meta-analytic data was stratified according to gender, where possible. Interestingly, in 
contrast to the results attained by Azzam et al. (2003), who observed no significant 
differences when meta-analyses were conducted according to gender, results from the present 
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study indicate that a significantly higher proportion of male controls carry the G(val158)-
allele, compared to male OCD subjects, thus again implicating the A(met158)-allele allele as a 
susceptibility allele (Figure III.57[b]).  
 
These results are intriguing for a number of reasons. The COMT val158met polymorphism 
has been found to be functional: the A-allele (coding for the met158 codon) is associated with 
a three-to fourfold reduction in COMT enzymatic activity (section I.6.1.2.1[vi]). The main 
function of this enzyme is to catabolise certain catecholamines, including dopamine. 
Consequently, a reduction in activity may result in the accumulation of extraneuronal 
dopamine, eventually resulting in a hyperdopaminergic state, which, in mice, has been found 
to elicit behaviour reminiscent of OCD or TS (Berridge et al., 2005) (section I.6.1.2).  
 
The gender-biased results are also interesting, given that the influence of gonadal steroids on 
brain development has been found to be associated with sex differences in brain organisation, 
neuropsychological performance and learning and memory function (McEwen et al., 1997). 
Indeed, the expression of MB-COMT is driven by an ERE, indicating that estrogen regulates 
the expression of the gene. Moreover, unpublished results, presented at the Endocrine 
Society’s annual meeting in San Diego (2005) indicated that male mice who were deficient in 
aromatase (which converts testosterone to estrogen) exhibited OCD-like behaviour: they ran 
excessively on their running wheels and spent twice as long grooming themselves compared 
to control littermates. Interestingly, they also possessed lower levels of COMT. Female mice 
deficient in estrogen did not exhibit the same patterns of behaviour, suggesting that estrogen 
interacts with certain components in the male and female brain differently. It may well be 
these differences in the interactions between estrogen and COMT that bring about the gender-
biased association observed in the present study. Further investigation is, however, required to 
elucidate the exact mechanism by which changes in the estrogen-COMT interaction may 
bring about the clinical phenotype in males more often than in females. 
 
IV.2.2.1.3. BDNF val66met 
BDNF was selected as a candidate gene in the present study on the basis of its pivotal role in 
neurodevelopment in the brain. Three SNPs (rs988748, rs2049046 and val66met [rs6265]), 
each exhibiting a high degree of pairwise LD (Table III.6), were included in the present study. 
Significantly different val66met allele frequencies were observed between male case and 
control individuals, with the G(val66)-allele found to represent the protective allele, with a 
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greater frequency amongst the male control individuals (Table III.9). The A (met66)-allele has 
previously been found to affect the intracellular processing of the pro-BDNF polypeptide, 
thereby inhibiting the release of BDNF from activated neurons (Egan et al., 2003). This allele 
has also been implicated as the risk allele in a restrictive subtype of anorexia nervosa (Ribases 
et al., 2003; 2004; 2005), which has features in common with OCD. In a more recent study, 
Jiang et al. (2005) concluded that the met66-allele may act as a risk factor in the development 
of anxiety disorders.  
 
The sex-selective effect of the BDNF val66met on OCD is interesting, since it has recently 
been proposed that estradiol may bring about its structural and functional effects in the brain 
via the action of intermediate signalling molecules such as growth factors (Miranda et al., 
1994; Scharfman and MacLusky, 2005). Indeed, BDNF has been found to possess a sequence 
similar to the EREs noted in other genes that are estrogen-regulated, such as COMT (Sohrabji 
et al., 1995). In the same study, the authors observed an estrogen-mediated increase in BDNF 
mRNA expression in the cerebral cortex and olfactory bulb in rats. Further impetus for the 
notion that BDNF is regulated by estrogen via ERE is the observation that ESRα have been 
found to co-localise with BDNF in male and female rat brains (Solum and Handa, 2001).  
 
Moreover, BDNF and estradiol have been found to possess similar effects, including the 
modulation of NMDA receptors (Lu, 2003; Foy et al., 1999), most notably GRIN2B (Yamada 
and Nabeshima, 2003; Adams et al., 2004) which has been investigated as a candidate gene in 
the present study, and has subsequently been found to be associated with severity and age at 
onset of OCD (section IV.2.3.1 and IV.2.4.1). Furthermore, like BDNF, estrogen has been 
found to be associated with neuronal differentiation and survival, and to play an important 
role in brain development by influencing the maturation of neural systems and by affecting 
sexual differentiation of brain structure and function (Solum and Handa, 2001). Moreover, in 
males with epilepsy, a disorder thought to be mediated via a dysfunction in estrogen-BDNF 
interaction, serum estrogen concentrations have been found to rise, and it is thought that this 
might contribute to the subsequent seizures (Herzog, 1999; Murialdo et al., 1994). Thus, 
given the close relationship between BDNF and estrogen, it is plausible that the gender-
specific effects in OCD are mediated via a dysfunction in the estrogen-BDNF interaction. 
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IV.2.2.1.4. ACE Alu ins/del 
One of the genes characterised as a “novel” candidate in the present study, ACE, was found to 
be associated with the formal, dichotomous diagnosis of OCD. Here, the DD-genotype was 
found be protective against the development of OCD (Table III.8). This observation is 
interesting, given that ACE D-allele carriers have been shown to have higher plasma ACE 
concentrations (Rigat et al., 1990), although this effect has been proposed to be a result of 
polymorphisms in LD with the ACE Alu ins/del (Tiret et al., 1992; Cox et al., 2002), and the 
effect of these polymorphisms on brain ACE levels have yet to be determined. However, the 
possibility does exist that ACE D-allele carriers will possess a higher capability for the 
hydrolysis of angiotensin I into AngII, and for the degradation of SP and other neuropeptides 
(section I.6.1.5.4).  
 
AngII has been found to co-localise and indeed stimulate, certain types of neurotransmission, 
including dopamine, in various regions of the CNS, including the striatum and substantia 
nigra (Jenkins et al., 1995; Hasenörhl et al., 2000; Mendelsohn et al., 1993; Reardon et al., 
2000). To this end, it has also been found that ACE inhibitors increase dopaminergic 
neurotransmission in the brain (Jenkins et al., 1997; Reardon et al., 2000). From these results 
it could be suggested that a decrease in activity in ACE is likely to result in an increase in 
dopaminergic neurotransmission. It may thus be that ACE Alu ins/del II-carriers, due to their 
lower ACE activity, may experience an increase in dopaminergic neurotransmission, which is 
thought to underlie some aspects of OCD pathology. However, this remains speculative, 
because, at present, the exact mechanism by which ACE interacts with the dopaminergic 
system is unclear, and the role of other substrates upon which ACE acts cannot be excluded.  
 
Indeed, the role that ACE plays in the degradation of SP may also be relevant to the present 
association: D-allele carriers will possess higher SP degradation capabilities, which may 
confer protection against the development of OCD. Indeed, antagonism of the SP-NK1R 
pathway has been found to result in antidepressant and anxiolytic effects (Kramer et al., 
1998); a decreased SP concentration in D-allele carriers may thus have resulted in the 
observed protective effect.  Moreover, in a recent genetic association study, Baghai et al. 
(2004) observed that depressed females carrying at least one ACE D-allele exhibited a better 
therapeutic outcome with different antidepressants, compared to II-carrying females, and 
males. 
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A gender-biased effect in the direction of males was also observed in the present study, with 
the D-allele and DI- and DD-genotypes implicated as the protective factors (Table III.9). The 
sex-specific effect may be due to the influence of gonadal steroids on the expression of ACE. 
For example, estrogen has been found to reduce ACE mRNA concentrations, thereby 
regulating tissue ACE protein activity (Gallagher et al., 1999), whilst testosterone has been 
found to enhance the activities of ACE in various animal studies (Jaiswal et al., 1985; 
Freshour et al., 2002). However, these investigations concentrated on the expression of ACE 
in peripheral tissues, and not in the CNS. The role that the gonadal hormones may play in the 
regulation of ACE activity in the brain thus remains speculative.  
 
The present study represents the first to show an association between OCD and the ACE Alu 
ins/del polymorphism, and requires independent replication in a larger sample. Moreover, 
given the recent proposition that the ACE Alu ins/del does not function independently in 
determining ACE levels, it would be of interest to perform haplotype-based investigations, 
utilising polymorphisms across the length of the gene (Cox et al., 2002). 
 
IV.2.3. Severity of OCD (as assessed by total Y-BOCS score) 
The quantitative phenotype of OCD, as defined by the total Y-BOCS score, was used in 
addition to the formal diagnosis of OCD in genetic analyses, as the use of quantitative instead 
of categorical variables can increase the power of a study. This is because categorising a 
continuous variable results in a reduction of the amount of information available, and a 
consequent lack of sensitivity. In the present study, associations were noted between three 
genes and total Y-BOCS score; these are discussed below.  
 
IV.2.3.1. GRIN2B 
First, when the entire OCD population was considered, the GRIN2B rs890 gene (analogous to 
the 5072T/G polymorphism investigated in a family-based study by Arnold et al. [2004]) was 
found to be associated with the severity of the disorder. OCD subjects carrying the CC-
genotype were found to exhibit more severe forms of the disorder, as evidenced by the higher 
total Y-BOCS score (Table III.18[c]). Interestingly, Arnold et al. (2004) found that an 
increased Y-BOCS score in their family-based sample was associated with a trend for 
increased transmission of the 5072G-allele (corresponding to the rs890 C-allele in the present 
study) under the recessive model, and with a decreased transmission of the 5072T-allele under 
the dominant model.  
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The GRIN2B rs1806191 variant, situated in exon 13, was not found to be associated with 
severity of the disorder in the single locus analysis; however, haplotype analysis revealed that 
the rs1806191-rs890 A-C haplotype was associated with a significantly higher Y-BOCS score 
(and subsequently a more severe form of OCD) compared to the other haplotypes (p = 0.021) 
(Table III.24). On the other hand, the more common G-A haplotype was found to be 
significantly associated with a lower Y-BOCS score compared to the other haplotypes (p = 
0.022) (Table III.24). 
 
This finding is interesting, since a two-locus haplotype (G-T), combining the rs890 (5072G/T) 
variant and the 5988T/C variant situated in the 3’UTR, was found by Arnold et al. (2004) to 
be associated with the dichotomous diagnosis of OCD, and nominally associated with lifetime 
severity of the disorder. Although the 5988T/C variant was not included in the present study, 
the findings indicate that GRIN2B may be involved in the development of at least some 
aspects of OCD. However, the present results are difficult to interpret, since no function has, 
as yet, been elucidated for either of the two variants under investigation in the present study. 
The rs1806191 SNP represents a synonymous mutation in exon 13, which is unlikely to affect 
function, and rs890 represents a variant in the 3’UTR. However, it can be speculated that 
rs890, by virtue of its position in the 3’UTR, may well affect mRNA processing, thereby 
altering the quantity of protein. In order to delineate the role that the gene (and, in particular, 
rs890) may play in mediating the development of severe OCD, additional variants, throughout 
the gene, need to be genotyped to determine whether rs890 exhibits LD with a functional 
variant that increases susceptibility to OCD characterised by more severe symptomatology. In 
the absence of such a functional variant being detected, functional analyses to determine 
whether the rs890 variant does, in fact, alter the levels of expression of GRIN2B, would be 
warranted. 
 
The lack of association of the rs890 variant with the formal, dichotomous, diagnosis in the 
present study may be due to a number of factors, the most probable being the lack of 
sufficient power in the case-control analysis to reject the alternative hypothesis with certainty. 
Indeed, the power for the case-control genotypic analyses of rs890 and rs1806191 amounted 
to 5.9% and 8.2% respectively (Table III.8), indicating that there is a possibility that chance 
may have played a role in obtaining those results. The association may be observed in the 
severity subtype analysis due to the increase in power afforded by the quantitative analysis. 
Moreover, no significantly gender-biased effects were observed, with the same trend noted in 
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both genders (i.e. the association of the CC-genotype with increased severity) (Table 
III.18[c]). This observation could thus lead one to conclude that the association is not sex-
specific, although further studies using larger male and female OCD subsets would be 
required to determine whether the association is, in fact, gender-dependent. 
 
IV.2.3.2. BDNF 
Associations were also observed between the BDNF val66met variant and total Y-BOCS 
score, although this association was only observed amongst the female subset. Here, 
individuals carrying the GG(val66val)-genotype were found to be possess higher Y-BOCS 
score compared to female individuals carrying at least one A(met66)-allele (p = 0.013) (Table 
III.18[c]). This finding contradicts observations from the present case-control analysis, where 
an association between the same variant and a dichotomous diagnosis of OCD in males was 
noted, with the A(met66)-allele representing the risk allele, and may be indicative of the 
gender differences that have been found to exist between male and female OCD patients. 
Indeed, both the A(met66) and G(val66)- alleles have been implicated as risk factors in 
various neuropsychiatric disorders (section I.6.1.4.1[i]), and BDNF has been found to interact 
in a complex manner with estrogen to modulate certain neurodevelopmental aspects (section 
IV.2.2.1.3). It may be that the G(val66)-allele, by means of female-specific epigenetic 
interaction, increases the risk for a more severe form of OCD in females, but not in males. 
Alternatively, it must be considered that the association may not have been detected in the 
case-control association studies due to a lack of power of afforded by the categorical analysis.  
 
IV.2.3.3. DRD1  
Finally, a marginal association was noted between DRD1 A-48G and severity of OCD, with 
male OCD patients homozygous for the G-allele exhibiting significantly higher Y-BOCS 
scores compared to those carrying the AG- or AA-genotypes (Table III.18[c]). Interestingly, 
evidence from a transgenic model has indicated that the chronic potentiation of DRD1-
containing neurons in the cortex and amygdala, known to induce efferent glutamatergic 
neurotransmission to the striatum, induces compulsive behaviours in mice (Campbell et al., 
1999; McGrath et al., 2000). From these results, it could be hypothesised that an increase in 
dopaminergic stimulation of DRD1 may result in an efflux of glutamate in the striatum, which 
could result in increased severity of the disorder. Indeed, it has been suggested that DRD1-
antagonists, which could attenuate the glutamatergic output to the striatum, may be more 
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efficacious in treating OCD. This is an exciting result, given that the GRIN2B rs890 was 
found to be associated with the severity of OCD in the present study (section IV.2.3.1). 
 
The gender-specific effect of the DRD1 A-48G variant is intriguing: it has been found that 
male mice exhibit a marked overproduction and elimination of striatal dopaminergic receptors 
during childhood and adolescence, but that extensive pruning of the dopamine receptors in the 
striatum occurs after puberty (Andersen et al., 2000). It may be that a dysfunction in the 
DRD1 gene prevents the pre-programmed pruning in males, resulting in the increased severity 
of the disorder, although this requires further investigation. Nonetheless, the observation by 
Andersen et al. (2000) indicates a sex-specific effect in brain structure, which may, at least 
partially, explain the present results.  
 
The present study represents the first to investigate the role that the A-48G variant may play in 
mediating the development of OCD and OCD-related subtypes. However, the functional role 
of the DRD1 A-48G promoter variant has not yet been elucidated; it is thus difficult to 
determine whether the variant itself, or one in LD with it, mediates the development of more 
severe forms of OCD. Therefore, the present result requires replication in a larger sample. In 
addition, future studies to investigate the possibility of an epistatic interaction between the 
DRD1 and GRIN2B genes should be conducted to elucidate the role that they may play in the 
development of OCD. 
 
IV.2.4. Age at Onset of OCD 
Family history of OCD was more prevalent for patients with EO OCD (median = 10 years), 
compared to those with LO OCD (median = 15 years) (p<0.001) (Table III.27), in line with 
previous investigations where significantly higher rates of OCD amongst first degree relatives 
of EO probands were observed, compared to LO probands (Pauls et al., 1995; Nestadt et al., 
2000[a]; Grados et al., 2001; Rosario-Campos et al., 2005). However, in contrast to previous 
studies reporting a gender bias in age at onset (with EO OCD more prevalent in males [Geller 
et al., 1998; Millet et al., 2004; Fontenelle et al., 2003]), ages at onset were not found to differ 
between the sexes in the present study, in fact, they were remarkably similar (median age at 
onset was 14 years for males and 15 years for females).  
 
Although the median age at onset for patients presenting with co-morbid tics was found to be 
lower than those without co-morbid tic disorders, this did not reach statistical significance in 
 345
the present sample (Table III.27), in contrast to previous results where co-morbid tics have 
been found to be associated with a significantly earlier age at onset (Swedo et al., 1992; 
Rosario-Campos et al., 2001). However, it should be mentioned that patients presenting with 
co-morbid TS, a disorder which presents with tics, experienced significantly earlier ages at 
onset compared to those who did not present with co-morbid TS. The cumulative data thus 
point towards the possibility that EO OCD may represent a clinically (and, perhaps a 
genetically) homogeneous OCD subtype. The present study thus investigated the role that 
selected genetic variants may play in mediating the development of EO OCD.  
 
Since there is no agreement as to the precise age at onset threshold that constitutes early- and 
late-onset of OCD, Kaplan-Meier survival function analyses were implemented in the present 
study. This provides a quantitative measure of the differences in age at onset for the 
genotypes of each variant, and as such, represents a more powerful analysis than if one were 
to categorically divide patients into early- and late onset, based on some arbitrary threshold. 
The Kaplan Meier logrank test provides additional power compared to numerical univariate 
analyses in that it investigates not only the difference between the medians of onset for each 
genotype, but also compares the number of observed OCD patients at each age group  with 
the number of patients that would be expected based on the number of OCD patients in the 
combined groups. 
 
IV.2.4.1. GRIN2B rs890 and rs1806191 variants 
When the OCD sample was stratified according to gender, males carrying the GRIN2B rs890 
CC-genotype exhibited a significantly earlier age at onset compared to AA- or AC-carrying 
males (Table III.28[c]). This result is particularly interesting in light of the fact that 
individuals homozygous for the C-allele were also found to experience more severe forms of 
the disorder in the present study (section IV.2.2.1), and that EO OCD has often been found to 
present with a more severe phenotype, and, at least in other studies, to occur in males more 
often than females (Geller et al., 1998; Millet et al., 2004; Fontenelle et al., 2003; section 
I.4.2.2.4). This finding underscores the gender-differentiated development and manifestation 
of OCD, and, in the light of the common age at onset between male and female OCD in the 
present study, may indicate that other or additional factors may be participating in the 
development of severe and/or early onset OCD in females. However, it should be noted that, 
for the rs890 variant, although no association was observed between age at onset and 
genotype for the female subset, only three females were found to carry the CC-genotype, 
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which may have skewed the results slightly. Indeed, females with the CC-genotype, like their 
male counterparts, were found to experience earlier ages at onset compared to those carrying 
the AA- or AC-genotypes (Table III.28[c]). 
 
A marginally significant association was also observed between GRIN2B rs1806191 and age 
at onset in the female subgroup (p = 0.049) (Table III.28[c]), with AA-carrying females 
presenting with earlier ages at onset compared to either those homozygous for the G-allele, or 
to heterozygous females. A trend towards association of the AA-genotype with earlier onset 
was also noted for the male subset (p = 0.087) and the total OCD population (p = 0.090). Like 
the association between rs890 CC-genotype and age at onset, female OCD subjects carrying 
the AA-genotype also presented with higher Y-BOCS scores than AG-or GG- carrying 
females, although this difference was not found to be statistically significant (p = 0.373) 
(Table III.18[c]).  
 
Haplotype analysis, performed on the entire OCD dataset, revealed that the rs1806191-rs890 
G-A haplotype was significantly associated with a later age at onset (p = 0.010), whilst the A-
C haplotype was associated with a significantly earlier age at onset (p = 0.018). 
Unfortunately, given the small dataset available for haplotype analysis, the data could not be 
stratified according to gender. It is thus difficult to determine whether the single variant 
effects are indeed gender-specific or not; further work using larger samples would be required 
to answer this question. 
 
IV.2.4.2. PLC-γ1 ser279gly  
Another intriguing finding was the association of the PLC-γ1 variant with age at onset of 
OCD. When the total OCD population was considered, the individuals carrying the 
PLC-γ1 GG(gly279gly)-genotype were found to experience significantly earlier ages at onset 
compared to those carrying either the GA(ser279gly)- or AA(ser279ser)-genotypes. Although 
male and female subjects homozygous for the G(gly279)-allele were found to experience 
earlier ages at onset when analysed separately, these differences were not significant (Table 
III.28[d]). However, due to the low numbers of the GG-genotype in both the male and female 
subsets, the gender-stratified subjects were grouped according to the presence or absence of at 
least one G(gly279)-allele. Here, subjects of either gender who carried at least one G(gly279)-
allele were found to experience significantly earlier ages at onset of OCD compared to those 
who were homozygous for the A(ser279)-allele.  
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Although no functional role has, as yet, been ascribed to the PLC-γ1 variant under 
investigation, the association with EO OCD is intriguing, considering the role that 
PLC-γ1 may play in the intracellular signalling cascades activated by growth factors, 
including BDNF (section I.6.1.4.1[i]), which was shown to be associated with EO OCD in 
the male OCD subset in the present study (discussed in section IV.2.4.3). The possible 
functional relationship between PLC-γ1 and BDNF is thus relevant to the present 
investigation. It may be that a dysfunction in BDNF-mediated responses involving PLC-γ1 
could result in an abnormality in the activation of downstream nuclear transcription factors, 
which may be responsible for the activation of genes necessary for neurodevelopment, 
ultimately resulting in the expression of OCD at an early age.  
 
IV.2.4.3. BDNF val66met 
The BDNF val66met variant was found to be associated with EO OCD in males, with 
AA(met66met)-carriers found to exhibit significantly lower ages at onset (median = 5 years) 
compared to those who were homozygous for the G(val66)-allele, or heterozygotes (Table 
III.28[c]). The findings are intriguing not only because of the gender-dependent effect that 
was noted, but also because, in a recent investigation by Hall et al. (2003), it was found that 
the BDNF val66met G(val66)-allele, rather than the A(met66)-allele, was overtransmitted to 
EO OCD probands (although their sample was not stratified according to gender).  
  
As already discussed in section IV.2.2.1.3, one possible explanation for the gender-specific 
effects of BDNF is a dysfunction in the estrogen-mediated regulation of BDNF expression. 
Moreover, with relevance to its association with EO OCD, it has been hypothesised that the 
manner in which estrogen and BDNF interact is highly dependent on developmental stage, 
because concentrations of nuclear estrogen receptors, which are thought to mediate the 
estrogen-BDNF interactions, have been found to vary drastically during postnatal life (Solum 
and Handa, 2001). 
 
No evidence of association with the age at onset of OCD was found for BDNF rs2049046 or 
rs988748 variants in the present study (Table III.28[d]), although Hall et al. (2003) 
demonstrated a significant overtransmission of the rs988748 C- and rs2049046 T-alleles to 
EO OCD probands. Moreover, haplotype analysis in the present study, involving all three of 
the above BDNF polymorphisms, revealed no significant associations with any of the 
phenotypes (Table III.35). However, in the present study, the 3-locus haplotype analysis 
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involved only 32 OCD subjects; therefore it is possible that the analyses are underpowered to 
detect any small effects that the variants may have on the development of EO OCD.  
 
The cumulative findings from the present study and that by Hall et al. (2003) suggest that 
BDNF may play a role in mediating the development of EO OCD. The question remains, 
however, as to why the discrepancy in val66met risk alleles for the variant exists between the 
two separate studies. One reason for the contradictory results may be population-based 
differences in allele frequencies: although the alleles associated with age at onset differ 
between the studies, it may be that the val66met variant is not itself the causal variant, but that 
either of these alleles are in LD with the disease-susceptibility variant depending on the 
population involved. Indeed, although in both the present study and that by Hall et al. (2003), 
a high degree of LD was observed across BDNF, the LD was not complete. Therefore, the 
possibility remains that, whilst the G(val66)-allele is in LD with the risk allele in a North 
American Caucasian population, the A(met66)-allele may be in LD with the risk allele in the 
Afrikaner population.  
 
Appropriate to this discussion, another potential OCD candidate gene has been found to be 
located approximately 140kb upstream from BDNF. This gene, named MALS3, encodes a 
protein that plays an important role in recruiting enzymes and receptors to specific synaptic 
sites (Jo et al., 1999). Interestingly, one of the functions of the gene is to ensure the proper 
localisation of GRIN2B to neuronal postsynaptic density. This relationship is potentially 
important to the aetiology of EO OCD, given that GRIN2B was also found, in the present 
study, to be associated with EO OCD (section IV.2.4.1).  
 
It is therefore possible that variant(s) within MALS3, in LD with the val66met variant in 
BDNF, may represent the actual risk factor in the development of EO OCD. Alternatively, 
functional MALS3 variants may be in LD with those in BDNF, creating a “super-allele” the 
possession of which represents a risk factor in developing EO OCD. Given the 
aforementioned role that BDNF and MALS3 play in regulating GRIN2B functioning, it may 
well be that variants occurring in all three of genes (and possibly more) interact epistatically, 
and together may be required for the expression of the EO OCD phenotype. The cumulative 
results are exciting, and necessitate the further investigation of more densely-spaced SNPs in 
BDNF, in conjunction with those in the nearby MALS3 gene, in order to elucidate the role that 
the gene(s) may play in mediating the development of EO OCD in males.  
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IV.2.4.4. DAT 40bp VNTR 
Three dopaminergic candidates (DAT, DRD3 and COMT) were also found to play a role in 
mediating the development of EO OCD in males. First, the DAT 40bp VNTR was found to be 
associated with age at onset, but only in the male population. The results are difficult to 
interpret due to the small number of males carrying the A10/A11 and A9/A9-genotypes (Table 
III.31). Nonetheless, it was decided not to group the genotypes, since the function of the 
polymorphism has not yet been clearly elucidated: Heinz et al. (2000) found that the A10/A10-
genotype resulted in a higher density of DAT, whilst Jacobsen et al. (2000) found that the 
A10/A10 genotype yielded a lower DAT density than the A9/A10 repeat. On the other hand, a 
study by Martinez et al. (2001) suggested that the polymorphism did not play a role in 
affecting the density of DAT. Consequently, pooling the genotypes may have resulted in a 
loss of information. Ideally, in order to maximise the likelihood of relating the functional 
variant to the phenotype under investigation, the grouping of genotypes should be performed 
on the basis of function, or allele grouping should be based on the evolutionary relationship.  
 
It is clear from the Kaplan-Meier curve in Figure III.50(b) that the males with the A10/A11 
genotypes experience significantly earlier ages at onset compared to those carrying any of the 
other genotypes. This finding is difficult to reconcile, since firstly, the A11-allele is a rare 
allele, and as already mentioned, has no function ascribed to it. Secondly, it is evident that the 
A10-allele is associated with a later age at onset, albeit non-significantly, in the male 
population. Therefore, if the A10/A11 genotype really is associated with early age at onset, it 
implies that it is the A11 allele that brings about the effect in a dominant manner. However, 
while it may be that the observation is due to chance, one cannot exclude the possibility that 
the genotype does indeed play a role in mediating the development of EO OCD; or is in LD 
with a variant that is associated with the phenotype. Indeed, although not directly associated 
with age at onset in OCD, recent evidence from a DAT-knockdown experiment in mice 
suggests that a decrease in DAT (resulting in an increase in dopamine) results in excessive 
sequential stereotypic behaviours that are characteristic of disorders such as OCD and TS 
(Berridge et al., 2005). Thus the role that the gene plays in mediating OCD, or aspects of the 
phenotype, cannot be negated; further studies conducted using a larger population are required 
to reach a definitive conclusion.  
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IV.2.4.5. DRD3 ser9gly 
The DRD3 ser9gly polymorphism was also found to be associated with age at onset in the 
male population, with the ser9gly heterozygotes exhibiting a significantly lower age at onset 
than either of the homozygotes. The present observation of the association of the heterozygote 
with EO OCD may be representative of molecular heterosis (Comings and MacMurray, 
2000). Molecular heterosis refers to the phenomenon whereby heterozygous individuals show 
a significantly greater (positive heterosis) or lesser (negative heterosis) effect than 
homozygous individuals. Since the mean age at onset for male ser9gly-carriers is significantly 
lower than DRD3 ser9gly homozygotes, the present association could perhaps be considered a 
form of negative heterosis. Molecular heterosis has been previously reported for the DRD3 
ser9gly polymorphism: a decrease in heterozygote frequency has been observed amongst 
schizophrenic subjects in three separate studies (Crocq et al., 1992; Mant et al., 1994; 
Asherson et al., 1996). Interestingly, all three of these associations were noted only in male 
subsets, indicating that molecular heterosis at the DRD3 ser9gly locus may be gender-
specific. 
 
However, although the phenomenon of heterosis represents an appealing explanation for the 
association between DRD3 ser9gly heterozygote genotype and OCD, functional studies are 
required to support the hypothesis. Presently, the in vivo functional significance of this 
polymorphism is unknown; however, in vitro analysis suggests that gly9-homozygotes may 
have a higher binding affinity for dopamine (Lundstrom and Turpin, 1996). Thus, although 
the variant may indeed be functional, in order to support the hypothesis of negative heterosis, 
one requires proof that the heterozygote variant functions differently to either of the 
homozygote variants. 
 
The present observation represents the first to suggest a sexually dimorphic relationship 
between the DRD3 ser9gly variant and EO OCD in males. The finding is interesting, given 
that a relationship has been suggested to exist between BDNF and DRD3: BDNF has been 
found to be responsible for the appearance and maintenance of DRD3 during development 
and adulthood (Guillin et al., 2003). In the present study, BDNF val66met variant was also 
found to be associated with age at onset of the disorder (section IV.2.4.3), indicating the 
possibility of an epistatic interaction existing between the two genes. The effect that BDNF 
has in regulating DRD3 may also explain, at least in part, the gender-specifc effects that were 
observed: estrogen has been found to regulate the transcription of BDNF mRNA, and as such, 
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may also play a role in mediating the transcription of DRD3 mRNA. Indeed, in the female 
population in the present study, although non-significant, the effects that genotype have on 
age at onset of OCD are opposite to those observed for males, with the heterozygotes 
exhibiting the latest ages at onset. These observations may reflect the effect that estrogen, via 
BDNF, has on DRD3 in males and females. 
 
The present findings are particularly interesting, given that, as will be discussed (section 
IV.3.1.2), the DRD3 meta-analysis also indicated that an association existed between the 
DRD3 ser9gly polymorphism and the diagnosis of OCD. Taken together, the results are 
suggestive of a role for the DRD3 ser9gly variant, or one in LD with it, in mediating the 
development of OCD, and perhaps EO OCD in particular. Further analysis is, however, 
required to elucidate the precise role the variant(s) play. 
 
IV.2.4.6. COMT rs362204 
The final dopaminergic candidate found to be associated with EO OCD in males was the 
COMT rs362204 variant, where males homozygous for the D-allele experienced significantly 
earlier ages at onset compared to heterozygous males (Table III.28[b]). As already discussed, 
this variant was also found to be associated with the dichotomous diagnosis of OCD in the 
male sample. The variant has not been found to be functional (DeMille et al., 2002), and, 
although it is in LD with the val158met variant in the present study, the latter was not found 
to be associated with EO OCD in the present study. The possibility thus exists that either the 
COMT rs362204 variant is functional (this possibility is mentioned in section IV.2.2.1.2) and 
is thus responsible for the observation, or that the variant is in LD with another functional 
variant that contributes to the development of EO OCD in males. The observed gender 
dimorphism may be due to the effect that estrogen has on the transcription, and thus activity 
of COMT (discussed previously in section IV.2.2.1.2). 
 
IV.2.4.7. 5-HT2A 
When the serotonergic candidate genes were investigated for the role they may play in 
mediating EO OCD, the only association observed was with the 5-HT2A T102C (rs6313) 
variant in the male subset (Table III.28[a]). Here, the T102T genotype was found to be 
associated with a significantly earlier age at onset. This finding contradicts that of Walitza et 
al. (2004), who observed an association between the A-allele of the 5-HT2A -1438A/G (rs6311) 
variant and OCD in a juvenile OCD sample. Interestingly, the 5-HT2A -1438A/G and T102C 
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variants were found to exhibit a high degree of pairwise LD in the present study, with the 
T102 allele mostly co-occurring with the -1438A allele. However, no statistically significant 
association between the -1438A/G variant and age at onset was noted in the present study, 
although individuals carrying the AA-genotype were found to experience earlier ages at onset 
compared to heterozygotes, or GG-homozygotes. Both the 5-HT2A T102T genotype and -
1438A allele have been found to be associated with increased 5-HT2A receptor density 
(Parsons et al., 2004; Khait et al., 2005; Polesskaya and Sokolov, 2002) (section 
I.6.1.1.1[iia]). On the contrary, however, Bray et al. (2004) and Spurlock et al. (1998) 
observed no functional differences between the alleles comprising the 5-HT2A T102C and -
1438A/G variants, respectively. The present findings are difficult to interpret, given the 
abovementioned inconsistent findings with respect to functional analyses conducted on the 5-
HT2A T102C polymorphism.  
 
Moreover, when haplotype analysis involving the two variants was conducted in the present 
study, no association with age at onset was noted. However, although the variants were found 
to exhibit a high degree of pairwise LD, this was not complete; consequently, it may be that 
the 5-HT2A T102C (rs6313) variant, in the Afrikaner population, is in LD with the causal 
variant, whilst the -1438 A/G (rs6311) variant is not. Obviously, the converse may be true for 
the German population studied by Walitza et al. (2004).  
 
The sexually dimorphic effects may be due to the effect that estrogen has been found to exert 
on the serotonergic system; indeed, the administration of estrogen has been found to increase 
the density (Sumner et al., 1999; Cyr et al. 1998; 2000) and ligand binding (Kugaya et al., 
2003) of prefrontal 5-HT2A receptors. Clearly, further investigations involving variants within 
the 5-HT2A gene are required in order to elucidate the role that this gene may play in 
mediating the development of EO OCD. 
 
IV.2.4.8. HoxB8 rs2303486 
An exploratory investigation was undertaken in order to determine the role that the HOXB8 
variant, rs2303486, may play in the categorical diagnosis of OCD, severity of OCD or the age 
at onset of OCD. Indeed, in the female OCD population, those carrying the AA-genotype 
experienced significantly earlier ages at onset compared to heterozygous or TT-homozygous 
females (p = 0.024) (Table III.28[c]). However, these results are best viewed in a cautionary 
light, since no function has yet been ascribed to the investigated polymorphism, and the wide 
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95% CIs (the upper limits of the medians for all genotypes could not be calculated, as they 
approximated infinity) indicate that chance may play a role in the observed results. Thus, 
although an interesting finding in light of the developmental aspects of OCD (section 
1.6.1.4), replication in a larger sample, and perhaps in a haplotypic context, is required.  
 
IV.2.5. Subtyping According to Co-morbidity 
 
IV.2.5.1. Co-morbid MDD 
MDD has been found to be the most common disorder occurring co-morbidly with OCD in a 
number of studies (section 1.4.2.2.1), indicating that the two disorders may share some 
functional commonality, which may extend to the genetic level. Indeed, in line with previous 
studies, MDD was found to be the most frequent co-morbid disorder amongst the OCD 
patient sample, with 64.6% of the patients presenting with this disorder. However, in contrast 
to results from other studies, no significant differences in family history of OCD, OCS or tic 
disorders were observed between OCD patients with co-morbid MDD and those without; this 
may be an effect of sample size.  
 
The frequency of symptom dimensions was also found to differ between the two OCD 
subsets: significantly more OCD subjects with co-morbid MDD experienced sexual/religious 
obsessions and compulsions, compared to those without co-morbid MDD (p = 0.042), 
consistent with recent observations by Hasler et al. (2005). This association appears to be the 
only clinical distinction between OCD patients exhibiting co-morbid MDD and those not, 
although the limited sample size may prevent the detection of further clinical associations. 
Therefore, based on previous evidence indicating the possible genetic contribution to OCD 
and selected co-morbid disorders, including MDD (Nestadt et al., 2003), the genetic aetiology 
of the OCD subtype characterised by co-morbid MDD was warranted.  
 
IV.2.5.1.1. 5-HT6 T267C 
The significant differences in allele distribution of the 5-HT6 T267C between OCD patients 
with co-morbid MDD (Table III.39[a]), and those without co-morbid MDD is interesting, 
given that the current study represents the first time that 5-HT6 has been investigated as a 
candidate gene in OCD-related analyses. Indeed, it represents a plausible candidate, due to its 
proposed involvement in the regulation of dopaminergic release in the CNS, and in its role in 
mediating the development of 5-HT neurons (section 1.6.1.1.1[iii]).  
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Although the gene has not yet been investigated for the role that it may play in major 
depressive disorder per se, the receptor has been shown to exhibit a high affinity for tricyclic 
antidepressants (Monsma et al., 1993; Roth et al., 1994; Boess et al.,1997), implicating its 
possible involvement in the aetiology of the MDD or related disorders. In the present study, 
the C267-allele was observed at a significantly greater frequency amongst the group of OCD-
MDD patients, indicating that it may confer protection against developing co-morbid MDD.  
 
The T267C variant does not alter the predicted amino acid sequence of the receptor and is 
thus unlikely to be functional. It is, however, possible that a causal variant is in LD with the 
T267C polymorphism, resulting in the observed association. 
 
IV.2.5.1.2. COMT rs2097603 
When the allelic frequencies of COMT rs2097603 SNP in individuals with MDD were 
compared to those without MDD, a statistically significant difference was noted, with the A-
allele representing a possible protective effect against the development of co-morbid MDD 
(Table III.39[a]). Since the function, if any, of the polymorphism has yet to be elucidated, the 
interpretation of the role that COMT itself may play in the pathophysiology of the 
development of co-morbid MDD is complex. The variant does, however, lie within the 
estrogen-sensitive P2 promoter region of the gene, and as such, may play a role in regulating 
its expression. However, further functional studies are required to elucidate the role (if any) 
that this variant may play in regulating the expression of COMT. The rs2097603 variant was 
not found to be in LD with either the rs4680 or rs362204 COMT variants in the present study; 
it may thus be that functional variants situated at the 5’ end of the gene may be responsible for 
susceptibility to co-morbid MDD. 
 
The collective results do, however, provide putative evidence for the distinct clinical and 
genetic aetiology of OCD+MDD, which warrant further investigation using a suitably sized 
dataset.  
 
IV.2.5.2. Co-morbid tics  
Research has indicated a substantial overlap between tic disorders and OCD, implicating the 
possibility of shared neurobiological and genetic underpinnings (Pauls et al., 1995; Leckman 
et al., 1995; Pauls, 1992), prompting the present genetic investigation. The present data 
indicates that a larger number of males exhibit co-morbid tics compared to females (Table 
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III.7), and that the age at onset of those patients exhibiting co-morbid tic disorders is earlier 
than those without co-morbid tic disorders (Table III.27). These data, although not 
statistically significant in the present study, are in line with results from previous 
investigations (Leonard et al., 1992; Grados et al., 2001). In addition, significantly more OCD 
patients presenting with co-morbid tics also experienced contamination obsessions and 
compulsions (90.9%) compared to those who did not exhibit co-morbid tic disorder (56.8%) 
(Table III.42).   
 
The COMT val158met and BDNF val66met variants were found to be associated with the 
presence or absence of co-morbid tics in the present study. For the COMT val158met variant, 
the functionality of which has been discussed in section IV.2.2.1.2., the frequency of 
genotypes containing at least one G(val158)-allele was found to be significantly higher in the 
OCD-tics group (Table III.39[a]), suggesting that the G(val158)-allele may confer protection 
against the development of co-morbid tics. This finding is interesting, given the results from 
the COMT val158met meta-analysis conducted in the present study, where this allele was 
found to confer protection against the development of the global OCD phenotype in males 
(section IV.2.2.1.2).  
 
The association between the presence of tics and the BDNF val66met variant is also 
interesting, in view of the fact that, in the present study, the A(met66) variant (the 
functionality of which has been discussed in section IV.2.2.1.3) was found to be associated 
with both the formal diagnosis of OCD and with EO OCD in males. 
 
Unfortunately, because of the small sample sizes after stratifying the OCD sample according 
to the presence or absence of tics, it was not feasible to further stratify the sample by gender; 
consequently, it is not known whether the association of the COMT val158met and BDNF 
val66met variants with co-morbid tics is gender-specific. However, a non-significant trend 
towards a higher frequency of co-morbid tics in males, compared to females, was noted 
(19.1% versus 8.5%; p=0.126) (Table III.7). The cumulative, preliminary, results thus suggest 
that the COMT val158met A(met158) allele may be involved in increasing susceptibility to 
tic-related OCD in males, and that the BDNF A(met66)-allele (or variants in LD with it) may 
increase the risk for developing EO (section IV.2.4.3), tic-related OCD in males.  
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IV.2.6. Subtyping According to Symptom Dimensions 
 
IV.2.6.1. Hoarding  
In previous studies, the hoarding symptom dimension has been found to correlate with 
increased co-morbidity, familial aggregation and poor treatment response (Mataix-Cols et al., 
2005; 2002; 1999; Black et al., 1998; Abramowitz et al., 2003; Baer, 1994; Saxena et al., 
2002; Winsberg et al., 1999; Samuels et al., 2002). It was thus relevant to investigate this 
symptom dimension as a putative OCD subtype that may be linked to a specific genetic 
aetiology.  
 
Although no significant demographic correlates of hoarding were observed in the present 
study, more females were found to present with hoarding symptoms (32.7%) compared to 
male subjects (16.7%) (Table III.7), consistent with previous data (Hogstel, 1993). The 
present findings also support previous data, indicating familial aggregation of hoarding 
symptoms (Samuels et al., 2002): more than half of the OCD subjects presenting with 
hoarding symptoms also had a family history of OCD, whereas only 16% of the non-hoarders 
presented with a family history of OCD (p=0.008) (Table III.47). Interestingly, significant 
correlations were observed between hoarding and BDD and SIB, although not with co-morbid 
major depressive or tic disorder, as has previously been found (Zhang et al., 2002; Frost et al., 
2000). 
 
Single locus analysis of the DRD4 -521C/T (rs1800955) variant revealed an allelic association 
when the OCD patient group was stratified according to the hoarding symptom dimension. 
Here, the -521T-allele was found to be more prevalent amongst hoarders compared to non-
hoarders (p = 0.043), and to controls (p = 0.011) (Tables III.49[a] and [b]), and thus 
contributes to the risk of developing hoarding symptoms. In addition, the met158 allele of the 
COMT val158met variant was found to increase the risk of developing hoarding obsessions 
and compulsions. Given the putative functional roles of each of the associated polymorphisms 
(the T-allele of the DRD4 -521C/T polymorphism has been associated with lower DRD4 
transcriptional activity, and the met158 allele of the COMT val158met polymorphism has 
been associated with lower COMT enzymatic activity [and thus possibly an increase in 
dopamine levels]), the present results, taken together, suggest that the dopaminergic system 
may play a role in the pathophysiology of hoarding symptoms in OCD. This may provide an 
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explanation as to why OCD patients who present with hoarding symptoms exhibit a worse 
response to traditional SSRI treatment.  
 
It should also be noted that, when the OCD hoarders and non-hoarders were compared, 
significant differences in genotypic and allelic frequencies were noted for the ESRα 
rs9340799 variant, while a significant difference in genotypic frequency was noted for the 
ESRα 2234693 variant. However, when the genotypic and allelic frequencies of these two 
polymorphisms were compared between the hoarders and healthy controls, no differences in 
genotypic or allelic frequencies were observed for either of the variants, suggesting that some 
characteristic within the non-hoarding OCD group may be associated with variation in ESRα. 
Nevertheless, given the already small sample size of this group, it was decided not to stratify 
the group to investigate the putative association further. This does, however, remain an aspect 
of future work, and also highlights the importance of using a control population against which 
to test the association observed within case-only investigations.  
 
IV.2.6.2. Symmetry/ordering symptom subtype 
Symmetry/ordering obsessive-compulsive symptoms, along with those characterised by 
aggressive, sexual and religious obsessions and checking compulsions, have previously been 
found to possess a strong familial component (Alsobrook et al., 1999; Leckman et al., 2003). 
This implies, indirectly, that these symptom dimensions may comprise a genetic component. 
Although Leckman et al. (2003) provided evidence consistent with a dominant major gene 
effect for both of the aforementioned symptoms, the present study represents the first to 
investigate which genes may contribute to their genetic aetiologies.  
 
From a clinical perspective, very few significant differences in family history or co-morbidity 
were observed between patients with the symmetry/ordering phenotype and those without 
(Table III.52). Interestingly, with regard to family history of tic disorders, a significantly 
lower number of patients with symmetry/ordering symptoms reported a positive family 
history of tic disorders (p = 0.032). In addition, less OCD patients suffering from 
symmetry/ordering obsessions and compulsions were found to present with co-morbid social 
phobia (p = 0.019). 
 
When the genetic aetiology of the symmetry/ordering dimension was investigated, no 
statistically significant differences were detected between the OCD subjects experiencing 
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symmetry/ordering symptoms and those not. However, when the OCD subset characterised 
by symmetry/ordering was compared to controls, a marginal genotypic association was noted 
for the ACE Alu ins/del variant (Table III.54[b]). As with the case-control analysis (section 
IV.2.2.1.4), a significantly increased frequency of individuals carrying the DD- and DI-
genotypes was noted amongst the control population, indicative of the possible dominant role 
that the D-allele may play in conferring protection against the development of OCD, 
particularly with regard to symmetry/ordering symptoms. The larger control size, compared to 
the size of the OCD subset lacking symmetry/ordering symptoms (n=134 and n=28, 
respectively), may have facilitated the detection of the effect that ACE has on 
symmetry/ordering in the OCD+symmetry/ordering vs control analysis.  
 
IV.2.6.3. Sexual/religious symptom subtype 
Demographically, significantly more males were found to experience sexual/religious 
symptoms compared to females in the present study. Clinically, OCD subjects experiencing 
sexual/religious obsessions and compulsions were found to exhibit significantly higher 
frequencies of co-morbid MDD (p = 0.017) and dysthymia (p = 0.016), and a significantly 
lower frequency of BDD (p = 0.019) compared to subjects who did not experience the 
symptoms (no subjects with sexual and religious symptoms were diagnosed with co-morbid 
BDD) (Table III.57).  
 
Investigating the genetic correlates yielded no significant results when the genotype and allele 
frequencies of selected candidate markers in individuals experiencing sexual/religious 
symptoms and those who did not, were compared. However, when the sexual/religious OCD 
subset was compared to the control sample, significant differences in genotypic frequencies 
were noted for the BDNF val66met and ACE Alu ins/del variants (Table III.59[a]).  
 
The significantly increased frequency of BDNF G(val66)-allele carriers amongst the control 
sample compared to the OCD sexual/religious subset is suggestive of the dominant mode in 
which this allele may protect against the development of sexual/religious symptoms in OCD. 
As mentioned in previous sections, this allele has also been found to be associated with 
protection against the formal diagnosis of OCD, EO OCD and the development of tics in 
males in the present study. It is interesting to note that, in the present study, the males 
experiencing sexual/religious symptoms far outweigh females experiencing the same 
symptoms. Although no formal gender stratification was performed for the current analysis 
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due to already small sample sizes, it may be that the association with the BDNF val66met 
variant is only present in the male subset. This would also provide an explanation as to why 
the difference is only observable between the OCD sexual/religious subset and controls, and 
not between the two OCD subsets: due to the larger control sample, detection of the small 
effect may be facilitated, given the increased power of the analysis. Indeed, if the association 
is, in fact, sexually dimorphic, it is possible that the development of the symptom subtype is 
mediated via the previously discussed estrogen-BDNF interaction. 
 
An association was also noted between the ACE Alu ins/del, against the larger control sample, 
and consequently increased power of analysis, making it possible to detect the small effect 
that the variant may have on the phenotype. Once again, the increased frequency of DD and 
DI-carriers amongst controls may point towards the dominant effect that this variant has in 
protecting against the development of sexual/religious symptoms.  
 
IV.2.6.4. Contamination symptom subtype 
Although the contamination/washing obsessions and compulsions represented the most 
frequently experienced symptom dimension in the present dataset, very few significant 
clinical differences were noted between those OCD subjects presenting with the subtype, and 
those not (Table III.62). Indeed, only one nominally significant difference in the frequency of 
co-morbid tic disorders was noted between the two groups (p = 0.045), with OCD subjects 
experiencing contamination/washing obsessions and compulsions also experiencing a greater 
frequency of tic disorders.  
 
In the genetic analyses, a significantly decreased frequency of the DRD4 48bp VNTR A4/A4-
genotypes was noted in the OCD subset characterised by the presence of contamination 
symptoms compared to the subset characterised by the absence of the symptoms, and to the 
control sample (Tables III.65[a], [b], [c] and [d].). This suggests that the A4-allele may be 
functioning in a recessive manner to protect against the development of 
contamination/washing symptoms. On the other hand, the A7-allele (in homozygous and 
heterozygous forms with A2 and A4) was present at an increased frequency in the OCD subset 
experiencing contamination symptoms (Table III.65[a]). This could be indicative of the A7-
allele functioning as a risk allele in a dominant mode.  
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The DRD4 48bp VNTR polymorphism has been found to be functional, although the most 
appropriate means of grouping alleles for genetic analyses is still under debate. The A4-allele 
has been found to possess a normal cAMP response, compared to the A7-allele, which has 
been found to encode a protein that has a blunted cAMP response, requiring at least three 
times more dopamine to induce a normal response compared to A4-containing DRD4 
receptors (Asghari et al., 1995). In addition, recent evidence has also indicated that the A2-
allele codes for a DRD4 receptor that has a blunted cAMP response that lies midway between 
that of A4- and A7-containing receptors, indicating a dissociation between length of the 
VNTR region and functionality (Wang et al., 2004). Therefore, on the basis of the cumulative 
biochemical and genetic data, Wang et al. (2004) have proposed that the most biologically 
efficient manner to group genotypes and/or alleles for genetic association studies may by 
grouping the A4-alleles and comparing them to other genotypes and/or alleles. However, 
although Wang et al’s proposed method of pooling alleles was employed in the present study, 
one must be mindful that grouping alleles and/or genotypes in polymorphisms for which 
functionality has not been completely established remains essentially arbitrary. Consequently, 
the involvement of the A7-or A2-allele in the observed association cannot be negated. 
 
Results obtained from the present study, following Wang et al’s proposal for allele-grouping, 
indicate that the development of contamination symptoms may be a result of a blunted cAMP 
response of DRD4 receptors, due to allelic composition. Since DRD4 acts principally to 
downregulate postsynaptic cAMP (section I.6.1.2.1[i]), the possession of a non-A4-containing 
DRD4 receptor (i.e. one containing the A7- or A2-repeat allele) may result in an increase in 
cAMP levels. Rat models have suggested that an activation of cAMP/protein kinase A second 
messenger systems in the PFC may impair certain prefrontal functions (Taylor et al., 1999). 
Thus, it is possible that decreased cAMP inhibition in patients with contamination/washing 
symptoms may result in neural cAMP-induced changes in cellular regulation and downstream 
events, which could manifest as contamination/washing symptomatology. 
 
A second association was observed when the OCD contamination/washing subset was 
compared to the control sample. Here, the ACE Alu ins/del polymorphism D-allele appeared 
to be acting in a dominant manner to protect against the development of OCD with 
contamination/washing symptoms. Given the involvement of ACE (albeit indirectly) in 
controlling dopaminergic concentrations in the brain (section I.6.1.5.4), the cumulative data 
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point towards the possibility that a dopaminergic mechanism may be involved in the 
aetiopathology of OCD with contamination/washing symptoms.  
 
IV.2.6.5. Aggressive symptom subtype 
As mentioned in the previous section, evidence exists to suggest that aggressive obsessions 
and compulsions are genetically transmitted in a dominant manner. This symptom dimension 
has also been found to be associated with an increase in social phobia co-morbidity (Hasler et 
al., 2005). In the present study, however, no association between aggressive symptoms and 
co-morbidity with the any disorders considered in this study were observed. These apparently 
discrepant results may be due to the fact that in the Hasler et al. (2005) model, four main 
symptom dimensions were described: aggressive symptoms were grouped with sexual and 
religious symptoms, whereas in the present study the aggressive symptoms were grouped 
separately.  
 
Despite the lack of clinical distinctions between OCD subjects experiencing aggressive 
symptoms and those not, the possibility exists that the sample numbers investigated in the 
present study are too small to detect an effect of small to moderate size. Thus, the compelling 
evidence that aggressive symptoms possess a familial (and thus perhaps, genetic) component 
(Leckman et al., 2003; Alsobrook et al.,1999) prompted the investigation into the possibility 
of a genetic aetiology of this symptom subtype.   
 
Disappointingly, but perhaps not surprisingly considering the sample numbers, no candidate 
markers investigated in the present study were found to be associated with the aggressive 
symptom subtype. Further studies comprising greater statistical power are required to 
determine whether the candidates can be excluded as playing a role in the development of the 
subtype. 
 
IV.2.7. Summary of Subtype Genetic Association Studies 
There is no doubt that some interesting results, worthy of further discussion, have emerged 
from the present genetic study. These results are summarised below to provide a greater 
overview of the implications of the findings of the present study.  
 
Firstly, the association of BDNF val66met polymorphism with the formal, dichotomous 
diagnosis and age at onset of OCD in males, and the concurrent finding that it is also 
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associated with the tic-related phenotype, are potentially indicative of a distinct EO, tic-
related OCD phenotype in males that is a distinct clinical and genetic entity. Moreover, these 
results represent a partial replication of those obtained by Hall et al. (2003), who investigated 
the role that BDNF polymorphisms may play in mediating the development of EO OCD. 
Although different val66met alleles were implicated as risk factors in both studies, this is 
likely to be the result of population-based differences, as already discussed in section 
IV.2.4.3.  
 
Secondly, the association of COMT rs362204 variant with the formal diagnosis of OCD and 
EO OCD, both in males, also represents a potentially interesting finding. It was noted that the 
COMT val158met variant (found to be in pairwise LD with rs362204 in the present study) 
was found to be associated with the tic-related phenotype (the COMT rs362204 variant was 
not included in the OCD+tics subtype analysis, due to small sample size). It is thus tempting 
to speculate that, as stated in the previous paragraph, the EO, tic-related phenotype in males 
may represent a genetically distinct subtype, and, although it may not be the rs362204 and 
val158met variants per se that are involved, they may be in LD with the causative 
polymorphism.  
 
The finding that both genes are regulated, at least in part, by estrogen, via EREs makes for an 
even more intriguing result, in that one could thus hypothesise that sex-specific estrogen-
mediated effects, perhaps at certain stages during neurodevelopment, may underlie the 
aetiology of some aspects (particularly the age at onset and development of co-morbid tics) of 
the disorder. It would also be interesting, and perhaps fruitful, to conduct an investigation into 
possible epistatic interactions between the COMT and BDNF genes, to determine whether 
they function synergistically to increase susceptibility to the EO, tic-related OCD phenotype. 
 
The third result worthy of further mention is the observation that the GRIN2B rs890, in 
particular, and possibly rs1806191, were found to play a role in severity and age at onset of 
the disorder. The results are interesting, since not only were they corroborated by the results 
obtained in the haplotype investigation in the present study, but also in a family-based study 
by Arnold et al. (2004), who observed an association between the GRIN2B rs890 and the 
severity of OCD. The glutamatergic system has only recently gained popularity as one of the 
systems that may be affected in OCD, and, given the present results, it seems ever more likely 
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that investigation will continue into the role that the system may play in the aetiology of 
OCD.  
 
Overall, the gender-specificity of the observed associations is striking, especially for the age 
at onset analyses, where approximately two-thirds of the observed associations were observed 
only in males. This may imply that a gender-specific dysfunction, perhaps at different stages 
of neural development, may be playing a role in mediating certain aspects of the disorder. 
Certainly, the role that estrogen may play in regulating many of the products encoded by the 
candidate genes investigated has been touched upon, but it is suspected that the interactions 
may be highly complex. The notion that ESRα may play a role in the development of OCD 
and related subtypes was also investigated in the present study. Although no statistically 
significant associations between either of the selected ESRα intronic variants and OCD, or 
subtypes of OCD, were observed in the present study, including variants in genes encoding 
gonadal hormones and related products in future studies is probably a worthwhile endeavour.  
 
IV.2.8. Limitations to Categorisation by Subtype 
It is important to note that the classification of OCD subjects into the respective symptom 
dimensions is not mutually exclusive: a single patient can present with one or more of these 
symptom dimensions. The focus of the study was thus on the genetic aetiology of each group 
of symptom dimensions, not on groups of patients.  
 
It is also notable that one of the major disadvantages when subtyping a patient dataset is a 
reduction in sample size, and consequent reduction in the power of the analysis. One way of 
overcoming this would be to focus beyond the diagnosis of OCD, and on individuals in the 
broader population who may suffer from sub-syndromal OCD. In addition, the possibility 
exists that one could include patients suffering from other psychiatric disorders that are 
known to present with similar obsessions and compulsions; for example, TS and TTM. 
Unfortunately, such data was not available for investigation in the present study, but the 
acquisition thereof remains a future goal. 
 
It is also important to bear in mind that the aforementioned subtypes are by no means the only 
ones that characterise the disorder. Recently, a large amount of interest has been invested in 
identifying “endophenotypes” of complex disorders. Endophenotypes are described as 
“measurable components unseen by the unaided eye along the pathway between disease and 
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distal phenotype” (Gottesman and Gould, 2003). Simply put, they are intermediate 
phenotypes that are more closely linked to genetic substrates than the global OCD phenotype. 
Presently, very few reliable endophenotypes for OCD have been identified, although 
proposals include the use of neuroimaging data to identify structural and functional indices of 
brain function in OCD patients, and measurements from neurocognitive tasks that highlight 
cognitive and behavioural inhibitory processes at play in OCD (Chamberlain et al., 2005; 
Miguel et al., 2005).   
 
IV.3. FAILURE TO REPLICATE POSITIVE CASE-CONTROL ASSOCIATIONS  
Failure to confirm previously identified susceptibility loci seems to be fairly commonplace in 
association studies. Indeed, in the present study, a number of non-replications of previously 
reported positive results were observed. In analysing these discrepancies, it is necessary to 
consider both procedural and statistical issues (Owen et al., 1997). Statistical issues include 
the power of the individual studies and correction for multiple testing, whilst procedural 
issues involve investigating the possibility of population stratification, differences in 
diagnostic procedures and sample ascertainment.  
 
IV.3.1. Meta-analyses of Case-control Association Studies 
Meta-analyses were conducted using the present data obtained in case-control analyses for the 
5-HT2A -1438A/G, 5-HT2A T102C, 5-HT2C cys23ser, DRD3 ser9gly, DAT 40 bp VNTR, 
COMT val158met and DRD4 48bp VNTR polymorphisms, and combining this with 
previously published data from population-based case-control studies investigating the same 
variants. Results obtained from the 5-HT2C cys23ser and COMT val158met meta-analyses 
have already been discussed in the appropriate sections (sections IV.2.2.1.1 and IV.2.2.1.2, 
respectively). Data generated for the remaining meta-analyses will be discussed in the 
following subsections. 
 
IV.3.1.1. 5-HT2A -1438A/G (rs6311) 
The results obtained from the present case-control analysis involving the 5-HT2A -1438A/G 
(rs6311) variant indicated that no significant association between the variant and OCD 
existed, in line with those obtained using a Turkish population (Tot et al., 2003). These results 
are in contrast to two other studies, in which evidence for the A-allele as a possible risk factor 
in increasing susceptibility to OCD, was provided (Enoch et al., 2001; Walitza et al., 2004). 
However, Enoch et al. (2001) observed this association only in the female population, 
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comprising 48 cases and 77 controls, whilst Walitza et al. (2002) observed only a marginally 
significant association for genotype distribution (p=0.046). Interestingly, when calculating the 
OR values of each study prior to the present meta-analysis, our analyses of Walitza et al’s 
data indicated a non-significant allelic association, with an OR=0.70 (95% CI: 0.46-1.07). As 
mentioned, Walitza et al. (2002) had originally reported only a nominally significant finding 
(p=0.046); it is likely that the difference in methods in calculating significance values 
between the present meta-analysis and the Walitza et al. (2002) investigation is responsible 
for this slight discrepancy. 
 
Nonetheless, it is of note that Walitza et al. (2002) utilised an OCD population comprising 
adolescents, with an average age at onset of 12.11 years, lower than that obtained for any of 
the other studies. Such differences in datasets are important to account for, given that they 
may result in inconsistent findings, and perhaps even Type I or Type II errors in a meta-
analysis (the limiting factors in a meta-analysis are discussed in section IV.3.1.6). However, 
given that no significant heterogeneity was observed between the studies, the results of their 
study were included in the current meta-analysis. 
 
Combining the results of the association studies in a meta-analysis revealed no evidence for 
association between the variant and OCD (Figure III.51). However, it is interesting that an 
association between EO OCD in males and 5-HT2A T102C, found to be in LD with the -1438 
A/G variant, was observed in the present study. The reasons for the contradictory results have 
already been discussed (section IV.2.4.7): it may thus be that, by stratifying OCD according 
to age at onset, residual background “noise” is eliminated, enabling the identification of the 
variant involved in this OCD subtype. However, the information available from the published 
studies was, unfortunately, insufficient to allow an analysis into the relationship between 5-
HT2A and EO OCD. Further haplotype-based studies should nonetheless be conducted in order 
to determine whether the gene plays any role in mediating development of EO OCD. 
 
IV.3.1.2. 5-HT2A T102C (rs6313) 
When the genotype and allele frequencies of the 5-HT2A T102C (rs6313) variant were 
compared between the non-stratified OCD and control subjects in the present study, no 
statistically significant differences were noted. These findings are in line with results obtained 
from previous investigations in Jewish (Frisch et al., 2000), Turkish (Tot et al., 2003) and 
Mexican (Meira-Lima et al., 2004) populations. However, all of these case-control association 
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investigations (including the present) were of modest size: indeed, in the present study, the 
power to accept the null hypothesis with certainty was only 6% for the genotypic association, 
and 5.3% for the allelic association. It is thus likely that none of the aforementioned studies 
possessed sufficient power to exclude 5-HT2A T102C as a candidate marker.  
 
Results from the meta-analysis, which investigated the relationship between the dichotomous 
diagnosis of OCD and the 5-HT2A T102C variant, did not reveal any significant association 
between the variant and OCD (Figure III.52). However, given the observation, in the present 
study, that the variant may be linked to EO OCD in males, provides sufficient support for the 
variant (or, indeed, the gene) to continue to be investigated as a potential candidate. 
 
IV.3.1.3. DRD2 Taq1A polymorphism (rs1800497) 
Only two studies were included in the meta-analysis investigating the role that the DRD2 
Taq1A variant may play in OCD. Another study, conducted by Billet et al. (1998) had also 
been conducted, but the author found that their data proved to be unreliable (the genotype 
frequencies reported totalled more than one for the OCD population; hence reliable genotypic 
counts could not be derived from the published data). This highlights the importance of 
ensuring that all data reported, such as frequencies of genotypes and alleles, are correct. No 
statistically significant associations between the variant and OCD were noted for either of the 
studies included in the meta-analysis (Table III.55), but, due to the relatively small sample 
sizes attained even in the meta-analysis (173 cases and 231 controls), the possibility that the 
variant did not play a role could not be excluded. However, an increase in power and accuracy 
of the observation was noted by the corresponding decrease in width of the 95% CIs.  
 
IV.3.1.4. DRD3 ser9gly (rs6280) 
Although no studies (including the present) have yielded evidence for the association of the 
DRD3 ser9gly polymorphism with OCD (Nicolini et al., 1996; Catalano et al., 1994) 
including these data in a meta-analysis indicated otherwise (Figure III.56). With a combined 
sample of 260 cases and 275 controls available for use in the meta-analysis, it was found that 
the ser9-allele was associated with an increased susceptibility to OCD. It is interesting to note 
that the present study and that by Catalano et al. (1994) present with very similar ORs and 
corresponding 95% CIs, and, although both individually produced a result with no 
association; it thus seems that, by increasing the sample size, sufficient power was attained, 
enabling the narrowing of the CI so that the significant effect could be detected.  
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This is an intriguing finding, and represents the first to find an association between the DRD3 
gene and OCD. Moreover, given the proposed functionality of the polymorphism, with the 
gly9-homozygote and heterozygote exhibiting a higher binding affinity for dopamine than the 
ser9-homozygote (Lundstrom and Turpin, 1996), it is possible that this may translate into a 
hyperdopaminergic state, which may play a role in the expression of OCD. In addition, it has 
recently been found that DRD2 and DRD3 form functional heterodimers in the brain that are 
able to inhibit cellular inhibition of AC more effectively than DRD2 alone (Scarselli et al., 
2001). It could therefore be hypothesised that the ser9-containing DRD3 variant exhibits a 
reduced capacity to form functional heterodimers, possibly leading to less efficient signal 
transduction processes. It may thus be worthwhile, in future studies, to investigate the 
possible epistatic interaction that may occur between DRD2 and DRD3 to result in increased 
susceptibility to OCD. 
 
 
IV.3.1.5. DAT 40bp VNTR 
Two previous studies, conducted in a Jewish (Frisch et al., 2000) and a North American 
Caucasian (Billet et al. 1998) population had previously indicated that no association existed 
between the DAT 40bp VNTR and OCD. However, given the relatively small sample sizes of 
these studies (103 cases and controls in Billet et al. [1998] and 75 cases and 172 controls in 
Frisch et al. [2000]), it may well have been that the sample sizes were too small to detect an 
effect of small to moderate size that the DAT variant played in the development of OCD. A 
meta-analysis, combining the study performed by Frisch et al. (2000) and the present study 
was thus performed in an effort to improve power of the individual analyses. The Billet et al. 
[1998] data was not included, due to inconsistencies in their data: the investigators only 
reported genotype frequencies, which when added, exceeded 1 for both the OCD and control 
groups). Only the three most common alleles (the A9/A9, A9/A10 and A10/A10) were included 
in the meta-analysis, due to lack of insufficient data concerning the other genotypes in the 
study by Frisch et al. (2000). However, the meta-analysis revealed no association between the 
variant and the development of  OCD (Table III.54). 
 
IV.3.1.6. DRD4 48bp VNTR 
The A2-allele of the DRD4 48bp VNTR has been found to confer protection against the 
development of OCD in a French population- and family-based association study (Millet et 
al., 2002), whilst in a previous population-based study in a Jewish population, the A7-allele 
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was found to be less frequent in OCD Jews of non-Ashkenazi origin (Frisch et al., 2000). 
Data by Billet et al. (1998) was excluded (please refer to section IV.3.1.3 for explanation). In 
contrast, in the present study, no significant differences in genotype or allele frequencies were 
noted between OCD and controls. 
 
Due to lack of information regarding the nature and amounts of the observed genotypes by 
Frisch et al. (2000), it was decided that three separate meta-analyses should be conducted: one 
investigating the role that the A2-allele (given the findings by Millet et al. [2002]), one 
investigating the role that the A7-allele may play (given the preliminary findings by Frisch et 
al. [2000]), and one investigating the role that the A4-allele may play, a grouping suggested 
by Wang et al. [2004] and Grady et al. [2003] (section I.6.1.21[i]).   
 
Although no heterogeneity was observed amongst ORs for the DRD4 A4-allele meta-analysis, 
a significant amount of heterogeneity was observed between studies for the A2-A7-allele 
meta-analyses, hence these were not conducted. Heterogeneity in a meta-analysis refers to the 
diversity of characteristics of the investigations and can arise as a result of numerous factors, 
including differences in sample selection (e.g. age, gender, method of diagnosis), differences 
in methods (e.g. genotyping methods), or it may be due to real differences between the 
populations, such as race, or interaction with other risk factors (this would include differences 
in allele frequencies and/or LD between populations). In meta-analyses including a large 
number of studies, it is possible to determine the source of heterogeneity by stratifying the 
data according to sources of potential heterogeneity. This was not plausible in the present 
study, given the small number of investigations included.  
 
When the meta-analysis was conducted according to the presence or absence of the DRD4 A4-
allele, no statistically significant differences were noted. However, the fact that the finding 
pertaining to the protective effect of the DRD4 A2-allele by Millet et al (2003) was replicated 
in a subsequent family-based analysis by the same investigators, and that the polymorphism 
was found to be associated with OCD in a haplotypic context in the present study (section IV. 
2.1), provides sufficient evidence for further studies, perhaps using more densely-spaced 
markers across the whole DRD4 gene, to be undertaken. 
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IV.3.1.7. Limitations of meta-analyses 
As already mentioned, meta-analyses are systematic reviews that are aimed at increasing the 
sample size, and consequently the power, of an association study. However, although they 
represent a replicable and defensible method of synthesising findings across studies, the 
method is not without limitations. First, the quality and usefulness of any meta-analysis is 
dependent on the quality of the component studies. The data in each study included in the 
meta-analysis should be carefully assessed for methodological errors; for example, HWE 
should preferably exist amongst the control individuals. A departure from HWE amongst 
controls can indicate, amongst other things, genotyping error; any studies with controls in 
HW disequilibrium should thus be excluded from the meta-analysis. In the present meta-
analyses, all studies were re-assessed for HWE, and were only included if HWE was met. 
 
Secondly, meta-analyses require some degree of commonality between studies, since the 
pooling of data is done under the assumption that variations between studies are minimal, and 
are due to chance. As already discussed (section IV.3.1.6), departures from homogeneity 
amongst studies may be a result of different phenotypic measurements, genotypic 
measurements, differing disease definition, variations in gene-environment interactions, and 
variations in LD with functional alleles in different populations (Davey, 2003). Where no 
statistical heterogeneity was observed in any of the present meta-analyses, it is reasonable to 
assume that differences between studies are due to chance fluctuations. However, in larger 
meta-analyses, a more detailed examination of heterogeneity should be conducted, stratifying 
data according to all potential sources of heterogeneity and performing the meta-analyses 
accordingly. Obviously, the small number of studies included in each meta-analysis in the 
present investigation did not allow for such stratification. 
 
A third limiting factor may occur in the form of publication bias, which refers to publishing of 
significant associations more readily than non-significant ones. In the present meta-analyses, 
no formal test for publication bias was performed (section I.4.5.1) given the small numbers of 
studies in each meta-analysis, and the fact that, on average, more negative studies were 
published compared to positive associations. 
 
The method employed in the present study, i.e. the pooling of individual studies by allele 
frequencies, also introduces a bias. Generally, the odds ratios in such a case represent the odds 
that an individual has the allele, given that he is a case or control subjects, which does not 
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easily translate into a risk of disease given the genotype. On the other hand, as previously 
discussed (section IV.2.6.4), to pool genotypes, one requires a validated biological model in 
order to know which genotypes  to pool. Moreover, one is required to test different modes of 
inheritance, which introduces the problem of multiple testing.  
 
In addition, it should be considered that when performing meta-analyses using data from 
different populations, in which discrepant results have been found, that one may in fact be 
diluting the signal of the genetic susceptibility factor. In association studies, one is often not 
looking at the susceptibility gene itself, but at an allele or locus that may be in LD with the 
disease gene. Subsequently, divergent findings may well be real, and reflect differences in 
population histories and genetic make-up. Combining such populations in meta-analyses 
would then affect the power to detect association of a particular allele with the phenotype. 
Moreover, if population admixture or stratification is present in some samples, which itself 
could lead to conflicting results being generated between research groups utilising different 
populations, this effect would be perpetuated in any meta-analyses utilising such data. 
 
Positive meta-analyses findings point the way to future studies; however, the present meta-
analyses still did not generate sample sizes that were sufficiently large to conclusively exclude 
any of the genes as potential candidates. This may simply be a reflection of the infancy of 
genetic studies in OCD; hopefully as more statistically sound genetic association studies are 
conducted, they will enable the implementation of more powerful meta-analyses. 
 
IV.4. STATISTICAL POWER 
The power of a genetic association study depends on numerous interrelated variables, 
including the underlying genetic model that is assumed, effect size, the level of agreement 
between the susceptibility and marker allele frequencies, the degree of linkage disequilibrium 
between the susceptibility and marker alleles, case and control sample sizes and the end-point 
(or phenotype) under investigation (Section I.4.4.2). By virtue of the design of the association 
study, many of these variables will always be unknown, and therefore need to be 
approximated, rendering the calculation of the actual power of the study very difficult.  
 
Moreover, in complex, multifactorial disorders, it is speculated that the genetic component of 
risk may be spread across several loci, necessitating analyses of sufficient power to detect a 
modest (and most likely, small) contribution by the individual genes. Where negative 
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associations are observed, a review of the power of the study to detect effects of small to 
moderate size is imperative, since one can only truly reject the null hypothesis (and thus 
conclusively state that no association exists between the two parameters) if certain limitations 
are set. Post-test power calculations were therefore performed in the present study, and it is 
clear from the values obtained that the power to detect small effects (especially for less 
common variants) is low. It should be mentioned, however, that post-test power is simply an 
indication of the power of the study, assuming that the observed effect size in that study is the 
true effect size. Consequently, one cannot compare such post-test powers between studies, 
unless the effect sizes that are observed are exactly the same; they thus simply serve the 
purpose of indicating the degree to which a Type II error might occur in that particular 
analysis.  
 
For example, assuming the control:case ratio is 2:1, and the risk allele has a frequency of 0.55 
in the control population, a case sample of 316 and control sample of 632 is required to attain 
a power of 80% (DuPont and Plummer, 1990) (Figure IV.1) (these power calculations are 
based on the CD/CV hypothesis. If the “geneticists nightmare” is true, with many rare alleles 
contributing to the aetiology of the disorder in a population-specific manner, the sample size 
required to achieve 80% power to detect an OR of 1.2 is in the region of 20 000!). One also 
needs to remember that multiple testing will result in a decrease in the significance level, 
which ultimately decreases the power of the study, hence the sample sizes reported here are 
optimistically based on a significance level of 0.05, and assume that the marker and disease 
alleles possess the same frequency. Indeed, in a recent study, it was estimated that the 
minimal number of cases and controls required to achieve a power of 80% power at α=0.05 is 
usually far greater than 200 when the disease-susceptibility allele is not tested directly, even 
under the most favourable of circumstances (Pfeiffer and Gail, 2003). 
 
It can thus be stated that the analyses in the present study in which candidate markers that 
were found to have no statistically significant association with the phenotype can, at best, be 
described as inconclusive. Further studies using larger sample sizes are required to determine 
whether one can, with certainty, exclude the marker as a potential candidate.  
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Figure IV.1. Power calculations for a risk allele frequency of 0.55 to detect an OR of at least 
1.5 at a significance level of 0.05. The control sample size required is twice that of the size of 
the required case sample.  
 
The small sample sizes obtained in this study are a result of the difficulty experienced in 
recruiting OCD cases from the general community. Most patients are too ashamed of their 
symptoms to seek help, viewing their disorder as a purely psychological “taint”. This places 
severe restrictions on the number of patients who are willing to participate in the investigative 
research. This desire for secrecy also limits the type of association analysis that can be 
performed, since it confines the number of relatives participating in the study, placing 
restrictions on conducting family-based association analyses. Moreover, more female than 
male controls seemed to be recruited for the study (n=56 versus n=162). There may be many 
reasons to explain this phenomenon, one being that female subjects (both case and control), 
when approached, were more willing to participate and more ready to offer personal 
information more readily compared ro male subjects. The excess of female control subjects 
compared to male control subjects could represent a potential limitation in the current 
investigation, but the fact that the OCD case subjects were matched for gender should all but 
eliminate this restraining factor.  
 
In addition, when planning to perform haplotype analyses, where the same individuals need to 
be investigated at a host of different variants and different genes, a renewable source of DNA 
for these individuals, such as cell lines, is crucial, particularly if the time-span of the project is 
of the duration of several years. Insufficient DNA of good quality can eventually result in 
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small sample numbers for particular analyses, even if the number of patients enrolled at first 
were greater.  
 
One way to overcome small sample sizes typical of OCD case-control association studies, 
including the present study, is to conduct meta-analyses where possible. Due to the 
combination of samples from various studies, meta-analyses present one with a means of 
increasing the power of a study, at the same time collating the data to extract useful 
information.  
 
IV.5. MULTIPLE COMPARISONS 
It has been found that the most likely reason for failure to replicate the results of association 
studies is Type I errors: many investigators fail to account, in some way, for number of tests 
performed (Berry et al., 1998; Colhoun et al., 2003). The appropriate means of correcting for 
multiple testing remains a point of contention amongst researchers. The present belief is that 
applying the Bonferroni correction produces a p-value that is too conservative (Perneger et al., 
1998; Macciardi et al., 2003), and may thus lead to false negative (Type II error) results, 
especially where data is not independent.  
 
The current study utilises both single locus and haplotype analyses in an effort to determine 
the underlying genetic aetiology of OCD, and thus not all of the genetic data presented is 
strictly independent; consequently, employing the Bonferroni correction would constitute 
overadjustment. Moreover, in the present study, an extensive amount of subtyping has been 
conducted in an effort to determine whether certain genetic substrates are more closely related 
to selected clinical subtypes than to the higher order construct of OCD. Although the degree 
to which these phenotypic subtypes may correlate is presently not known, they are all likely to 
be related in some way, given that they are all clinical manifestations of OCD. It is thus 
difficult to determine how many independent factors need to be corrected for. Indeed, 
correcting for multiple testing using Bonferroni’s correction would have resulted in many of 
the associations observed in the present study being represented as non-significant, with the 
exception of the “very” significant association between the DAT 40bp VNTR and age at 
onset.  
 
Given the present uncertainty regarding the most appropriate means of adjusting for multiple 
comparisons, the p-values were presented as is in the present study, with the obvious caution 
 374
that most of the observed associations remain to be validated by means of replication, using 
larger samples. In the present study, p-values for haplotype tests are also presented 
uncorrected, since the correction for multiple testing for haplotype investigations has not yet 
been well-established (Chapman et al., 2003). 
 
IV.6. CHOICE OF CANDIDATE GENES 
The role that genes may play in mediating the development of OCD was investigated by 
means of candidate gene association studies, in which an a priori hypothesis between 
exposure to a given factor (the genotype in this case) and the disorder is assessed. However, 
one of the most important confounding factors in any psychiatric association analysis is that 
the research relies, to a large extent, on the knowledge and understanding of the genetic 
aetiology of the disorder, which, at least for OCD, is currently incomplete.  
 
The result is that most of the candidate genes that are investigated possess low prior 
probability of being involved in the disorder; unless the prior probability of a candidate gene 
is reasonably high (in the order of 1/1000), Bayes theorem indicates that most of the positive 
associations observed are likely to be false positives. Unfortunately there are, as of yet, no 
criteria that are agreed upon for setting a value for the prior probability of a candidate gene.  
The candidates in the present study included the “usual suspects” from the serotonergic and 
dopaminergic pathways, due to the role that they play in encoding products that are targeted 
by the pharmacological agents used to treat the disorder. However, while the acute effect of 
anti-OCD drugs is located at the neurotransmitter synapse, this may not be the region of their 
therapeutic effect. Indeed, they may interact with other neurotransmitters and/or initiate a 
cascade of events, including the activation of secondary messenger signalling pathways and 
subsequent gene transcription that alleviate the symptomatology.  
 
Obviously, the use of functional polymorphisms in association studies provides the 
investigator with the advantage that, if a significant association between the candidate gene 
and OCD is detected, it could be ascribed to altered function of the encoded protein. 
However, many of the previous endeavours to identify OCD susceptibility genes have been 
hindered by attempts of researchers to transfer the Mendelian model of single gene 
inheritance to the model of polygenic inheritance proposed for complex disorders, by 
focussing on mutations occurring in the exons of candidate genes (Comings, 1998).  
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It is hypothesised that the susceptibility loci for many of the psychiatric disorders may, in 
fact, be positioned in the non-exonic gene regulatory regions (Comings, 1998; Comings et al., 
1991). These regulatory regions are presently viewed as “black boxes” by most molecular 
biologists, even in the present era of technological advance. It is hoped that the non-functional 
polymorphisms used in genetic association studies might be in LD with, and thus point the 
way to, the identification of functional polymorphisms in the regulatory regions of genes 
which may be involved in the aetiology of OCD. 
 
Indeed, in the present study, the functionality of many of the variants shown to be associated 
with OCD, or related subtypes, has only previously been speculated upon, especially those 
occurring within regulatory and 3’ UTRs. Thus promoter assays to determine whether variants 
situated in (or near) the 5’ region affect gene expression levels, and mRNA studies to assess 
the effect of synonymous intragenic or 3’UTR variants on mRNA stability are required. 
Moreover, it will also be relevant to screen and/or sequence whole gene transcripts, in order to 
identify potentially functional variants which may be in LD with the OCD-associated 
variants. 
 
IV.7. EPISTATIC INTERACTIONS 
It is speculated that susceptibility genes may operate in unison with one another such that a 
particular combination of alleles may have a much stronger effect on vulnerability to OCD 
than each separate allele (Nothen et al, 1993; Souery et al., 2001). In other words, the 
susceptibility loci could be acting in unison to bring about the clinical phenotype in such a 
way that a particular combination of alleles may have a much stronger effect on susceptibility 
to OCD than a single susceptibility locus on its own. Consequently, epistatic effects could 
understate the impact that a single locus may have in contributing to the development of 
OCD, and looking at just a single candidate marker may thus lack power and reproducibility. 
It has been stated that epistasis may, in fact, be one of the factors that contributes to failure to 
replicate genetic association studies (Williams et al., 2004): therefore, genetic association 
studies should not only focus on investigating potential candidate genes, but also explore the 
possible pleiotropic, epistatic and environment dependent effects of the candidate gene.  
 
Such analyses would, however, require sufficient knowledge regarding the genes involved in 
the aetiology of the disorder, and the genetic environment and functional pathways in which 
those genes occur (Comings, 1998), something which is currently lacking in the realm of 
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psychiatric disorders (including OCD). Moreover, the identification and characterisation of 
genes that increase susceptibility to complex disorders is a statistically and computationally 
intensely challenging. Data becomes sparse when multiple genetic risk factors are considered 
simultaneously, increasing the possibility of a false positive error using methods such as 
logistic regression (Peduzzi et al., 1996). On the other hand, by implementing methods such 
as step-wise model-fitting procedures, the risk of a Type II error increases, given that 
interaction effects are only tested for those variables found to have an independent main 
effect; polymorphisms with an interaction, but not main, effect will consequently be 
overlooked.  However, alternative analytical strategies, including those based on neural 
network algorithms (Ritchie et al., 2003) have been, and are presently being, developed.   
 
An investigation into the epistatic interactions between candidate genes in the current study 
would perhaps have facilitated an understanding of the genetic aetiology of the disorder. For 
example, the possible epistatic interactions between GRIN2B and BDNF (section IV.2.3.1), 
and between BDNF and DRD3 (section IV.2.4.5) would be important to investigate. In 
addition, epistatic interactions between genes encoding gonadal hormones and COMT and 
BDNF represent important ones to follow up. Moreover, given the possible interaction, on a 
physiological level, between ACE and dopaminergic neurotransmission, it is also relevant to 
investigate whether these interactions translate to their genetic substrates. However, due to the 
limited sample size and consequently, power, of the present dataset, such an investigation 
could not, at this stage, be conducted. Nonetheless, as this is an ongoing study, the analysis of 
epistatic interactions remains a definite possibility in the near future. 
 
IV.8. FUTURE RESEARCH DIRECTIONS  
The present study forms part of a larger ongoing collaborative research investigation in which 
polymorphisms in candidate genes in the relatively genetically homogeneous Afrikaner 
population are screened, to elucidate the potential role they might play in the aetiology of 
OCD.  
 
Evidence is presently being gathered to support the notion of susceptibility alleles that are 
common to related psychiatric disorders. A single common genetic foundation seems 
improbable, but it may be that certain “building blocks” could be shared. In this regard it 
might be useful to look beyond traditional diagnostic boundaries for shared genetic 
aetiologies to certain symptom subtypes. As the numbers of Afrikaner OCD subjects recruited 
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in the coming years increases, the genetic analyses within such subgroups should yield 
sufficient statistical power to rule out the possibility of Type I or Type II errors.  
 
It may also be of use to employ other quantitative approaches in the design of the 
investigation. For example, many of the obsessions experienced by OCD patients are 
endorsed as “worries” by psychologically normal individuals - the possibility should therefore 
be considered that OCD symptoms can be broken down into multiple dimensions that are 
continuous with the normal population (Leckman et al., 2001; Leboyer et al., 1998). This 
would represent an important route to disentangling the complex inheritance of OCD. The 
results obtained from genetic investigations should be incorporated with clinical and 
epidemiological parameters to correctly elucidate the cause of OCD. 
 
Moreover, future studies should be extended to incorporate the screening of more 
polymorphisms within the context of a larger Afrikaner population, and high resolution 
mapping within specific chromosomes will improve knowledge regarding the impact of 
genetic diversity within the genes or linked chromosomal regions in OCD. The advantages of 
a “gene-based” instead of a “SNP-based” approach are becoming ever more apparent (Neale 
and Sham, 2004): therefore, a more complete assessment of candidate genes, possibly 
utilising haplotype blocks that span larger regions, is proposed. A systematic genome-wide 
approach is also required in order to identify currently unknown susceptibility genes for OCD. 
To this end, an exciting ongoing collaboration with the New York State Psychiatric Institute 
has presented our teams with the opportunity to conduct genome-wide association studies, 
using the Afrikaner population.  
 
Increasing the amount of information on human genome sequences and polymorphisms will 
make it possible to characterise the amount of sequence variation expressed in the brain, and 
to delineate the potential effects that these variations may have on the development of OCD. 
Knowledge of new functional variants will emerge as researchers gain an appreciation of the 
potential for genetic variants in the coding and regulatory regions to impact on gene 
expression.  
 
It seems that, presently, technological advances in the molecular biology arena are 
superseding those in the statistical genetics arena. Novel statistical methods capable of 
identifying genes with small to moderate effects amongst a variety of homogeneous factors is 
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needed. Available statistical methodology needs to be re-examined and improved to make it 
more applicable to genetics and molecular biology. They should be empirically tested in order 
to compare and contrast the relative strengths and weaknesses of methods specific to 
particular genetic association questions.  
 
Finally, a serious effort at collaboration should be made between neurogeneticists, 
neurologists, psychiatrists, psychologists, bioinformaticians and statisticians involved in 
unravelling the complex aetiology of OCD. This would, however, require a more critical, 
standardised use of clinical information in order to increases the comparability of global data, 
and facilitate the assimilation of the data. The competitive nature of many research teams, and 
lack of incentive to re-analyse old data may mar the initiation of such collaborations, but they 
may be the only hope we have of identifying disease-susceptibility genes amidst a labyrinth of 
genetic, clinical and environmental heterogeneity. 
 
IV.9. CONCLUSION 
 
The preliminary and frequently inconsistent nature of the data represented in the majority of 
psychiatric genetic association studies attempting to find genetically-based aetiological factors 
for OCD might seem discouraging. However, these studies represent the initial forays into 
what promises to be an exciting frontier. The maze of genetic susceptibility and 
environmental factors contributing to the development of OCD has posed an enormous 
challenge to psychiatric geneticists, but many researchers have responded to this challenge by 
developing increasingly powerful molecular and statistical tools. 
 
Given the small effects that each identified, validated, susceptibility genotype will have in 
contributing to OCD, the predictive value of any single susceptibility variant is going to be 
very limited. However identifying susceptibility genes may afford researchers a better 
understanding of the role that a dysfunction in a particular protein may play in disease 
causation. These may include the interaction of the gene product with other protein or genetic 
substrates and the possible effect of environmental modification on protein levels and 
functions. So far, many of the environmental risk factors that play a role in OCD have proven 
elusive: hopefully, they will be identified as a result of the elimination of genetic “noise” as 
identification and comprehension of predisposing genetic factors improves. Such genetic 
characterisation of OCD individuals may offer insight into molecular and biochemical sub-
categories of the disorder, previously indiscernible by clinicians. This, in turn, could lead to 
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the improvement in diagnostic and treatment approaches, since treatments may be better 
tailored to target the major contributing sub-phenotype comprising the disorder, instead of 
implementing a more global treatment regime, which may prove to be ineffective. 
 
The present results yield some exciting and interesting preliminary observations, which are to 
be followed up, in a larger sample and with additional gene variants in the associated genes, 
and will employ additional LD tests and functional assays to verify the causal implications of 
verified associations. Indeed, the small sample size (especially after stratification) remains the 
most important limitation, and efforts are underway to improve and increase the Afrikaner 
OCD sample size. However, although certain characteristics of the Afrikaner population, such 
as genetic, cultural and diagnostic homogeneity may have a major impact on simplifying the 
identification of susceptibility loci involved in the aetiology of OCD, the probability exists 
that several genetic and environmental factors with relatively small individual effect 
contribute to the risk of developing OCD, even in the Afrikaner population. In the 
forthcoming years, researchers will hopefully gain insight into these aspects of OCD, which 
should prove to be invaluable to establishing the aetiology, with the subsequent introduction 
of new treatment strategies for this incapacitating psychiatric disorder. 
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APPENDIX I 
 
BUFFERS, MARKERS AND SOLUTIONS 
 
1. DNA EXTRACTION SOLUTIONS 
 
Cell Lysis Buffer 
Sucrose     0.32M 
Triton-X-100     1% 
MgCl2      5mM 
Tris-HCl     10mM 
H2O      1litre 
 
3M Sodium acetate 
Sodium Acetate    40.81g 
H2O      50ml 
Adjust pH to 5.2 with glacial acetic acid (Merck) and adjust volume to 100ml 
with ddH2O 
 
Na-EDTA solution 
 NaCl (Merck)     18.75ml of 4M stock solution 
 EDTA (B&M Scientific)   250ml of a 100mM stock solution 
 Mix well 
 
Phenol/Chloroform 
Phenol (saturated with 1XTE) (Merck) 50ml 
Chloroform (Merck)    48ml 
8-hydroxyquinone (Merck)   2ml 
Mix well, store at 4˚C 
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Chloroform/octanol (24:1) 
 Chloroform (Merck)    96ml 
 Octanol (Merck)    4ml 
            Mix well, store at 4˚C 
 
TE-Buffer (10x stock) 
Tris OH      0.1M(pH 8.00) 
EDTA(pH8)     0.01M (pH 8.00) 
H2O      150ml 
 
2. ELECTROPHORESIS STOCK SOLUTIONS 
 
TBE-buffer (10x stock) 
Tris-HCl (Biorad)    108g 
Boric Acid (Merck)    58g 
Na2EDTA (Merck)    9.3g 
ddH2O to a final volume of 1 litre 
 
Bromophenol Blue 
Bromophenol blue    0.2%(w/v) 
Glycerol     50% 
Tris (pH8)     10mM 
 
Ethidium Bromide 
 Ethidium Bromide    500mg 
 ddH2O     50ml 
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3. MOLECULAR SIZE MARKERS 
Bacteriophage Lambda DNA (250μg)  100μl 
Buffer M (Boerhinger Mannhein)   15μl 
PstI (Boerhinger Mannheim)    11μl 
H2O       32μl 
Incubate at 37°C for 2 hours followed by heat inactivation at 65°C for 5 minutes. 
Load 2μl onto polyacrylamide gels. 
 
4. SOLUTIONS FOR SILVER STAINING 
 
0.1% AgNO3 (Solution B) 
AgNO3       1g 
H2O       1litre 
 
Developing Solution (Solution C) 
NaOH       15g 
NaBH4       0.1g 
Formaldehyde      4ml 
H2O up to a final volume of 1 litre 
 
5. SOLUTIONS FOR POLYACRYLAMIDE GELS 
 
10% Ammonium persulphate (APS) 
APS       2g 
H2O       20ml 
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6. GELS 
 
12% POLYACRYLAMIDE GEL 
30 acrylamide/0.8% bis-acrylamide stock   4ml 
10xTBE       1ml 
Distilled H2O       5ml 
APS        80μl 
TEMED       30μl 
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APPENDIX II 
LIST OF SUPPLIERS 
 
6-FAM       Applied Biosystmes 
Acrylamide       Merck 
AgNO3       Merck 
Ammonium persulphate     Merck 
ApoI        New England Biolabs 
BglI        Promega 
BlpI        New England Biolabs 
Bis-acrylamide      Merck 
Boric acid       Merck 
Bromophenol blue      Merck 
DdeI        Roche Applied Science 
dGTP        Boerhinger Mannheim 
dCTP        Boerhinger Mannheim 
dTTP        Boerhinger Mannheim 
dATP        Boerhinger Mannheim 
EcoRV        Promega 
EDTA        Boerhinger Mannheim 
Ethanol       Boerhinger Mannheim 
ExoI        Amersham 
FokI        New England Biolabs 
Formamide       Merck 
Formaldeyde       Merck 
FspI        New England Biolabs 
GeneScan-120 LIZ internal sizing standard   Applied Biosystmes 
Glycerol       FMC 
HhaI        Promega 
HindIII       Promega 
Hi-Di formamide      Applied Biosystmes 
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HincII        Promega  
HpaII        Promega 
K-acetate       Sigma 
KCl        Merck 
Lambda DNA       Promega 
MnlI        New England Biolabs 
MscI        Roche Applied Science 
MspI        Promega  
NaAc        Merck 
NaCl        BDH Chemicals 
NaOH        Sigma 
NlaIII        New England Biolabs 
Oligonucleotide primers Department of                
Biochemistry, University of 
Cape Town School 
PBS Sigma 
POP4 (performance optimizimg polymer) Applied Biosystmes 
Phenol/Chloroform Merck 
Phenol/Octanol Merck 
Proteinase K Sigma 
PstI Promega 
PvuII Promega 
Qiagen Kit Stratagene 
RsaI Promega 
ROX100 fragment size standard Applied Biosystmes 
SAP Roche Applied Science 
SDS Sigma 
SNaPshot Multiplex Ready Reactiohn mix Applied Biosystems 
TaqI Promega 
Taq polymerase Bioline 
TEMED Sigma 
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Tris Merck 
Tris-OH Merck 
Tris-HCl Merck 
XbaI Promega 
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APPENDIX III 
PATIENT INFORMATION AND INFORMED CONSENT 
Genetics of Anxiety Disorders 
 
PURPOSE: 
 
This study is part of a research project we are conducting to learn more about the 
genetic causes and symptoms of anxiety disorders (including obsessive-
compulsive and spectrum disorders, panic disorder or social phobia).  We would 
like to discuss your life experiences and those of your other family members with 
you.  Doctors and scientists at the MRC Unit on Anxiety and Stress Disorders 
and the University of Stellenbosch, in collaboration with qualified researchers 
from other research institutions worldwide, hope to identify the genes that may 
increase susceptibility to these disorders. 
This is not a treatment study.  Information is being collected for research 
purposes only. 
 
STUDY PROCEDURE: 
 
If you decide to participate, we shall ask you to attend an interview (which may be videotaped) 
with a researcher.  This interview will include neuropsychological tasks and a number of 
questions related to your current illness, your prior history of treatment for psychiatric conditions, 
and particular symptoms you may have experienced as part of your illness.  In addition, we may 
ask to take photographs of your face and hands.  This whole procedure will last about 4-5 hours 
(two 2-hour sessions with a break in-between).   
 
You will also be asked to have your blood drawn.  Approximately 48 ml (3 
tablespoons) of blood will be drawn from your arm.  We may need to contact you 
again to get another blood sample should we fail to get a DNA sample from your 
blood.  The blood sample you give may be used to create a cell line.  This is 
done by changing some of your blood cells so that they can grow forever.  The 
cell line is living tissue and it can be used to make more of your DNA at any time 
in the future.  This process will take place at the MRC Centre for Molecular and 
Cellular Biology and the Division of Medical Biochemistry, Faculty of Health 
Sciences, at the University of Stellenbosch.  The DNA will then be taken from the 
cell line and saved for scientific analyses which will be performed now, and 
possibly in the future.   
 
We may contact you later for further information, or request you to complete another interview at 
a later date, in order to obtain follow-up information that may be of use in our genetic analyses.  
This may involve an assessment similar to the current assessment, including a series of 
interviews and/or another blood sample.  Your current participation is in no way binding to your 
future participation. 
 
We would like your permission to contact your relatives in order to get more information about 
any family history of mental illness.  You can still participate in the study even if your relatives do 
not. 
 
Personal information that could be used to identify you (such as your name, 
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contact information, etc) will not be given out.  Your data and DNA is likely to be 
made available to qualified scientists around the world to study your particular 
anxiety disorder.  Your cell line and DNA will be maintained permanently, unless 
you request to have it removed.  If at any time in the future you wish to have your 
DNA, cell lines or clinical data removed from the storage site, you may do so by 
contacting the researchers conducting this study (Christine Lochner at 021 - 938 
9179). 
 
The researchers who will have access to your DNA include those who work with 
private and/or for profit companies.  These researchers may be interested in 
eventually developing commercial medical products using the DNA from you and 
other participants.  They may sell or patent discoveries based on this research 
and thus benefit financially.  Please note that you or your heirs will not receive 
any compensation if this occurs.    
 
We do not expect to discover any information of direct benefit to your condition, 
or your treatment, during the next few years.  If later on, diagnostic tests or new 
ways to treat your condition are discovered, this information will have to be 
obtained from properly licensed clinical labs, clinics, or your physician, and will 
not be available from the research team. 
 
If you are hospitalized at a psychiatry facility or have received any treatment from 
a mental health professional, we would like your permission to review your 
treatment records, which will be obtained from your doctor. 
 
RISKS:     
 
There are no more than minimal medical or psychological risks associated with 
this study.  If you feel fatigued, tired, uncomfortable, or in any way upset during 
any part of the session(s), you may ask to stop for a rest break or have the 
interview discontinued.  The research interview does not take the place of a full 
psychiatric evaluation.  You may experience some emotional discomfort when 
answering some questions.  If any particular question makes you feel 
uncomfortable, you may discuss its importance with the specially trained 
interviewer.  You may choose not to answer any question which you are still 
uncomfortable with. 
 
You may feel some pain associated with having blood withdrawn from a vein.  
You may experience discomfort, bruising and/or other bleeding at the site where 
the needle is inserted.  Occasionally, some people experience fleeting dizziness 
or feel faint when their blood is drawn. 
 
Some insurance companies may mistakenly assume that your participation in this study is an 
indication that you are at higher risk of a genetic disease, and this could hurt your access to 
health or other insurance.  We will not share any information about you, or your family, with an 
insurance company.  However, if you discuss your participation in this study with your doctor, and 
he or she records it in your medical record, it is possible that an insurance company may access 
the information as part of a medical record review.  It is the opinion of the investigators that 
participation in this study does not constitute genetic testing.  Although one long-term goal of this 
research is the development of a genetic test for the anxiety disorders, at the current time, no 
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information from your DNA sample that would be useful in the treatment of your disorder will be 
obtained.  Therefore, participation in this study should not be reported as genetic testing.   
 
Your unidentified DNA and cell line will be available to qualified researchers 
permanently.  
 
BENEFITS:   
 
There are no direct benefits to you.  However, individuals who might develop one or more of 
these anxiety disorders in the future, their family members, and future generations may benefit if 
we can locate the genes that lead to such disorders.  That knowledge could then lead to the 
development of methods for prevention and new treatments for curing these diseases.   
 
CONFIDENTIALITY:    
 
If you consent to participate in this study, your identity will be kept confidential.  
Your answers will not be shared with other family members or anyone else 
except for staff members involved in this study.  All data will be kept in locked file 
cabinets accessible only to the research staff.  All research information obtained 
will not be associated with your name; research staff will use only a coded 
number and/or your initials.  Blood samples will be safely stored and identified by 
code number and access will be limited to authorized scientific investigators.  
Copies of treatment records from hospitals or mental health professionals are 
kept in locked files and are reviewed by members of the research team only.  
Any publications resulting from this study will not identify you by name.   
 
VOLUNTARY PARTICIPATION: 
 
Your participation in this study is voluntary and you may refuse to participate or withdraw from the 
study at any time without any loss of benefits to which you are otherwise entitled.  Some 
members of the team of investigators conducting this study may be responsible for your clinical 
care.  Refusal to participate in this study will not change your clinical care. 
 
 
RESEARCH QUESTIONS AND CONTACTS: 
 
If you are interested in genetic counseling, you will be given information about 
where you can receive such counseling and a new blood sample may be 
required at that time.  DNA information about a relative will be released only if the 
genetic counsellor confirms that the relative in question is deceased or cannot be 
found and that the information is essential for clinical counseling. 
 
The researchers will answer any questions you might have about the procedures 
described above, or about the results of the study.  If you have any questions, 
you may call Christine Lochner at (021) 938 9179.   
 
The University of Stellenbosch Research Subcommittee C has approved 
recruitment and participation of individuals for this study. 
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You have been given a copy of this consent form to keep.   
 
INFORMED CONSENT: 
 
I have read the above patient information, my questions have been answered, 
and I consent voluntarily to participate in this study. 
 
 
Print name:  _____________________________      Signature:  
____________________________ 
 
Date: ________________________________ 
 
 
I have discussed the proposed research with this subject and, in my opinion, this 
patient understands the benefits, risks, and alternatives (including non-
participation) and is capable of consenting to voluntary participation. 
 
Print name:  ______________________________      Signature:  
____________________________ 
  Study Investigator or Designee 
 
Date: ________________________________ 
 
 
Print name:  _______________________________     Signature:  
____________________________ 
  Witness (if applicable) 
 
Date: ________________________________ 
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PASIëNTINLIGTING EN INGELIGTE TOESTEMMING 
Genetika van Angssteurings 
 
 
DOELWIT: 
 
Hierdie projek is deel van 'n navorsingsprojek wat tans onderneem word om 
meer uit te vind oor die genetiese oorsake en simptome van angssteurings 
(insluitend obsessief-kompulsiewe- en spektrumversteurings, paniek-, of sosiale 
angssteuring).  Ons wil graag oor u lewenservarings en dié van u gesinslede met 
u gesels.  Dokters en wetenskaplikes by die MNR Eenheid vir Angs- en 
Stressteurings en die Universiteit van Stellenbosch, in samewerking met 
gekwalifiseerde navorsers van ander navorsingsinstellings wêreldwyd, hoop om 
die gene wat vatbaarheid vir hierdie angssteurings laat toeneem, te identifiseer. 
Dit is nie 'n behandelingstudie nie.  Inligting word alleenlik vir 
navorsingsdoeleindes versamel. 
 
PROJEKPROSEDURE: 
 
Indien u besluit om deel te neem, sal ons u vra om 'n onderhoud (wat moontlik op 
videoband vasgelê kan word,) met 'n navorser te voer.  Hierdie onderhoud sluit 
neurosielkundige take en 'n aantal vrae in wat met die volgende aspekte verband 
kan hou: u huidige siekte, u geskiedenis van behandeling vir psigiatriese 
steurings, en spesifieke simptome wat u dalk kon ervaar as deel van u siekte.  
Daarmee saam, kan ons u vra om foto's van u hande en gesig te neem.  Hierdie 
hele prosedure sal ongeveer 4-5 ure duur (twee 2-uur sessies met 'n pouse 
tussen-in). 
 
U sal ook gevra word om toe te laat dat u bloed getrek word.  Ons kan dalk weer 
met u in verbinding moet tree om nog 'n bloedmonster te trek in geval ons nie 
daarin kon slaag om 'n DNA monster van u bloed te verkry nie.  Die 
bloedmonster wat u gee, kan gebruik word om 'n sellyn te skep.  Dit word gedoen 
deur sommige van u bloedselle te verander sodat dit vir altyd kan groei.  Die 
sellyn is lewende weefsel en dit kan gebruik word om meer van u DNA in die 
toekoms te maak.  Hierdie proses sal plaasvind by die MNR Sentrum vir 
Molekulêre en Sellulêre Biologie en die Afdeling Geneeskundige Biochemie, 
Fakulteit Gesondheidswetenskappe, Universiteit van Stellenbosch.  Die DNA sal 
dan van die sellyn geneem en gehou word vir wetenskaplike analise wat nou, en 
moontlik in die toekoms gedoen sal word.  
 
Ons kan met u in aanraking kom vir verdere inligting, of u vra om nog 'n 
onderhoud te voltooi op 'n latere stadium, ten einde opvolg-inligting te bekom wat 
gebruik kan word in ons genetika-analise.  Dit kan 'n soortgelyke assessering as 
die huidige wees, insluitend 'n reeks van onderhoude en/of ander bloedmonsters 
behels.  U huidige deelname verbind u onder geen omstandighede tot 
toekomstige deelname nie. 
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Ons wil graag u toestemming hê om met u familielede in aanraking te kom ten 
einde meer inligting oor enige familiegeskiedenis van geestessiekte te bekom.  U 
kan steeds deelneem aan die projek selfs al is u familielede nie betrokke nie. 
 
Persoonlike inligting wat gebruik kan word om u te identifiseer (soos u naam, 
kontakbesonderhede, ens.), sal nie uitgegee word nie.  U data en DNA sal 
moontlik aan gekwalifiseerde wetenskaplikes regoor die wêreld beskikbaar gestel 
word om u betrokke angssteuring te bestudeer.  U sellyn en DNA sal permanent 
gehou word, behalwe wanneer u vereis dat dit verwyder word.  Indien u op enige 
stadium in die toekoms besluit om u DNA, sellyne of kliniese inligting uit die 
bergingsplek te laat verwyder, kan u dit doen deur die navorsers wat hierdie 
projek behartig, te vra om dit te doen (Christine Lochner by 021 - 938 9179). 
 
Die navorsers wat tot u DNA toegang het, sluit diegene in wat werk met private 
en/of winsgeoriënteerde maatskappye.  Hierdie navorsers kan ook daarin 
geïnteresseerd wees om uiteindelik kommersiële mediese produkte te ontwikkel 
deur van u en die ander deelnemers se DNA gebruik te maak.  Hulle kan hierdie 
uitvindings, wat op hierdie navorsing gebaseer is, verkoop of patenteer en 
sodoende finansieel daaruit voordeel trek.  Let asseblief daarop dat u of u 
erfgename nie enige kompensasie hiervoor sal ontvang indien dit wel gebeur nie. 
 
Ons verwag nie om enige inligting te bekom wat van direkte nut vir u toestand of 
u behandeling gedurende die volgende paar jare sal wees nie.  Indien daar in die 
toekoms diagnostiese toetse of nuwe wyses om u toestand te behandel, ontdek 
word, sal hierdie inligting van behoorlik gelisensieërde kliniese laboratoria, 
klinieke, of u mediese dokter verkry moet word, en dus nie van die 
navorsingspan nie. 
 
Indien u by 'n psigiatrie fasiliteit gehospitaliseer word, of behandeling van 'n 
geestesgesondheidswerker ontvang, wil ons graag u toestemming hê om u 
behandelingsrekords, wat van u dokter verkry sal word, na te gaan. 
 
RISIKO'S: 
 
Daar is nie meer as die minimum mediese en sielkudige risiko's geassosieer met 
hierdie projek nie.  Indien u uitgeput, ongemaklik, of ontsteld raak tydens enige 
gedeelte van die sessie(-s), kan u vra om te onderbreek vir 'n ruskansie of om 
die onderhoud te beëindig.  Die onderhoud wat met u gevoer word, neem nie die 
plek van 'n deeglike psigiatriese evaluasie nie.  U kan dalk 'n mate van 
emosionele ongemak verduur wanneer u sommige van die vrae beantwoord.  
Indien enige vraag u ongemaklik laat voel, kan u die belang daarvan met die 
spesiaal opgeleide onderhoudvoerder bespreek.  U kan verkies om enige vraag 
waarmee u steeds ongemaklik voel, nie te beantwoord nie. 
 
 393
U kan moontlik 'n mate van pyn ervaar wanneer die bloed getrek word.  U kan 
ongemak, kneusing en/of bloeding by die plek waar die naald ingesteek word, 
ervaar.  Soms ervaar sommige persone verbygaande duiseligheid of 'n flou 
gevoel wanneer hulle bloed getrek word. 
 
Sommige versekeringsmaatskappye kan verkeerdelik aanneem dat u deelname 
aan hierdie projek 'n aanduiding is dat u 'n verhoogde risiko het vir 'n genetiese 
siekte, en dit kan u toegang tot gesondheid- of ander versekering skaad.  Ons sal 
nie enige inligting oor u, of u familie aan 'n versekeringsmaatskappy bekendmaak 
nie.  Indien u egter u deelname met u dokter bepreek, en hy/sy maak 'n nota 
daarvan in u mediese rekord, is dit moontlik dat 'n versekeringsmaatskappy 
hierdie inligting as deel van 'n hersiening van mediese rekords kan bekom.  Dit is 
die mening van die navorsers dat deelname aan hierdie studie nie genetiese 
toetsing is nie.  Alhoewel een langtermyn-doelwit van hierdie navorsing die 
ontwikkeling van 'n genetiese toets vir die angssteurings is, sal geen inligting van 
u DNA-monster wat nuttig kan wees in die behandeling van u toestand, tans 
verkry word nie.  Daarom behoort deelname aan hierdie studie nie as genetiese 
toetsing beskryf te word nie. 
 
U ongeïdentifiseerde DNA en sellyn sal permanent aan gekwalifiseerde 
navorsers beskikbaar wees.    
 
VOORDELE: 
 
Daar is geen direkte voordele vir u nie.  Individue wat egter in die toekoms een of 
meer van hierdie angssteurings ontwikkel, hulle familielede, en toekomstige 
generasies, kan voordeel daaruit put as ons die gene wat tot sulke versteurings 
aanleiding kan gee, kan identifiseer.  Hierdie kennis kan dan lei tot die 
ontwikkeling van metodes vir voorkoming en nuwe behandelingswyses vir 
genesing van die siektes. 
 
VERTROULIKHEID: 
 
Indien u toestem tot deelname aan die projek, sal u identiteit vertroulik gehou 
word.  U antwoorde sal nie met u familielede of enige iemand anders behalwe 
die personeellede wat gemoeid is met hierdie projek, gedeel word nie.  Alle 
inligting sal in geslote liasseringskabinette wat slegs vir navorsingspersoneel 
toeganklik is, gehou word.  Alle navorsingsinligting wat verkry word, sal nie met u 
naam verbind kan word nie; navorsingspersoneel sal bloot 'n kodenommer en/of 
u voorletters gebruik.  Bloedmonsters sal veilig gestoor en geïdentifiseer word 
deur die kodenommer, en toegang sal tot die gemagtigde wetenskaplike 
navorsers beperk wees.  Kopieë van behandelingsrekords van hospitale of 
geestesgesondheidswerkers word in geslote lêers gehou en word slegs deur 
lede van die navorsingspan deurgegaan.  Enige publikasie wat uit hierdie projek 
voorspruit, sal u nie by name identifiseer nie. 
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VRYWILLIGE DEELNAME: 
 
U deelname aan hierdie projek is vrywillig en u kan deelname weier of u op enige 
stadium van die projek onttrek sonder verlies van enige voordele waartoe u 
andersins geregtig is.  Sommige lede van die span navorsers wat hierdie projek 
uitvoer, kan moontlik verantwoordelik wees vir u kliniese versorging.  Weiering 
om deel te neem aan hierdie studie sal nie u kliniese versorging verander nie. 
 
VRAE OOR DIE NAVORSING EN KONTAKBESONDERHEDE: 
 
Indien u wel in genetiese berading geïnteresseerd is, sal u inligting oor waar 
sodanige berading beskikbaar is, ontvang en 'n nuwe bloedmonster kan op 
daardie stadium vereis word.  DNA-inligting van 'n familielid sal slegs beskikbaar 
gestel word indien die genetiese berader bevestig dat die familielid oorlede is of 
nie opgespoor kan word nie en dat die inligting noodsaaklik is vir kliniese 
berading. 
 
Die navorsers sal enige vrae wat u mag hê oor bogenoemde prosedures of oor 
die resultate van die projek, beantwoord.  Indien u enige navrae het, kan u 
Christine Lochner by 021 - 938 9179 skakel. 
 
Die Navorsingsubkomitee C van die Universiteit van Stellenbosch het die 
werwing en deelname van individue aan hierdie projek goedgekeur. 
 
U het 'n afskrif van hierdie toestemmingsvorm ontvang om te bewaar. 
 
INGELIGTE TOESTEMMING: 
 
Ek het die bostaande pasiëntinligting gelees, my vrae is beantwoord, en ek stem 
vrywillig in om aan hierdie projek deel te neem. 
 
 
Naam: _____________________________  Handtekening:
 _____________________________ 
 
Datum: _____________________________ 
 
 
Ek het die voorgestelde projek met die deelnemer bespreek en, na my mening, 
verstaan die deelnemer die voordele, risiko's, en alternatiewe (inlsuitend nie-
deelname) en is in staat om toestemming te gee vir vrywillige deelname. 
 
Naam: ______________________________      Handtekening:
 ___________________________ 
 Navorser of Gemagtigde 
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Datum: ______________________________ 
 
 
Naam: ______________________________      Handtekening:
 ___________________________ 
 Getuie (indien van toepassing) 
 
Datum: ______________________________ 
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